{"1": ["\u949f\u5357\u5c71 \u9662\u58eb \u56e2\u961f \u56db\u5341\u4f59 \u4e2d\u6210\u836f \u4e2d\u836f \u65b9\u5242 \u7b5b\u9009 \u7814\u7a76 \u5305\u62ec \u75c5\u6bd2 \u6291\u5236 \u8bd5\u9a8c \u4e34\u5e8a\u8bd5\u9a8c \u7814\u7a76 \u5960\u5b9a \u7406\u8bba \u57fa\u7840 \u836f\u7269 \u7b5b\u9009 \u8fc7\u7a0b \u4e2d \u7814\u7a76\u8005 \u8bc1\u5b9e \u8fde\u82b1\u6e05 \u761f \u80f6\u56ca \u4e2d\u836f 2019 - nCoV \u611f\u67d3 \u7ec6\u80de \u75c5\u53d8 \u6291\u5236\u4f5c\u7528 \u6291\u5236 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u6d3b\u6027 \u51cf\u5c11 \u75c5\u6bd2 \u542b\u91cf \u4f5c\u7528 \u6291\u5236 \u708e\u75c7 \u56e0\u5b50 \u8fc7\u5ea6 \u8868\u8fbe ", "\u4e2d\u79d1\u9662 \u6b66\u6c49 \u75c5\u6bd2 \u6240\u77f3 \u6b63\u4e3d \u56e2\u961f \u6210\u529f \u5f00\u53d1 SARS - CoV - 2   hACE2 \u8f6c\u57fa\u56e0 \u5c0f\u9f20 C3B6 \u5c0f\u9f20 \u4e2d\u4e3a HFH4 - hACE2 \u611f\u67d3 \u6a21\u578b \u7ed3\u679c\u8868\u660e hACE2 \u5c0f\u9f20 \u6d4b\u8bd5 \u6f5c\u5728 \u75ab\u82d7 \u6cbb\u7597\u5242 \u4ef7\u503c \u5de5\u5177 ", "\u7ebd\u7ea6 \u897f\u5948\u5c71 \u4f0a\u574e \u533b\u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u9f3b \u4e0a\u76ae \u4e2d \u53d1\u73b0 \u5e74\u9f84 \u4f9d\u8d56\u6027 ACE2 \u57fa\u56e0 \u8868\u8fbe ACE2 \u57fa\u56e0 \u8868\u8fbe \u5e74\u5e7c \u513f\u7ae5 \u4e2d \u6700\u4f4e \u5e74\u9f84 \u589e\u957f \u589e\u52a0 \u591a\u9879\u5f0f \u6b63\u4ea4 \u8d8b\u52bf \u6d4b\u8bd5\u8868\u660e \u5e74\u9f84 \u589e\u957f ACE2 \u8868\u8fbe \u53d8\u5316 \u5448 \u7ebf\u6027 \u8d8b\u52bf \u513f\u7ae5 \u4e2d ACE2 \u8868\u8fbe \u964d\u4f4e \u6709\u52a9\u4e8e \u89e3\u91ca \u513f\u7ae5 \u4e2d COVID - 19 \u6d41\u884c \u7387 \u4f4e ", "\u7f8e\u56fd \u764c\u75c7 \u7814\u7a76\u6240 \u7814\u7a76 \u4eba\u5458 \u95ee\u5377\u8c03\u67e5 \u91c7\u8bbf \u5f62\u5f0f \u5168\u7403 \u80bf\u7624 \u4e34\u5e8a\u8bd5\u9a8c \u7814\u7a76\u8005 \u6c9f\u901a IQVIA ClinicalTrials . gov \u4e2d \u80bf\u7624 \u4e34\u5e8a\u8bd5\u9a8c \u6570\u636e \u5206\u6790 \u7814\u7a76 \u663e\u793a COVID - 19 \u75ab\u60c5 \u786e\u5b9e \u80bf\u7624 \u4e34\u5e8a\u8bd5\u9a8c \u60a3\u8005 \u62db\u52df \u5de5\u4f5c \u5e26\u6765 \u5f71\u54cd \u7f8e\u56fd \u6b27\u6d32\u5730\u533a ", "\u4e0a\u6d77\u5e02 \u516c\u5171\u536b\u751f \u4e34\u5e8a \u4e2d\u5fc3 \u8f6c\u5316 \u533b\u5b66 \u56fd\u5bb6 \u79d1\u6280 \u57fa\u7840\u8bbe\u65bd \u7814\u7a76 \u4eba\u5458 \u63ed\u793a \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u6027\u80ba\u708e \u5206\u5b50 \u6d41\u884c\u75c5\u5b66 \u4e34\u5e8a\u8868\u73b0 \u7279\u5f81 \u53d1\u73b0 \u91cd\u75c7 \u8f6c\u5316 \u5173\u952e \u9884\u8b66 \u56e0\u5b50 \u6307\u51fa \u75be\u75c5 \u7a0b\u5ea6 \u56e0\u7d20 \u5bbf\u4e3b \u56e0\u7d20 \u5e74\u9f84 \u6dcb\u5df4\u7ec6\u80de \u51cf\u5c11 \u75c7 \u76f8\u5173 \u7ec6\u80de\u56e0\u5b50 \u98ce\u66b4 \u75c5\u6bd2 \u9057\u4f20\u53d8\u5f02 \u5173\u8054 ", "\u7f8e\u56fd\u54c8\u4f5b\u5927\u5b66\u533b\u5b66\u9662 \u7334\u5b50 \u63a5\u79cd \u539f\u578b \u75ab\u82d7 \u6297\u4f53 \u53ef\u9632 \u65b0\u51a0 \u75c5\u6bd2 \u7814\u7a76 \u4eba\u5458 25 \u7334\u5b50 \u6ce8\u5c04 \u75ab\u82d7 8 \u4fdd\u62a4 ", "\u82f1\u56fd \u56fd\u6c11 \u533b\u7597 \u670d\u52a1\u4f53\u7cfb NHS \u4e00\u9879 \u7814\u7a76 \u53d1\u73b0 \u82f1\u56fd \u7ea6 \u4e09\u5206\u4e4b\u4e00 \u65b0\u51a0 \u80ba\u708e \u6b7b\u4ea1 \u75c5\u4f8b \u7cd6\u5c3f\u75c5 1 \u578b \u7cd6\u5c3f\u75c5 \u60a3\u8005 \u65b0\u51a0 \u80ba\u708e \u6b7b\u4ea1\u7387 2 \u578b \u7cd6\u5c3f\u75c5 \u60a3\u8005 \u66f4\u9ad8 NHS \u7814\u7a76 \u8bc1\u5b9e \u7cd6\u5c3f\u75c5 \u589e\u52a0 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3\u8005 \u6b7b\u4ea1 \u98ce\u9669 ", "\u7f8e\u56fd \u7814\u7a76 \u4eba\u5458 \u4e24\u9879 \u7334\u5b50 \u7814\u7a76 \u63d0\u4f9b \u6700\u521d \u79d1\u5b66 \u8bc1\u636e \u8bc1\u660e \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u5eb7\u590d \u611f\u67d3 \u514d\u75ab\u529b \u8fd9\u4e00 \u4e50\u89c2 \u8ff9\u8c61 \u9884\u793a \u7814\u53d1 \u65b0\u51a0 \u75ab\u82d7 \u53d6\u5f97\u6210\u529f ", "\u7f8e\u56fd\u65af\u5766\u798f\u5927\u5b66 \u533b\u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u68c0\u9a8c \u4e00\u79cd \u65b0\u578b HIV \u75ab\u82d7 \u4fdd\u62a4 \u6548\u679c \u7315\u7334 \u8eab\u4e0a \u5b9e\u9a8c \u663e\u793a \u65b0 \u75ab\u82d7 \u5f3a\u6709\u529b \u514d\u75ab \u5e94\u7b54 \u66f4\u597d \u9884\u9632 \u611f\u67d3 \u5e26\u6765 \u6301\u4e45 \u4fdd\u62a4 \u6548\u679c ", "\u82f1\u56fd \u591a\u56fd \u79d1\u5b66\u5bb6 \u56e2\u961f \u7814\u7a76 \u6307\u51fa \u75ab\u82d7 \u653f\u5e9c 50 \u5929 \u5c01\u9501 30 \u5929 \u653e\u677e \u4ea4\u66ff \u9632\u63a7 \u65b9\u6cd5 \u63a7\u5236 \u65b0\u51a0 \u75c5\u6bd2\u4f20\u64ad \u51cf\u8f7b \u533b\u7597 \u538b\u529b \u7b56\u7565 ", "\u54c8\u4f5b \u533b\u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u5efa\u7acb SARS - CoV - 2 \u611f\u67d3 \u6052\u6cb3 \u7334 \u6a21\u578b \u89c2\u5bdf \u7315\u7334 \u547c\u5438\u9053 \u4e2d \u9ad8 \u75c5\u6bd2 \u8f7d\u91cf \u4f53\u6db2 \u7ec6\u80de \u514d\u75ab \u75c5\u6bd2\u6027 \u80ba\u708e \u75c5\u7406\u5b66 \u8bc1\u636e \u7814\u7a76 \u53d1\u73b0 SARS - CoV - 2 \u611f\u67d3 \u975e\u4eba\u7c7b \u7075\u957f\u7c7b \u52a8\u7269 \u4e2d \u8bf1\u5bfc \u66b4\u9732 \u4fdd\u62a4\u6027 \u514d\u75ab \u4f5c\u7528 ", "\u4e2d\u79d1\u9662 \u6b66\u6c49 \u75c5\u6bd2 \u6240\u77f3 \u6b63\u4e3d \u56e2\u961f \u57fa\u56e0 \u86cb\u767d \u6c34\u5e73 \u9610\u660e \u8759\u8760 SARS \u6837 \u51a0\u72b6\u75c5\u6bd2 SARSr - CoV \u523a\u7a81 \u86cb\u767d S \u86cb\u767d \u81ea\u7136 \u5bbf\u4e3b \u53d7\u4f53 \u57fa\u56e0 \u4e4b\u95f4 \u519b\u5907\u7ade\u8d5b Arms   race \u534f\u540c \u8fdb\u5316 \u5173\u7cfb \u9a71\u52a8 \u8759\u8760 SARS \u6837 \u51a0\u72b6\u75c5\u6bd2 S \u57fa\u56e0 \u9057\u4f20 \u591a\u6837\u6027 SARSr - CoV \u5bf9\u4eba ACE2 \u9ad8 \u4eb2\u548c\u529b \u75c5\u6bd2 \u8de8 \u7269\u79cd \u4f20\u64ad \u53ef\u80fd\u6027 ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 ( World   Health   Organization ) \u8fd1\u65e5 \u5065\u5eb7 \u5fd7\u613f\u8005 \u76ee\u7684\u6027 \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2   ( SARS - CoV - 2 ) \u8fd9\u4e00 \u505a\u6cd5 \u4e89\u8bae \u957f\u8fdc \u52a0\u5feb \u75ab\u82d7 \u7814\u53d1 \u8fdb\u7a0b ", "\u674e\u5f66\u5b8f \u5efa\u8bae \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u671f\u95f4 \u91c7\u96c6 \u4e2a\u4eba\u4fe1\u606f \u8bbe\u7acb \u9000\u51fa \u673a\u5236 \u6536\u96c6 \u6570\u636e \u89c4\u8303\u6027 \u7ba1\u7406 \u9650\u5ea6 \u964d\u4f4e \u6570\u636e \u6cc4\u9732 \u6ee5\u7528 \u98ce\u9669 ", "\u82f1\u56fd \u81ea\u7136 \u533b\u5b66 \u6742\u5fd7 \u65e5\u524d \u53d1\u5e03 \u4e00\u9879 \u65b0 \u7814\u7a76 \u663e\u793a \u7814\u7a76 \u4eba\u5458 \u5bf9\u80a0\u7c7b \u5668\u5b98 \u75c5\u60a3 \u7caa\u4fbf \u6837\u672c \u5206\u6790 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u611f\u67d3 \u5bbf\u4e3b \u80a0 \u7ec6\u80de \u547c\u5438\u9053 \u4e4b\u5916 \u65b0\u51a0 \u75c5\u6bd2 \u4f20\u64ad \u9014\u5f84 ", "\u7f8e\u56fd \u79d1\u5b66\u5bb6 \u4e00\u9879 \u65b0 \u7814\u7a76 \u65b0\u51a0 \u75c5\u6bd2 \u5eb7\u590d\u8005 \u5065\u5eb7 \u4eba\u58eb \u643a\u5e26 \u540d\u4e3a T \u7ec6\u80de \u514d\u75ab \u7ec6\u80de \u7ec6\u80de \u4eba\u4f53 \u5bf9\u6297 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 \u6709\u52a9 \u60a3\u8005 \u5eb7\u590d \u5176\u80fd \u5927\u7a0b\u5ea6 \u53d1\u6325\u4f5c\u7528 \u672a\u77e5\u6570 ", "\u54c8\u4f5b \u516c\u5171\u536b\u751f \u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u516d\u4e2a \u4e9a\u6d32 \u56fd\u5bb6 \u5730\u533a \u75ab\u60c5 \u65e9\u671f \u9636\u6bb5 \u65b0\u51a0 \u75c5\u6bd2 \u5de5\u4f5c \u573a\u6240 \u4f20\u64ad \u75be\u75c5 \u4f20\u64ad \u4e2d \u53d1\u6325 \u4f5c\u7528 \u8fd9\u9879 \u7814\u7a76 \u5de5\u4f5c \u76f8\u5173 \u75c5\u4f8b \u53d1\u751f \u533b\u62a4\u4eba\u5458 \u804c\u4e1a ", "\u7f8e\u56fd\u666e\u6797\u65af\u987f\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u6c14\u5019 \u6d41\u884c\u75c5 \u6a21\u578b \u6a21\u62df SARS - CoV - 2 \u6d41\u884c \u5df2\u77e5 \u51a0\u72b6\u75c5\u6bd2 \u751f\u7269\u5b66 \u8c03\u67e5 \u60c5\u51b5 \u7814\u7a76 \u53d1\u73b0 \u63a7\u5236\u63aa\u65bd \u6f6e\u6e7f \u6c14\u5019 \u7206\u53d1 \u75ab\u60c5 \u590f\u5b63 \u5929\u6c14 \u6d41\u884c \u589e\u957f \u5929\u6c14 \u8fd1\u671f \u6c14\u5019 \u9884\u62a5 \u6709\u52a9\u4e8e \u9884\u6d4b \u6700\u521d \u6d41\u884c \u9636\u6bb5 \u8fc7\u540e \u7ee7\u53d1 \u66b4\u53d1 ", "\u51b7\u6cc9\u6e2f \u5b9e\u9a8c\u5ba4 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u663e\u793a \u9999\u70df \u70df\u96fe \u556e\u9f7f\u52a8\u7269 \u80ba \u4e2d \u5242\u91cf \u4f9d\u8d56\u6027 \u4e0a\u8c03 SARS - CoV - 2 \u53d7\u4f53 \u8840\u7ba1 \u7d27\u5f20 \u7d20 \u8f6c\u5316\u9176 2 ACE2 \u89e3\u91ca \u5438\u70df\u8005 \u7279\u522b SARS - CoV - 2 \u611f\u67d3 \u5f71\u54cd \u7814\u7a76 \u5de5\u4f5c ACE2 \u8bc6\u522b \u80ba \u7ec6\u80de \u4e2d \u5e72\u6270\u7d20 \u523a\u6fc0 \u57fa\u56e0 SARS - CoV - 2 \u611f\u67d3 \u6b63\u53cd\u9988 \u56de\u8def \u589e\u52a0 ACE2 \u6c34\u5e73 \u75c5\u6bd2 \u4f20\u64ad ", "\u4e0a\u6d77\u4ea4\u901a\u5927\u5b66 \u8521\u5b87 \u4f3d \u56e2\u961f \u516c\u5e03 \u4e00\u79cd \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u5019\u9009 \u75ab\u82d7 ShaCoVacc BD131 \u52a8\u7269 \u6570\u636e ShaCoVacc BD131 \u81ea\u4e3b \u7814\u53d1 mRNA \u9012\u9001 \u6838\u5fc3 \u5e73\u53f0 \u6280\u672f Virus - like   particle   ( VLP ) \u5f00\u53d1 \u8fd9\u662f \u4e00\u79cd \u75c5\u6bd2 \u6a21\u62df \u9897\u7c92 Virus   Simulating   Particles \u65b0\u578b \u6280\u672f ", "\u7f8e\u56fd \u75be\u75c5 \u63a7\u5236 \u9884\u9632 \u4e2d\u5fc3 CDC \u8ba1\u5212 \u542f\u52a8 \u4e00\u9879 \u5927\u89c4\u6a21 \u6297\u4f53 \u7814\u7a76 \u5168\u56fd \u591a\u8fbe 32.5 \u4e07\u4eba \u8840\u6db2 \u68c0\u6d4b \u8ffd\u8e2a \u65b0\u51a0 \u75c5\u6bd2 \u660e\u5e74 \u7f8e\u56fd \u4f20\u64ad ", "\u6e05\u534e\u5927\u5b66 \u673a\u6784 \u7814\u7a76 \u4eba\u5458 \u65b0 \u51fa\u9662 \u5eb7\u590d \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u75c5\u6bd2 \u7279\u5f02\u6027 \u6297\u4f53 T \u7ec6\u80de \u60a3\u8005 \u514d\u75ab \u5b8c\u5168\u76f8\u540c \u7814\u7a76 \u53d1\u73b0 \u4f53\u5185 \u4e2d \u6297\u4f53 \u6c34\u5e73 S - RBD / S - RBD \u7279\u5f02\u6027 IgG \u6297\u4f53 \u5448 \u6b63 \u76f8\u5173 S - RBD \u6709\u671b \u672a\u6765 \u65b0\u51a0 \u80ba\u708e \u75ab\u82d7 \u7814\u5236 \u9776\u6807 ", "\u82f1\u56fd\u4f26\u6566\u5927\u5b66 \u5b66\u9662 \u673a\u6784 \u7814\u7a76 \u4eba\u5458 \u5206\u6790 7500 \u591a\u540d COVID - 19 \u611f\u67d3\u8005 \u75c5\u6bd2 \u57fa\u56e0\u7ec4 SARS - CoV - 2 \u75c5\u6bd2 \u57fa\u56e0\u7ec4 \u591a\u6837\u6027 \u6a21\u5f0f \u6307\u5bfc \u53d1\u73b0 \u836f\u7269 \u75ab\u82d7 \u9776\u6807 \u63d0\u4f9b \u7ebf\u7d22 \u8fd9\u9879 \u7814\u7a76 \u8fdb\u4e00\u6b65 \u652f\u6301 \u75c5\u6bd2 2019 \u5e74\u672b \u5168\u7403 \u4f20\u64ad ", "\u7f8e\u56fd mRNA \u6280\u672f \u516c\u53f8 Moderna \u53d1\u5e03\u516c\u544a \u81ea\u4e3b \u7814\u53d1 \u65b0\u51a0 \u80ba\u708e COVID - 19 \u75ab\u82d7 mRNA - 1273   1 \u671f \u4e34\u5e8a\u8bd5\u9a8c \u4e2d \u8868\u73b0 \u5fd7\u613f\u8005 \u4f53\u5185 \u9ad8\u6ef4\u5ea6 \u6297\u4f53 \u75ab\u82d7 2 \u671f \u4e34\u5e8a \u9636\u6bb5 \u8ba1\u5212 7 \u6708 3 \u671f \u4e34\u5e8a \u9636\u6bb5 ", "\u6b66\u6c49\u5927\u5b66 \u533b\u9662 \u9ec4\u4ece \u65b0 \u6559\u6388 \u56e2\u961f \u5206\u6790 COVID - 19 \u91cd\u75c7 \u60a3\u8005 \u53d1\u751f \u5fc3\u808c \u635f\u4f24 \u53d8\u5316\u8d8b\u52bf \u4e34\u5e8a\u610f\u4e49 \u7814\u7a76 COVID - 19 \u91cd\u75c7 \u60a3\u8005 \u5fc3\u8840\u7ba1 \u5e76\u53d1\u75c7 \u53d1\u751f \u98ce\u9669 \u63d0\u4f9b \u9884\u8b66 \u6307\u6807 \u63d0\u793a \u4e34\u5e8a \u53ca\u65e9 \u8bc6\u522b \u5e72\u9884 \u76d1\u6d4b \u51cf\u5c11 \u5fc3\u808c \u635f\u4f24 \u9662\u5185 \u6b7b\u4ea1 \u98ce\u9669 \u63d0\u9ad8 \u6551\u6cbb \u6210\u529f\u7387 \u6df1\u523b\u7406\u89e3 COVID - 19 \u5fc3\u810f \u5f71\u54cd \u63d0\u4f9b \u8be6\u5b9e \u8bc1\u636e \u5168\u7403 \u75ab\u60c5 \u9632\u6cbb \u5efa\u8bbe\u6027 \u610f\u4e49 ", "\u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u540c\u6d4e \u533b\u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u5229\u7528 3 \u751f\u7269 \u6807\u5fd7\u7269 \u673a\u5668 \u5b66\u4e60 \u7b97\u6cd5 \u81f3\u5c11 \u63d0\u524d 10 \u5929 \u9884\u6d4b \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u4e2a\u4f53 \u6b7b\u4ea1\u7387 \u51c6\u786e\u7387 \u8d85\u8fc7 90% 3 \u751f\u7269 \u6807\u5fd7\u7269 \u4e73\u9178 \u8131\u6c22\u9176 \u6dcb\u5df4\u7ec6\u80de \u8d85\u654f C \u86cb\u767d \u6c34\u5e73 ", "\u9999\u6e2f\u5927\u5b66 \u674e\u5609\u8bda \u533b\u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u4ed3\u9f20 \u52a8\u7269 \u5b9e\u9a8c \u8bc1\u660e \u53d7 \u611f\u67d3 \u4ed3\u9f20 \u6838\u9178 \u68c0\u6d4b \u6301\u7eed 14 \u5929\u5185 \u5448 \u9633\u6027 \u75c5\u6bd2\u4f20\u64ad \u6709\u6548\u671f \u5c0f\u4e8e 6 \u5929 \u6838\u9178 \u68c0\u6d4b \u9633\u6027 \u4ee3\u8868 \u611f\u67d3\u8005 \u4f20\u67d3 \u529b ", "\u7f8e\u56fd \u62c9\u970d\u4e9a \u8fc7\u654f \u514d\u75ab\u5b66 \u7814\u7a76\u6240 \u7814\u7a76 \u56e2\u961f \u53d1\u73b0 \u53d7 \u611f\u67d3 \u4f53\u5185 \u542b\u6709 \u65b0\u51a0 \u75c5\u6bd2 T \u7ec6\u80de \u6709\u52a9\u4e8e \u5eb7\u590d \u611f\u67d3 \u4e2a\u4f53 \u4e2d \u68c0\u6d4b \u7ec6\u80de \u9632\u5fa1\u80fd\u529b \u662f\u56e0\u4e3a \u611f\u67d3 \u51a0\u72b6\u75c5\u6bd2 ", "\u7f8e\u56fd \u6d1b\u514b\u83f2\u52d2 \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u65b0\u51a0 \u5eb7\u590d\u8005 \u8840\u6d46 \u4e2d \u63d0\u53d6 \u9274\u5b9a \u6297\u4f53 \u53d1\u73b0 \u9ad8\u4e2d \u6d3b\u6027 \u7a00\u6709 \u53cd\u590d RBD \u7279\u5f02\u6027 \u6297\u4f53 \u63d0\u793a \u6297\u4f53 \u7814\u53d1 \u75ab\u82d7 \u5927\u4f17 ", "\u9999\u6e2f\u5927\u5b66 \u8881\u56fd\u52c7 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u8759\u8760 \u6765\u6e90 \u7c7b \u5668\u5b98 SARS - CoV - 2 \u611f\u67d3 \u654f\u611f \u5f3a\u5927 \u75c5\u6bd2 \u590d\u5236 \u80fd\u529b \u7814\u7a76 \u5efa\u7acb \u8759\u8760 \u80a0 \u4e0a\u76ae \u7b2c\u4e00\u4e2a \u6269\u5c55 \u7c7b \u5668\u5b98 \u57f9\u517b \u7cfb\u7edf \u63d0\u4f9b SARS - CoV - 2 \u611f\u67d3 \u8759\u8760 \u80a0 \u7ec6\u80de \u8bc1\u636e   \u80a0\u9053 SARS - CoV - 2 \u4f20\u64ad \u9014\u5f84 ", "\u6cd5\u56fd \u536b\u751f \u533b\u5b66 \u7814\u7a76\u6240 \u673a\u6784 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u8840\u6db2 \u5e72\u7ec6\u80de \u514d\u75ab \u8bb0\u5fc6 \u52a8\u7269 \u5b9e\u9a8c \u663e\u793a \u79fb\u690d \u7279\u5b9a \u8840\u6db2 \u5e72\u7ec6\u80de \u589e\u5f3a \u514d\u75ab \u529f\u80fd \u8fd9\u9879 \u53d1\u73b0 \u6709\u52a9\u4e8e \u63a8\u52a8 \u75ab\u82d7 \u7814\u53d1 \u5de5\u4f5c ", "\u5317\u4eac\u5927\u5b66 \u5317\u4eac \u672a\u6765 \u57fa\u56e0 \u8bca\u65ad \u9ad8\u7cbe\u5c16 \u521b\u65b0 \u4e2d\u5fc3 \u7814\u7a76 \u4eba\u5458 \u5229\u7528 \u9ad8\u901a\u91cf \u5355\u7ec6\u80de \u6d4b\u5e8f \u6280\u672f \u65b0\u51a0 \u80ba\u708e \u5eb7\u590d \u671f \u60a3\u8005 \u8840\u6d46 \u4e2d \u6210\u529f \u7b5b\u9009 \u591a\u4e2a \u9ad8\u6d3b\u6027 \u4e2d \u6297\u4f53 \u4e2d \u6297\u4f53 \u4eba\u4f53 \u514d\u75ab\u7cfb\u7edf \u963b\u6b62 \u75c5\u6bd2\u611f\u67d3 \u7ec6\u80de ", "\u4e2d\u56fd \u75ab\u82d7 \u5382\u5546 \u79d1\u5174 \u751f\u7269 \u82f1\u56fd\u725b\u6d25\u5927\u5b66 \u8a79\u7eb3 \u7814\u7a76\u6240 \u75ab\u82d7 \u7814\u53d1 \u56e2\u961f \u62ab\u9732 \u65b0\u51a0 \u75ab\u82d7 \u52a8\u7269 \u8bd5\u9a8c \u6570\u636e \u4f20\u9012 \u65b0\u51a0 \u75ab\u82d7 \u7814\u53d1 \u4fe1\u53f7 y \u82f1\u56fd \u4e13\u5bb6 \u52a8\u7269 \u8bd5\u9a8c \u6570\u636e \u8bc1\u660e \u75ab\u82d7 \u6709\u6548\u6027 ", "\u590d\u65e6\u5927\u5b66 \u57fa\u7840 \u533b\u5b66\u9662 \u5e94 \u5929\u96f7 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u4e00\u7cfb\u5217 \u6297\u65b0\u51a0 \u5168\u4eba\u6e90 \u7eb3\u7c73 \u6297\u4f53 \u9776\u5411 \u65b0\u51a0 \u75c5\u6bd2 \u53d7\u4f53 \u533a\u4e0a \u4e94\u7c7b \u8868\u4f4d \u8fd9\u9879 \u7814\u7a76 \u6709\u52a9\u4e8e \u5f00\u53d1 \u6210 \u9632\u6cbb \u836f\u7269 \u65b0\u51a0 \u80ba\u708e \u4e34\u5e8a \u6551\u6cbb ", "\u4e16\u536b \u7ec4\u7ec7 \u79d1\u5b66\u5bb6 \u63a7\u5236 \u65b0\u51a0 \u80ba\u708e \u6d41\u884c 4 5 \u5e74 \u75ab\u82d7 \u63a7\u5236 \u75ab\u60c5 \u65b9\u6cd5 \u75ab\u82d7 \u6210\u529f \u9694\u79bb \u63aa\u65bd \u6700\u7ec8 \u65b0\u51a0 \u80ba\u708e \u6d41\u884c \u6301\u7eed \u65f6\u95f4 ", "\u4ee5\u8272\u5217 \u6c99\u7c73\u5c14 \u533b\u5b66\u4e2d\u5fc3 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u7ae5\u5e74 \u9636\u6bb5 \u63a5\u79cd \u5361\u4ecb\u82d7 \u65b0\u51a0 \u4fb5\u5bb3 ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u949f\u5357\u5c71 \u56e2\u961f \u6574\u5408 \u4e34\u5e8a \u98ce\u9669 \u56e0\u7d20 \u5efa\u7acb \u65b0\u51a0 \u80ba\u708e \u5371\u91cd\u75c7 \u9884\u6d4b \u6a21\u578b \u51c6\u786e\u6027 88% \u6a21\u578b \u524d\u671f \u96f7 \u795e\u5c71 \u533b\u9662 \u6e56\u5317 \u591a\u5bb6 \u533b\u9662 \u5f00\u653e \u540c\u884c \u8ba4\u53ef \u6a21\u578b \u5efa\u7acb \u4e2d\u56fd 1590 \u4f8b\u65b0\u51a0 \u80ba\u708e \u60a3\u8005 LASSO \u56de\u5f52 72 \u4e34\u5e8a \u56e0\u7d20 \u7b5b\u9009 \u53d1\u73b0 10 \u5173\u952e \u72ec\u7acb \u98ce\u9669 \u56e0\u5b50 ", "\u4e0a\u6d77\u4ea4\u5927 \u9644\u5c5e \u745e\u91d1\u533b\u9662 \u7814\u7a76 \u56e2\u961f \u7814\u7a76 \u7f9f \u6c2f\u55b9 \u63d0\u5347 \u8f7b\u5ea6 \u4e2d\u5ea6 \u65b0\u51a0 \u4f4f\u9662 \u60a3\u8005 \u6838\u9178 \u8f6c\u9634 \u51e0\u7387 \u526f\u4f5c\u7528 \u9ad8\u4e8e \u6807\u51c6 \u6cbb\u7597 ", "\u5a01\u65af\u5eb7\u661f\u5927\u5b66 \u9ea6\u8fea\u900a \u5206\u6821 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u65b0\u51a0 \u75c5\u6bd2 \u54fa\u4e73\u7c7b \u52a8\u7269 \u5bbf\u4e3b \u72d7 \u732b \u5bc6\u5207\u76f8\u5173 \u54fa\u4e73\u52a8\u7269 \u6613\u611f ", "\u9999\u6e2f\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u9999\u6e2f \u5341\u4e94\u53ea \u72d7 \u4e2d 2 SARS - CoV - 2 \u611f\u67d3 \u8bc1\u636e \u8fd9\u662f SARS - CoV - 2 \u52a8\u7269 \u4f20\u64ad \u5b9e\u4f8b \u5c1a \u53d7 \u611f\u67d3 \u72d7 \u75c5\u6bd2\u4f20\u64ad \u52a8\u7269 \u4f20\u64ad \u4eba\u7c7b ", "\u9999\u6e2f\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u91d1\u8272 \u53d9\u5229\u4e9a \u4ed3\u9f20 \u4e2d SARS - CoV - 2 \u611f\u67d3 \u7c7b\u4f3c \u8f7b\u5ea6 \u611f\u67d3 \u4eba\u7c7b \u7279\u5f81 \u589e\u52a0 \u4e00\u79cd \u52a8\u7269\u6a21\u578b \u7814\u7a76 \u65b0\u51a0 \u75c5\u6bd2 \u53d1\u75c5 \u673a\u7406 \u81f4\u75c5 \u673a\u5236 ", "\u4e2d\u56fd \u751f\u7269 \u8463\u4e8b\u957f \u79d1\u6280\u90e8 863 \u8ba1\u5212 \u75ab\u82d7 \u9879\u76ee \u9996\u5e2d \u79d1\u5b66\u5bb6 \u6768\u6653\u660e \u505a\u597d \u6295\u4ea7 \u75ab\u82d7 \u83b7\u6279 \u751f\u4ea7 \u4e24\u5bb6 \u5355\u4f4d \u5e74\u4ea7 \u53ef\u8fbe 2 \u4ebf \u5242\u91cf ", "\u4e16\u536b \u7ec4\u7ec7 \u7d27\u6025 \u9879\u76ee \u8d1f\u8d23\u4eba \u65b0\u51a0 \u75c5\u6bd2 \u957f\u671f \u5f88\u96be \u9884\u6d4b \u6218\u80dc \u75c5\u6bd2 \u4e16\u536b \u7ec4\u7ec7 \u603b\u5e72\u4e8b \u8c2d \u5fb7\u585e \u63d0\u51fa \u5efa\u8bae \u6566\u4fc3 \u56fd\u5bb6 \u8b66\u6212 ", "\u5c71\u4e1c \u7b2c\u4e00 \u533b\u79d1\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u53bb\u5e74 \u4e91\u5357 \u52d0\u814a\u53bf \u8759\u8760 \u6837\u672c \u4e2d \u53d1\u73b0 \u4e00\u79cd \u65b0 \u51a0\u72b6\u75c5\u6bd2 \u75c5\u6bd2 \u6700\u957f \u7f16\u7801 \u57fa\u56e0 \u533a 1ab \u65b0\u51a0 \u75c5\u6bd2 SARS - CoV - 2 \u9ad8\u5ea6 \u4e00\u81f4\u6027 SARS - CoV - 2 S1 S2 \u4ea4\u754c\u5904 \u6c28\u57fa\u9178 \u63d2\u5165 \u4eba\u5de5 \u75d5\u8ff9 \u8bc1\u660e \u8d77\u6e90\u4e8e \u81ea\u7136 ", "\u610f\u5927\u5229 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u610f\u5927\u5229 \u66b4\u53d1 \u65b0\u51a0 \u75ab\u60c5 \u513f\u7ae5 \u7c7b\u4f3c \u5ddd\u5d0e \u75c5 \u75c7\u72b6 \u65b0\u51a0 \u75c5\u6bd2 \u75c7\u72b6 \u5173\u8054 \u786e\u5207 \u7ed3\u8bba \u8fd9\u9879 \u7814\u7a76 \u7814\u7a76 \u65b0\u51a0 \u75c5\u6bd2 \u513f\u7ae5 \u5f71\u54cd \u63d0\u4f9b \u8bc1\u636e ", "\u65e5\u672c NHK \u5b9e\u9a8c \u63ed\u79d8 COVID - 19 \u4f20\u64ad\u901f\u5ea6 \u5916\u8fb9 \u6d3b\u52a8 \u8c28\u614e ", "\u79d1\u7f57\u62c9\u591a \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u9690\u6027 \u7f3a\u6c27 \u5bfc\u81f4 COVID - 19 \u60a3\u8005 \u6b7b\u4ea1 \u6cbb\u7597 \u8fc7\u7a0b \u4e2d \u8c28\u614e \u65b9\u6848 ", "\u4ee5\u8272\u5217 \u96f7\u970d\u6c83\u7279 \u9b4f\u8328 \u66fc \u79d1\u5b66 \u7814\u7a76\u6240 \u7814\u7a76 \u4eba\u5458 \u5f00\u53d1 \u5206\u6790 \u5bbf\u4e3b - \u75c5\u6bd2\u611f\u67d3 \u8c31 \u8ba1\u7b97 \u6846\u67b6 \u611f\u67d3 \u7ec6\u80de \u611f\u67d3 \u75c5\u6bd2 \u8ddf\u8e2a \u6392\u5e8f \u63ed\u793a \u75c5\u6bd2 \u8bf1\u5bfc \u57fa\u56e0 \u8868\u8fbe \u53d1\u73b0 SARS - CoV - 2 \u611f\u67d3 \u4e0a\u76ae\u7ec6\u80de \u6539\u53d8 \u91cd\u75c7 \u60a3\u8005 \u514d\u75ab \u529f\u80fd \u53d1\u73b0 \u611f\u67d3 SARS - Cov - 2 hMPV \u5f71\u54cd \u5355\u6838\u7ec6\u80de \u6291\u5236 \u5e72\u6270\u7d20 ", "\u4ee5\u8272\u5217 \u751f\u7269 \u516c\u53f8 Stero CBD \u7c7b\u56fa\u9187 \u6cbb\u7597 COVID - 19 \u7814\u7a76 \u4eba\u5458 \u5e0c\u671b \u8fd9\u9879 \u7814\u7a76 \u4ee5\u8272\u5217 \u4e16\u754c\u5404\u5730 \u8d8a\u6765\u8d8a COVID - 19 \u60a3\u8005 \u66f4\u5feb \u53d7\u76ca ", "\u6df1\u5733\u5e02 \u7b2c\u4e09 \u533b\u9662 \u7814\u7a76 \u4eba\u5458 \u4ecb\u7ecd \u4e00\u79cd \u79f0\u4e3a Viral - Track \u65b0 \u8ba1\u7b97 \u5de5\u5177 \u5de5\u5177 \u65e8\u5728 \u6620\u5c04 \u7b56\u7565 \u7cfb\u7edf\u5730 \u626b\u63cf \u751f\u7406 \u75c5\u6bd2\u611f\u67d3 scRNA - seq \u6570\u636e \u4e2d \u75c5\u6bd2 RNA \u7814\u7a76 \u5206\u6790 \u663e\u793a SARS   CoV - 2 \u75c5\u6bd2 \u91cd\u75c7 \u60a3\u8005 \u514d\u75ab\u7cfb\u7edf \u5f71\u54cd \u8f7b\u75c7 \u76f8\u6bd4 \u53d1\u73b0 SARS - CoV - 2 \u611f\u67d3 \u4e0a\u76ae \u5de8\u566c\u7ec6\u80de \u4e9a\u7fa4 ", "\u7f8e\u56fd NIH \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 SARS - CoV - 2 \u611f\u67d3 \u6052\u6cb3 \u7334\u4e2d \u547c\u5438\u9053 \u75be\u75c5 \u75be\u75c5 \u6301\u7eed 8 - 16 \u5929 \u80ba\u90e8 X\u5149 \u7247 \u80ba\u90e8 \u6d78\u6da6 \u8fd9\u662f \u4eba\u7c7b \u75be\u75c5 \u6807\u5fd7 \u7814\u7a76 \u4eba\u5458 \u6307\u51fa \u6052\u6cb3 \u7334 COVID - 19 \u6a21\u578b \u5efa\u7acb \u589e\u52a0 \u75be\u75c5 \u53d1\u75c5 \u673a\u7406 \u6709\u52a9\u4e8e \u533b\u5b66 \u5bf9\u7b56 \u5f00\u53d1 \u6d4b\u8bd5 ", "\u4f26\u6566\u5927\u5b66 \u5b66\u9662 \u4e00\u9879 \u65b0 \u7814\u7a76 \u9884\u6d4b \u53d7   COVID - 19   \u6d41\u884c\u75c5 \u5f71\u54cd \u672a\u6765   12   \u6708 \u82f1\u56fd \u65b0 \u8bca\u65ad \u764c\u75c7 \u60a3\u8005 \u6b7b\u4ea1\u7387 \u81f3\u5c11 \u589e\u52a0   20% ", "\u56fd\u5916 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u4e00\u79cd \u4e2d SARS - CoV - 2 \u75c5\u6bd2 \u5355\u514b\u9686 \u6297\u4f53 \u9700 \u8fdb\u4e00\u6b65 \u63a2\u7d22 \u7814\u7a76 \u8f6c\u5316 \u4e34\u5e8a ", "\u610f\u5927\u5229 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u513f\u7ae5 \u5148\u5929 \u514d\u75ab\u7cfb\u7edf SARS - CoV - 2 \u4fdd\u62a4\u6027 \u6613\u611f\u6027 \u5dee\u5f02 \u5173\u952e \u513f\u7ae5 \u5305\u62ec SARS - CoV - 2 \u5728\u5185 \u65b0\u578b \u75c5\u539f\u4f53 \u514d\u75ab \u51e0\u4e2a \u56e0\u7d20 \u4e00\u662f \u611f\u67d3 \u65e9\u671f \u9636\u6bb5 \u5929\u7136 \u6297\u4f53 \u4f5c\u7528 \u4e8c\u662f \u513f\u7ae5 \u80fd\u529b \u6027 \u5929\u7136 \u6297\u4f53 ", "\u591a\u4f26\u591a \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u7eac\u5ea6 \u6e29\u5ea6 \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u4f20\u64ad \u5173\u8054 \u5173\u8054 \u6e7f\u5ea6 \u75ab\u60c5 \u4f20\u64ad \u5173\u8054\u6027 \u5f31 \u708e\u70ed \u5929\u6c14 \u65b0\u51a0 \u80ba\u708e \u6d41\u884c \u8fdb\u7a0b \u5f71\u54cd ", "\u7f8e\u56fd \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u7cd6\u5c3f\u75c5 \u60a3\u8005 \u4f4f\u9662 \u6b7b\u4ea1\u7387 \u4f4f\u9662 \u65f6\u95f4 \u589e\u52a0 4 \u500d COVID - 19 \u4f4f\u9662 \u7cd6\u5c3f\u75c5 \u60a3\u8005 \u8840\u7cd6 \u63a7\u5236 \u4e0d\u826f \u60a3\u8005 \u6b7b\u4ea1\u7387 \u66f4\u9ad8 ", "\u610f\u5927\u5229 \u7814\u7a76 \u4eba\u5458 \u8bc4\u4f30 SARS - CoV - 2 \u611f\u67d3 \u60a3\u8005 \u55c5\u89c9 \u5473\u89c9 \u6539\u53d8 \u60a3\u75c5\u7387 \u5f3a\u5ea6 \u65f6\u95f4 \u7814\u7a76 \u53d1\u73b0 \u8f7b\u5fae \u75c7\u72b6 SARS - CoV - 2 \u611f\u67d3 \u60a3\u8005 \u62a5\u544a \u55c5\u89c9 \u5473\u89c9 \u6539\u53d8 \u7b2c\u4e00\u4e2a \u75c7\u72b6 \u7814\u7a76 \u5c40\u9650\u6027 \u89e3\u91ca \u8c28\u614e ", "\u4e16\u536b \u7ec4\u7ec7 \u5de5\u4f5c\u4eba\u5458 \u79f0 \u7814\u7a76 \u53d1\u73b0 \u5df2\u6709 \u65b0\u51a0 \u80ba\u708e \u6297\u4f53 \u4eba\u7fa4 \u6bd4\u4f8b \u4f4e \u7814\u7a76 \u4f4d\u4e8e 1% 10% \u533a\u95f4 \u7814\u7a76 \u663e\u793a \u7ea6 14% 15% ", "\u82f1\u56fd \u7ea6\u7ff0\u900a \u653f\u5e9c \u9996\u6b21 \u5efa\u8bae \u82f1\u683c\u5170 \u6c11\u4f17 \u5916\u51fa \u7ec7\u7269 \u906e\u6321 \u53e3 \u9f3b \u7ea6\u7ff0\u900a \u96be\u4ee5 \u793e\u4ea4 \u8ddd\u79bb \u5c01\u95ed \u573a\u6240 \u7ec7\u7269 \u906e\u6321 \u53e3 \u9f3b \u51cf\u5c11 \u75be\u75c5 \u4f20\u64ad ", "\u8377\u5170 \u683c\u7f57\u5b81\u6839 \u5927\u5b66 \u533b\u5b66\u4e2d\u5fc3 \u7814\u7a76 \u4eba\u5458 \u5206\u6790 \u6570\u5343\u540d \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u4e34\u5e8a \u6570\u636e \u65b0\u51a0 \u75c5\u6bd2 \u5165\u4fb5 \u4f53\u7ec6\u80de \u53d7\u4f53 ACE2 \u7537\u6027 \u8840\u6db2 \u4e2d \u6d53\u5ea6 \u9ad8\u4e8e \u5973\u6027 \u6709\u52a9\u4e8e \u89e3\u91ca \u7537\u6027 \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 ", "\u4e0a\u6d77\u4ea4\u901a\u5927\u5b66 \u533b\u5b66\u9662 \u9644\u5c5e \u7b2c\u4e5d \u533b\u9662 \u7814\u7a76 \u4eba\u5458 \u9996\u6b21 \u63ed\u793a ACE2 \u9057\u4f20\u5b66 \u8868\u89c2 \u9057\u4f20 \u6cdb\u764c \u5206\u6790 \u56fe\u8c31 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u5165\u4fb5 \u7ec6\u80de \u53d7\u4f53 ACE2 \u591a\u79cd \u80bf\u7624 \u4e2d \u9ad8 \u8868\u8fbe \u80bf\u7624 \u4e2d ACE2 \u7a81\u53d8 \u62f7\u8d1d\u6570 \u5f02\u5e38 \u6269\u589e \u9057\u4f20\u5b66 \u5f02\u5e38 \u80bf\u7624 \u5408\u5e76 \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u63d0\u4f9b \u610f\u4e49 \u8bca\u7597 \u53c2\u8003 ", "\u667a\u5229 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u6c14\u5019 \u56e0\u7d20 \u654f\u611f \u5305\u62ec \u5f3a \u7d2b\u5916\u7ebf \u8f90\u5c04 \u589e\u957f\u7387 \u592a\u9633\u8f90\u5c04 \u5f3a\u5ea6 \u76f8\u5173\u6027 \u8f83\u5f3a \u592a\u9633\u8f90\u5c04 \u4e0d\u5229\u4e8e \u65b0\u51a0 \u75c5\u6bd2\u4f20\u64ad ", "\u897f \u5b89\u5927\u7565 \u5927\u5b66 \u673a\u6784 \u79d1\u5b66\u5bb6 \u7814\u7a76 \u5229\u7528 \u673a\u5668 \u5b66\u4e60 \u6280\u672f \u8bc6\u522b 29 COVID - 19   DNA \u5e8f\u5217 \u6f5c\u5728 \u57fa\u56e0\u7ec4 \u7279\u6027 \u65b0\u578b \u6570\u636e \u53d1\u73b0 \u5de5\u5177 \u7814\u7a76 \u4eba\u5458 \u5feb\u901f \u51e0\u5206\u949f SARS - CoV - 2 \u81f4\u6b7b \u6027 \u75c5\u6bd2 \u5206\u7c7b ", "\u7f8e\u56fd \u7ea6\u7ff0\u65af \u970d\u666e\u91d1\u65af\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u80ba\u708e \u7cbe\u795e \u5065\u5eb7 \u6f5c\u5728 \u957f\u671f \u5f71\u54cd ", "\u519b\u4e8b\u79d1\u5b66\u9662 \u519b\u4e8b\u533b\u5b66 \u7814\u7a76\u9662 \u9648\u8587 \u9662\u58eb \u56e2\u961f \u5355\u7ec6\u80de \u6280\u672f \u8868\u5f81 COVID - 19 \u4e2d \u6062\u590d 10 \u4f8b \u60a3\u8005 \u5916\u5468\u8840 \u5355\u6838\u7ec6\u80de \u8f6c\u5f55 \u53d8\u5316 \u7814\u7a76 \u63d0\u4f9b \u6062\u590d \u521d\u671f \u708e\u75c7 \u514d\u75ab \u7279\u5f81 \u7b2c\u4e00\u4e2a \u8bc1\u636e COVID - 19 \u60a3\u8005 \u51fa\u9662 \u8106\u5f31 \u7814\u7a76 \u65b0\u578b BCR \u4fe1\u53f7\u8f6c\u5bfc \u9274\u5b9a \u5bfc\u81f4 \u5f00\u53d1 \u7528\u4e8e \u6cbb\u7597 COVID - 19 \u75ab\u82d7 \u6297\u4f53 ", "\u7f8e\u56fd\u660e\u5c3c\u82cf\u8fbe\u5927\u5b66 \u674e\u653e \u6559\u6388 \u56e2\u961f \u63ed\u793a \u65b0\u51a0 \u75c5\u6bd2 \u5165\u4fb5 \u514d\u75ab \u9003\u9038 \u65b0\u673a\u5236 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 COVID - 19 \u60a3\u8005 \u5eb7\u590d \u91cd\u8981\u9014\u5f84 \u4f53\u5185 \u75c5\u6bd2 \u94a5\u5319 \u5c16\u7aef \u6297\u4f53 \u8fd9\u9879 \u7814\u7a76 \u6e05\u6670 \u65b0\u51a0 \u75c5\u6bd2 \u5f3a\u52b2 \u611f\u67d3\u529b \u514d\u75ab \u9690\u8eab \u6297\u4f53 \u836f\u7269 \u75ab\u82d7 \u7814\u53d1 ", "\u897f\u6e56 \u5927\u5b66 \u5468\u5f3a \u56e2\u961f \u5229\u7528 \u51b7\u51bb\u7535 \u955c \u89e3\u6790 \u65b0\u51a0 \u75c5\u6bd2 S \u86cb\u767d \u4e2d \u6297\u4f53 4A8 \u590d\u5408\u7269 \u7ed3\u6784 \u6297\u4f53 \u9648\u8587 \u9662\u58eb \u56e2\u961f \u65b0\u51a0 \u5eb7\u590d \u75c5\u4eba \u514d\u75ab \u7ec6\u80de \u4e2d \u7b5b\u9009 \u9274\u5b9a \u65b0\u51a0 \u75c5\u6bd2 S \u86cb\u767d N \u7aef \u7ed3\u6784\u57df \u5f3a \u75c5\u6bd2 \u4e2d \u80fd\u529b \u8fd9\u9879 \u7814\u7a76 \u9776\u5411 S \u86cb\u767d N \u7aef \u7ed3\u6784\u57df \u836f\u7269 \u8bbe\u8ba1 \u6cbb\u7597 \u7b56\u7565 \u63d0\u4f9b \u57fa\u7840 ", "\u5317\u4eac\u5927\u5b66 \u751f\u547d\u79d1\u5b66 \u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u8759\u8760 \u51a0\u72b6\u75c5\u6bd2 RaTG13 \u57fa\u56e0\u7ec4 \u603b\u4f53 \u5dee\u5f02 \u57fa\u56e0\u7ec4 \u4e2d\u6027 \u8fdb\u5316 \u4f4d\u70b9 \u5dee\u5f02 \u9ad8\u8fbe 17% \u65b0\u51a0 \u75c5\u6bd2 \u8fdb\u5316 \u8fc7\u7a0b \u4e2d \u7ecf\u5386 \u5f3a \u81ea\u7136\u9009\u62e9 \u65b0\u51a0 \u75c5\u6bd2 \u9a6c\u6765 \u7a7f\u5c71\u7532 \u51a0\u72b6\u75c5\u6bd2 \u6838\u82f7\u9178 \u63a8\u6d4b \u65b0\u51a0 \u75c5\u6bd2 \u5206\u6b67 \u4e8b\u4ef6 \u8fd1\u671f \u53d1\u751f \u65b0\u51a0 \u75c5\u6bd2 \u8d77\u6e90 ", "\u5317\u4eac\u534f\u548c\u533b\u9662 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u60a3\u6709 \u80bf\u7624 \u6dcb\u5df4 \u9020\u8840 \u7cfb\u7edf \u6076\u6027\u80bf\u7624 LHM \u60a3\u8005 COVID - 19 \u9884\u540e \u8f83\u5dee \u6297\u80bf\u7624 \u6cbb\u7597 \u6b7b\u4ea1\u7387 \u6570\u636e \u89d2\u5ea6 \u51fa\u53d1 \u65b0\u51a0 \u80ba\u708e \u6d41\u884c \u671f\u95f4 \u66f4\u5e94 \u8c28\u614e \u975e \u7d27\u6025 \u6297\u80bf\u7624 \u6cbb\u7597 ", "\u65e5\u672c\u7b51\u6ce2\u5927\u5b66 \u533b\u5b66 \u7814\u7a76 \u4eba\u5458 \u53d1\u5e03 \u62a5\u544a \u79f0 \u53bb\u5e74 8 \u6708 \u60a3\u75c5 \u60a3\u8005 \u8840\u6e05 \u4e2d \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u6297\u4f53 \u79f0\u65b0\u51a0 \u75c5\u6bd2 2019 \u5e74 8 \u6708 \u65e5\u672c \u53bb\u5e74 \u79cb\u5929 \u65e5\u672c \u8513\u5ef6 ", "\u533b\u5b66\u671f\u520a \u67f3\u53f6\u5200 \u53d1\u5e03 \u4e00\u9879 \u6700\u65b0 \u4e34\u5e8a\u8bd5\u9a8c \u7ed3\u679c\u663e\u793a \u65e9\u671f \u6d1b\u5339 \u97e6 / \u5229\u6258 \u97e6 + \u5229\u5df4\u97e6 \u6797 + \u5e72\u6270\u7d20 \u03b2 - 1b \u4e09\u8054 \u7597\u6cd5 \u52a0\u5feb \u8f7b\u4e2d\u75c7 \u65b0\u51a0 \u60a3\u8005 \u75c5\u6bd2 \u6838\u9178 \u68c0\u6d4b \u8f6c\u9634 \u75c7\u72b6 \u6539\u5584 \u7f29\u77ed \u60a3\u8005 \u4f4f\u9662 \u65f6\u95f4 ", "\u4e16\u536b \u7ec4\u7ec7 \u536b\u751f \u7d27\u6025 \u9879\u76ee \u8d1f\u8d23\u4eba \u65b0\u51a0 \u75c5\u6bd2 \u547c\u5438\u7cfb\u7edf \u4f20\u64ad \u60a3\u8005 \u708e\u75c7 \u5fc3\u8840\u7ba1 \u8eab\u4f53 \u90e8\u4f4d \u75c5\u4f8b \u8111\u708e \u80bf\u80c0 \u8111\u90e8 \u708e\u75c7 \u8fdb\u4e00\u6b65 \u7814\u7a76 ", "\u4e2d\u56fd \u75be\u63a7\u4e2d\u5fc3 \u4e3b\u4efb \u9ad8\u798f \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 B38 H4 \u6297\u4f53 \u963b\u6b62 \u65b0\u51a0 \u75c5\u6bd2 S \u86cb\u767d \u53d7\u4f53 \u533a\u57df RBD \u4f53\u7ec6\u80de \u53d7\u4f53 ACE2 \u4e4b\u95f4 \u4e24\u79cd \u6297\u4f53 \u964d\u4f4e \u5c0f\u9f20 \u611f\u67d3 \u80ba\u90e8 \u75c5\u6bd2 \u8f7d\u91cf \u7814\u7a76 \u75ab\u82d7 \u8bbe\u8ba1 \u63d0\u4f9b \u7ed3\u6784 \u57fa\u7840 ", "\u9999\u6e2f\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u5305\u62ec \u6297 \u827e\u6ecb\u75c5 \u75c5\u6bd2 \u836f\u7269 \u6d1b\u5339 \u97e6\u548c\u5229\u6258 \u97e6 \u5728\u5185 \u4e09\u79cd \u836f\u7269 \u8054\u7528 \u6807\u51c6 \u62a4\u7406 \u914d\u5408 2 \u671f \u4e34\u5e8a\u8bd5\u9a8c \u4e2d \u8f7b\u81f3 \u4e2d\u5ea6 \u75c7\u72b6 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3\u8005 \u5c55\u73b0\u51fa \u6cbb\u7597 \u6548\u679c \u7814\u7a76 \u4eba\u5458 \u9700 \u8fdb\u4e00\u6b65 \u8bd5\u9a8c \u9a8c\u8bc1 \u7597\u6548 ", "\u9999\u6e2f\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u773c\u775b \u4eba\u7c7b \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u91cd\u8981\u9014\u5f84 \u65b0\u51a0 \u75c5\u6bd2 SARS \u75c5\u6bd2 \u6613 \u611f\u67d3 \u4eba\u7c7b \u547c\u5438\u9053 \u773c\u7ed3\u819c \u89e3\u91ca \u65b0\u51a0 \u80ba\u708e SARS \u4eba\u7fa4 \u4e2d \u4f20\u64ad \u529b\u5ea6 \u66f4\u5f3a ", "\u7f8e\u56fd \u98df\u54c1 \u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40 FDA \u7d27\u6025 \u6388\u6743 CRISPR / Cas \u57fa\u56e0\u4fee\u9970 \u6280\u672f \u539f\u7406 \u65b0\u51a0 \u75c5\u6bd2\u68c0\u6d4b \u8bd5\u5242\u76d2 \u8bd5\u5242\u76d2 \u5c0f\u65f6 \u51c6\u786e\u7387 100% \u7f8e\u56fd FDA \u6388\u6743 \u9996\u6b3e \u7c7b\u578b \u8bd5\u5242\u76d2 ", "\u7f8e\u56fd\u6d1b\u65af\u963f\u62c9\u83ab\u65af\u56fd\u5bb6\u5b9e\u9a8c\u5ba4 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 S \u86cb\u767d \u523a\u7a81 \u7cd6\u86cb\u767d \u4e2d 13 \u79ef\u7d2f \u7a81\u53d8 \u4e00\u79cd \u7a81\u53d8 \u75c5\u6bd2 \u682a \u6b63 \u5360\u636e \u4e3b\u5bfc \u4f18\u52bf \u7814\u7a76 \u56e2\u961f \u8bc1\u5b9e \u6bd2\u682a \u4e4b\u95f4 \u53d1\u751f \u91cd\u7ec4 \u63d0\u793a \u591a\u91cd \u6bd2\u682a \u611f\u67d3 \u53d1\u73b0 SARS - CoV - 2 \u4f20\u64ad \u53d1\u75c5 \u673a\u5236 \u514d\u75ab \u5e72\u9884 \u610f\u4e49 ", "\u534e\u5357\u519c\u4e1a\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u9a6c\u6765\u4e9a \u7a7f\u5c71\u7532 \u4e2d \u5206\u79bb \u4e00\u79cd \u51a0\u72b6\u75c5\u6bd2 E M N S \u57fa\u56e0 \u4e2d SARS - CoV - 2 100 98.6 97.8 90.7 \u6c28\u57fa\u9178 \u540c\u4e00\u6027 SARS - CoV - 2 \u6e90\u81ea \u7a7f\u5c71\u7532 - CoV - \u6837 \u75c5\u6bd2 \u8759\u8760 - CoV - RaTG13 - \u6837 \u75c5\u6bd2 \u91cd\u7ec4 ", "\u745e\u5fb7 \u897f\u97e6 \u65e5\u672c \u56fd\u5bb6 \u5c1a\u672a \u8bb8\u53ef \u6279\u51c6 \u4e34\u5e8a\u8bd5\u9a8c \u8bc4\u4f30 \u5b89\u5168\u6027 \u6709\u6548\u6027 ", "\u4e2d\u56fd \u7814\u7a76 \u4eba\u5458 \u611f\u67d3\u8005 \u7cbe\u6db2 \u4e2d \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u589e\u52a0 \u75c5\u6bd2 \u6027\u884c\u4e3a \u4f20\u64ad \u53ef\u80fd\u6027 \u611f\u67d3\u8005 \u7cbe\u6db2 \u4e2d \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u589e\u52a0 \u75c5\u6bd2 \u6027\u884c\u4e3a \u4f20\u64ad \u53ef\u80fd\u6027 ", "\u82f1\u56fd \u5357\u5b89\u666e\u987f \u5927\u5b66 \u533b\u5b66\u7cfb \u7814\u7a76 \u4eba\u5458 \u7814\u5236 \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u65b0\u578b \u836f\u7269 SNG001 \u5357\u5b89\u666e\u987f \u5927\u5b66 \u533b\u9662 \u547c\u5438\u79d1 \u4e34\u5e8a\u8bd5\u9a8c \u7814\u7a76 \u4eba\u5458 \u9884\u8ba1 \u4e34\u5e8a\u8bd5\u9a8c 6 \u6708\u5e95 \u540e\u671f \u8fdb\u5c55 \u987a\u5229 \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u836f\u7269 \u5c06\u4f1a \u4e0b\u534a\u5e74 \u6279\u91cf\u751f\u4ea7 ", "\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662 \u533b\u5b66 \u5b9e\u9a8c \u52a8\u7269 \u7814\u7a76\u6240 \u79e6\u5ddd \u56e2\u961f \u8bd5\u9a8c \u89c4\u6a21 \u751f\u4ea7 \u4e00\u79cd \u7eaf\u5316 \u706d\u6d3b SARS - CoV - 2 \u75c5\u6bd2 \u5019\u9009 \u75ab\u82d7 PiCoVacc PiCoVacc \u975e\u4eba\u7c7b \u7075\u957f\u7c7b \u52a8\u7269 \u4e2d \u5f15\u53d1 \u4f53\u6db2 \u514d\u75ab \u5e94\u7b54 \u5168\u7403 \u8086\u8650 SARS - CoV - 2 \u75c5\u6bd2 \u682a \u63d0\u4f9b \u4fdd\u62a4 \u6052\u6cb3 \u7334 \u4e34\u5e8a \u4f53\u5f81 \u8840\u6db2\u5b66 \u751f\u5316 \u6307\u6807 \u7cfb\u7edf\u5206\u6790 \u7814\u7a76 \u4eba\u5458 \u75ab\u82d7 ", "\u4f26\u6566\u5927\u5b66 \u5b66\u9662 \u79d1\u5b66\u5bb6 \u5206\u6790 \u5168\u7403 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3\u8005 \u8d85\u8fc7 7500 \u75c5\u6bd2 \u57fa\u56e0\u7ec4 \u6570\u636e \u65b0\u51a0 \u75c5\u6bd2 \u9057\u4f20 \u591a\u6837\u6027 \u5206\u6790 \u663e\u793a \u75c5\u6bd2 2019 \u5e74 \u5e74\u5e95 \u5168\u7403 \u5e7f\u6cdb\u4f20\u64ad ", "\u738b\u8fb0 \u66f9\u5f6c NEJM \u53d1\u6587 \u5c1a\u65e0 \u6279\u51c6 \u7528\u4e8e Covid - 19 \u6cbb\u7597 \u65b9\u6cd5 SARS - CoV - 2 \u5168\u7403 \u4f20\u64ad \u5bfc\u81f4 \u836f\u7269 \u77ed\u7f3a \u653e\u5f03 \u6d1b\u5339 \u97e6 - \u5229\u6258 \u97e6 Covid - 19 \u6cbb\u7597 \u6307\u5357 \u6682\u65f6 \u4fdd\u7559 \u6d1b\u5339 \u97e6 - \u5229\u6258 \u97e6 \u7b49\u5f85 \u4e16\u754c\u536b\u751f\u7ec4\u7ec7 SOLIDARITY \u8bd5\u9a8c ", "\u82f1\u56fd \u73ed\u6208 \u5927\u5b66 \u7814\u7a76 \u56e2\u961f \u5229\u7528 \u751f\u6d3b \u6c61\u6c34 \u4e2d \u65b0\u51a0 \u75c5\u6bd2 \u542b\u91cf \u7814\u7a76 \u75ab\u60c5 \u53d1\u5c55 \u60c5\u51b5 \u7814\u7a76 \u4eba\u5458 \u79f0 \u7814\u7a76 \u6c61\u6c34 \u79d1\u5b66\u5bb6 \u63d0\u524d \u81f3\u5c11 \u4e24\u5468 \u9884\u6d4b \u75ab\u60c5 \u6ce2 \u66b4\u53d1 \u9ad8\u5cf0 \u60a3\u8005 \u75c7\u72b6 \u524d \u6700\u65e9 \u4e24\u5468 \u65f6\u95f4 \u60a3\u8005 \u7caa\u4fbf \u4e2d \u75c5\u6bd2 ", "\u7f8e\u56fd\u5eb7\u5948\u5c14\u5927\u5b66 \u751f\u7269\u5b66\u5bb6 \u65b0\u51a0 \u75c5\u6bd2 \u86cb\u767d \u4e2d \u53d1\u73b0 \u4e00\u79cd 4 \u6c28\u57fa\u9178 \u5e8f\u5217 \u7ed3\u6784 \u73af \u7ed3\u6784 \u73af \u5e38\u89c1\u4e8e \u4eba\u7c7b \u51a0\u72b6\u75c5\u6bd2 \u75c5\u6bd2 \u7262\u56fa\u5730 \u9644\u7740 \u7ec6\u80de \u8868\u9762 \u75c5\u6bd2 \u6613 \u4fb5\u5165 \u7ec6\u80de \u8fd9\u9879 \u7814\u7a76 \u65b0\u51a0 \u80ba\u708e \u75c5\u6bd2 \u4f20\u64ad \u80fd\u529b \u7a33\u5b9a\u6027 ", "\u610f\u5927\u5229 \u836f\u7406\u5b66 \u5b89\u5a1c \u4e3d\u838e \u57fa\u4e4c\u7d22\u6d1b \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u81f4\u75c5 \u673a\u5236 \u65b0\u51a0 \u75c5\u6bd2 \u7834\u574f \u8840\u7ea2\u86cb\u767d \u8840\u7ea2\u86cb\u767d \u8840\u6db2 \u4e2d \u7528\u4e8e \u8fd0\u8f93 \u6c27\u6c14 \u86cb\u767d\u8d28 ", "\u82f1\u56fd \u5357\u5b89\u666e\u6566 \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u4f4d\u70b9 \u7279\u5f02\u6027 \u8d28\u8c31 \u65b9\u6cd5 \u63ed\u793a \u91cd\u7ec4 SARS - CoV - 2   S \u86cb\u767d \u514d\u75ab\u539f \u805a\u7cd6 \u7ed3\u6784 \u5206\u6790 \u7ed8\u5236 \u8de8 \u4e09\u805a\u4f53 \u75c5\u6bd2 \u523a\u7a81 \u86cb\u767d \u805a\u7cd6 \u52a0\u5de5 \u72b6\u6001 \u56fe\u8c31 \u836f\u7269 \u5f00\u53d1 \u75ab\u82d7 \u8bbe\u8ba1 \u63a8\u52a8 \u4f5c\u7528 ", "\u6e05\u534e\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u75c5\u6bd2 \u51fa\u9662 COVID - 19 \u60a3\u8005 \u4e2d \u6536\u96c6 \u8840\u6db2 8 \u4f4d\u65b0 \u51fa\u9662 \u60a3\u8005 \u4e2d \u68c0\u6d4b SARS - CoV - 2 \u7279\u5f02\u6027 \u4f53\u6db2 \u7ec6\u80de \u514d\u75ab \u51fa\u9662 2 \u5468\u5bf9 \u53e6\u4e00\u7ec4 6 \u540d \u60a3\u8005 \u968f\u8bbf \u5206\u6790 \u663e\u793a \u51fa\u9ad8\u6ef4\u5ea6 IgG \u6297\u4f53 \u7814\u7a76 \u5de5\u4f5c \u8fdb\u4e00\u6b65 \u5206\u6790 SARS - CoV - 2 \u4fdd\u62a4\u6027 \u514d\u75ab COVID - 19 \u53d1\u75c5 \u673a\u7406 \u75c5\u4f8b \u4e2d \u63d0\u4f9b \u57fa\u7840 ", "\u590d\u65e6\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u5229\u7528 \u6d41\u884c\u75c5\u5b66 \u533f\u540d \u4eba\u7c7b \u8fd0\u52a8 \u6570\u636e \u7814\u7a76 \u5efa\u7acb \u5efa\u6a21 \u6846\u67b6 \u6a21\u578b \u65e5\u5e38 \u65c5\u884c \u7f51\u7edc \u6a21\u62df \u4e2d\u56fd \u7206\u53d1 \u5e72\u9884 \u60c5\u666f \u7814\u7a76 \u7ed3\u679c\u8868\u660e \u4e2d\u56fd \u5f3a\u6709\u529b \u7efc\u5408\u6027 \u975e \u836f\u7269\u6027 \u5e72\u9884 \u63aa\u65bd \u5168\u56fd \u5730\u533a \u9632\u63a7 \u6548\u679c \u963b\u65ad \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u4f20\u64ad \u904f\u5236 \u75ab\u60c5 \u8fdb\u4e00\u6b65 \u6269\u6563 \u5168\u7403 \u65b0\u51a0 \u75c5\u6bd2 \u9632\u63a7 \u5b9d\u8d35 \u65f6\u95f4 ", "\u7f8e\u56fd\u6d1b\u65af\u963f\u62c9\u83ab\u65af\u56fd\u5bb6\u5b9e\u9a8c\u5ba4 \u79d1\u5b66\u5bb6 \u53d1\u8868 \u6700\u65b0 \u7814\u7a76 \u62a5\u544a \u62a5\u544a \u6307\u51fa \u53d1\u73b0 \u4e00\u79cd \u65b0 \u65b0\u51a0 \u75c5\u6bd2 \u6bd2\u682a \u6bd4\u65b0\u51a0 \u75c5\u6bd2 \u6d41\u884c \u521d\u671f \u4f20\u64ad \u6bd2\u682a \u66f4\u5177 \u4f20\u67d3\u6027 ", "\u7f8e\u56fd \u5236\u836f \u5de8\u5934 \u8f89\u745e \u751f\u4ea7 \u65b0\u51a0 \u75c5\u6bd2 \u75ab\u82d7 5 \u6708 4 \u65e5\u8d77 \u7f8e\u56fd \u4eba\u4f53 \u6d4b\u8bd5 \u6d4b\u8bd5 \u5065\u5eb7 \u5fd7\u613f\u8005 \u8eab\u4e0a \u8bd5\u9a8c \u6210\u529f \u75ab\u82d7 \u6700\u65e9 9 \u6708 \u505a\u597d \u7f8e\u56fd \u7d27\u6025 ", "\u6cd5\u56fd \u7814\u7a76 \u4eba\u5458 \u68c0\u6d4b 14 2019 \u5e74 12 \u6708 2 \u65e5\u5230 2020 \u5e74 1 \u6708 16 \u65e5 \u671f\u95f4 \u56e0\u7c7b \u6d41\u611f \u75be\u75c5 \u91cd\u75c7 \u76d1\u62a4 \u75c5\u4eba \u4fdd\u5b58 \u9f3b\u54bd \u62ed \u5b50\u6837\u672c \u53d1\u73b0 \u4e00\u4eba \u65b0\u51a0 \u75c5\u6bd2 \u9633\u6027 \u60a3\u8005 \u5e76\u672a \u4e2d\u56fd ", "\u519b\u4e8b\u533b\u5b66\u79d1\u5b66\u9662 \u751f\u7269\u5de5\u7a0b \u7814\u7a76\u6240 \u9648\u8587 \u9662\u58eb \u56e2\u961f \u9996\u6b21 \u63cf\u8ff0 COVID - 19 \u60a3\u8005 \u65e9\u671f \u6062\u590d \u9636\u6bb5 ( ERS ) \u708e\u75c7 \u514d\u75ab \u7279\u5f81 \u7814\u7a76 \u8bc1\u636e COVID - 19 \u60a3\u8005 \u51fa\u9662 \u8106\u5f31 \u7814\u7a76 \u4eba\u5458 \u9274\u5b9a \u65b0 B \u7ec6\u80de \u53d7\u4f53 ( BCR ) \u6709\u52a9\u4e8e COVID - 19 \u75ab\u82d7 \u6297\u4f53 \u5f00\u53d1 ", "\u52a0\u62ff\u5927 \u82f1 \u5c5e \u54e5\u4f26\u6bd4\u4e9a\u5927\u5b66 \u52a8\u7269\u5b66 \u7cfb \u751f\u7269 \u591a\u6837\u6027 \u7814\u7a76 \u4e2d\u5fc3 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 2019 \u5e74\u5e95 \u9996\u6b21 \u68c0\u6d4b SARS - CoV - 2 \u6709\u5229\u4e8e \u4eba\u7c7b \u4e2d \u4f20\u64ad \u9002\u5e94\u6027 \u53d8\u5316 \u7a0b\u5ea6 \u7c7b\u4f3c \u665a\u671f \u6d41\u884c SARS - CoV ", "\u6b66\u6c49\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 COVID - 19 \u60a3\u8005 \u5929\u51ac\u6c28\u9178 \u8f6c\u6c28\u9176 AST \u5f02\u5e38 \u6b7b\u4ea1 \u98ce\u9669 \u76f8\u5173 \u809d \u635f\u4f24 \u6307\u6807 \u5347\u9ad8 \u76f8\u5173 \u5e38\u89c1 \u56e0\u7d20 \u6dcb\u5df4\u7ec6\u80de \u8ba1\u6570 \u51cf\u5c11 \u4e2d\u6027 \u7c92\u7ec6\u80de \u8ba1\u6570 \u589e\u52a0 \u6027\u522b \u7537\u6027 \u7814\u7a76 \u4eba\u5458 \u809d \u635f\u4f24 \u6307\u6807 \u52a8\u6001 \u6a21\u5f0f \u6f5c\u5728 \u5371\u9669 \u56e0\u7d20 COVID - 19 \u76f8\u5173 \u809d \u635f\u4f24 \u63d0\u4f9b \u89e3\u91ca ", "\u4f26\u6566\u5927\u5b66 \u5b66\u9662 \u57fa\u56e0 \u7814\u7a76\u6240 \u7814\u7a76 \u4eba\u5458 \u5168\u7403 7600 \u591a\u540d \u65b0\u51a0 \u60a3\u8005 \u57fa\u56e0 \u5206\u6790 \u7ed3\u679c\u663e\u793a \u65b0\u51a0 \u75c5\u6bd2 \u53bb\u5e74 10 \u6708 11 \u6708 \u9996\u6b21 \u611f\u67d3 \u4eba\u7c7b \u6781\u5feb \u901f\u5ea6 \u5168\u7403 \u4eba\u53e3 \u4e2d \u4f20\u64ad ", "\u745e\u58eb \u5fb7\u56fd \u4fc4\u7f57\u65af \u591a\u5bb6 \u79d1\u7814\u673a\u6784 \u7814\u7a76 \u4eba\u5458 \u5df2\u77e5 \u65b0\u51a0 \u75c5\u6bd2\u57fa\u56e0 \u5e8f\u5217 \u57fa\u7840 \u9996\u6b21 \u8bd5\u9a8c \u4e2d \u53cd\u5411 \u9057\u4f20\u5b66 \u624b\u6bb5 \u9175\u6bcd\u83cc \u4e2d \u5feb\u901f \u6784\u5efa \u65b0\u51a0 \u75c5\u6bd2 \u8fd9\u9879 \u7814\u7a76 \u6539\u53d8 \u75c5\u6bd2 \u53d1\u75c5 \u673a\u5236 \u75ab\u82d7 \u5f00\u53d1 ", "\u4ee5\u8272\u5217 \u751f\u7269 \u7814\u7a76\u6240 \u65b0\u51a0 \u75c5\u6bd2 \u6297\u4f53 \u7814\u5236 \u8fdb\u5c55 \u7814\u7a76\u6240 \u7814\u5236 \u6297\u4f53 \u5c5e \u5355\u7ec6\u80de \u6297\u4f53 \u65b0\u51a0 \u75c5\u6bd2 \u7814\u7a76\u6240 \u4e13\u5229 \u6ce8\u518c \u5de5\u4f5c \u4e00\u6b65 \u56fd\u9645 \u533b\u836f\u516c\u53f8 \u5408\u4f5c \u6297\u4f53 \u5546\u4e1a\u5316 \u751f\u4ea7 ", "\u91d1\u51ac\u96c1 \u79d1\u5b66 \u516c\u76ca \u7ec4\u7ec7 \u672a\u6765 \u8bba\u575b \u53d1\u8d77 \u7b2c\u4e94\u671f \u7406\u89e3 \u672a\u6765 \u79d1\u5b66 \u8bb2\u5ea7 \u75c5\u6bd2 \u4eba\u7c7b \u5065\u5eb7 - \u4e13\u9898 \u79d1\u666e \u5206\u4eab \u4eba\u7c7b \u51a0\u72b6\u75c5\u6bd2 \u524d\u4e16 \u4eca\u751f \u524d 6 \u4eba\u7c7b \u51a0\u72b6\u75c5\u6bd2 HIV \u7814\u7a76 \u5e26\u6765 \u6297\u51fb \u65b0\u51a0 \u601d\u8def ", "\u4e2d\u65e5\u53cb\u597d\u533b\u9662 \u66f9\u5f6c \u6559\u6388 \u56e2\u961f \u6307\u51fa \u745e\u5fb7 \u897f\u97e6 \u540c\u60c5 \u7528\u836f \u7814\u7a76 \u6587\u7ae0 \u6570\u636e \u745e\u5fb7 \u897f\u97e6 \u5efa\u7acb \u9700 \u614e\u91cd \u745e\u5fb7 \u897f\u97e6 \u6cbb\u7597 \u91cd\u75c7 \u60a3\u8005 \u8bc4\u4f30 \u7597\u6548 \u7b49\u5f85 \u968f\u673a \u5b89\u6170\u5242 \u5bf9\u7167 \u4e34\u5e8a\u8bd5\u9a8c ( RCT ) ", "\u4e2d\u56fd\u79d1\u5b66\u9662 \u9662\u58eb \u738b\u798f\u751f \u91c7\u7528 \u5e72\u7ec6\u80de \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u4e34\u5e8a \u7814\u7a76 \u5c55\u5f00 \u5e94\u6025 \u653b\u5173 \u521d\u6b65 \u7814\u7a76\u6210\u679c ", "\u519b\u4e8b\u79d1\u5b66\u9662 \u519b\u4e8b\u533b\u5b66 \u7814\u7a76\u9662 \u751f\u7269\u5de5\u7a0b \u7814\u7a76\u6240 \u9648\u8587 \u9662\u58eb \u56e2\u961f \u7814\u53d1 \u817a\u75c5\u6bd2 \u8f7d\u4f53 \u91cd\u7ec4 \u65b0\u51a0 \u75c5\u6bd2 \u75ab\u82d7 12 \u65e5 \u4e8c\u671f \u4e34\u5e8a\u8bd5\u9a8c ", "\u4e2d\u5c71\u5927\u5b66 \u516c\u5171\u536b\u751f \u5b66\u9662 \u738b\u8302 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u6e29\u5ea6 \u75c5\u6bd2\u4f20\u64ad \u4f4e\u6e29 \u73af\u5883 \u5e73\u5747\u6e29\u5ea6 1 \u65e5 \u786e\u8bca \u4eba\u6570 \u589e\u52a0 0.83 \u5e73\u5747\u6c14\u6e29 8.72 \u65f6 \u65e5 \u7d2f\u8ba1 \u786e\u8bca \u4eba\u6570 \u5cf0\u503c \u65e5 \u786e\u8bca \u4eba\u6570 \u6c14\u6e29 \u8fdb\u4e00\u6b65 \u51cf\u5c11 ", "\u4e2d\u534e \u4e2d\u533b\u836f\u5b66\u4f1a \u4e2d\u592e \u5e7f\u64ad\u7535\u89c6 \u603b\u53f0 \u4e2d\u56fd \u56fd\u9645 \u7535\u89c6\u53f0 CGTN \u4e3b\u529e \u5168\u7403 \u75ab\u60c5 \u8bca\u5ba4 \u4e2d\u533b \u4e13\u9898 \u8282\u76ee \u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u9ec4\u7490\u7426 \u5206\u4eab \u4e2d\u533b\u836f \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u7ecf\u9a8c ", "\u8ba4\u53ef \u65b0\u51a0 \u75c5\u6bd2 \u6765\u6e90\u4e8e \u8759\u8760 \u4e2d\u79d1\u9662 \u6b66\u6c49 \u75c5\u6bd2 \u6240\u77f3 \u6b63\u4e3d \u7814\u7a76\u5458 \u56e2\u961f 2013 \u5e74 \u4e2d\u56fd \u4e91\u5357 \u91c7\u96c6 RaTG13 \u6837\u672c \u76f8\u4f3c\u6027 96.2% \u6700\u65b0 \u7814\u7a76 \u63a8\u6d4b \u72d7 \u65b0\u51a0 \u4f20\u67d3\u7ed9 \u4eba\u7c7b \u5bbf\u4e3b \u75c5\u6bd2 \u72d7 \u80a0\u9053 \u4e2d \u8fdb\u5316 \u611f\u67d3 \u80fd\u529b ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u4e54\u6770 \u56de\u987e\u6027 \u5206\u6790 \u6b66\u6c49 \u5730\u533a 50 \u5bb6 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u80ba\u708e \u8bca\u6cbb \u5b9a\u70b9\u533b\u9662 \u5b55\u4ea7\u5987 \u6d41\u884c\u75c5\u5b66 \u4e34\u5e8a \u7279\u5f81 \u5b9e\u9a8c\u5ba4 \u5f71\u50cf\u5b66 \u6cbb\u7597 \u9884\u540e \u6570\u636e \u7814\u7a76 \u56e2\u961f \u5b55\u4ea7\u5987 \u611f\u67d3 SARS - CoV - 2 \u53d1\u5c55 \u91cd\u75c7 \u98ce\u9669 \u9ad8\u4e8e \u4eba\u7fa4 \u5b55\u4ea7\u5987 \u611f\u67d3 \u6d41\u884c\u6027 \u611f\u5192 \u75c5\u6bd2 \u4e34\u5e8a \u7c7b\u4f3c ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u9ec4\u7490\u7426 \u7387\u9886 \u7b2c\u4e00\u652f \u56fd\u5bb6 \u4e2d\u533b \u533b\u7597\u961f \u8d76\u8d74 \u75ab\u60c5 \u6b66\u6c49 \u6574 \u5efa\u5236 \u63a5\u7ba1 \u6b66\u6c49 \u91d1\u94f6 \u6f6d \u533b\u9662 \u72ec\u7acb \u75c5\u533a 3 \u6708 30 \u65e5 \u533b\u7597\u961f \u56de\u4eac \u6536\u6cbb 150 \u591a\u540d \u60a3\u8005 \u6cbb\u6108 \u51fa\u9662 \u7387 88.61% \u533b\u62a4\u4eba\u5458 \u65e0\u4e00\u4eba \u611f\u67d3 ", "\u52a0\u62ff\u5927 \u5b98\u65b9 \u53cd\u5bf9\u515a \u4fdd\u5b88\u515a \u8bae\u5458 \u516c\u5171\u536b\u751f \u8bc4\u8bba\u5458 \u6770\u7eb3\u9c81 Matt   Jeneroux \u65e5\u524d \u63d0\u51fa \u52a8\u8bae \u4e16\u536b \u7ec4\u7ec7 \u52a9\u7406 \u603b\u5e72\u4e8b \u52a0\u62ff\u5927 \u6d41\u884c\u75c5\u5b66 \u5bb6 \u5e03\u9c81\u65af . \u827e\u5c14\u6c83\u5fb7 Bruce   Aylward \u63a5\u53d7 \u52a0\u62ff\u5927 \u8bae\u4f1a \u8d28\u8be2 ", "\u66f9\u5f6c \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u91cd\u75c7 \u65b0\u51a0 \u60a3\u8005 \u4e34\u5e8a\u8868\u73b0 \u7b26\u5408 \u8113\u6bd2\u75c7 \u8113\u6bd2\u75c7 \u4f11\u514b \u8bca\u65ad \u6807\u51c6 \u4e8c\u8005 \u81f4\u75c5 \u673a\u7406 \u76f8\u4f3c\u4e4b\u5904 \u75c5\u6bd2\u6027 \u8113\u6bd2\u75c7 \u65b0\u51a0 \u80ba\u708e \u5173\u952e \u81f4\u75c5 \u673a\u5236 \u5047\u8bf4 \u5c1a \u5b8c\u5584 ", "\u4e2d\u56fd\u79d1\u5b66\u9662 \u9662\u58eb \u738b\u798f\u751f \u56e2\u961f \u8bc4\u8bba \u6587\u7ae0 COVID - 19 \u76f8\u5173 \u809d \u635f\u4f24 \u8bca\u6cbb \u6311\u6218 \u6307\u51fa \u65b0\u51a0 \u80ba\u708e \u8f7b\u75c7 \u91cd\u75c7 \u60a3\u8005 \u4e2d \u6bd4\u4f8b \u809d\u810f \u529f\u80fd \u5f02\u5e38\u60c5\u51b5 ", "\u674e\u5170\u5a1f \u9662\u58eb \u91cd\u75c7 \u6551\u6cbb \u56db\u6297 \u5e73\u8861 \u65b9\u6848 \u4eba\u5de5 \u809d \u5fae \u751f\u6001 \u5e72\u7ec6\u80de \u65b0 \u6280\u672f \u8d77\u5230 \u6548\u679c ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u738b\u8fb0 \u8be6\u7ec6 \u4ecb\u7ecd \u6b66\u6c49 16 \u5bb6 \u65b9\u8231 \u533b\u9662 \u9632\u63a7 \u65b0\u51a0\u4e2d \u53d1\u6325 \u4f5c\u7528 ", "\u949f\u5357\u5c71 \u56e2\u961f \u6210\u5458 \u5468\u8363 \u6559\u6388 \u63d0\u51fa \u5927\u80c6 \u65b0 \u5efa\u8bae \u5168\u7403 \u8054\u624b \u7814\u7a76 \u75c5\u6bd2 \u76ae\u4e0b \u808c\u6ce8 \u65b9\u5f0f \u6fc0\u8fdb \u65b9\u6cd5 \u52a0\u901f \u75ab\u82d7 \u7814\u53d1 ", "\u8881\u56fd\u52c7 \u9662\u58eb \u56e2\u961f \u7cfb\u7edf\u5206\u6790 \u65b0\u51a0 \u75c5\u6bd2 \u4eba\u4f53 \u7ec4\u7ec7\u7ec6\u80de \u7269\u79cd \u7ec6\u80de \u504f\u597d \u75c5\u6bd2 \u590d\u5236 \u7ec6\u80de \u635f\u4f24 SARS \u75c5\u6bd2 \u53d1\u73b0 \u7ec4\u7ec7 \u7ec6\u80de\u57f9\u517b \u6c34\u5e73 \u89e3\u91ca \u65b0\u51a0 \u75c5\u6bd2 SARS \u75c5\u6bd2 \u4e34\u5e8a\u8868\u73b0 \u4f20\u64ad \u6027\u4e0a \u5dee\u5f02 ", "\u6e05\u534e\u5927\u5b66 \u9976\u5b50 \u9662\u58eb \u56e2\u961f \u8ba1\u7b97\u673a\u8f85\u52a9 \u8bbe\u8ba1 \u53d1\u73b0 \u75c5\u6bd2 \u6291\u5236\u5242 N3 \u9ad8\u901a\u91cf \u7b5b\u9009 \u7ec6\u80de \u5b9e\u9a8c \u7b5b\u9009 6 \u6d3b\u6027 \u5316\u5408\u7269 \u5305\u62ec \u65e9\u5df2 \u4e0a\u5e02 NSAID   Ebselen ( \u4f9d\u5e03 \u7852 ) ", "\u4e2d\u79d1\u9662 \u4e0a\u6d77 \u836f\u7814 \u53d1\u5e03 \u58f0\u660e \u8be5\u6240 \u67f3\u7ea2 \u8bb8\u53f6\u6625 \u848b\u534e\u826f \u56e2\u961f \u8054\u5408 \u4e0a\u6d77 \u79d1\u6280 \u5927\u5b66 \u6768 \u6d77\u6d9b \u9976\u5b50 \u56e2\u961f \u4e2d\u79d1\u9662 \u6b66\u6c49 \u75c5\u6bd2 \u5f20\u78ca \u7822 \u8096\u5e9a\u5bcc \u56e2\u961f \u5408\u4f5c \u6297 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u836f\u7269 \u7814\u7a76 \u4e2d \u8fdb\u5c55 \u53d1\u73b0 \u4e00\u7c7b \u7ed3\u6784 \u65b0\u9896 \u9ad8\u6548 \u6297\u75c5\u6bd2 \u5019\u9009 \u836f\u7269 ", "\u6e05\u534e\u5927\u5b66 \u533b\u5b66\u9662 \u9976\u5b50 \u9662\u58eb \u56e2\u961f \u65b0\u51a0 \u75c5\u6bd2 \u6297\u75c5\u6bd2 \u836f\u7269 \u6838\u5fc3 \u9776\u70b9 \u4e3b \u86cb\u767d\u9176 Mpro RNA \u4f9d\u8d56 RNA \u805a\u5408\u9176 RdRp \u4e09\u7ef4 \u7ed3\u6784 \u7814\u7a76 \u4e2d \u8fdb\u5c55 \u6297\u65b0\u51a0 \u75c5\u6bd2 \u836f\u7269 \u7814\u53d1 \u63d0\u4f9b \u5173\u952e \u7ed3\u6784 \u751f\u7269\u5b66 \u57fa\u7840 ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u5f20\u4f2f\u793c \u56fd\u5bb6\u836f\u76d1\u5c40 \u6279\u51c6 \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u7eb3\u5165 \u4e09\u836f \u91d1\u82b1 \u6e05\u611f \u9897\u7c92 \u8fde\u82b1\u6e05 \u761f \u9897\u7c92 \u80f6\u56ca \u8840\u5fc5\u51c0 \u6ce8\u5c04\u6db2 \u65b0 \u836f\u54c1 \u9002\u5e94\u75c7 \u4e2d ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u5f20\u4f2f\u793c \u6297\u51fb \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u7279\u522b\u5956 \u4e00\u7b49\u5956 \u75ab\u60c5 \u4e2d \u5f20\u4f2f\u793c \u9662\u58eb \u5e26\u9886 \u56e2\u961f \u5f00\u62d3 \u4e2d\u533b \u65b9\u8231 \u533b\u9662 \u5236\u5b9a \u4e2d\u533b\u836f \u6551\u6cbb \u6a21\u5f0f \u6551\u6cbb 564 \u4f8b \u60a3\u8005 0 \u8f6c\u91cd 0 \u6b7b\u4ea1 \u76ee\u6807 \u9879\u76ee\u7ec4 \u63a2\u7d22 \u4e2d\u533b\u836f \u5168\u8fc7\u7a0b \u4ecb\u5165 \u75ab\u60c5 \u9632\u6cbb \u79d1\u6280\u653b\u5173 \u673a\u5236 \u6297\u51fb \u65b0\u51a0 \u80ba\u708e \u4e2d \u53d1\u6325 \u652f\u6491 \u4f5c\u7528 ", "\u6e05\u534e\u5927\u5b66 \u9976\u5b50 \u9662\u58eb \u56e2\u961f \u62a5\u544a \u8840\u5c0f\u677f \u51cf\u5c11 \u75c7 \u4f34\u968f \u91cd\u5ea6 \u53d1\u70e7 \u7efc\u5408\u5f81 \u75c5\u6bd2 SFTSV L \u86cb\u767d \u5168\u957f \u51b7\u51bb\u7535 \u955c \u7ed3\u6784 \u5206\u8fa8\u7387 3.4 \u00c5 L \u86cb\u767d \u5305\u542b \u4e09\u4e2a \u529f\u80fd \u539f\u5b50 \u6a21\u578b \u6838\u9178 \u5185\u5207 \u9176 RNA \u4f9d\u8d56\u6027 RNA \u805a\u5408\u9176 \u5e3d \u7ed3\u6784\u57df \u4e24\u4e2a \u7ed3\u6784\u57df \u963b\u65ad\u5242 \u57fa\u5e8f \u81c2 \u7ed3\u6784\u57df \u7fa7\u57fa \u672b\u7aef \u5957\u7d22 \u7ed3\u6784\u57df ", "\u9646\u519b \u519b\u533b\u5927\u5b66 \u535e\u4fee \u6559\u6388 \u6b7b \u5fc3\u8840\u7ba1 \u610f\u5916 COVID - 19 \u75c5\u4eba \u9f3b\u54bd \u62ed \u5b50\u6837\u672c \u4e09\u4e2a \u8fde\u7eed PCR \u68c0\u6d4b SARS - CoV - 2 \u9634\u6027 \u6b7b \u75c5\u7406\u5b66 \u7814\u7a76 \u75c5\u7406 \u68c0\u67e5 \u663e\u793a SARS - CoV - 2 - \u75c5\u6bd2 \u6b8b\u7559 \u80ba \u7ec6\u80de \u4e2d \u75c5\u6bd2 \u80ba\u90e8 \u75c5\u7406\u53d8\u5316 ", "\u9646\u519b \u519b\u533b\u5927\u5b66 \u535e\u4fee \u6559\u6388 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u60a3\u8005 \u5eb7\u590d \u51fa\u9662 \u80ba\u90e8 \u6df1\u5904 \u4f9d\u7136 \u643a\u5e26 \u75c5\u6bd2 \u5e38\u89c4 \u68c0\u6d4b \u624b\u6cd5 \u53d1\u73b0 \u75c5\u6bd2 ", "\u6fb3\u5927\u5229\u4e9a \u58a8\u5c14\u672c\u5927\u5b66 \u7814\u7a76 \u7814\u7a76\u5458 \u8bc1\u636e \u8bc1\u660e \u5361\u4ecb\u82d7 \u9700 \u4e16\u536b \u7ec4\u7ec7 \u5efa\u8bae \u53ea\u80fd \u968f\u673a\u5bf9\u7167 \u8bd5\u9a8c \u4e2d \u5361\u4ecb\u82d7 \u9a8c\u8bc1 \u51cf\u8f7b \u65b0\u51a0 \u5f71\u54cd \u9a8c\u8bc1 \u6ee5\u7528 \u5361\u4ecb\u82d7 \u5e26\u6765 \u4e00\u7cfb\u5217 \u8fde\u9501 \u8d1f\u9762 ", "\u6cd5\u56fd \u65e5\u524d \u53d1\u73b0 \u8be5\u56fd \u6700\u65e9 \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u60a3\u8005 \u53bb\u5e74 12 \u6708 \u65e9 \u611f\u67d3 \u60a3\u8005 ", "\u7ea6\u7ff0\u970d\u666e\u91d1\u65af \u5927\u5b66 \u533b\u5b66\u9662 \u7814\u7a76 \u53d1\u73b0 75% \u5e74\u8f7b\u4eba \u5904\u4e8e \u80a5\u80d6 \u72b6\u6001 BMI \u4e2d\u4f4d\u6570 29 3   kg   / m \u00b2 25 BMI \u4f4e\u4e8e 26   kg   / m \u00b2 25 BMI \u8d85\u8fc7 34 7   kg   / m \u00b2 \u6027\u522b \u5dee\u5f02 \u7814\u7a76 \u80a5\u80d6 \u53d1\u751f\u7387 \u9ad8 \u4eba\u7fa4 \u4e2d COVID - 19 \u5e74\u8f7b \u4eba\u53e3 \u5f71\u54cd \u62a5\u9053 ", "Ralph   Baric   \u56e2\u961f SARS \u51a0\u72b6\u75c5\u6bd2 \u9aa8\u67b6 \u4e2d\u534e \u83ca\u5934\u8760 SHC014 \u51a0\u72b6\u75c5\u6bd2 \u8868\u9762 \u86cb\u767d \u5de5\u7a0b\u5316 \u6539\u9020 \u5b9e\u9a8c\u5ba4 \u521b\u9020 \u4e00\u79cd \u6742\u4ea4 \u51a0\u72b6\u75c5\u6bd2 \u8fd9\u4e00 \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u547c\u5438\u9053 \u7ec6\u80de \u5c0f\u9f20 \u75be\u75c5 \u7814\u7a76 SHC014 \u51a0\u72b6\u75c5\u6bd2 \u8868\u9762 \u86cb\u767d \u611f\u67d3 \u4eba\u7c7b \u7ec6\u80de \u80fd\u529b \u8bc1\u5b9e \u75c5\u6bd2 \u8759\u8760 \u4e2d \u53d1\u73b0 \u51a0\u72b6\u75c5\u6bd2 \u65e0\u9700 \u5bbf\u4e3b \u611f\u67d3 \u4eba\u7c7b \u62c5\u5fe7 ", "\u91cd\u5e86 \u533b\u79d1\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u75c7\u72b6 \u53d1\u4f5c 19 \u5929\u5185 100 \u60a3\u8005 \u6297\u75c5\u6bd2 \u514d\u75ab \u7403\u86cb\u767d G IgG \u68c0\u6d4b \u5448 \u9633\u6027 \u8be5\u9879 \u7814\u7a76 \u7cfb\u7edf\u5206\u6790 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 \u673a\u4f53 \u6297\u4f53 \u89c4\u5f8b \u6297\u4f53 \u68c0\u6d4b \u6838\u9178 \u68c0\u6d4b \u8865\u5145 \u8f85\u52a9 COVID - 19 \u8bca\u65ad \u7591\u4f3c\u75c5\u4f8b \u786e\u8bca SARS - CoV - 2 \u771f\u5b9e \u611f\u67d3 \u6d41\u884c \u60c5\u51b5 \u8c03\u67e5 \u5927\u6709 ", "\u5f20\u6587\u5b8f \u6559\u6388 \u56e2\u961f   Cell   Research   \u671f\u520a \u53d1\u8868\u6587\u7ae0 \u6587\u7ae0 \u91cd\u75c7 \u65b0\u51a0 \u60a3\u8005 \u7ba1\u7406 \u7b56\u7565 \u8ba8\u8bba \u6297\u75c5\u6bd2 \u836f\u7269 \u7cd6 \u76ae\u8d28\u6fc0\u7d20 \u6f5c\u5728 \u7528\u9014 ", "\u7ea6\u7ff0 \u970d\u666e\u91d1\u65af\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u4eba\u7c7b \u5c0f\u80a0 \u7c7b \u5668\u5b98 hSIOs \u4e2d \u80a0 \u7ec6\u80de SARS - CoV SARS - CoV - 2 \u611f\u67d3 \u80a0 \u4e0a\u76ae \u652f\u6301 SARS - CoV - 2 \u590d\u5236 hSIOs \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u751f\u7269\u5b66 \u5b9e\u9a8c \u6a21\u578b ", "\u4e2d\u56fd \u79d1\u5b66\u6280\u672f \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u6258\u73e0 \u5355\u6297 \u6539\u5584 \u91cd\u75c7 COVID - 19 \u60a3\u8005 \u4e34\u5e8a \u75c7\u72b6 \u6551\u6cbb \u65b0\u51a0 \u80ba\u708e \u91cd\u75c7 \u60a3\u8005 \u65b9\u6cd5 \u7814\u7a76 \u968f\u673a \u53cc\u76f2 \u8bd5\u9a8c \u6545\u6709 \u4e34\u5e8a\u8bd5\u9a8c \u9a8c\u8bc1 \u6258\u73e0 \u5355\u6297 \u4e34\u5e8a \u4f5c\u7528 ", "\u7f8e\u56fd \u7814\u7a76 \u4eba\u5458 \u6807\u8bb0 \u8868\u8fbe 29 SARS - CoV - 2 \u86cb\u767d \u4e2d 26 \u4e24\u5957 \u6297\u75c5\u6bd2 \u6d3b\u6027 \u836f\u7406 \u5242 mRNA \u7ffb\u8bd1 \u6291\u5236\u5242 Sigma1 Sigma2 \u53d7\u4f53 \u9884\u671f \u8c03\u8282\u5242 \u7814\u7a76 \u4ee3\u8868 \u4e00\u79cd \u65b0 \u836f\u7269 \u53d1\u73b0 \u65b9\u6cd5 \u4e8e\u5168 \u75c5\u6bd2 \u7b56\u7565 \u75be\u75c5 \u5b66\u79d1 \u534f\u4f5c \u65b9\u6cd5 \u63a8\u52a8 \u79d1\u5b66 \u53d1\u5c55 \u901f\u5ea6 ", "\u590d\u65e6\u5927\u5b66 \u516c\u5171\u536b\u751f \u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u5206\u6790 \u65b0\u51a0 \u75ab\u60c5 \u66b4\u53d1 \u75ab\u60c5 \u66b4\u53d1 \u671f\u95f4 \u6b66\u6c49 \u4e0a\u6d77 \u63a5\u89e6 \u8c03\u67e5 \u6570\u636e \u7814\u7a76 \u53d1\u73b0 \u6267\u884c \u793e\u4f1a \u8ddd\u79bb \u758f\u8fdc \u653f\u7b56 \u671f\u95f4 \u6b66\u6c49 \u4e0a\u6d77 \u4e24\u5730 \u5e73\u5747 \u63a5\u89e6 \u51cf\u5c11 80% \u5927\u90e8\u5206 \u4e92\u52a8 \u4ec5\u9650\u4e8e \u5bb6\u5ead \u7814\u7a76 \u53d1\u73b0 0 - 14 \u5c81 \u513f\u7ae5 15 - 64 \u5c81 \u6210\u5e74\u4eba SARS - CoV - 2 \u611f\u67d3 \u76f8\u6bd4\u4e4b\u4e0b 65 \u5c81 \u53d7\u5230\u611f\u67d3 ", "\u4e2d\u5916 \u7814\u7a76 \u56e2\u961f \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 0 - 14 \u5c81 \u513f\u7ae5 15 - 64 \u5c81 \u6210\u4eba \u611f\u67d3 \u65b0\u51a0 \u611f\u67d3 \u65b0\u51a0 \u51e0\u7387 0.34 65 \u5c81 \u8001\u4eba \u611f\u67d3 \u611f\u67d3 \u51e0\u7387 15 - 64 \u5c81 \u6210\u4eba 1.47 \u500d ", "\u7f8e\u56fd\u660e\u5c3c\u82cf\u8fbe\u5927\u5b66 \u4f20\u67d3\u75c5 \u7814\u7a76 \u4e2d\u5fc3 \u4e00\u4efd \u62a5\u544a \u663e\u793a \u65b0\u51a0 \u75c5\u6bd2 \u5177\u5907 \u4eba\u9645 \u4e2d \u4f20\u64ad \u5bfc\u81f4 \u611f\u67d3 \u53d1\u75c5 \u75c7\u72b6 \u80fd\u529b \u65b0\u51a0 \u75c5\u6bd2 \u63a7\u5236 \u4eba\u7c7b \u5386\u53f2 \u6d41\u611f\u75c5\u6bd2 \u56f0\u96be \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u6301\u7eed \u4e24\u5e74 \u65f6\u95f4 \u5168\u7403 \u4e09\u5206\u4e4b\u4e8c \u4eba\u53e3 \u611f\u67d3 \u75c5\u6bd2 \u62a5\u544a \u63d0\u9192 \u5404\u56fd \u65f6\u523b \u505a\u597d \u5e94\u5bf9 \u4e24\u5e74 \u65f6\u95f4 \u91cc \u66b4\u53d1 \u75ab\u60c5 ", "\u7f8e\u56fd\u8036\u9c81\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u8bc4\u4f30 \u9f3b\u54bd \u62ed\u5b50 \u553e\u6db2 \u6837\u672c \u4e2d SARS - CoV - 2 \u68c0\u6d4b \u53d1\u73b0 \u63a8\u8350 \u9f3b\u54bd \u62ed\u5b50 \u65b9\u6cd5 \u76f8\u6bd4 \u4ece\u53e3 \u91c7\u96c6 \u553e\u6db2 \u6837\u672c \u611f\u67d3 \u8fc7\u7a0b \u4e2d \u63d0\u4f9b \u9ad8 \u68c0\u6d4b \u7075\u654f\u5ea6 \u4e00\u81f4\u6027 \u7814\u7a76 \u5f97\u51fa\u7ed3\u8bba \u553e\u6db2 \u6837\u672c \u81ea\u6211 \u91c7\u96c6 \u53d8\u5f02\u6027 ", "\u4e16\u536b \u7ec4\u7ec7 \u8bc4\u4f30 \u65b0\u51a0 \u75ab\u60c5 \u6d41\u884c \u6f14\u53d8 \u60c5\u51b5 \u6d41\u884c \u56fd\u9645 \u5173\u6ce8 \u7a81\u53d1 \u516c\u5171\u536b\u751f \u4e8b\u4ef6 PHEIC \u5b9a\u6027 \u75c5\u6bd2 \u6e90\u4e8e \u81ea\u7136\u754c ", "\u5317\u4eac \u9996\u90fd\u533b\u79d1\u5927\u5b66 \u9644\u5c5e \u540c\u4ec1\u533b\u9662 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u53d1\u73b0 \u7537\u6027 \u5973\u6027 \u611f\u67d3   COVID - 19   \u98ce\u9669 \u5dee\u5f02 \u7537\u6027   COVID - 19   \u60a3\u8005 \u6b7b\u4ea1 \u98ce\u9669 \u9ad8\u4e8e \u5973\u6027 \u7ea6 \u5973\u6027 \u60a3\u8005   2.5   \u500d \u8fd9\u4e00 \u7814\u7a76 \u9996\u6b21 \u63ed\u793a \u65b0\u51a0 \u80ba\u708e \u6027\u522b\u5dee\u5f02 \u7537\u6027 \u5973\u6027 \u611f\u67d3 \u65b0\u51a0 \u80ba\u708e \u75c5\u6bd2 \u98ce\u9669 \u7537\u6027 \u75c5\u60c5\u6076\u5316 \u6b7b\u4ea1 \u53ef\u80fd\u6027 \u66f4\u9ad8 ", "\u65b0\u52a0\u5761\u56fd\u7acb\u5927\u5b66 \u82cf\u745e\u798f \u516c\u5171\u536b\u751f \u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u6b27\u7f8e\u56fd\u5bb6 \u91c7\u7528 \u5c45\u5bb6 \u9694\u79bb \u4e2d\u56fd\u5f0f \u9694\u79bb \u65b0\u51a0 \u75ab\u60c5 \u4f20\u64ad \u5f71\u54cd \u6587\u7ae0 \u53d1\u73b0 \u9694\u79bb \u66f4\u597d \u51cf\u5c11 \u5bb6\u5ead \u793e\u533a \u4f20\u64ad ", "\u7f8e\u56fd \u75be\u63a7\u4e2d\u5fc3 \u7814\u7a76 \u4eba\u5458 \u53d1\u5e03 \u62a5\u544a \u590d\u76d8 \u7f8e\u56fd \u65b0\u51a0 \u75ab\u60c5 \u53d1\u5c55 \u62a5\u544a \u6301\u7eed \u65c5\u5ba2 \u8f93\u5165 \u5927\u89c4\u6a21 \u805a\u4f1a \u7f3a\u5c11 \u9632\u62a4 \u63aa\u65bd \u4fc3\u4f7f \u75c5\u6bd2 \u9ad8\u5371 \u573a\u6240 \u4eba\u53e3 \u5bc6\u96c6\u533a \u6269\u6563 \u68c0\u6d4b \u65e0\u75c7\u72b6 \u611f\u67d3 \u5bfc\u81f4 \u75c5\u6bd2 \u672a \u5bdf\u89c9 \u60c5\u51b5 \u4f20\u64ad \u56db\u5927 \u56e0\u7d20 \u7f8e\u56fd \u75ab\u60c5 \u52a0\u901f \u8513\u5ef6 ", "\u6bd4\u5229\u65f6 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u7f8a\u9a7c \u8840\u6db2 \u4e2d \u5206\u5b50 \u65b0\u51a0 \u75c5\u6bd2 \u66b4\u53d1 \u65f6 \u8d77\u5230 \u6cbb\u7597 \u4f5c\u7528 \u7f8a\u9a7c \u6297\u4f53 \u53ef\u884c\u6027 \u503c\u5f97 \u8fdb\u4e00\u6b65 \u7814\u7a76 ", "\u82f1\u56fd\u4f26\u6566 \u56fd\u738b \u5b66\u9662 \u53cc\u80de\u80ce \u7814\u7a76 \u9057\u4f20 \u6d41\u884c\u75c5\u5b66 \u7cfb \u7814\u7a76 \u4eba\u5458 \u65b0\u51a0 \u80ba\u708e \u75c7\u72b6 \u7ecf\u5178 \u53cc\u80de\u80ce \u7814\u7a76 \u53d1\u73b0 \u5bbf\u4e3b \u57fa\u56e0\u578b \u5f71\u54cd \u673a\u4f53 \u65b0\u51a0 \u75c5\u6bd2 \u6613\u611f\u6027 \u75c7\u72b6 \u8868\u73b0 \u8fd9\u4e00 \u7814\u7a76\u6210\u679c \u4e34\u5e8a \u9884\u4f30 \u60a3\u8005 \u9884\u540e \u75c5\u60c5 \u8d70\u5411 \u6781\u4e3a\u91cd\u8981 \u5206\u914d \u7a00\u7f3a \u533b\u7597 \u8d44\u6e90 \u7279\u522b \u91cd\u75c7 \u76d1\u62a4 \u75c5\u5e8a \u63d0\u4f9b \u5b9e\u7528\u4ef7\u503c ", "\u7f8e\u56fd \u8def\u6613\u65af\u5b89\u90a3\u5dde \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u91cd\u75c7 \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u4f53\u5185 \u7f3a\u4e4f \u7ef4\u751f\u7d20 D \u7ef4\u751f\u7d20 D \u7f3a\u4e4f \u91cd\u75c7 \u65b0\u51a0 \u80ba\u708e \u4e4b\u95f4 \u7ef4\u751f\u7d20 D \u7f3a\u4e4f \u65b0\u51a0 \u80ba\u708e \u75be\u75c5 \u72b6\u6001 \u8fdb\u5c55 \u4e2d\u8d77 \u4f5c\u7528 ", "\u4e2d\u56fd \u745e\u5fb7 \u897f\u97e6 \u5168\u7403 \u9996\u4e2a \u968f\u673a \u53cc\u76f2 \u5b89\u6170\u5242 \u5bf9\u7167 \u4e2d\u5fc3 \u4e34\u5e8a\u8bd5\u9a8c \u7814\u7a76 \u53d1\u73b0 \u6297\u75c5\u6bd2 \u836f\u7269 \u745e\u5fb7 \u897f\u97e6 \u6cbb\u7597 \u5371\u91cd\u75c7 \u4f4f\u9662 \u60a3\u8005 \u5e76\u672a \u52a0\u5feb \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u6062\u590d \u901f\u5ea6 \u672a \u964d\u4f4e \u75c5\u6b7b\u7387 ", "\u6cd5\u56fd \u7814\u7a76 \u4eba\u5458 \u6536\u96c6 \u6cd5\u56fd 90 \u591a\u540d \u60a3\u8005 \u6837\u672c \u53d1\u73b0 \u75c5\u6bd2 1 \u6708 \u65f6 \u90a3\u6279 \u4eba\u5458 \u611f\u67d3 \u75c5\u6bd2 \u6bd2\u682a 90 \u591a\u4e2a \u6837\u672c \u4e2d \u6700\u65e9 \u6837\u672c 2 \u6708 19 \u65e5 \u4e00\u540d \u60a3\u8005 \u8eab\u4e0a \u91c7\u96c6 \u60a3\u8005 \u65c5\u884c \u53f2 \u6d77\u5916 \u5f52\u56fd \u65c5\u884c\u8005 \u63a5\u89e6 \u7814\u7a76 \u4eba\u5458 \u4e00\u79cd \u89e3\u91ca \u65b0\u51a0 \u75c5\u6bd2 \u6cd5\u56fd \u4f20\u64ad \u5df2\u6709 \u4e00\u6bb5\u65f6\u95f4 \u5927\u90e8\u5206 \u60a3\u8005 \u75c7\u72b6 \u8f7b\u5fae \u75c7\u72b6 \u6cd5\u56fd\u653f\u5e9c \u53d1\u73b0 \u75c5\u6bd2 ", "\u590d\u65e6\u5927\u5b66 \u516c\u5171\u536b\u751f \u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u4e00\u9879 \u6d41\u884c\u75c5\u5b66 \u6a21\u578b \u7814\u7a76 \u7814\u7a76 \u53d1\u73b0 \u75ab\u60c5 \u66b4\u53d1 \u671f\u95f4 \u6b66\u6c49 \u4e0a\u6d77 \u5e73\u5747 \u6bcf\u4eba \u6bcf\u65e5 \u63a5\u89e6 \u4eba\u6570 \u51cf\u5c11 \u7ea6 80% \u589e\u52a0 \u793e\u4f1a \u8ddd\u79bb \u4eba\u7fa4 \u6539\u53d8 \u5927\u5e45 \u964d\u4f4e \u4eba\u5747 \u6bcf\u65e5 \u63a5\u89e6 \u4eba\u6570 \u63a5\u89e6 \u63a7\u5236 \u5bb6\u5ead \u5185\u90e8 \u51cf\u5c11 \u65b0\u51a0 \u75c5\u6bd2 \u4f20\u64ad ", "\u52a0\u62ff\u5927 \u536b\u751f\u90e8 \u53d7\u7406 \u6211\u56fd \u91cd\u7ec4 \u65b0\u51a0 \u75ab\u82d7 \u4e34\u5e8a\u8bd5\u9a8c \u7533\u8bf7 \u524d \u4f1a\u8bae \u8bf7\u6c42 ", "\u897f\u6e56 \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u80a0\u9053 \u83cc\u7fa4 \u4eba\u4f53 \u4fc3 \u708e\u75c7 \u56e0\u5b50 \u5448 \u6b63 \u76f8\u5173 \u5065\u5eb7 \u4e2a\u4f53 \u91cd\u75c7 COVID - 19 \u6613\u611f\u6027 \u57fa\u7840 ", "\u9646\u519b \u519b\u533b\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 SARS - CoV - 2 - \u75c5\u6bd2 \u6b8b\u7559 \u80ba \u7ec6\u80de \u4e2d \u75c5\u6bd2 \u80ba\u90e8 \u75c5\u7406\u53d8\u5316   \u7814\u7a76 SARS - CoV - 2 \u53d1\u75c5 \u673a\u7406 \u63d0\u4f9b \u65b0 \u89c1\u8bc6 \u6709\u52a9\u4e8e \u6539\u5584 \u75c5\u6bd2 \u904f\u5236 \u75be\u75c5 \u7ba1\u7406 \u4e34\u5e8a \u6307\u5357 ", "\u4e2d\u79d1\u9662 \u6b66\u6c49 \u75c5\u6bd2 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u53d1\u73b0 COVID - 19 \u60a3\u8005 \u4ee3\u8c22\u7269 \u8840\u8102 \u53d8\u5316 \u75be\u75c5 \u8fdb\u7a0b \u76f8\u5173\u6027 COVID - 19 \u75c5\u60c5 \u53d1\u5c55 \u5f71\u54cd \u60a3\u8005 \u5168\u8eab \u4ee3\u8c22 \u8fd9\u9879 \u5de5\u4f5c \u63d0\u4f9b COVID - 19 \u76f8\u5173 \u8840\u6d46 \u751f\u7269 \u6807\u5fd7\u7269 \u6f5c\u5728 \u6cbb\u7597 \u9776\u70b9 \u5b9d\u8d35 \u77e5\u8bc6 \u8fdb\u4e00\u6b65 \u7814\u7a76 COVID - 19 \u53d1\u75c5 \u673a\u7406 \u8d44\u6e90 ", "\u6b66\u6c49 \u7814\u7a76 \u4eba\u5458 \u6b66\u6c49 \u4e24 \u533b\u9662 \u6c14\u6eb6\u80f6 \u6837\u54c1 \u91c7\u96c6 \u5229\u7528 \u56e2\u961f \u524d\u671f \u7814\u53d1 \u65b0\u51a0 \u75c5\u6bd2 \u6570\u5b57 PCR \u68c0\u6d4b \u6280\u672f \u5b9a\u91cf\u5206\u6790 \u91c7\u6837 \u70b9 \u6837\u54c1 \u65b0\u51a0 \u75c5\u6bd2 \u6c14\u6eb6\u80f6 \u8f7d\u91cf \u7a7a\u6c14 \u52a8\u529b\u5b66 \u7279\u5f81 \u7814\u7a76 \u53d1\u73b0 \u9632\u63a7 \u6761\u4ef6 \u4e24\u6240 \u533b\u9662 \u516c\u5171 \u73af\u5883 \u603b\u4f53 \u60a3\u8005 \u5395\u6240 \u4e2d \u6c14\u6eb6\u80f6 \u75c5\u6bd2 \u8f7d\u91cf \u9ad8 \u63d0\u793a \u60a3\u8005 \u5927\u5c0f\u4fbf \u51b2\u6c34 \u8fc7\u7a0b \u75c5\u6bd2 \u6c14\u6eb6\u80f6 \u6765\u6e90 \u4eba\u6d41 \u805a\u96c6 \u8d85\u5e02 \u533b\u9662 \u697c\u680b \u901a\u9053 \u68c0\u51fa \u6c14\u6eb6\u80f6 \u75c5\u6bd2 \u8f7d\u91cf \u4eba\u5458 \u805a\u96c6 \u65f6 \u75c5\u6bd2 \u643a\u5e26\u8005 \u4eba\u7fa4 \u6f5c\u5728 \u6c14\u6eb6\u80f6 \u4f20\u64ad \u98ce\u9669 ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u6307\u51fa \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u4e00\u4e24\u5468 \u6297\u4f53 \u5c1a\u65e0 \u8bc4\u4f30 \u6297\u4f53 \u514d\u75ab \u76f8\u5173 \u7814\u7a76 \u7ed3\u8bba \u8bf4 \u6297\u4f53 \u610f\u5473\u7740 \u62e5\u6709 \u514d\u75ab\u529b ", "\u897f\u6e56 \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u6784\u5efa 20 \u9884\u6d4b \u91cd\u75c7 \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u8840\u6db2 \u751f\u7269 \u6807\u5fd7\u7269 \u86cb\u767d\u8d28 \u7ec4 \u98ce\u9669 \u8bc4\u5206 \u7cfb\u7edf \u53d1\u73b0 \u91cd\u75c7 \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u9ad8\u98ce\u9669 \u8bc4\u5206 \u4fc3 \u708e\u75c7 \u56e0\u5b50 \u5448 \u6b63 \u76f8\u5173 \u4eba\u4f53 \u80a0\u9053 \u83cc\u7fa4 \u5bc6\u5207\u76f8\u5173 \u8fd9\u9879 \u7814\u7a76 \u4eba\u7fa4 \u4e4b\u95f4 \u6613\u611f\u6027 \u5dee\u5f02 \u80cc\u540e \u6f5c\u5728 \u751f\u7269\u5b66 \u673a\u5236 ", "\u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u540c\u6d4e \u533b\u5b66\u9662 \u4f4f\u9662 \u8840\u6db2 \u80bf\u7624 \u60a3\u8005 \u7f79\u60a3 COVID - 19 \u6d41\u884c\u75c5\u5b66 \u4e34\u5e8a \u7279\u5f81 \u7814\u7a76 \u4e24\u5bb6 \u4e2d\u5fc3 \u4e00\u7ebf \u533b\u52a1\u4eba\u5458 COVID - 19 \u611f\u67d3 \u6570\u636e \u7814\u7a76 \u53d1\u73b0 \u8840\u6db2 \u80bf\u7624 \u60a3\u8005 \u7f79\u60a3 COVID - 19 \u9884\u540e \u51f6\u9669 \u8fd9\u9879 \u7814\u7a76 \u5904\u4e8e COVID - 19 \u5168\u7403 \u6d41\u884c \u6001\u52bf \u8840\u6db2 \u80bf\u7624 \u4f4f\u9662 \u60a3\u8005 \u8bca\u7597 \u601d\u8def \u53c2\u8003\u4ef7\u503c ", "\u4e2d\u56fd \u751f\u7269 \u5317\u4eac \u751f\u7269\u5236\u54c1 \u7814\u7a76\u6240 \u4e0b\u79f0 \u5317\u4eac \u751f\u7269 \u7814\u53d1 \u65b0\u51a0\u706d \u6d3b\u75ab\u82d7 \u56fd\u5bb6\u836f\u76d1\u5c40 \u4e34\u5e8a\u8bd5\u9a8c \u6279\u4ef6 \u5e76\u4e8e 4 \u6708 28 \u65e5 \u6cb3\u5357 \u6b63\u5f0f \u542f\u52a8 \u4e34\u5e8a\u8bd5\u9a8c ", "\u817e\u8baf \u533b\u5178 \u643a\u624b \u4e2d\u56fd \u56fd\u9645 \u7535\u89c6\u53f0 ( CGTN )   \u9762\u5411 \u5168\u7403 \u63a8 \u65b0\u51a0 \u80ba\u708e \u81ea\u7b5b \u5de5\u5177 \u56fd\u9645\u7248 CGTN \u5168 \u5e73\u53f0 \u6e20\u9053 \u5168\u7403 \u7528\u6237 \u63d0\u4f9b \u5de5\u5177 \u6b64\u524d \u817e\u8baf Together   We   Can \u5168\u7403 \u6218 \u75ab \u4fe1\u606f \u5e73\u53f0 \u53d1\u5e03 ", "\u91d1\u65af\u745e \u751f\u7269 \u7f8e\u56fd \u897f\u5948\u5c71 \u4f0a\u574e \u533b\u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u5f00\u53d1 \u9776\u5411 \u5f15\u53d1 \u65b0\u51a0 \u80ba\u708e COVID - 19 SARS - CoV - 2 \u75c5\u6bd2 \u6297\u4f53 \u836f\u7269 \u8fbe\u6210 \u5408\u4f5c \u6297\u4f53 \u65e8\u5728 \u963b\u6b62 \u75c5\u6bd2 \u4eba\u80ba \u7ec6\u80de \u65b0\u51a0 \u80ba\u708e \u4e00\u79cd \u6f5c\u5728 \u6cbb\u7597 \u65b9\u6848 ", "\u4e2d \u79d1\u666e \u745e \u6607 \u516c\u53f8 \u4e2d\u56fd\u79d1\u5b66\u9662 \u5408\u80a5 \u7269\u8d28 \u79d1\u5b66 \u7814\u7a76\u9662 \u8054\u5408 \u79d1\u6280\u653b\u5173 \u56e2\u961f \u5229\u7528 \u7ec6\u80de\u5de5\u7a0b \u6280\u672f \u5206\u5b50\u751f\u7269\u5b66 \u76f8\u5173 \u6280\u672f \u7d27\u6025 \u5f00\u53d1 \u8367\u5149\u7d20\u9176 \u62a5\u544a \u4f53\u7cfb \u57fa\u7840 \u65b0\u51a0 \u75c5\u6bd2 3C \u86cb\u767d\u9176 \u836f\u7269 \u9ad8\u901a\u91cf \u68c0\u6d4b \u7ec6\u80de \u4f53\u7cfb ", "\u6c99\u7279\u653f\u5e9c \u4e2d\u56fd \u4f01\u4e1a \u5408\u4f5c \u5efa\u8bbe \u5b9e\u9a8c\u5ba4 \u63d0\u9ad8 \u75c5\u6bd2\u68c0\u6d4b \u80fd\u529b \u9884\u8ba1 5 \u4e07\u6b21 \u65b0\u51a0 \u75c5\u6bd2 \u6d4b\u8bd5 \u603b\u8ba1 900 \u4e07\u4eba\u6b21 \u75c5\u6bd2 \u6d4b\u8bd5 ", "\u8377\u5170 \u8c82 \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u75c5\u4f8b \u906d \u517b\u6b96\u573a \u96c7\u5458 \u4f20\u67d3 \u8377\u5170\u653f\u5e9c \u4e0b\u4ee4 \u4e24\u5ea7 \u517b\u6b96\u573a \u9694\u79bb \u68c0\u75ab \u63a5\u53d7 \u8c03\u67e5 \u5305\u62ec \u7a7a\u6c14 \u571f\u58e4 \u68c0\u6d4b \u7981\u6b62 \u65e0\u5173 \u4eba\u5458 \u517b\u6b96\u573a \u5468\u8fb9 400 \u7c73 \u4ee5\u5185 ", "\u56fd\u9645 \u7814\u7a76 \u56e2\u961f \u5bf9\u897f \u5370\u5ea6\u6d0b \u5730\u533a 36 \u8759\u8760 \u643a\u5e26 \u51a0\u72b6\u75c5\u6bd2 \u5206\u6790 \u53d1\u73b0 \u79cd\u7c7b \u8759\u8760 \u72ec\u7279 \u51a0\u72b6\u75c5\u6bd2 \u682a \u8759\u8760 \u51a0\u72b6\u75c5\u6bd2 \u8fdb\u5316 \u6570\u767e\u4e07\u5e74 ", "\u82f1\u56fd \u7ef4\u5eb7 \u6851\u683c \u7814\u7a76\u6240 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 SARS - CoV - 2 \u75c5\u6bd2 \u5bbf\u4e3b \u65b9\u5f0f \u76f8\u5173 \u57fa\u56e0 \u7279\u5b9a \u5065\u5eb7\u4eba \u547c\u5438\u9053 \u89d2\u819c \u80a0 \u4e0a\u76ae\u7ec6\u80de \u4e2d\u5747 \u8868\u8fbe \u9f3b\u90e8 \u7ec4\u7ec7 \u75c5\u6bd2\u611f\u67d3 \u4f20\u64ad \u6e05\u9664 \u8fc7\u7a0b \u4e2d \u8d77\u5230 \u4f5c\u7528 ", "\u66f9\u5f6c \u6559\u6388 \u7275\u5934 \u745e\u5fb7 \u897f\u97e6 \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u91cd\u75c7 \u60a3\u8005 \u4e34\u5e8a\u8bd5\u9a8c \u7ed3\u679c\u8868\u660e \u6807\u51c6 \u62a4\u7406 \u63a7\u5236 \u76f8\u6bd4 \u745e\u5fb7 \u897f\u97e6 \u4e34\u5e8a \u6539\u5584 \u65f6\u95f4 \u5173\u7cfb ", "\u6df1\u5733\u5e02 \u5987\u5e7c\u4fdd\u5065 \u9662 \u79d1\u7814\u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u96c4\u6027 \u5c0f\u9f20 \u836f \u745e\u5fb7 \u897f\u97e6\u540e \u7cbe\u5b50 \u603b\u6570 \u8fd0\u52a8 \u7cbe\u5b50 \u7387 \u5448 \u4e0b\u964d \u8d8b\u52bf \u5f02\u5e38 \u7cbe\u5b50 \u7387 \u5448\u4e0a\u5347 \u8d8b\u52bf \u745e\u5fb7 \u897f\u97e6 \u777e\u4e38 \u6bd2\u6027 \u5bfc\u81f4 \u7cbe\u5b50 \u8d28\u91cf \u4e0b\u964d ", "\u5357\u4eac\u533b\u79d1\u5927\u5b66 \u7b2c\u4e00 \u9644\u5c5e \u533b\u9662 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u663e\u793a \u91c7\u96c6 \u6062\u590d\u671f \u60a3\u8005 \u7cbe\u6db2 \u75c5\u6b7b \u777e\u4e38 \u6837\u672c \u65b0\u51a0 \u75c5\u6bd2 RNA \u68c0\u6d4b \u7686 \u5448 \u9634\u6027 \u6062\u590d\u671f \u91cd\u75c7 \u671f \u65b0\u51a0 \u80ba\u708e \u7537\u6027 \u60a3\u8005 \u777e\u4e38 \u751f\u6b96\u9053 \u5e76\u672a \u65b0\u51a0 \u75c5\u6bd2 \u611f\u67d3 ", "\u4e2d\u56fd \u751f\u7269 \u65b0\u51a0 \u75c5\u6bd2 \u706d \u6d3b\u75ab\u82d7 \u6b63\u5f0f \u2161 \u671f \u4e34\u5e8a \u7814\u7a76 \u8ddd\u79bb \u75ab\u82d7 \u2160 \u671f \u4e34\u5e8a \u5f00\u542f 12 \u5929 \u8fd9\u662f \u4e2d\u56fd \u7b2c\u4e8c\u4e2a \u2161 \u671f \u4e34\u5e8a \u7814\u7a76 \u65b0\u51a0 \u75ab\u82d7 ", "\u82f1\u56fd \u56fd\u9645 \u4f19\u4f34 \u5305\u62ec \u6b27\u76df \u65e5\u672c \u6c99\u7279\u963f\u62c9\u4f2f \u632a\u5a01 \u5357\u975e 5 \u6708 4 \u65e5 \u4e3b\u529e \u51a0\u72b6\u75c5\u6bd2 \u5168\u7403 \u5e94\u5bf9 \u5cf0\u4f1a ", "\u6fb3\u95e8 \u79d1\u6280 \u5927\u5b66 \u673a\u6784 \u7814\u7a76 \u4eba\u5458 4154 \u540d \u60a3\u8005 \u5927\u578b \u8ba1\u7b97\u673a\u65ad\u5c42\u626b\u63cf CT \u6570\u636e\u5e93 \u5f00\u53d1 \u8bca\u65ad \u65b0\u51a0 \u80ba\u708e \u5e38\u89c1 \u80ba\u708e \u5bf9\u7167 \u533a\u5206 \u5f00 AI \u7cfb\u7edf \u4e34\u5e8a \u6570\u636e AI \u7cfb\u7edf \u63d0\u4f9b \u51c6\u786e \u4e34\u5e8a \u9884\u540e \u4e34\u5e8a \u533b\u751f \u65e9\u671f \u4e34\u5e8a \u6cbb\u7597 \u5206\u914d\u8d44\u6e90 ", "\u9ad8\u798f \u9662\u58eb \u56e2\u961f \u7814\u7a76 \u63cf\u8ff0 \u6838\u5fc3 \u805a\u5408\u9176 \u590d\u5408\u7269 \u539f\u5b50 \u5206\u8fa8\u7387 \u7ed3\u6784 \u7ed3\u6784 \u9ad8\u5ea6 \u7c7b\u4f3c SARS - CoV \u7ed3\u6784 \u75c5\u6bd2 RNA \u4f9d\u8d56\u6027 RNA \u805a\u5408\u9176 \u4fdd\u5b88 \u57fa\u5e8f \u6697\u793a \u8f85\u56e0\u5b50 \u6fc0\u6d3b \u673a\u5236 \u7814\u7a76 SARS - CoV - 2 \u6838\u5fc3 \u805a\u5408\u9176 \u590d\u5408\u7269 \u7ed3\u6784 \u751f\u5316 \u5206\u6790 \u63d0\u9ad8 \u75c5\u6bd2 RdRps \u5408\u6210 RNA \u673a\u7406 ", "\u6b27\u6d32 \u5317\u7f8e \u591a\u4e2a \u7814\u7a76 \u673a\u6784 \u63d0\u51fa \u4e00\u79cd \u9884\u9632 SARS - CoV - 2 \u611f\u67d3 \u65b0\u601d\u8def \u5229\u7528 \u4f53\u5916 \u7eaf\u5316 \u91cd\u7ec4 \u4eba\u7c7b ACE2 \u86cb\u767d \u4e2d \u65b0\u51a0 \u75c5\u6bd2 \u4f53\u7ec6\u80de \u9884\u9632 \u611f\u67d3 \u76ee\u7684 ", "\u6d59\u6c5f\u5927\u5b66 \u533b\u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u6e29\u5dde \u8f93\u5165 \u6027\u65b0\u51a0 \u75c5\u6bd2 \u6d41\u884c\u75c5\u5b66 \u5206\u6790 \u7ed3\u679c\u8868\u660e \u6e29\u5dde \u5b9e\u65bd \u793e\u533a \u63a7\u5236\u63aa\u65bd 2020 \u5e74 3 \u6708\u521d \u65b0\u51a0 \u75c5\u6bd2 \u6d41\u884c \u7ed3\u675f \u7d27\u5bc6 \u53d1\u73b0 \u9694\u79bb \u65e0\u75c7\u72b6 \u4e2a\u4f53 \u9694\u79bb ( \u4f4f\u9662 ) \u75c7\u72b6 \u53d7 \u611f\u67d3 \u4e2a\u4f53 ", "\u52a0\u5dde\u5927\u5b66 \u65e7\u91d1\u5c71 \u5206\u6821 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 TMPRSS2 ACE2 \u5171\u8868\u8fbe \u524d\u5217\u817a \u4e0a\u76ae\u7ec6\u80de \u4e2d \u7537\u6027 \u5973\u6027 \u4e4b\u95f4 \u80ba \u7ec4\u7ec7 \u4e2d ACE2 \u8868\u8fbe \u663e\u793a \u7537\u6027 \u8868\u8fbe \u9ad8 \u7537\u6027 II \u578b \u80ba \u7ec6\u80de \u4e2d ACE2   + \u7ec6\u80de \u6bd4\u4f8b \u66f4\u5927 \u521d\u6b65 \u8bc1\u636e \u80ba \u4e0a\u76ae\u7ec6\u80de \u7c7b\u578b II \u578b \u80ba \u7ec6\u80de \u663e\u793a ACE2 \u8868\u8fbe ", "\u7f8e\u56fd \u9996\u4f8b \u6b7b\u4ea1 \u75c5\u4f8b \u5c38\u68c0 \u62a5\u544a \u663e\u793a \u4e00\u540d \u5973\u5b50 \u7f8e\u56fd \u6700\u65e9 \u8bb0\u5f55 \u65b0\u51a0 \u80ba\u708e \u6b7b\u4ea1 \u75c5\u4f8b \u6b7b\u56e0 \u65b0\u51a0 \u80ba\u708e \u5fc3\u810f\u75c5 \u62a5\u544a \u663e\u793a \u5fc3\u810f \u56ca\u4e2d \u5145\u6ee1 \u8840\u6db2 \u6700\u7ec8 \u5bfc\u81f4 \u5fc3\u810f \u53d7\u538b \u7834\u88c2 ", "\u5e7f\u5dde\u5e02 \u533b\u7597 \u4fdd\u969c\u5c40 \u53d1\u5e03 \u6025\u6027 \u547c\u5438 \u7efc\u5408\u5f81 \u51a0\u72b6\u75c5\u6bd2 \u6297\u4f53 \u6d4b\u5b9a \u9879\u76ee \u4ef7\u683c \u901a\u77e5 ( \u5f81\u6c42\u610f\u89c1 \u7a3f ) \u62df\u5c06 \u51a0\u72b6\u75c5\u6bd2 \u6297\u4f53 \u6d4b\u5b9a \u7eb3\u5165 \u5e7f\u5dde \u533b\u4fdd ", "\u4e2d\u56fd \u4e13\u5bb6 \u53d1\u73b0 \u75c5\u4eba \u8d85\u957f \u6392\u6bd2 \u671f \u4e00\u90e8\u5206 \u60a3\u8005 \u6392\u6bd2 \u671f\u957f \u8fbe 50 - 60 \u5929 \u6838\u9178 \u9633\u6027 \u60c5\u51b5 \u7559\u9662 \u89c2\u5bdf ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u5c1a\u65e0 \u7814\u7a76 \u65b0\u51a0 \u75c5\u6bd2 \u6297\u4f53 \u8d4b\u4e88 \u4eba\u7c7b \u75c5\u6bd2 \u514d\u75ab\u529b \u8bc4\u4f30 \u5bf9\u4eba \u4f53\u5185 \u65b0\u51a0 \u75c5\u6bd2 \u6297\u4f53 \u5b9e\u9a8c\u5ba4 \u68c0\u6d4b \u8fdb\u4e00\u6b65 \u9a8c\u8bc1 \u68c0\u6d4b \u51c6\u786e\u6027 \u53ef\u9760\u6027 ", "\u7f8e\u56fd \u52a0\u5dde \u5723\u514b\u62c9\u62c9 \u53bf\u653f\u5e9c \u516c\u5171 \u536b\u751f\u90e8\u95e8 \u672c\u5468 \u516c\u5e03 \u6700\u65b0 \u68c0\u6d4b \u62a5\u544a \u663e\u793a \u65e9 2 \u6708 6 \u65e5 \u6709\u4eba \u6b7b\u4e8e \u65b0\u51a0 \u80ba\u708e \u8fd9\u6bd4 \u7f8e\u56fd \u6b64\u524d \u516c\u5e03 \u9996\u4f8b \u65b0\u51a0 \u6b7b\u4ea1 \u75c5\u4f8b \u65f6\u95f4 \u63d0\u524d 20 \u591a\u5929 ", "\u7f8e\u56fd \u5f17\u5409\u5c3c\u4e9a \u5927\u5b66 \u673a\u6784 \u7814\u7a76\u8005 \u516c\u5e03 \u7f8e\u56fd \u9000\u4f0d\u519b\u4eba COVID - 19 \u4f4f\u9662 \u60a3\u8005 \u4e2d \u7f9f \u6c2f\u55b9 \u7814\u7a76 \u7ed3\u679c\u663e\u793a \u7f9f \u6c2f\u55b9 \u6cbb\u7597 \u7ec4 \u7f9f \u6c2f\u55b9 \u8054\u5408 \u963f\u5947 \u9709\u7d20 \u6cbb\u7597 \u7ec4 \u672a \u63a5\u53d7 \u7f9f \u6c2f\u55b9 \u6cbb\u7597 \u7ec4 \u6b7b\u4ea1\u7387 27.8% 22.1% 11.4% \u7814\u7a76\u8005 \u5f97\u51fa\u7ed3\u8bba \u53d1\u73b0 \u8bc1\u636e \u7f9f \u6c2f\u55b9 \u963f\u5947 \u9709\u7d20 \u8054\u7528 \u964d\u4f4e COVID - 19 \u4f4f\u9662 \u60a3\u8005 \u673a\u68b0 \u901a\u6c14 \u98ce\u9669 \u63a5\u53d7 \u7f9f \u6c2f\u55b9 \u5355\u836f \u6cbb\u7597 \u60a3\u8005 \u4e2d \u53d1\u73b0 \u603b\u6b7b\u4ea1\u7387 \u589e\u52a0 \u76f8\u5173\u6027 ", "\u610f\u5927\u5229 \u591a\u5bb6 \u79d1\u7814\u673a\u6784 \u610f\u5927\u5229 \u5317\u90e8 \u75ab\u60c5 \u7206\u53d1 \u533a \u5ba4\u5916 \u7a7a\u6c14 \u9897\u7c92\u7269 \u4e2d \u68c0\u6d4b \u65b0\u51a0 \u75c5\u6bd2 RNA \u65b0\u51a0 \u75c5\u6bd2 RNA \u5ba4\u5916 \u7a7a\u6c14 \u4e2d \u9897\u7c92\u7269 \u65b0\u51a0 \u75c5\u6bd2 \u5ba4\u5916 PM \u6210\u7c07 \u964d\u4f4e \u6269\u6563\u7cfb\u6570 \u589e\u5f3a \u75c5\u6bd2 \u5927\u6c14 \u4e2d \u6301\u4e45\u6027 ", "\u54c8\u4f5b \u533b\u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u6c14\u9053 \u4e0a\u76ae\u7ec6\u80de \u4e2d ACE2 \u5e72\u6270\u7d20 \u523a\u6fc0 \u57fa\u56e0 ISG \u7814\u7a76 \u6570\u636e SARS - CoV - 2 \u5229\u7528 \u7269\u79cd \u7279\u5f02\u6027 \u5e72\u6270\u7d20 \u9a71\u52a8 ACE2 \u8c03\u6765 \u589e\u5f3a \u611f\u67d3 ", "\u6d59\u6c5f\u5927\u5b66 \u6881\u5ef7\u6ce2 \u56e2\u961f 55 \u540d \u60a3\u8005 59 \u7caa\u4fbf \u4e2d 39 \u540d \u60a3\u8005 41 \u8840\u6e05 \u4e2d \u68c0\u6d4b RNA \u7caa\u4fbf \u6837\u672c \u4e2d SARS - CoV - 2 \u6301\u7eed\u65f6\u95f4 \u547c\u5438\u9053 \u8840\u6e05 \u6837\u672c \u4e2d \u66f4\u957f \u51f8\u663e \u9884\u9632 \u63a7\u5236 \u6d41\u884c\u75c5 \u4e2d \u7caa\u4fbf \u6837\u672c \u7ba1\u7406 \u75c5\u6bd2 \u91cd\u75c7 \u60a3\u8005 \u4e2d \u547c\u5438 \u7ec4\u7ec7 \u4e2d\u4ee5 \u66f4\u957f \u65f6\u95f4 \u8d1f\u8377 \u6301\u7eed \u5cf0\u503c \u65f6\u95f4 \u665a ", "\u4e16\u536b \u7ec4\u7ec7 \u73b0\u6709 \u8bc1\u636e \u65b0\u51a0 \u75c5\u6bd2 \u6e90\u81ea \u52a8\u7269 \u5b9e\u9a8c\u5ba4 \u4eba\u5de5\u5e72\u9884 \u5236\u9020 \u800c\u6765 ", "\u745e\u5178 \u7814\u7a76 \u5c0f\u7ec4 \u5f00\u53d1 \u4e00\u79cd \u7075\u654f \u53ef\u9760 \u68c0\u6d4b \u7a7a\u6c14 \u4e2d\u65b0\u51a0 \u75c5\u6bd2 \u751f\u7269 \u4f20\u611f\u5668 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 \u4e34\u5e8a \u8bca\u65ad \u65b9\u6cd5 \u7528\u4e8e \u5b9e\u65f6 \u76d1\u6d4b \u706b\u8f66\u7ad9 \u533b\u9662 \u4eba\u6d41 \u5bc6\u96c6 \u573a\u6240 \u7a7a\u6c14 \u4e2d \u65b0\u51a0 \u75c5\u6bd2 ", "\u82f1\u56fd\u653f\u5e9c \u725b\u6d25 \u56e2\u961f \u63d0\u4f9b 2000 \u4e07\u82f1\u9551 \u8d44\u52a9 \u65b0\u51a0 \u75ab\u82d7 \u4e34\u5e8a\u8bd5\u9a8c \u9636\u6bb5 \u82f1\u56fd \u536b\u751f \u5927\u81e3 \u9a6c\u7279 \u6c49\u8003\u514b 4 \u6708 23 \u65e5 \u4eba\u4f53 \u8bd5\u7528 \u75ab\u82d7 ", "\u82f1\u56fd\u653f\u5e9c \u82f1\u56fd \u6b63 \u5904\u4e8e \u65b0\u51a0 \u75c5\u6bd2 \u75ab\u60c5 \u9ad8\u5cf0\u671f \u82f1\u56fd \u8fdb\u4e00\u6b65 \u65b0\u51a0 \u75c5\u6bd2\u68c0\u6d4b \u89c4\u6a21 \u52a0\u5927 \u7efc\u5408 \u63aa\u65bd \u529b\u5ea6 \u6b7b\u4ea1\u7387 \u6301\u7eed \u4e0b\u964d ", "\u6700\u65b0 \u516c\u5e03 \u5c38\u68c0 \u7ed3\u679c\u8868\u660e \u7f8e\u56fd \u9996\u4f8b \u65b0\u51a0 \u6b7b\u4ea1 \u5b98\u65b9 2 \u6708 29 \u65e5\u8981 \u65e9 \u4e09\u5468 \u6697\u793a \u65b0\u51a0 \u75c5\u6bd2 \u7f8e\u56fd \u4f20\u64ad \u8ffd\u6eaf\u5230 1 \u6708\u4efd \u65e9 ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u949f\u5357\u5c71 \u56e2\u961f \u9996\u6b21 \u5f00\u53d1 \u54bd\u6f31\u6db2 \u6837\u672c \u7528\u4e8e \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u6838\u9178 \u68c0\u6d4b \u9f3b \u62ed\u5b50 \u68c0\u51fa\u7387 \u53d1\u73b0 \u54bd\u6f31\u6db2 \u9633\u6027\u7387 \u9ad8\u4e8e \u9f3b \u62ed\u5b50 \u6807\u672c ", "\u6d59\u6c5f\u5927\u5b66 \u533b\u5b66\u90e8 \u6881\u5ef7\u6ce2 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 SARS - CoV - 2 \u786e\u8bca \u60a3\u8005 \u4f53\u5185 \u7ec4\u7ec7 \u6837\u672c \u75c5\u6bd2 \u65f6\u95f4 \u8f7d\u91cf \u65b0 \u7814\u7a76 \u7caa\u4fbf \u4e2d \u75c5\u6bd2 \u6301\u7eed\u65f6\u95f4 \u547c\u5438\u9053 \u8840\u6e05 \u6837\u672c \u4e2d \u957f\u5f97 \u7caa\u4fbf \u4e2d \u75c5\u6bd2 \u8f7d\u91cf \u5cf0\u503c \u665a ", "\u7f8e\u56fd \u75be\u75c5 \u63a7\u5236 \u9884\u9632 \u4e2d\u5fc3 \u4f4d\u4e8e \u7f8e\u56fd \u7ebd\u7ea6\u5dde \u4e24\u53ea \u5bb6\u517b \u5ba0\u7269\u732b \u786e\u8ba4 \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u8fd9\u662f \u7f8e\u56fd \u9996\u6b21 \u53d1\u73b0 \u5bb6\u517b \u5ba0\u7269 \u611f\u67d3 \u7ebd\u7ea6\u5e02 \u5e03\u6717 \u514b\u65af \u52a8\u7269\u56ed 4 \u8001\u864e 3 \u975e\u6d32\u72ee \u786e\u8ba4 \u611f\u67d3 ", "\u6e05\u534e\u5927\u5b66 \u533b\u5b66\u9662 \u9976\u5b50 \u9662\u58eb \u9886\u5bfc \u56e2\u961f \u65b0\u51a0 \u75c5\u6bd2 \u6297\u75c5\u6bd2 \u836f\u7269 \u6838\u5fc3 \u9776\u70b9 \u4e3b \u86cb\u767d\u9176 Mpro RNA \u4f9d\u8d56 RNA \u805a\u5408\u9176 RdRp \u4e09\u7ef4 \u7ed3\u6784 \u7814\u7a76 \u4e2d \u8fdb\u5c55 \u6297\u65b0\u51a0 \u75c5\u6bd2 \u836f\u7269 \u7814\u53d1 \u63d0\u4f9b \u5173\u952e \u7ed3\u6784 \u751f\u7269\u5b66 \u57fa\u7840 ", "\u4e2d\u56fd\u79d1\u5b66\u9662 \u4e0a\u6d77 \u836f\u7269 \u7814\u7a76\u6240 \u67f3\u7ea2 / \u8bb8\u53f6\u6625 \u7814\u7a76 \u53d1\u73b0 SARS - CoV - 2   Mpro 11a 11b \u590d\u5408\u7269 X\u5c04\u7ebf \u6676\u4f53\u7ed3\u6784 1.5 \u5206\u8fa8\u7387 \u6d4b\u5b9a 11a 11b \u919b \u57fa \u5171\u4ef7\u952e \u5408\u5230 Mpro Cys145 \u4e24\u79cd \u5316\u5408\u7269 \u4f53\u5185 \u663e\u793a PK \u7279\u6027 11a \u6bd2\u6027 \u4f4e \u5316\u5408\u7269 \u524d\u9014 \u5019\u9009 \u836f\u7269 ", "\u6b66\u6c49\u5927\u5b66 \u674e\u7ea2\u826f \u6559\u6388 \u56f4\u7ed5 COVID - 19 \u5fc3\u8840\u7ba1 \u7cfb\u7edf \u5f71\u54cd \u4e34\u5e8a \u57fa\u7840 \u89d2\u5ea6 COVID - 19 \u7cfb\u7edf\u5730 \u68b3\u7406 \u9610\u8ff0 \u7814\u7a76 COVID - 19 \u7d2f\u53ca \u5fc3\u8840\u7ba1 \u7cfb\u7edf \u5408\u5e76 \u5fc3\u8840\u7ba1 \u75be\u75c5 COVID - 19 \u60a3\u8005 \u75c5\u60c5 \u6b7b\u4ea1 \u98ce\u9669 \u66f4\u9ad8 \u9610\u660e COVID - 19 \u5fc3\u8840\u7ba1 \u7cfb\u7edf \u5173\u7cfb \u76f8\u5173 \u75c5\u4eba \u6551\u6cbb \u75be\u75c5 \u7406\u89e3 \u81f3\u5173\u91cd\u8981 ", "\u5357\u5361\u7f57\u6765\u7eb3 \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u63a5\u53d7 \u7f9f \u6c2f\u55b9 \u6cbb\u7597 \u60a3\u8005 \u4e2d \u53d1\u73b0 \u603b\u6b7b\u4ea1\u7387 \u589e\u52a0 \u53d1\u73b0 \u91c7\u7528 \u836f\u7269 \u7b49\u5f85 \u524d\u77bb\u6027 \u968f\u673a \u5bf9\u7167 \u7814\u7a76 \u91cd\u8981\u6027 ", "\u7f8e\u56fd\u7ebd\u7ea6 \u533b\u9662 \u591a\u4f4d \u533b\u751f \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u5bfc\u81f4 \u8f7b\u75c7 \u65e0\u75c7\u72b6 \u5e74\u8f7b \u611f\u67d3\u8005 \u4e2d\u98ce ", "\u5fb7\u56fd \u536b\u751f\u90e8 \u75ab\u82d7 \u5ba1\u6279 \u673a\u6784 \u4fdd\u7f57 \u57c3\u5c14\u5229 \u5e0c \u7814\u7a76\u6240 \u6279\u51c6 \u5fb7\u56fd \u9996\u4e2a \u65b0\u51a0 \u75c5\u6bd2 \u75ab\u82d7 \u4e34\u5e8a\u8bd5\u9a8c \u673a\u6784 \u79f0 \u8fd9\u662f \u5168\u7403 \u7b2c\u4e94\u4e2a \u6388\u6743 \u4e34\u5e8a\u8bd5\u9a8c \u65b0\u51a0 \u75c5\u6bd2 \u5019\u9009 \u75ab\u82d7 ", "\u4e16\u754c\u6c14\u8c61\u7ec4\u7ec7 \u53d1\u5e03 \u516c\u62a5 \u8bf4 \u65b0\u51a0 \u75ab\u60c5 \u6682\u65f6 \u51cf\u5c11 \u6e29\u5ba4 \u6c14\u4f53 \u6392\u653e \u6301\u7eed \u6c14\u5019 \u75ab\u60c5 \u9632\u63a7 \u5e94\u5bf9 \u6c14\u5019\u53d8\u5316 \u4e24\u624b\u6293 ", "\u6d59\u6c5f\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u91cd\u75c7 \u98ce\u9669 \u9ad8\u8840\u538b \u5fc3\u8840\u7ba1 \u75be\u75c5 \u6162\u6027 \u80be\u75c5 \u7cd6\u5c3f\u75c5 \u76f8\u5173 \u6162\u6027 \u809d\u75c5 \u76f8\u5173\u6027 \u5f3a \u65b0\u51a0 \u6b7b\u4ea1 \u98ce\u9669 \u91cd\u75c7 \u60a3\u8005 \u6025\u6027 \u5fc3\u810f \u80be\u810f \u635f\u4f24 \u9ad8\u5ea6 \u76f8\u5173 \u504f\u501a \u75c5\u53f2 \u91cd\u75c7 \u8f6c\u5316 \u4e4b\u95f4 \u56e0\u679c\u5173\u7cfb ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u53d1\u8a00\u4eba \u5df2\u77e5 \u8bc1\u636e \u75c5\u6bd2 \u6e90\u81ea \u81ea\u7136\u754c \u52a8\u7269 \u4e00\u79cd \u4eba\u4e3a \u64cd\u7eb5 \u5408\u6210 \u75c5\u6bd2 ", "\u4e1c\u90e8 \u6218\u533a \u603b\u533b\u9662 \u751f\u6b96 \u533b\u5b66\u4e2d\u5fc3 \u7814\u7a76 \u53d1\u73b0 \u5e76\u672a \u7537\u6027 \u65b0\u51a0 \u60a3\u8005 \u777e\u4e38 \u68c0\u6d4b \u65b0\u51a0 \u75c5\u6bd2 \u7537\u6027 \u6027\u817a \u5f71\u54cd ", "\u56fd\u836f \u96c6\u56e2 \u4e2d\u56fd \u751f\u7269 \u6b66\u6c49 \u751f\u7269\u5236\u54c1 \u7814\u7a76\u6240 \u7814\u53d1 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u706d \u6d3b\u75ab\u82d7 \u6b63\u5f0f \u2161 \u671f \u4e34\u5e8a \u7814\u7a76 ", "\u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u540c\u6d4e \u533b\u5b66\u9662 \u9644\u5c5e \u540c\u6d4e \u533b\u9662 \u5987\u4ea7\u79d1 \u7814\u7a76 \u4eba\u5458 \u62a5\u544a \u4e24\u540d \u6000\u5b55 \u65e9\u671f \u8bca\u65ad \u60a3\u6709 COVID - 19 \u5b55\u5987 \u7f8a\u6c34 \u4e2d SARS - CoV - 2 \u68c0\u6d4b \u53d1\u73b0 \u5448\u73b0 \u9634\u6027 \u65b0\u51a0 \u80ba\u708e \u75c5\u6bd2 \u6297\u4f53 \u957f\u671f\u5b58\u5728 \u7f8a\u6c34 \u4e2d \u68c0\u6d4b \u65b0\u51a0 \u75c5\u6bd2 ", "\u5fb7\u56fd \u9a6c\u4e01\u8def\u5fb7 \u54c8\u52d2 \u7ef4\u817e \u8d1d\u683c \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u80ba\u708e \u9ad8 \u81f4\u6b7b\u7387 \u75c5\u6bd2 \u60a3\u8005 \u8eab\u4f53\u72b6\u51b5 \u7a7a\u6c14\u6c61\u67d3 ", "\u6df1\u5733\u5e02 \u5987\u5e7c\u4fdd\u5065 \u9662 \u6df1\u5733\u5e02 \u533b\u9662 \u7814\u7a76 \u4eba\u5458 \u53d1\u5e03 \u4e00\u9879 \u7814\u7a76 \u63ed\u793a \u745e\u5fb7 \u897f\u97e6 GS - 5734 \u96c4\u6027 \u5c0f\u9f20 \u751f\u6b96 \u6bd2\u6027 \u521d\u6b65 \u7814\u7a76 \u7814\u7a76 \u663e\u793a \u9ad8 \u5242\u91cf GS - 5734 \u8bf1\u5bfc \u777e\u4e38 \u6bd2\u6027 ", "\u82cf\u5dde\u5927\u5b66 \u9644\u5c5e \u7b2c\u4e00 \u533b\u9662 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u7537\u6027 COVID - 19 \u60a3\u8005 \u6bd4\u4f8b \u9ad8\u4e8e \u5973\u6027 COVID - 19 \u60a3\u8005 COVID - 19 \u7537\u6027 \u60a3\u8005 \u4e2d \u75be\u75c5 \u8fdb\u5c55 \u7387 \u81f4\u6b7b\u7387 \u9ad8\u4e8e \u5973\u6027 ", "\u7f8e\u56fd \u56fd\u571f \u5b89\u5168\u90e8 \u5b98\u5458 \u63ed\u793a \u8fd1\u671f \u65b0\u51a0 \u75c5\u6bd2 \u7814\u7a76\u6210\u679c \u65f6 \u65b0\u51a0 \u75c5\u6bd2 \u7814\u7a76 \u53d1\u73b0 \u7d2b\u5916\u7ebf \u6709\u52a9\u4e8e \u6740\u706d \u75c5\u6bd2 \u9ad8\u6e29 \u9ad8\u6e7f \u6709\u52a9\u4e8e \u6740\u6bd2 ", "\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662 \u79e6\u5ddd \u56e2\u961f \u7814\u7a76 \u5f00\u53d1 \u7eaf\u5316 \u706d\u6d3b SARS - CoV - 2 \u75c5\u6bd2 \u5019\u9009 \u75ab\u82d7 PiCoVacc \u75ab\u82d7 \u5c0f\u9f20 \u5927\u9f20 \u975e\u4eba\u7c7b \u7075\u957f\u7c7b \u52a8\u7269 \u4e2d \u8bf1\u5bfc SARS - CoV - 2 \u7279\u5f02\u6027 \u4e2d \u6297\u4f53 \u76d1\u6d4b \u7315\u7334 \u4e34\u5e8a \u4f53\u5f81 \u8840\u6db2\u5b66 \u751f\u5316 \u6307\u6807 \u7ec4\u7ec7 \u5f62\u6001\u5b66 \u5206\u6790 PiCoVacc \u7cfb\u7edf \u8bc4\u4ef7 \u6570\u636e \u652f\u6301 \u4eba\u7c7b SARS - CoV - 2 \u75ab\u82d7 \u5feb\u901f \u4e34\u5e8a \u5f00\u53d1 ", "\u7f8e\u56fd\u52a0\u5229\u798f\u5c3c\u4e9a\u5927\u5b66 \u65e7\u91d1\u5c71 \u5206\u6821 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u62a5\u544a \u4e00\u79cd \u5feb\u901f < 40 \u5206\u949f \u6613\u4e8e CRISPR \u2013 Cas12 \u7cbe\u786e \u5206\u6790 \u6280\u672f \u5f00\u53d1 \u6280\u672f \u7528\u4e8e \u547c\u5438 \u62ed\u5b50 RNA \u63d0\u53d6\u7269 \u4e2d \u68c0\u6d4b SARS - CoV - 2 \u7814\u7a76 \u68c0\u6d4b SARS - CoV - 2 \u9633\u6027 \u9884\u6d4b \u7387\u8fbe 95 \u9634\u6027 \u9884\u6d4b \u7387\u8fbe 100 ", "\u7f8e\u56fd \u5fb7\u514b\u8428\u65af \u5927\u5b66 \u5965\u65af\u6c40 \u5206\u6821 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u63cf\u8ff0 SARS - CoV - 1 MERS - CoV   RBD \u4e24\u4e2a \u4e2d VHH \u6297\u4f53 \u5206\u79bb VHH \u4e2d MERS - CoV SARS - CoV - 1   S \u5047\u578b \u75c5\u6bd2 \u8fdb\u4e00\u6b65 \u8bc1\u660e VHH - Fc \u878d\u5408 \u86cb\u767d \u5de5\u4e1a \u6807\u51c6 CHO \u7ec6\u80de \u7cfb\u7edf \u4e2d\u4ee5 \u9ad8 \u4ea7\u91cf \u4e34\u5e8a \u610f\u4e49 ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u674e\u5170\u5a1f \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u5207\u5b9e \u5f71\u54cd \u81f4\u75c5\u6027 \u7a81\u53d8 \u836f\u7269 \u75ab\u82d7 \u7814\u53d1 \u5de5\u4f5c \u7a81\u53d8 \u7eb3\u5165 \u7814\u7a76 \u4eba\u5458 \u6307\u51fa \u65b0\u51a0 \u75c5\u6bd2 \u682a \u53d8\u5f02 \u591a\u6837\u6027 \u4f4e\u4f30 \u53d8\u5f02 \u6bd2\u682a \u7ec6\u80de \u75c5\u53d8 \u6548\u5e94 \u75c5\u6bd2 \u8f7d\u91cf \u5dee\u5f02 \u53ef\u8fbe 270 \u500d \u4e00\u79cd \u6838\u82f7\u9178 \u7a81\u53d8 \u589e\u5f3a \u75c5\u6bd2 \u590d\u5236 \u901f\u7387 \u81f4\u75c5 \u80fd\u529b \u53d1\u73b0 \u7a81\u53d8 \u75c5\u4eba 45 \u5929 \u6838\u9178 \u9633\u6027 ", "\u6885\u96f7\u8fea\u601d - \u74e6 \u5fb7\u66fc \u65b0\u51a0 \u80ba\u708e \u53d1\u751f \u591a\u4f4d \u810f\u5668 \u635f\u4f24 \u60a3\u8005 \u4e34\u5e8a \u7279\u5f81 \u76f8\u5173 \u6570\u636e \u8bba\u8ff0 \u65b0\u51a0 \u75c5\u6bd2 \u653b\u51fb \u4eba\u4f53 \u810f\u5668 \u7bc7\u6587\u7ae0 \u7406\u89e3 \u65b0\u578b \u7ba1\u72b6 \u75c5\u6bd2 \u75c5 COVID - 19 \u60a3\u8005 \u75c7\u72b6 \u65e9\u671f \u8bca\u65ad \u7406\u89e3 \u75c5\u7406 \u751f\u7406 \u8fc7\u7a0b \u6539\u5584 \u9884\u540e \u5eb7\u590d \u4ef7\u503c ", "Alexion \u5236\u836f \u516c\u53f8 \u542f\u52a8 \u4e00\u9879 \u5168\u7403 III \u671f \u7814\u7a76 \u8bc4\u4f30 Ultomiris ( ravulizumab - cwvz ) \u6cbb\u7597 \u80ba\u708e \u6025\u6027 \u547c\u5438 \u7a98\u8feb \u7efc\u5408\u5f81 ARDS \u4f4f\u9662 \u91cd\u75c7 \u6210\u4eba COVID - 19 \u60a3\u8005 \u7597\u6548 ", "\u4e2d\u5c71\u5927\u5b66 \u9644\u5c5e \u7b2c\u516d \u533b\u9662 \u5170\u5e73 \u6559\u6388 \u56e2\u961f \u7814\u7a76 \u4eba\u5458 \u6536\u96c6 232 \u4f4d \u533f\u540d \u65b0\u51a0 \u75c5\u4eba \u75c5\u5386 \u7814\u7a76 \u4e2d \u53d1\u73b0 21% \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3\u8005 \u4f4f\u9662 \u671f\u95f4 \u8179\u6cfb \u75c7\u72b6 \u9ad8\u4e8e \u539f\u5148 \u62a5\u9053 \u4e2d 3% \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 \u60a3\u8005 \u6709\u8840 \u75c7\u72b6 \u652f\u6301 \u65b0\u51a0 \u75c5\u6bd2 \u7ecf\u7531 \u6d88\u5316\u9053 \u4f20\u64ad \u673a\u5236 ", "\u82f1\u56fd \u536b\u751f\u90e8 \u8be5\u56fd \u7b2c\u4e8c\u4e2a \u5927\u578b \u65b0\u51a0 \u75c5\u6bd2\u68c0\u6d4b \u5b9e\u9a8c\u5ba4 \u5f53\u5929 \u6b63\u5f0f \u6295\u5165 \u8fd0\u8425 \u8fdb\u4e00\u6b65 \u5145\u5b9e \u8be5\u56fd \u75c5\u6bd2\u68c0\u6d4b \u7f51\u7edc \u5927\u5e45 \u63d0\u5347 \u5168\u56fd \u68c0\u6d4b \u80fd\u529b \u5960\u5b9a \u57fa\u7840 ", "\u745e\u58eb \u5236\u836f \u5546 \u8bfa\u534e \u516c\u53f8 \u6297\u759f\u836f \u7269 \u7f9f \u6c2f\u55b9 \u83b7\u6279 \u7f8e\u56fd \u6295\u5165 \u4e34\u5e8a\u8bd5\u9a8c \u68c0\u9a8c \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 ", "\u8377\u5170 \u9e7f\u7279\u4e39 \u4f0a\u62c9\u65af \u59c6\u65af \u75c5\u6bd2 \u7814\u7a76 \u4e2d\u5fc3 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u98df\u87f9 \u7334\u5747 \u672a \u4e34\u5e8a \u75c7\u72b6 \u7814\u7a76 \u56e2\u961f \u98df\u87f9 \u7334 \u611f\u67d3 \u6a21\u578b \u79d1\u5b66\u5bb6 \u4eba\u7c7b \u65e0\u75c7\u72b6 \u611f\u67d3\u8005 \u7fa4\u4f53 ", "\u725b\u6d25\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u5fb7\u5a01\u514b \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u975e\u6bd4\u5bfb\u5e38 \u7cd6\u57fa\u5316 \u7a0b\u5ea6 \u75c5\u6bd2 \u591a\u79cd \u7a81\u53d8 \u5236\u5907 \u6548\u679c \u75ab\u82d7 ", "\u6b27\u7f8e \u79d1\u7814\u4eba\u5458 \u8fd1\u671f \u53d1\u8868 \u4e00\u7cfb\u5217 \u65b0\u51a0 \u75c5\u6bd2 \u7814\u7a76 \u62a5\u544a \u663e\u793a \u65e0\u75c7\u72b6 \u611f\u67d3\u8005 \u6bd4\u4f8b \u9884\u60f3 \u9ad8 \u610f\u5473\u7740 \u65b0\u51a0 \u75c5\u6bd2 \u6574\u4f53 \u6740\u4f24\u529b \u4f4e\u4e8e \u60f3\u8c61 \u5e26\u6765 \u56e0\u7d20 \u6c11\u4f17 \u65e0\u4ece \u5f97\u77e5 \u8eab\u8fb9 \u770b\u4f3c \u5065\u5eb7 \u643a\u5e26 \u75c5\u6bd2 \u4f20\u67d3 \u8fd9\u4e00 \u60c5\u51b5 \u4ee4 \u590d\u5de5 \u590d\u4ea7 \u51b3\u7b56 \u8fc7\u7a0b \u590d\u6742\u5316 ", "\u82f1\u56fd \u56fd\u5bb6 \u533b\u7597 \u670d\u52a1\u4f53\u7cfb NHS \u4e2d \u8840\u6db2 \u79fb\u690d NHSBT \u90e8\u95e8 \u65b0\u51a0 \u80ba\u708e \u5eb7\u590d \u4eba\u5458 \u63a5\u89e6 \u5e0c\u671b \u5229\u7528 \u8840\u6d46 \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 ", "\u6d59\u6c5f\u5927\u5b66 \u738b\u798f \u4fe4 \u6559\u6388 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u9ad8\u8840\u538b \u5fc3\u8840\u7ba1 \u75be\u75c5 \u6162\u6027 \u80be\u75c5 \u7cd6\u5c3f\u75c5 \u6162\u6027 \u75be\u75c5 \u589e\u52a0 \u65b0\u51a0 \u80ba\u708e COVID - 19 \u91cd\u75c7 \u53d1\u751f \u98ce\u9669 \u6025\u6027 \u5fc3\u810f \u80be\u810f \u635f\u4f24 \u6b7b\u4ea1 \u98ce\u9669 \u9ad8\u5ea6 \u76f8\u5173 \u7814\u7a76 \u79d1\u5b66 \u7b5b\u67e5 \u65b0\u51a0 \u80ba\u708e \u91cd\u75c7 \u6b7b\u4ea1 \u9ad8\u5371 \u4eba\u7fa4 \u4f18\u5316 \u8bca\u7597 \u65b9\u6848 \u964d\u4f4e \u6b7b\u4ea1\u7387 \u63d0\u4f9b \u53ef\u9760 \u5faa\u8bc1 \u533b\u5b66 \u8bc1\u636e ", "\u6fb3\u5927\u5229\u4e9a \u4e2d\u56fd\u53f0\u6e7e\u5730\u533a \u5b66\u8005 \u5206\u6790 \u6e90\u81ea 12 \u56fd\u5bb6 106 SARS - CoV - 2 \u57fa\u56e0\u7ec4 \u5e8f\u5217 \u7814\u7a76 \u53d1\u73b0 \u75c5\u6bd2 \u4f20\u64ad SARS - CoV - 2 \u523a\u7a81 \u86cb\u767d \u65b0 \u53d8\u5f02 \u53d8\u5f02 \u5f71\u54cd \u523a\u7a81 \u86cb\u767d \u53d7\u4f53 ACE2 \u523a\u7a81 \u86cb\u767d \u7814\u53d1 \u75ab\u82d7 \u67d0\u79cd\u7a0b\u5ea6 \u524a\u5f31 \u673a\u4f53 \u514d\u75ab \u5e94\u7b54 \u672a\u77e5 \u7a81\u53d8 \u75c5\u6bd2 \u53d1\u6325\u4f5c\u7528 \u75ab\u82d7 \u5f00\u53d1 \u5e26\u6765 \u6311\u6218 ", "\u7f8e\u56fd \u56fd\u7acb \u536b\u751f \u7814\u7a76\u9662 NIH \u7814\u7a76 \u4eba\u5458 \u53d1\u8868 \u65b0\u82f1\u683c\u5170 \u533b\u5b66\u6742\u5fd7 \u7814\u7a76 \u5e73\u9759 \u5730\u4ee5 \u97f3\u91cf \u8bb2\u8bdd \u65f6\u4f1a \u6db2\u6ef4 \u6db2\u6ef4 \u7a7a\u6c14 \u4e2d \u60ac\u6d6e \u8db3\u591f \u957f \u65f6\u95f4 \u5176\u4ed6\u4eba \u547c\u5438\u9053 \u589e\u52a0 COVID - 19 \u75c5\u6bd2\u4f20\u64ad \u98ce\u9669 ", "\u5317\u4eac\u5927\u5b66\u7b2c\u4e09\u533b\u9662 \u4e54\u6770 \u9662\u58eb \u7814\u7a76 \u56de\u987e\u6027 \u5206\u6790 2019 \u5e74 12 \u6708 8 \u65e5\u81f3 2020 \u5e74 3 \u6708 20 \u65e5 \u6b66\u6c49 \u5730\u533a 50 \u5bb6 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u80ba\u708e \u8bca\u6cbb \u5b9a\u70b9\u533b\u9662 \u5b55\u4ea7\u5987 \u6d41\u884c\u75c5\u5b66 \u4e34\u5e8a \u7279\u5f81 \u5b9e\u9a8c\u5ba4 \u5f71\u50cf\u5b66 \u6cbb\u7597 \u9884\u540e \u6570\u636e \u7814\u7a76 \u7ed3\u679c\u663e\u793a 2019 \u5e74 12 \u6708 8 \u65e5\u81f3 2020 \u5e74 3 \u6708 20 \u65e5 \u671f\u95f4 \u6b66\u6c49 \u5730\u533a \u5171\u6709 118 \u540d \u5b55\u4ea7\u5987 \u611f\u67d3 SARS - CoV - 2 \u5360\u540c \u65f6\u95f4\u6bb5 \u6b66\u6c49 \u5730\u533a COVID - 19 \u60a3\u8005 0.24% \u611f\u67d3 \u5b55\u4ea7\u5987 \u4e2d\u4f4d \u5e74\u9f84 31 \u5c81 52% \u60a3\u8005 \u521d\u4ea7\u5987 64% \u60a3\u8005 \u5b55\u665a\u671f \u611f\u67d3 \u5e38\u89c1 \u75c7\u72b6 \u53d1\u70ed 75% \u54b3\u55fd 73% \u53e6\u6709 7% \u60a3\u8005 \u8179\u6cfb \u75c7\u72b6 44% \u60a3\u8005 \u6dcb\u5df4\u7ec6\u80de \u51cf\u5c11 \u75c7 79% \u60a3\u8005 CT \u68c0\u67e5 \u53d1\u73b0 \u53cc\u4fa7 \u80ba\u90e8 \u53d7\u7d2f \u60c5\u51b5 ", "\u7f8e\u56fd \u56fd\u7acb \u536b\u751f \u7814\u7a76\u9662 \u7814\u7a76 \u4eba\u5458 \u745e\u5fb7 \u897f\u97e6 \u6cbb\u7597 \u6052\u6cb3 \u7334 \u547c\u5438\u9053 \u75c7\u72b6 \u80ba\u90e8 \u708e\u75c7 \u51cf\u5c11 \u80ba\u90e8 \u75c5\u6bd2 \u8f7d\u91cf \u964d\u4f4e \u7814\u7a76 \u53d1\u73b0 \u745e\u5fb7 \u897f\u97e6 \u6cbb\u7597 \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u6052\u6cb3 \u7334\u65f6 \u4f53\u73b0 \u7f13\u89e3 \u547c\u5438\u9053 \u75c7\u72b6 \u51cf\u5c11 \u80ba\u4e2d \u75c5\u6bd2 \u590d\u5236 \u7597\u6548 \u643a\u5e26 \u75c5\u6bd2 \u671f\u95f4 \u6052\u6cb3 \u7334 \u6392\u6bd2 viral   shedding \u5e76\u672a \u51cf\u5c11 \u4f20\u64ad \u6027 ", "\u4e2d\u65e5\u53cb\u597d\u533b\u9662 \u526f \u9662\u957f \u66f9\u5f6c \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u91cd\u75c7 \u60a3\u8005 \u4e34\u5e8a\u8868\u73b0 \u75c5\u6bd2\u6027 \u8113\u6bd2\u75c7 \u76f8\u7b26 \u66f9\u5f6c \u63d0\u51fa \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 \u7ec6\u80de\u56e0\u5b50 \u98ce\u66b4 \u6dcb\u5df4\u7ec6\u80de \u964d\u4f4e \u5168\u8eab \u810f\u5668 \u53d7\u7d2f \u56e0\u7d20 \u6700\u7ec8 \u5bfc\u81f4 \u75c5\u4eba \u53d1\u4f5c \u75c5\u6bd2\u6027 \u8113\u6bd2\u75c7 \u65b0\u51a0 \u80ba\u708e \u5173\u952e \u81f4\u75c5 \u673a\u5236 ", "\u8377\u5170 \u9e7f\u7279\u4e39 \u4f0a\u62c9\u65af \u59c6\u65af \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u611f\u67d3 SARS - CoV - 2 \u7315\u7334 \u4e2d \u4e34\u5e8a \u4f53\u5f81 \u60c5\u51b5 \u75c5\u6bd2 \u9f3b \u5589\u4e2d \u6392\u51fa \u5f25\u6f2b\u6027 \u80ba\u6ce1 \u635f\u4f24 \u7076 \u9f3b \u652f\u6c14\u7ba1 \u652f\u6c14\u7ba1 \u7ea4\u6bdb \u4e0a\u76ae\u7ec6\u80de I \u578b II \u578b \u80ba \u7ec6\u80de \u4e2d \u68c0\u6d4b \u75c5\u6bd2   \u6570\u636e SARS - CoV - 2 \u7315\u7334 \u4e2d \u7c7b\u4f3c COVID - 19 \u75be\u75c5 \u6d4b\u8bd5 \u9884\u9632 \u6cbb\u7597 \u7b56\u7565 \u63d0\u4f9b \u65b0 \u6a21\u578b ", "\u7f8e\u56fd\u7ebd\u7ea6 \u897f\u5948\u5c71 \u4f0a\u574e \u533b\u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u63d0\u4f9b SARS - CoV - 2 \u547c\u5438\u9053 \u75c5\u6bd2 \u76f8\u6bd4 \u8f6c\u5f55 \u6df1\u5165\u5206\u6790 SARS - CoV - 2 \u611f\u67d3 \u7ec6\u80de \u52a8\u7269\u6a21\u578b COVID - 19 \u60a3\u8005 \u8f6c\u5f55 \u8840\u6e05 \u6982\u51b5 \u5206\u6790 \u5916 \u59cb\u7ec8 \u663e\u793a \u72ec\u7279 \u5f02\u5e38 \u708e\u75c7 \u51cf\u5f31 \u514d\u75ab \u75c5\u6bd2 \u6301\u7eed \u590d\u5236 \u53d1\u73b0 \u89e3\u91ca \u5408\u5e76\u75c7 \u60a3\u8005 \u4e2d \u89c2\u5bdf COVID - 19 \u75c5\u4f8b ", "Incyte \u542f\u52a8 \u4e00\u9879 \u4ee3\u53f7 RUXCOVID \u5168\u7403\u6027 \u968f\u673a \u53cc\u76f2 \u5b89\u6170\u5242 \u5bf9\u7167 III \u671f \u4e34\u5e8a\u8bd5\u9a8c \u8ba1\u5212 \u5168\u7403 \u62db\u52df \u7ea6 400 \u540d \u60a3\u8005 \u4e3a\u671f 29 \u5929 \u8bc4\u4f30 Jakafi \u82a6\u53ef\u66ff \u5c3c \u8054\u5408 \u6807\u51c6 \u62a4\u7406 SoC \u76f8\u6bd4 \u5b89\u6170\u5242 \u8054\u5408 SoC 12 \u5c81 COVID - 19 \u60a3\u8005 \u7ec6\u80de\u56e0\u5b50 \u98ce\u66b4 \u7597\u6548 \u5b89\u5168\u6027 \u5dee\u5f02 ", "\u5c71\u4e1c\u5927\u5b66 \u738b\u57f9\u4f1a \u6559\u6388 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 SARS - CoV - 2 \u75c5\u6bd2 \u7279\u5f02\u6027 \u6297\u4f53 COVID - 19 \u60a3\u8005 \u4f53\u5185 \u957f\u671f\u5b58\u5728 \u4e24\u4f8b \u60a3\u8005 \u4e2d \u89c2\u5bdf SARS - CoV - 2 \u7279\u5f02\u6027 IgG \u6297\u4f53 \u5171\u5b58 \u957f\u8fbe 50 \u5929 \u7279\u5f02\u6027 \u6297\u4f53 \u6e05\u9664 SARS - CoV - 2 \u5fc5\u8981\u6761\u4ef6 \u63ed\u793a \u4e2a\u4f53 \u611f\u67d3 SARS - CoV - 2 \u6297\u4f53 ", "\u5e7f\u5dde \u533b\u79d1\u5927\u5b66 \u674e\u65f6\u60a6 \u949f\u5357\u5c71 \u4e2d\u56fd \u5168\u56fd\u6027 \u6570\u636e \u96c6\u6765 \u63cf\u7ed8 COVID - 19 \u60a3\u8005 \u9759\u8109 \u8840\u6813 \u6813\u585e \u98ce\u9669 \u7814\u7a76 \u53d1\u73b0 \u9ad8\u98ce\u9669 \u9759\u8109 \u8840\u6813 \u6813\u585e COVID - 19 \u60a3\u8005 \u4f4e \u98ce\u9669 \u60a3\u8005 \u9884\u540e \u8f83\u5dee \u60a3\u8005 \u5feb\u901f \u6076\u5316 \u60c5\u51b5 \u5173\u6ce8 ", "\u4e16\u536b \u7ec4\u7ec7 \u536b\u751f \u7d27\u6025 \u9879\u76ee \u8d1f\u8d23\u4eba \u8fc8\u514b\u5c14 \u745e\u5b89 \u6e29\u5ea6 \u6e7f\u5ea6 \u6c14\u5019 \u56e0\u7d20 \u65b0\u51a0 \u75c5\u6bd2 \u5f71\u54cd \u4e5f\u8bb8 \u5b66\u4e60 \u5171\u5b58 ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u53d1\u5e03 \u6bcf\u65e5 \u75ab\u60c5\u62a5\u544a \u6307\u51fa \u8fc4\u4eca \u8bc1\u636e \u53e3\u670d \u810a\u9ad3\u7070\u8d28\u708e \u75ab\u82d7 \u4fdd\u62a4 \u514d\u53d7 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 \u63a8\u8350 \u63a5\u79cd \u75ab\u82d7 \u9884\u9632 \u65b0\u51a0 \u80ba\u708e ", "\u9999\u6e2f\u5927\u5b66 \u4e16\u536b \u4f20\u67d3\u75c5 \u6d41\u884c\u75c5\u5b66 \u63a7\u5236 \u5408\u4f5c \u4e2d\u5fc3 \u5218 \u6d69\u7136 \u5229\u7528 \u516c\u5f00 \u6570\u636e 77 \u4f20\u64ad ( transmission   pairs ) \u4fe1\u606f \u65b0\u51a0 \u80ba\u708e \u4f20\u67d3 \u529b \u7279\u5f81 \u5efa\u6a21 \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u80ba\u708e \u75c7\u72b6 \u524d \u4e24\u4e09\u5929 \u611f\u67d3 \u75c7\u72b6 \u524d 0.7 \u5929 \u5cf0\u503c \u4f30\u8ba1 44% \u7ee7\u53d1 \u75c5\u4f8b \u75c7\u72b6 \u524d \u9636\u6bb5 \u611f\u67d3 \u9884\u8ba1 \u75c5\u6bd2 \u4f20\u67d3 \u529b 7 \u5929\u5185 \u5feb\u901f \u4e0b\u964d ", "\u5e7f\u4e1c\u7701 \u75be\u75c5 \u9884\u9632 \u63a7\u5236\u4e2d\u5fc3 \u67ef\u660c\u6587 \u7814\u7a76 \u56e2\u961f \u6d41\u884c\u75c5\u5b66 \u7cfb\u7edf\u53d1\u80b2 \u5206\u6790 \u76f8\u7ed3\u5408 \u7ed3\u679c\u8868\u660e \u6d41\u884c \u521d\u671f \u75c5\u6bd2 \u9057\u4f20\u53d8\u5f02 \u4f4e \u7cfb\u7edf\u53d1\u80b2 \u805a\u7c7b \u5c1a \u7814\u7a76 \u7ed3\u679c\u8868\u660e \u5047\u5b9a \u4f20\u8f93 \u94fe \u65f6\u95f4 \u89c4\u6a21 \u6301\u7eed\u65f6\u95f4 \u56fd\u5bb6 \u51fa\u884c \u8be5\u7701 \u5927\u89c4\u6a21 \u5bc6\u96c6 \u76d1\u89c6 \u5e72\u9884 \u63aa\u65bd \u7ea6\u675f ", "\u798f\u5efa \u533b\u79d1\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 2020 \u5e74 4 \u6708 3 \u65e5 \u5171\u6709 23 \u540d \u536b\u751f\u4fdd\u5065 \u4e13\u4e1a \u4eba\u5458 \u6b7b\u4e8e Covid - 19 \u6b66\u6c49 \u4e2d\u56fd \u5730\u533a \u533b\u5b66 \u5b9e\u8df5 \u4e2d \u611f\u67d3 \u8868\u73b0 \u6025\u6027 \u547c\u5438 \u7a98\u8feb \u7efc\u5408\u5f81 ARDS \u5916 \u60a3\u8005 Covid - 19 \u5e76\u53d1\u75c7 \u5305\u62ec \u5fc3\u810f \u635f\u4f24 \u8d25\u8840 \u6027\u4f11\u514b \u5668\u5b98 \u529f\u80fd\u969c\u788d \u7efc\u5408\u5f81 \u9ad8\u51dd\u6027 \u5fc3 \u8840\u6813 \u83cc\u8840\u75c7 ", "\u6df1\u5733 \u7b2c\u4e09 \u533b\u9662 \u9648\u519b \u65b0\u51a0 \u75c5\u4eba \u809d\u529f\u80fd \u7279\u5f81\u5206\u6790 \u53d1\u73b0 \u6d1b\u5339 \u97e6 / \u5229\u6258 \u97e6 \u60a3\u8005 \u9ad8 \u809d\u810f \u635f\u4f24 \u98ce\u9669 \u7814\u7a76 \u5168\u7403 \u8513\u5ef6 \u65b0\u51a0 \u75ab\u60c5 \u63d0\u4f9b \u4e2d\u56fd \u7ecf\u9a8c \u4e34\u5e8a \u6570\u636e \u652f\u6301 \u7814\u7a76 \u56e2\u961f \u63d0\u51fa \u809d\u529f\u80fd \u5f02\u5e38 \u60a3\u8005 \u6613 \u53d1\u5c55 \u6210 \u75be\u75c5 \u72b6\u6001 \u4f4f\u9662 \u671f\u95f4 \u6cbb\u7597 \u836f\u7269 \u5bfc\u81f4 \u809d\u810f \u635f\u4f24 \u5e94 \u7ed9\u4e88 \u6301\u7eed \u76d1\u63a7 ", "\u5370\u5ea6 \u533b\u5b66 \u7814\u7a76 \u59d4\u5458\u4f1a ICMR \u7814\u7a76 \u4eba\u5458 \u4e09\u79cd \u8759\u8760 \u4e2d \u53d1\u73b0 6 \u79cd\u65b0 \u51a0\u72b6\u75c5\u6bd2 \u7814\u7a76 \u4eba\u5458 \u8fdb\u4e00\u6b65 \u7814\u7a76 \u516d\u79cd \u65b0\u75c5\u6bd2 \u8f6c\u79fb \u7269\u79cd \u4f53\u5185 \u53ef\u80fd\u6027 \u4eba\u7c7b \u5065\u5eb7 \u5f71\u54cd ", "\u7f8e\u56fd \u75be\u75c5 \u63a7\u5236 \u9884\u9632 \u4e2d\u5fc3 \u53d1\u5e03 \u7f8e\u56fd \u65b0\u51a0 \u80ba\u708e \u75c5\u4f8b \u4eba\u53e3 \u7edf\u8ba1\u5b66 \u7279\u5f81 \u6570\u636e \u62a5\u544a \u62a5\u544a \u4e2d \u63d0\u51fa \u73b0\u6709 \u7edf\u8ba1\u6570\u636e \u4e2d \u75c5\u4f8b \u5e74\u9f84 18 - 44 \u5c81 45 - 64 \u5c81 \u5e74\u9f84\u6bb5 \u95f4 73% \u75c5\u4f8b \u53d1\u751f 18 - 64 \u5c81 \u4e4b\u95f4 \u53e6\u6709 90619 \u4f8b \u75c5\u4eba \u8d85\u8fc7 65 \u5c81 \u79cd\u65cf \u767d\u4eba \u75c5\u4f8b \u4e2d 80% \u5e74\u9f84 \u8d85\u8fc7 65 \u5c81 45 - 64 \u5c81 \u5e74\u9f84\u7ec4 \u4e2d 34% \u75c5\u4f8b \u662f\u975e \u88d4 \u7f8e\u56fd \u9ed1\u4eba ", "\u5317\u6d77\u9053 \u5927\u5b66\u6559\u6388 \u897f\u6d66\u535a \u4eba\u5458 \u5916\u51fa \u4e25\u5389 \u63aa\u65bd \u65e5\u672c \u5c06\u4f1a 85 \u4e07\u4eba \u9677\u5165 \u91cd\u75c7 \u611f\u67d3 \u72b6\u6001 \u9884\u8ba1 \u4e00\u534a 42 \u4e07\u4eba\u4f1a \u6b7b\u4ea1 ", "\u4e2d\u56fd \u591a\u5730 \u533b\u52a1 \u5de5\u4f5c\u8005 \u7f9f\u57fa \u6c2f\u55b9 COVID - 19 \u60a3\u8005 \u62a4\u7406 \u6807\u51c6 \u4e2d \u63d0\u5347 \u60a3\u8005 \u65b0\u51a0 \u75c5\u6bd2 \u8f6c\u9634 \u7387 \u52a0\u901f \u4e34\u5e8a \u75c7\u72b6 \u7f13\u89e3 \u7f9f \u6c2f\u55b9 \u6709\u52a9\u4e8e \u65b0\u51a0 \u60a3\u8005 \u4e34\u5e8a \u75c7\u72b6 \u7f13\u89e3 \u63a5\u53d7\u8005 \u4e0d\u826f\u53cd\u5e94 \u660e\u663e\u589e\u52a0 \u5173\u6ce8 \u526f\u4f5c\u7528 ", "\u4e34\u5e8a\u8bd5\u9a8c \u6ce8\u518c \u7f51\u7ad9 clinicaltrials \u663e\u793a \u4e2d\u56fd \u745e\u5fb7 \u897f\u97e6 \u6cbb\u7597 \u91cd\u75c7 COVID - 19 \u4e34\u5e8a\u8bd5\u9a8c \u7ec8\u6b62 \u7406\u7531 \u4e2d\u56fd \u63a7\u5236 COVID - 19 \u6d41\u884c \u8db3\u591f \u60a3\u8005 \u5165\u7ec4 ", "\u52a0\u5dde\u5927\u5b66 \u65e7\u91d1\u5c71 \u5206\u6821 \u7814\u7a76 \u4eba\u5458 \u7814\u5236 \u4e00\u79cd CRISPR \u8bca\u65ad \u5de5\u5177 \u5feb\u901f \u68c0\u6d4b SARS - CoV - 2 \u8fd9\u4e00 \u8bca\u65ad \u5de5\u5177 45 \u5206\u949f \u7ed9\u51fa \u51c6\u786e\u6027 \u7f8e\u56fd \u75be\u75c5 \u9884\u9632 \u63a7\u5236\u4e2d\u5fc3 RT - PCR \u68c0\u6d4b \u76f8\u6bd4 \u6d4b\u8bd5 \u9633\u6027 \u9884\u6d4b \u7b26\u5408\u7387 95% \u9634\u6027 \u9884\u6d4b \u7b26\u5408\u7387 100% ", "\u4e0a\u6d77 \u4e2d\u533b\u836f\u5927\u5b66 \u9644\u5c5e \u66d9\u5149 \u533b\u9662 \u547c\u5438\u79d1 \u4e3b\u4efb \u5f20\u709c \u91cd\u75c7 \u60a3\u8005 \u4e2d 75% \u80ba\u7ea4\u7ef4\u5316 \u80ba\u7ea4\u7ef4\u5316 \u5bfc\u81f4 \u7f3a\u6c27 \u547c\u5438\u673a \u4f9d\u8d56 \u7528\u5230 ECMO \u4e2d\u533b \u80ba\u7ea4\u7ef4\u5316 \u8d77\u5230 \u4f5c\u7528 ", "\u56fd\u9645 \u6b27\u4e9a \u79d1\u5b66\u9662 \u9662\u58eb \u738b\u4f1f \u6e05\u80ba \u6392\u6bd2 \u6c64 28 \u7701\u5e02 \u6536\u5230 \u6548\u679c \u4e34\u5e8a \u6551\u6cbb \u7ec4 \u7814\u7a76 \u53d1\u73b0 \u6cbb\u6108\u7387 \u9ad8\u8fbe 99.28% \u4e34\u5e8a \u75c7\u72b6 \u6539\u5584 \u975e\u5e38\u660e\u663e ", "\u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u540c\u6d4e \u533b\u5b66\u9662 \u57fa\u7840 \u533b\u5b66\u9662 \u9ec4\u6ce2 \u6559\u6388 \u8bfe\u9898\u7ec4 \u7814\u7a76 \u53d1\u73b0 \u514d\u75ab \u7ec6\u80de \u7cd6\u539f \u4ee3\u8c22 \u901a\u8def \u63a7\u5236 \u7ec6\u80de\u56e0\u5b50 \u98ce\u66b4 \u7cd6\u539f \u6216\u80fd \u963b\u63a7 \u65b0\u51a0 \u80ba\u708e \u81f4\u547d \u98ce\u66b4 ", "\u6b66\u6c49 \u542f\u52a8 1.1 \u4e07\u4eba \u8840\u6e05 \u6d41\u884c\u75c5\u5b66 \u8c03\u67e5 \u8fd9\u9879 \u8c03\u67e5 \u610f\u4e49 \u6781\u4e3a\u91cd\u8981 \u6570\u636e \u65b0\u51a0 \u75c5\u6bd2 \u611f\u67d3\u7387 \u65e0\u75c7\u72b6 \u611f\u67d3 \u5360 \u6bd4\u4f8b \u6bd4\u4f8b \u672a\u6765 \u9632\u63a7 \u5f71\u54cd ", "\u6b66\u6c49\u5e02 \u6838\u9178 \u68c0\u6d4b \u5e73\u53f0 \u7edf\u8ba1\u6570\u636e 4 \u6708 8 \u65e5 4 \u6708 14 \u65e5 \u4e00\u5468 225999 \u6838\u9178 \u68c0\u6d4b \u53d1\u73b0 \u65e0\u75c7\u72b6 \u611f\u67d3\u8005 130 \u4f8b \u68c0\u51fa\u7387 0.0575% \u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u540c\u6d4e \u533b\u5b66\u9662 \u516c\u5171\u536b\u751f \u5b66\u9662 \u6d41\u884c\u75c5 \u536b\u751f\u7edf\u8ba1 \u5b66\u7cfb \u6559\u6388 \u9b4f\u665f \u6d41\u884c\u75c5\u5b66 \u89d2\u5ea6 \u73b0\u9636\u6bb5 \u6570\u91cf \u65e0\u75c7\u72b6 \u611f\u67d3\u8005 \u786e\u8bca \u75c5\u4f8b \u7b26\u5408 \u4f20\u67d3\u75c5 \u6d41\u884c \u57fa\u672c\u89c4\u5f8b \u5e02\u6c11 \u65e0\u9700 \u6050\u614c ", "\u7f8e\u56fd\u54c8\u4f5b\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u4e00\u9879 \u65b0 \u7814\u7a76 \u663e\u793a \u8fd9\u6ce2 \u65b0\u51a0 \u75ab\u60c5 \u75ab\u60c5 \u5468\u671f\u6027\u5730 \u51ac\u5b63 \u66b4\u53d1 \u73b0\u6709 \u793e\u4ea4 \u8ddd\u79bb \u63aa\u65bd \u5ef6\u957f 2022 \u5e74 ", "\u7f8e\u56fd \u65b0\u6cfd\u897f\u5dde \u7f57 \u683c\u65af \u5927\u5b66 \u751f\u7269\u5236\u5242 \u5b9e\u9a8c\u5ba4 \u7814\u53d1 \u5168\u7f8e \u9996\u9879 \u91c7\u96c6 \u553e\u6db2 \u68c0\u6d4b \u65b0\u51a0 \u75c5\u6bd2 \u6280\u672f \u5468\u516d \u7f8e\u56fd \u98df\u54c1 \u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40 FDA \u7d27\u6025 \u6388\u6743 \u6279\u51c6 60 \u4f4d \u60a3\u8005 \u553e\u6db2 \u9f3b\u54bd \u4e24\u79cd \u68c0\u6d4b \u7ed3\u679c\u663e\u793a \u553e\u6db2 \u6d4b\u8bd5 \u9f3b\u54bd \u6d4b\u8bd5 100% \u76f8\u7b26 ", "\u82ac\u5170 \u963f\u5c14\u6258 \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u4e00\u9879 \u75c5\u6bd2\u4f20\u64ad \u6a21\u62df\u5b9e\u9a8c \u5b9e\u9a8c \u663e\u793a \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u8d85\u5e02 \u5bc6\u95ed \u7a7a\u95f4 \u91cc \u54b3\u55fd \u75c5\u6bd2 \u77ac\u95f4 \u9053 \u6269\u6563 \u5f00\u6765 1 \u5206\u949f \u75c5\u6bd2 \u8513\u5ef6\u5230 \u901a\u9053 \u7a7f\u8fc7 \u8d27\u67b6 2 \u5206\u949f \u75c5\u6bd2 \u6269\u6563 \u65c1\u8fb9 \u9053 \u65b0\u51a0 \u75c5\u6bd2 \u8d85\u5e02 \u4f20\u64ad \u5f88\u8fdc \u8ddd\u79bb \u51e0\u5206\u949f \u4e4b\u5185 \u5b58\u7559 \u7a7a\u6c14 \u4e2d ", "\u5317\u4eac\u5927\u5b66 \u63f4\u9102 \u6297\u75ab \u56fd\u5bb6 \u533b\u7597\u961f \u9886\u5bfc \u7ec4\u7ec4\u957f \u4e54\u6770 \u9662\u58eb \u65b0\u51a0 \u75c5\u6bd2 \u5f71\u54cd \u751f\u6b96\u7cfb\u7edf \u6bcd\u5a74 \u5782\u76f4 \u4f20\u64ad \u8fdb\u4e00\u6b65 \u7814\u7a76 \u63ed\u793a \u5efa\u8bae \u65b0\u51a0 \u80ba\u708e \u6108\u540e \u60a3\u8005 \u4e09\u4e2a \u6708 \u534a\u5e74 \u751f\u80b2 ", "\u4e2d\u79d1\u9662 \u4e0a\u6d77 \u836f\u7269 \u6240\u8bb8 \u53f6\u6625 \u53f6\u9633 \u7814\u7a76 \u4eba\u5458 \u9ec4\u82a9 \u82f7 \u9ec4\u82a9 \u7d20 \u9274\u5b9a SARS - CoV - 2   3CLpro \u7b2c\u4e00\u79cd \u975e \u5171\u4ef7 \u975e\u62df \u80bd \u6291\u5236\u5242 \u7ec6\u80de \u7cfb\u7edf \u4e2d \u8868\u73b0 \u5f3a\u5927 \u6297\u75c5\u6bd2 \u6d3b\u6027 \u7814\u7a76 \u53d1\u73b0 \u9ec4\u82a9 \u82f7 \u9ec4\u82a9 \u7d20 \u7b80\u5355 \u5316\u5b66 \u7ed3\u6784 \u72ec\u7279 \u4f5c\u7528 \u65b9\u5f0f \u5f3a\u5927 \u4f53\u5916 \u6297\u75c5\u6bd2 \u6d3b\u6027 \u4e34\u5e8a\u8bd5\u9a8c \u5b89\u5168\u6027 \u6570\u636e \u9ec4\u82a9 \u7d20\u4e3a \u5f00\u53d1 \u6025\u9700 \u6297 \u51a0\u72b6\u75c5\u6bd2 \u836f\u7269 \u63d0\u4f9b \u673a\u4f1a ", "\u6e25\u592a\u534e \u5927\u5b66 \u751f\u7269\u5b66 \u6559\u6388 \u590f\u65ed\u534e \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u8759\u8760 \u8eab\u4e0a \u643a\u5e26 \u51a0\u72b6\u75c5\u6bd2 \u5148\u662f \u611f\u67d3 \u72ac\u79d1 \u52a8\u7269 \u80a0\u9053 \u72ac\u79d1 \u52a8\u7269 \u8eab\u4e0a \u53d1\u751f \u5feb\u901f \u53d8\u5f02 \u8fdb\u5316 \u9996\u6b21 \u611f\u67d3 \u4eba\u7c7b \u6d41\u6d6a\u72d7 \u4eba\u7c7b \u65b0\u51a0 \u75ab\u60c5 \u6d41\u884c \u6e90\u5934 ", "\u56db\u5ddd\u5927\u5b66 \u534e\u897f \u533b\u9662 \u7814\u7a76 \u4eba\u5458 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u80ba\u708e \u7f3a\u4e4f \u6cbb\u7597 \u836f\u7269 \u60c5\u51b5 \u56db\u5ddd\u7701 \u6551\u6cbb \u7ecf\u9a8c \u63d0\u793a \u65e9\u671f \u8bc6\u522b \u7ed9\u4e88 \u547c\u5438 \u652f\u6301 \u65b9\u5f0f \u91cd\u75c7 COVID - 19 \u60a3\u8005 \u75c5\u6b7b\u7387 \u4f4e\u6c34\u5e73 \u91cd\u75c7 COVID - 19 \u75c5\u7a0b \u65e9\u671f \u76d1\u6d4b \u4f20\u7edf \u6c27\u7597 \u4f18 \u6551\u6cbb \u63aa\u65bd ", "\u6b27\u6d32 \u76f8\u5173 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u8fd1\u671f \u91cd\u7ec4 \u4e8b\u4ef6 \u751f\u6210 \u4f30\u8ba1 \u8759\u8760 \u51a0\u72b6\u75c5\u6bd2 RaTG13 \u5206\u79bb \u65f6\u95f4 \u7ea6 1948 1982 \u5e74 \u4e4b\u95f4 \u8de8\u79cd \u611f\u67d3 \u53d1\u751f \u76f8\u5173 \u8fdb\u5316 \u83ca\u5934\u8760 \u79cd\u7fa4 \u4e2d ", "\u5168\u7403 120 \u591a\u540d \u79d1\u5b66\u5bb6 \u533b\u751f \u8d44\u52a9\u8005 \u751f\u4ea7\u5546 \u4e13\u5bb6\u7ec4 4 \u6708 13 \u65e5 \u53d1\u8868 \u516c\u5f00 \u5ba3\u8a00 \u627f\u8bfa \u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u534f\u8c03 \u5171\u540c\u52aa\u529b \u52a0\u5feb \u65b0\u51a0 \u75ab\u82d7 \u7814\u53d1 ", "\u79d1\u6280\u90e8 \u751f\u7269 \u4e2d\u5fc3 \u526f \u4e3b\u4efb \u5b59\u71d5\u8363 \u75ab\u60c5 \u53d1\u751f \u79d1\u7814 \u653b\u5173\u7ec4 \u7b2c\u4e00 \u65f6\u95f4 \u90e8\u7f72 \u5e94\u6025 \u79d1\u7814 \u653b\u5173\u9879\u76ee \u4e00\u7cfb\u5217 \u6210\u679c \u5305\u62ec \u4e34\u5e8a \u6279\u4ef6 \u4e34\u5e8a \u836f\u7269 4 \u9879 \u6307\u5bfc \u610f\u89c1 \u4e13\u5bb6 \u5171\u8bc6 5 \u9879 \u8d85\u8fc7 10 \u9879 \u6210\u679c \u7eb3\u5165 \u8bca\u7597 \u65b9\u6848 \u4e34\u5e8a \u6551\u6cbb \u4e2d \u4e00\u7cfb\u5217 \u6210\u679c ", "\u4e2d\u56fd \u4e24\u6b3e \u65b0\u51a0 \u75c5\u6bd2 \u706d \u6d3b\u75ab\u82d7 \u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40 \u4e8c\u671f \u5408\u5e76 \u4e34\u5e8a\u8bd5\u9a8c \u8bb8\u53ef \u76f8\u5173 \u4e34\u5e8a\u8bd5\u9a8c \u540c\u6b65 \u542f\u52a8 \u4e24\u6b3e \u65b0\u51a0 \u75c5\u6bd2 \u706d \u6d3b\u75ab\u82d7 \u56fd\u836f \u96c6\u56e2 \u4e2d\u56fd \u751f\u7269 \u6b66\u6c49 \u751f\u7269\u5236\u54c1 \u7814\u7a76\u6240 \u5317\u4eac \u79d1\u5174 \u4e2d \u7ef4\u751f\u7269 \u6280\u672f \u6709\u9650\u516c\u53f8 \u8054\u5408 \u79d1\u7814\u673a\u6784 \u5f00\u53d1 \u800c\u6210 ", "\u4e2d\u56fd \u4e34\u5e8a \u6cbb\u7597 \u65b0 \u6280\u672f \u7814\u53d1 \u4e00\u7cfb\u5217 \u8fdb\u5c55 \u5e72\u7ec6\u80de \u6cbb\u7597 \u7a81\u7834\u6027 \u8fdb\u5c55 \u6b66\u6c49 \u8d85\u8fc7 200 \u4f8b \u5e72\u7ec6\u80de \u6cbb\u7597 \u5e72\u7ec6\u80de \u65b0\u51a0 \u80ba\u708e \u4e34\u5e8a \u6cbb\u7597 \u5b89\u5168\u6027 \u4e34\u5e8a \u63d0\u793a \u6539\u5584 \u80ba\u90e8 \u708e\u75c7 \u63d0\u9ad8 \u91cd\u75c7 \u60a3\u8005 \u6551\u6cbb \u7387 \u91cd\u75c7 \u5eb7\u590d \u671f \u60a3\u8005 \u80ba\u7ea4\u7ef4\u5316 \u6539\u5584 \u4f5c\u7528 ", "\u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u540c\u6d4e \u533b\u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 214 \u540d \u60a3\u8005 \u8d85\u8fc7 \u4e09\u6210 36.4% \u795e\u7ecf\u7cfb\u7edf \u75c7\u72b6 \u795e\u7ecf \u4e34\u5e8a \u75c7\u72b6 \u5206 3 \u7c7b \u4e2d\u67a2\u795e\u7ecf \u7cfb\u7edf \u75c7\u72b6 \u5934\u6655 \u5934\u75db \u610f\u8bc6 \u969c\u788d \u6025\u6027 \u8111\u8840\u7ba1 \u75be\u75c5 \u5171\u6d4e\u5931\u8c03 \u766b\u75eb \u53d1\u4f5c \u5916\u5468 \u795e\u7ecf\u7cfb\u7edf \u75c7\u72b6 \u5473\u89c9 \u635f\u4f24 \u55c5\u89c9 \u635f\u4f24 \u89c6\u89c9 \u635f\u4f24 \u795e\u7ecf \u75bc\u75db \u9aa8\u9abc\u808c \u635f\u4f24 ", "\u7f8e\u56fd \u75be\u75c5 \u63a7\u5236 \u9884\u9632 \u4e2d\u5fc3 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 COVID - 19 \u75c5\u6bd2 \u978b\u5e95 \u4f20\u64ad \u4f20\u64ad \u8ddd\u79bb \u81f3\u5c11 4 \u7c73 ", "\u7ebd\u7ea6 \u54e5\u4f26\u6bd4\u4e9a\u5927\u5b66 \u6b27\u6587 \u533b\u5b66\u4e2d\u5fc3 \u7814\u7a76 \u4eba\u5458 \u5165\u9662 \u65f6 SARS - CoV - 2 \u9633\u6027 33 \u4f8b \u60a3\u8005 \u4e2d\u6709 29 \u4f8b 87.9 \u5c31\u8bca \u65f6 Covid - 19 \u75c7\u72b6 \u7b5b\u9009 \u65e0\u75c7\u72b6 \u60a3\u8005 \u81f3\u5173\u91cd\u8981 \u4fdd\u62a4 \u6bcd\u4eb2 \u5a74\u513f \u533b\u7597 \u56e2\u961f \u63d0\u4f9b \u673a\u4f1a ", "\u590d\u65e6\u5927\u5b66 \u4e0a\u6d77 \u516c\u5171\u536b\u751f \u4e34\u5e8a \u4e2d\u5fc3 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 30% \u60a3\u8005 \u6297\u4f53 \u6ef4\u5ea6 \u975e\u5e38\u4f4e 10 \u540d \u5eb7\u590d \u60a3\u8005 \u4f53\u5185 \u6297\u4f53 \u6ef4\u5ea6 \u672a \u68c0\u51fa \u6781\u9650\u503c \u8bc4\u4f30 NAb \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u75c5\u6bd2 \u6e05\u9664 \u75be\u75c5 \u8fdb\u5c55 \u5f71\u54cd \u5e94 \u8fdb\u4e00\u6b65 \u63a2\u7d22 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u4e2d \u75c5\u6bd2 \u5bbf\u4e3b \u514d\u75ab \u4e4b\u95f4 \u76f8\u4e92\u4f5c\u7528 \u5f00\u53d1 \u6297 SARS - CoV - 2 \u75c5\u6bd2 \u75ab\u82d7 ", "\u5fb7\u56fd \u751f\u7269 \u6280\u672f \u516c\u53f8 BioNTech \u8054\u5408 \u4e13\u6709 mRNA \u75ab\u82d7 \u5e73\u53f0 \u8f89\u745e \u75ab\u82d7 \u7814\u53d1 \u76d1\u7ba1 \u80fd\u529b \u5168\u7403 \u5236\u9020 \u5206\u9500 \u7f51\u7edc \u4e13\u4e1a\u77e5\u8bc6 \u63a8\u8fdb COVID - 19   mRNA \u75ab\u82d7 \u7814\u53d1 \u8ba1\u5212 4 \u6708\u5e95 \u7f8e\u56fd \u6b27\u6d32 \u591a\u4e2a \u5730\u70b9 BNT162 COVID - 19 \u5019\u9009 \u75ab\u82d7 \u4e34\u5e8a\u8bd5\u9a8c ", "\u65e5\u672c \u5bcc\u58eb \u80f6\u7247 \u516c\u53f8 \u65e5\u672c \u63a5\u53d7 \u6d4b\u8bd5 \u7528\u4e8e \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u6297\u75c5\u6bd2 \u836f\u7269 Avigan \u9a6c\u8428\u8bf8\u585e\u5dde \u6295\u5165 \u7f8e\u56fd \u9996\u6279 \u4e34\u5e8a\u8bd5\u9a8c ", "\u54c8\u4f5b\u5927\u5b66 \u7814\u7a76 \u53d1\u73b0 \u751f\u6d3b \u9ad8 \u6c61\u67d3\u73af\u5883 \u4f4e\u6536\u5165 \u4eba\u7fa4 \u65cf\u88d4 \u66f4\u6613 \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u75c5\u4ea1 ", "\u82f1\u7f8e \u79d1\u5b66\u5bb6 \u643a\u624b \u5236\u4f5c \u9996\u4e2a \u65b0\u51a0 \u75c5\u6bd2 \u523a\u7a81 \u86cb\u767d \u6a21\u578b \u63ed\u793a \u75c5\u6bd2 \u4f2a\u88c5 \u6f5c\u5165 \u4f53\u7ec6\u80de \u53d1\u73b0 \u7814\u7a76 \u4eba\u5458 \u79f0 \u523a\u7a81 \u86cb\u767d \u6297\u4f53 \u75ab\u82d7 \u7814\u7a76 \u6807\u9776 \u8fd9\u4e00 \u6700\u65b0 \u53d1\u73b0 \u5f00\u53d1 \u51fa\u65b0 \u51a0 \u75c5\u6bd2 \u75ab\u82d7 \u63d0\u4f9b \u4fe1\u606f ", "\u4e2d\u56fd\u79d1\u5b66\u9662 \u5927\u8fde \u5316\u5b66 \u7269\u7406 \u7814\u7a76\u6240 \u79d1\u7814\u4eba\u5458 \u63d0\u51fa \u4e00\u79cd \u5168\u65b0 \u5e2d\u592b\u78b1 \u6c34\u89e3 \u52a8\u6001 \u5171\u4ef7 \u5316\u5b66 \u65b9\u6cd5 \u553e\u6db2\u9178 \u7cd6\u94fe \u7cbe\u786e \u6355\u83b7 \u8fd9\u4e3a \u540e\u7eed \u63ed\u793a \u75c5\u6bd2 \u4fb5\u67d3 \u673a\u5236 \u53d1\u73b0 \u65b0 \u75be\u75c5 \u751f\u7269 \u6807\u8bb0 \u7269 \u836f\u7269 \u9776\u70b9 \u5f00\u53d1 \u6297\u75c5\u6bd2 \u836f\u7269 \u75ab\u82d7 \u6253\u4e0b\u57fa\u7840 ", "\u56fd\u836f \u96c6\u56e2 \u4e2d\u56fd \u751f\u7269 \u6b66\u6c49 \u751f\u7269\u5236\u54c1 \u7814\u7a76\u6240 \u6709\u9650\u8d23\u4efb \u516c\u53f8 \u7814\u53d1 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 COVID - 19 \u706d \u6d3b\u75ab\u82d7 Vero \u7ec6\u80de \u2160 / \u2161 \u671f \u4e34\u5e8a\u8bd5\u9a8c \u4e2d\u56fd \u4e34\u5e8a\u8bd5\u9a8c \u6ce8\u518c \u4e2d\u5fc3 \u6b63 \u5904\u4e8e \u5ba1\u6838 \u9884 \u6ce8\u518c \u72b6\u6001 \u8fd9\u662f \u4e2d\u56fd \u7b2c\u4e8c\u4e2a \u6ce8\u518c \u4e34\u5e8a\u8bd5\u9a8c \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u75ab\u82d7 ", "\u519b\u4e8b\u79d1\u5b66\u9662 \u519b\u4e8b\u533b\u5b66 \u7814\u7a76\u6240 \u751f\u7269\u5de5\u7a0b \u7814\u7a76\u6240 \u9648\u8587 \u9662\u58eb \u56e2\u961f \u7275\u5934 \u7814\u53d1 \u91cd\u7ec4 \u65b0\u51a0 \u75c5\u6bd2 \u817a\u75c5\u6bd2 \u8f7d\u4f53 \u75ab\u82d7   II   \u671f \u4eba\u4f53 \u4e34\u5e8a\u8bd5\u9a8c \u6b63\u5f0f \u6b66\u6c49 \u53d7\u8bd5\u8005 \u63a5\u79cd \u8bd5\u9a8c \u8fd9\u662f \u5168\u7403 \u9996\u6b3e   II   \u671f \u4eba\u4f53 \u4e34\u5e8a\u8bd5\u9a8c \u65b0\u51a0 \u75c5\u6bd2 \u75ab\u82d7 ", "\u6b66\u6c49\u5927\u5b66 \u674e\u7ea2\u826f \u7cfb\u7edf \u4ecb\u7ecd ACE2 \u751f\u7406\u5b66 \u529f\u80fd \u9610\u8ff0 ACE2 COVID - 19 \u4e2d \u6f5c\u5728 \u6cbb\u7597 \u4f5c\u7528 ", "\u5317\u4eac\u5927\u5b66 \u6765\u9c81\u534e \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u9ec4\u82a9 \u4e59\u9187 \u63d0\u53d6\u7269 \u4f53\u5916 \u6291\u5236 SARS - CoV - 2   3CLpro \u6d3b\u6027 SARS - CoV - 2 Vero \u7ec6\u80de \u4e2d \u590d\u5236 \u9ec4\u82a9 \u6210\u5206 \u4e2d \u9ec4\u82a9 \u7d20 \u6291\u5236 SARS - CoV - 2   3CLpro \u6d3b\u6027 \u9ec4\u82a9 \u63d0\u53d6\u7269 \u6297 SARS - CoV - 2 \u6d3b\u6027 \u9ec4\u82a9 \u7d20 \u7c7b\u4f3c\u7269 \u5f3a\u6548 SARS - CoV - 2   3CLpro \u6291\u5236\u5242 ", "\u5df4\u897f \u7814\u7a76 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u6c2f\u55b9 \u9ad8 \u5242\u91cf 12   g \u836f \u65b9\u6848 \u5b89\u5168\u9690\u60a3 \u5f3a\u70c8\u5efa\u8bae \u5242\u91cf \u5730\u65b9 \u7528\u4e8e \u6cbb\u7597 COVID - 19 \u66f4\u597d \u7406\u89e3 \u6c2f\u55b9 \u7f9f \u6c2f\u55b9 COVID - 19 \u4e2d \u4f5c\u7528 \u7814\u7a76 \u4eba\u5458 \u63a8\u8350 \u8bc4\u4f30 \u6c2f\u55b9 \u9884\u9632\u6027 \u836f\u7269 \u4e34\u5e8a\u8bd5\u9a8c \u8f7b / \u4e2d\u5ea6 COVID - 19 \u60a3\u8005 \u4e2d \u8c03\u67e5 \u8be5\u836f \u9884\u9632 \u75be\u75c5 \u91cd\u5ea6 \u8fdb\u5c55 \u7597\u6548 ", "\u6fb3\u5927\u5229\u4e9a \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u4f0a\u7ef4 \u83cc\u7d20 \u6291\u5236 \u65b0\u51a0 \u75c5\u6bd2 \u7814\u7a76 \u5c1a\u5904 \u521d\u59cb \u9636\u6bb5 \u836f\u7269 \u6740\u6b7b \u65b0\u51a0 \u75c5\u6bd2 \u51cf\u7f13 \u589e\u6b96 \u901f\u5ea6 \u8be5\u836f \u7528\u4e8e \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u9700 \u6d4b\u8bd5 ", "\u65b0\u82f1\u683c\u5170 \u533b\u5b66\u6742\u5fd7 NEJM \u520a\u53d1 \u745e\u5fb7 \u897f\u97e6 remdesivir \u540c\u60c5 \u7528\u836f \u60c5\u51b5 \u6cbb\u7597 \u91cd\u75c7 \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u8bd5\u9a8c \u8bd5\u9a8c \u7ed3\u679c\u8868\u660e 53 \u540d \u5168\u7403 \u91cd\u75c7 \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u745e\u5fb7 \u897f\u97e6\u540e 36 \u540d \u60a3\u8005 68% \u75c7\u72b6 \u7f13\u89e3 \u8bd5\u9a8c \u6570\u636e \u5c40\u9650\u6027 \u745e\u5fb7 \u897f\u97e6 \u7597\u6548 \u7b49\u5f85 \u968f\u673a\u5bf9\u7167 \u4e34\u5e8a\u8bd5\u9a8c ", "\u4e0a\u6d77 \u516c\u5171\u536b\u751f \u4e34\u5e8a \u7814\u7a76 \u4e2d\u5fc3 175 \u540d \u5eb7\u590d \u8f7b\u75c7 \u60a3\u8005 \u51fa\u9662 \u524d \u8840\u6e05 \u6297\u4f53 \u6ef4\u5ea6 \u7814\u7a76 \u53d1\u73b0 30% \u60a3\u8005 \u6297\u4f53 \u6ef4\u5ea6 \u975e\u5e38\u4f4e \u8840\u6e05 \u68c0\u6d4b \u68c0\u51fa\u7387 \u5e26\u6765 \u65b0 \u6311\u6218 ", "\u9976\u5b50 \u9662\u58eb \u56e2\u961f \u7387\u5148 \u56fd\u9645 \u6210\u529f \u89e3\u6790 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 RdRp RNA \u4f9d\u8d56 RNA \u805a\u5408\u9176 - nsp7 - nsp8 \u590d\u5408\u7269 \u539f\u5b50 \u5206\u8fa8\u7387 \u4e09\u7ef4\u7a7a\u95f4 \u7ed3\u6784 \u7814\u7a76\u6210\u679c \u7814\u7a76 \u63ed\u793a \u75c5\u6bd2 \u9057\u4f20\u7269\u8d28 \u8f6c\u5f55 \u590d\u5236 \u673a\u5668 \u6838\u5fc3 \u5f15\u64ce \u7ed3\u6784\u7279\u5f81 \u5f00\u53d1 COVID - 19 \u836f\u7269 \u5960\u5b9a \u57fa\u7840 ", "\u610f\u5927\u5229 \u9521\u8036\u7eb3 \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7edf\u8ba1 \u610f\u5927\u5229\u4eba ACE2 \u57fa\u56e0 \u9057\u4f20\u53d8\u5f02 \u9274\u5b9a 3 \u5e38\u89c1 \u53d8\u5f02 \u4f53 30 \u7f55\u89c1 \u9519\u4e49 \u53d8\u5f02 \u4f53 \u8fdb\u4e00\u6b65 \u63a8\u6d4b \u610f\u5927\u5229\u4eba ACE2 \u53d8\u5f02 SARS - CoV - 2 \u6613\u611f ", "\u5251\u6865\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 12 \u6708 24 \u65e5\u81f3 3 \u6708 4 \u65e5 GitHub \u5e73\u53f0 Nextstrian \u5168\u7403 160 \u4efd \u65b0\u51a0 \u611f\u67d3 \u6837\u672c \u5168 \u57fa\u56e0\u7ec4 \u5206\u6790 \u7ed8\u5236 \u65b0\u51a0 \u75c5\u6bd2 \u8fdb\u5316 \u56fe\u8c31 \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 3 \u53d8\u4f53 \u539f\u59cb \u6bd2\u682a \u7f8e \u6fb3 \u5206\u5e03 \u4e2d\u56fd \u4e8c\u4ee3 \u53d8\u5f02\u578b ", "\u52a0\u62ff\u5927 \u963f\u5c14\u4f2f \u5854 \u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u4e00\u79cd \u51a0\u72b6\u75c5\u6bd2 \u86cb\u767d\u9176 \u86cb\u767d\u9176 \u6291\u5236\u5242 \u7c7b\u836f\u7269 \u6cbb\u7597 \u732b \u51a0\u72b6\u75c5\u6bd2 \u5f88\u5927 \u5e0c\u671b \u7528\u4e8e COVID - 19 \u60a3\u8005 \u6cbb\u7597 ", "\u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u90ac\u5802 \u6625 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u4e00\u7cfb\u5217 \u591a\u65b9\u9762 \u516c\u5171\u536b\u751f \u5e72\u9884 \u63aa\u65bd \u65f6\u95f4 \u4e2d\u56fd \u6b66\u6c49\u5e02 COVID - 19 \u66b4\u53d1 \u63a7\u5236 \u6539\u5584 \u53d1\u73b0 \u6709\u52a9\u4e8e \u56fd\u5bb6 \u5730\u533a \u5236\u5b9a \u516c\u5171\u536b\u751f \u653f\u7b56 ", "\u65af\u5766\u798f\u5927\u5b66 \u6559\u6388 \u6234\u7ef4 M \u65af\u5854\u5fb7 \u7279 \u6559\u6388 \u5b66\u4e60 \u4e2d\u56fd \u5206\u533a \u5206\u7ea7 \u7cbe\u51c6 \u9632\u63a7 \u65b9\u6cd5 \u793e\u533a Covid - 19 \u6d41\u884c \u7a0b\u5ea6 \u8c03\u9ad8 \u8c03\u4f4e \u6d4b\u8bd5 \u65b9\u6848 \u7a0b\u5ea6 ", "\u7f8e\u56fd \u5357\u52a0\u5dde \u5927\u5b66 \u516c\u5171\u653f\u7b56 \u5b66\u9662 \u526f \u9662\u957f \u5c3c\u62c9 \u6770 \u82cf\u5fb7 \u6297\u4f53 \u68c0\u6d4b \u6838\u9178 \u68c0\u6d4b \u5f97\u77e5 \u4f20\u64ad \u65b0\u51a0 \u75c5\u6bd2 \u75c5\u6bd2 \u514d\u75ab \u5224\u65ad \u8fd4\u56de \u5de5\u4f5c\u5c97\u4f4d \u533b\u62a4\u4eba\u5458 \u4e00\u7ebf \u5de5\u4f5c\u8005 \u8d85\u5e02 \u836f\u5e97 \u5783\u573e\u5904\u7406 \u5c97\u4f4d \u5de5\u4f5c\u4eba\u5458 ", "\u82f1\u56fd \u7814\u7a76 \u4eba\u5458 \u8fdb\u5316 \u5173\u7cfb \u65b0\u51a0 \u75c5\u6bd2 \u53d8\u79cd \u5206\u4e3a A B C \u4e09\u7c7b A \u7c7b \u8759\u8760 \u7a7f\u5c71\u7532 \u8eab\u4e0a \u63d0\u53d6 \u75c5\u6bd2 \u6700\u4e3a \u53d1\u73b0 \u7f8e\u56fd \u6fb3\u5927\u5229\u4e9a \u53d7 \u611f\u67d3\u8005 \u7814\u7a76 \u4eba\u5458 \u79f0 A \u7c7b\u75c5\u6bd2 \u7206\u53d1 \u6839\u6e90 B \u7c7b \u6bd2\u682a \u4e2d\u56fd \u5883\u5185 \u7c7b\u578b C \u7c7b \u6b27\u6d32 \u5927\u89c4\u6a21 \u4f20\u64ad \u4e9a\u6d32\u5730\u533a \u9999\u6e2f \u65b0\u52a0\u5761 \u97e9\u56fd \u7c7b\u578b ", "\u4e2d\u56fd \u4e2d\u533b \u79d1\u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u9996\u6b21 \u62a5\u544a \u598a\u5a20 \u4e2d\u671f \u5206\u5a29 \u524d 37 \u5929 \u8bca\u65ad COVID - 19 \u611f\u67d3 \u5b55\u5987 \u75c5\u4f8b \u9634\u9053 \u6210\u529f \u5206\u5a29 SARS - CoV - 2 \u611f\u67d3 \u4ea7\u513f \u5987\u5973 \u598a\u5a20 \u665a\u671f \u53d1\u751f \u5bab\u5185 \u4f20\u64ad SARS - CoV - 2 ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u66f9\u96ea\u6d9b \u81ea\u7136 \u514d\u75ab\u5b66 \u7efc\u8ff0 \u5728\u7ebf \u53d1\u8868 \u9898\u4e3a \u65b0\u51a0 \u80ba\u708e \u514d\u75ab\u75c5\u7406 \u6cbb\u7597 \u542f\u793a \u8bc4\u8ff0 \u6587\u7ae0 \u6587\u7ae0 \u9610\u8ff0 \u514d\u75ab \u65b0\u51a0 \u80ba\u708e \u53d1\u75c5 \u6cbb\u7597 \u4e2d \u4f5c\u7528 \u514d\u75ab\u8c03\u8282 \u5f71\u54cd \u65b0\u51a0 \u80ba\u708e \u8f6c\u5f52 \u6cbb\u7597 \u8fdb\u4e00\u6b65 \u63a2\u7d22 \u65b0\u51a0 \u80ba\u708e \u6cbb\u7597 \u65b0 \u9776\u6807 \u5e72\u9884 \u65b0\u9014\u5f84 ", "\u725b\u6d25\u5927\u5b66 \u75ab\u82d7 \u5b66 \u6559\u6388 \u838e\u62c9 \u5409\u5c14\u4f2f\u7279 \u4e00\u5207\u987a\u5229 \u56e2\u961f \u7814\u53d1 \u65b0\u51a0 \u75c5\u6bd2 \u75ab\u82d7 \u79cb\u5b63 \u524d \u51c6\u5907\u5c31\u7eea ", "\u5eb7\u5e0c\u8bfa \u751f\u7269 \u80a1\u4efd\u516c\u53f8 \u79f0 \u519b\u4e8b\u79d1\u5b66\u9662 \u519b\u4e8b\u533b\u5b66 \u7814\u7a76\u9662 \u9662\u58eb \u9648\u8587 \u56e2\u961f \u5408\u4f5c \u7814\u53d1 \u91cd\u7ec4 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u75ab\u82d7 \u817a\u75c5\u6bd2 \u8f7d\u4f53 Ad5 - nCoV \u8fd1\u671f \u2161 \u671f \u4e34\u5e8a\u8bd5\u9a8c ", "\u949f\u5357\u5c71 \u9662\u58eb \u56e2\u961f \u79d1\u7814 \u8bba\u6587 2019 \u5e74 \u4e2d\u56fd \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u4e34\u5e8a \u4e2d 1099 \u4f8b\u65b0\u51a0 \u80ba\u708e \u786e\u8bca \u60a3\u8005 \u4e34\u5e8a \u7279\u5f81 \u56de\u987e\u6027 \u5206\u6790 \u7814\u7a76 \u53d1\u73b0 \u5438\u70df \u7537\u6027 COVID - 19 \u60a3\u8005 \u91cd\u75c7 \u6bd4\u4f8b \u9ad8\u4e8e \u975e \u5438\u70df \u7537\u6027 \u60a3\u8005 ", "\u81ea\u7136 \u6742\u5fd7 \u9898\u4e3a \u505c\u6b62 \u51a0\u72b6\u75c5\u6bd2 \u6c61\u540d \u5316 \u523b\u4e0d\u5bb9\u7f13 \u793e\u8bba \u6587\u7ae0 \u4e2d \u8fd9\u573a \u75ab\u60c5 \u6d41\u884c \u52a9\u957f \u53ef\u60b2 \u79cd\u65cf\u4e3b\u4e49 \u6b67\u89c6 \u4e9a\u6d32 \u6b67\u89c6 \u6559\u80b2 \u7814\u7a76 \u4ed8\u51fa\u4ee3\u4ef7 ", "\u9999\u6e2f \u76f8\u8fbe \u751f\u7269\u79d1\u6280 \u516c\u53f8 \u75ab\u60c5 \u7206\u53d1 \u7814\u53d1 \u65b0\u51a0 \u75c5\u6bd2 RNA \u63d0\u53d6 \u8bd5\u5242\u76d2 \u5229\u7528 \u6db2\u76f8 \u6838\u9178 \u63d0\u53d6 \u6280\u672f \u63d0\u51fa \u6838\u9178 \u4f20\u7edf \u65b9\u5f0f \u627e\u51fa \u66f4\u591a\u5047 \u9634\u6027 \u5f31\u9633\u6027 \u6848\u4f8b ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u603b\u5e72\u4e8b \u8c2d \u5fb7\u585e \u6307\u51fa \u65b0\u51a0 \u80ba\u708e \u75c5\u4ea1 \u7387 \u4f30\u8ba1 \u6d41\u611f \u9ad8 10 \u500d \u76ee\u7779 \u65b0\u51a0 \u75c5\u6bd2 \u53d1\u8fbe\u56fd\u5bb6 \u5371\u5bb3 \u8d2b\u7a77 \u8106\u5f31 \u56fd\u5bb6 \u7834\u574f \u672a \u663e\u73b0 ", "\u4e0a\u6d77 \u79d1\u6280 \u5927\u5b66 \u9976\u5b50 / \u6768 \u6d77\u6d9b \u56e2\u961f \u7387\u5148 \u56fd\u9645 \u6210\u529f \u89e3\u6790 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u5173\u952e \u836f\u7269 \u9776\u70b9 \u4e3b \u86cb\u767d\u9176 Mpro \u9ad8\u5206\u8fa8\u7387 \u4e09\u7ef4\u7a7a\u95f4 \u7ed3\u6784 \u7efc\u5408\u5229\u7528 3 \u836f\u7269 \u53d1\u73b0 \u7b56\u7565 \u627e\u5230 \u65b0\u51a0 \u75c5\u6bd2 \u6f5c\u5728 \u836f\u7269 ", "\u9999\u6e2f\u5927\u5b66 \u674e\u5609\u8bda \u533b\u5b66\u9662 \u6881\u5353\u4f1f \u80e1\u5b50 \u797a \u6881\u8bd7\u654f \u7814\u7a76 \u53d1\u73b0 \u56fd \u5b9e\u65bd \u4e00\u63fd\u5b50 \u975e \u836f\u7269 \u5e72\u9884 \u63aa\u65bd \u5305\u62ec \u793e\u4f1a \u9694\u79bb \u4eba\u53e3 \u6539\u53d8 \u5927\u5927\u964d\u4f4e COVID - 19 \u5168\u56fd \u4f20\u64ad \u80fd\u529b \u76d1\u6d4b \u77ac\u65f6 \u7e41\u6b96 \u6570\u91cf \u5b9e\u65f6 \u8c03\u6574 \u653f\u7b56 \u5e72\u9884 \u63aa\u65bd \u786e\u4fdd \u53ef\u63a7 \u6ce2 \u6d6a\u6f6e \u538b\u5012\u4e00\u5207 \u516c\u5171\u536b\u751f \u91cd\u70b9 ", "\u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u516c\u5171\u536b\u751f \u5b66\u9662 \u5f90\u987a\u6e05 \u7814\u7a76 \u53d1\u73b0 \u5404\u56fd \u653f\u5e9c \u5e94\u7acb\u5373 \u91c7\u53d6\u884c\u52a8 \u505a\u597d \u786e\u4fdd \u536b\u751f\u4fdd\u5065 \u7cfb\u7edf \u8db3\u591f \u52b3\u52a8\u529b \u8d44\u6e90 \u8bbe\u65bd \u7a0b\u5ea6 \u964d\u4f4e COVID - 19 \u6b7b\u4ea1 \u98ce\u9669 ", "\u7f8e\u56fd \u56fe\u5170 \u5927\u5b66 ( Tulane   University ) \u79d1\u7814\u4eba\u5458 \u7f57\u4f0a \u7814\u7a76 \u53d1\u73b0 \u6e7f\u70ed \u5b9e\u9a8c\u5ba4 \u73af\u5883 \u89c2\u5bdf \u65b0\u51a0 \u75c5\u6bd2 16 \u5c0f\u65f6 \u65b0\u51a0 \u75c5\u6bd2 \u5b58\u6d3b \u65f6\u95f4 \u6d41\u611f\u75c5\u6bd2 \u7334 \u75d8\u75c5\u6bd2 \u80ba\u7ed3\u6838 \u75c5\u6bd2 SARS \u75c5\u6bd2 \u957f ", "\u6570\u5764 ( \u5317\u4eac ) \u7f51\u7edc\u79d1\u6280 \u6709\u9650\u516c\u53f8 \u6210\u529f \u7814\u53d1 \u65b0\u51a0 \u80ba\u708e \u667a\u80fd \u5f71\u50cf \u5206\u6790 \u7cfb\u7edf \u7cfb\u7edf \u534f\u52a9 \u4e00\u7ebf \u533b\u751f \u5feb\u901f \u51c6\u786e \u6d77\u91cf \u80ba\u90e8 CT \u5f71\u50cf \u5927\u5e45 \u964d\u4f4e \u7591\u4f3c\u75c5\u4f8b \u7b5b\u67e5 \u8fc7\u7a0b \u4e2d \u4ea4\u53c9\u611f\u67d3 \u53ef\u80fd\u6027 ", "\u4e2d\u79d1\u9662 \u82cf\u5dde \u533b\u5de5 \u6c6a \u5927\u660e \u7814\u7a76\u5458 \u9886\u8854 \u56e2\u961f \u5f00\u53d1 \u4e00\u5957 \u65b0\u51a0 \u75c5\u6bd2 \u6838\u9178 \u5feb\u901f \u68c0\u6d4b \u7cfb\u7edf \u8fd9\u4e00 \u7cfb\u7edf \u5e38\u6e29 \u50a8\u5b58 \u8fd0\u8f93 45 \u5206\u949f \u5b9a\u6027 \u4eea\u5668 \u4f53\u79ef \u643a\u5e26 \u53ef\u5bf9 \u65b0\u51a0 \u75c5\u6bd2 \u6838\u9178 \u73b0\u573a \u5373\u65f6 \u68c0\u6d4b ", "\u6e05\u534e\u5927\u5b66 \u675c\u514b - \u65b0\u52a0\u5761\u56fd\u7acb\u5927\u5b66 \u7814\u7a76 \u56e2\u961f \u8759\u8760 \u57fa\u56e0 \u4e2d \u7b5b\u9009 \u75c5\u6bd2\u611f\u67d3 \u7ec6\u80de \u5173\u952e \u5bbf\u4e3b \u56e0\u5b50 \u53d1\u73b0 \u6291\u5236 \u5bbf\u4e3b \u56e0\u5b50 \u7269\u8d28 \u5236\u6210 \u5e7f\u8c31\u6297 \u75c5\u6bd2 \u836f\u7269 \u6f5c\u529b ", "\u6885\u5965 \u533b\u5b66\u4e2d\u5fc3 \u4f20\u67d3\u75c5 \u514d\u75ab \u5b9e\u9a8c\u5ba4 \u4e3b\u4efb \u63d0\u5965 ( Elitza   Theel ) \u6307\u51fa \u65b0\u51a0 \u80ba\u708e \u6d4b\u8bd5 \u627e\u5230 \u75c5\u6bd2 \u57fa\u56e0 \u6750\u6599 \u627e \u75c5\u6bd2 \u611f\u67d3 \u9a8c\u8bc1 \u6297\u4f53 \u627e \u6297\u75c5\u6bd2 \u514d\u75ab \u514d\u75ab \u53d1\u5c55 \u65f6\u95f4 ", "\u5fb7\u56fd\u8054\u90a6 \u836f\u54c1 \u533b\u7597\u5668\u68b0 \u7814\u7a76\u6240 \u65b0\u51a0 \u80ba\u708e \u91cd\u75c7 \u60a3\u8005 \u836f\u7269 \u6cbb\u7597 \u65b9\u6cd5 \u65e0\u6548 \u60c5\u51b5 \u745e\u5fb7 \u897f\u97e6 \u6cbb\u7597 ", "\u5409\u5229 \u5fb7 \u79d1\u5b66 Gilead \u4e24\u9879 \u745e\u5fb7 \u897f\u97e6 \u6cbb\u7597 \u4e2d \uff3c \u91cd\u75c7 COVID - 19d \u4e34\u5e8a\u8bd5\u9a8c \u5165\u7ec4 \u91cd\u5ea6 \u60a3\u8005 \u4eba\u6570 400 \u4f8b \u63d0\u9ad8 2400 \u4f8b \u4e2d\u5ea6 \u60a3\u8005 \u4eba\u6570 600 \u4f8b \u63d0\u9ad8 1600 \u4f8b \u9884\u8ba1 5 \u6708\u4efd \u8bd5\u9a8c ", "\u97e9\u56fd \u75be\u75c5 \u7ba1\u7406 \u672c\u90e8 \u97e9\u56fd \u8bca\u65ad \u68c0\u67e5 \u533b\u5b66\u4f1a \u79f0 \u6682\u672a \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u53d1\u751f \u53d8\u5f02 \u63a8\u5e7f Sample   Pooling \u65b9\u6cd5 \u75c5\u6bd2\u68c0\u6d4b ", "\u535a\u5fb7 \u7814\u7a76\u6240 \u5f20\u950b \u56e2\u961f \u63d0\u51fa LAMP - Seq \u6761\u5f62\u7801 \u9006\u8f6c\u5f55 \u5faa\u73af \u4ecb\u5bfc \u7b49\u6e29 \u6269\u589e RT - LAMP \u65b9\u6cd5 \u964d\u4f4e \u4eba\u53e3 \u89c4\u6a21 \u6d4b\u8bd5 \u6210\u672c \u590d\u6742\u6027 \u65b9\u6cd5 \u6269\u5c55 \u89c4\u6a21 \u6d4b\u5e8f \u5206\u6790 \u6570\u767e\u4e07\u4e2a \u6837\u54c1 ", "\u97e9\u56fd \u57fa\u7840\u79d1\u5b66 \u7814\u7a76\u6240 Dongwan   Kim \u7814\u7a76 \u4eba\u5458 \u5229\u7528 \u4e24\u79cd \u4e92\u8865 \u6d4b\u5e8f \u6280\u672f \u5c55\u793a SARS - CoV - 2 \u8f6c\u5f55 \u7ec4\u548c \u8868\u89c2 \u8f6c\u5f55 \u7ec4 \u9ad8\u5206\u8fa8\u7387 \u56fe \u8fd9\u9879 \u7814\u7a76 \u4e2d \u53d1\u73b0 \u672a\u77e5 \u8f6c\u5f55 RNA \u4fee\u9970 \u529f\u80fd \u7814\u7a76 SARS - CoV - 2 \u751f\u547d\u5468\u671f \u81f4\u75c5\u6027 \u7406\u89e3 \u5f00\u8f9f \u65b0 \u65b9\u5411 ", "\u4e2d\u56fd\u519c\u79d1\u9662 \u54c8\u5c14\u6ee8 \u517d\u533b \u7814\u7a76\u6240 \u9648\u5316\u5170 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u72d7 \u732a \u9e21 \u9e2d\u5b50 \u4e2d \u590d\u5236 \u80fd\u529b \u5f88\u5dee \u96ea \u8c82 \u732b \u8eab\u4e0a \u590d\u5236 \u7814\u7a76 \u56e2\u961f \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u547c\u5438\u9053 \u98de\u6cab \u732b \u4e4b\u95f4 \u4f20\u64ad \u732b \u75c5\u6bd2 \u4f20\u67d3\u7ed9 \u4eba\u7c7b ", "\u4e2d\u56fd \u7814\u7a76 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u6062\u590d\u671f \u8840\u6d46 \u4e2d \u75c5\u6bd2\u8840\u75c7 \u6539\u5584 \u91cd\u578b COVID - 19 \u60a3\u8005 \u4e34\u5e8a \u6f5c\u80fd \u6062\u590d\u671f \u8840\u6d46 \u6cbb\u7597 COVID - 19 \u60a3\u8005 \u6700\u4f73 \u5242\u91cf \u836f \u65f6\u95f4 \u786e\u5207 \u4e34\u5e8a \u6548\u76ca \u5927\u89c4\u6a21 \u5bf9\u7167 \u8bd5\u9a8c \u4e2d \u505a \u8fdb\u4e00\u6b65 \u7814\u7a76 ", "\u7231\u5c14\u5170 \u90fd\u67cf\u6797 \u5723\u4e09\u4e00 \u5927\u5b66 \u4e00\u9879 \u65b0\u51a0 \u75c5\u6bd2 \u7814\u7a76 \u62a5\u544a \u663e\u793a \u7ef4\u751f\u7d20 D \u62b5\u6297 \u9884\u9632 \u65b0\u51a0 \u80ba\u708e ", "\u6e56\u5317\u7701 \u6b66\u6c49\u5e02 \u75be\u63a7\u4e2d\u5fc3 \u7814\u7a76 \u4eba\u5458 \u56de\u987e\u6027 \u68c0\u6d4b \u7814\u7a76 \u53d1\u73b0 \u8fdf\u4e8e 1 \u6708 8 \u65e5 1 \u6708\u521d \u6b66\u6c49\u5e02 \u5468\u8fb9\u5730\u533a \u65b0\u51a0 \u75c5\u6bd2 \u793e\u533a \u4f20\u64ad \u8feb\u5207\u9700\u8981 \u7cfb\u7edf \u4eba\u7fa4 \u8840\u6e05\u5b66 \u8c03\u67e5 \u63ed\u793a COVID - 19 \u5b8c\u6574 \u4f20\u64ad \u72b6\u51b5 \u4f20\u64ad \u5386\u53f2 ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u5f20 \u6539\u5e73 \u5f00\u53d1 \u65b0\u51a0 \u75ab\u82d7 \u4e2d\u56fd\u79d1\u5b66\u9662 \u6b66\u6c49 \u75c5\u6bd2 \u7814\u7a76\u6240 \u516c\u5e03 \u65b0\u51a0 \u75c5\u6bd2\u57fa\u56e0 \u5e8f\u5217 \u8bbe\u8ba1 \u51fa\u65b0 \u75ab\u82d7 \u6297\u539f \u5206\u5b50 \u5efa\u7acb \u54fa\u4e73\u52a8\u7269 \u7ec6\u80de \u8868\u8fbe \u7cfb \u7eaf\u5316 \u6297\u539f \u86cb\u767d \u7528\u5fae \u5242\u91cf \u514d\u75ab \u52a8\u7269 \u52a8\u7269 5 \u5fae\u514b \u52a8\u7269 10 \u5fae\u514b \u9ad8\u8fbe \u767e\u4e07\u500d \u8bd5\u7eb8 \u6d4b\u8bd5 \u6548\u4ef7 \u6297\u4f53 ", "\u56fd\u836f \u96c6\u56e2 \u4e2d\u56fd \u751f\u7269 \u7814\u7a76 \u4eba\u5458 \u63a5\u53d7 \u6cbb\u7597 \u60a3\u8005 \u4e34\u5e8a \u6570\u636e \u7814\u7a76 \u53d1\u73b0 \u5eb7\u590d\u8005 \u8840\u6d46 \u6cbb\u7597 \u6539\u5584 \u91cd\u75c7 \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u4e34\u5e8a \u75c7\u72b6 \u964d\u4f4e \u75c5\u6bd2 \u8f7d\u91cf \u5b89\u5168\u6027 ", "\u81ea\u7136 \u6742\u5fd7 \u5b98\u65b9\u7f51\u7ad9 \u65e5\u524d \u53d1\u8868 \u793e\u8bba \u79f0 \u5168\u7403 \u5404\u56fd \u79d1\u5b66\u5bb6 \u96c6\u7ed3 \u8de8\u56fd \u8de8\u6d32 \u5408\u4f5c \u65f6\u95f4 \u60f3\u6cd5 \u4e13\u4e1a\u77e5\u8bc6 \u8bbe\u5907 \u91d1\u94b1 \u6e90\u6e90\u4e0d\u65ad \u6295\u5165 \u7d27\u6025 \u516c\u5171\u536b\u751f \u5de5\u4f5c \u4e2d \u5bfb\u627e \u5e94\u5bf9 \u75ab\u60c5 \u65b9\u6cd5 ", "\u4e2d\u56fd \u75be\u75c5 \u63a7\u5236\u4e2d\u5fc3 CDC \u539f\u526f \u4e3b\u4efb \u6768\u529f\u7115 \u6307\u51fa \u505c\u7559 \u6b66\u6c49 \u79bb\u5f00 \u6b66\u6c49 \u524d \u505a \u6838\u9178 \u68c0\u6d4b \u51cf\u5c11 \u75c5\u6bd2\u4f20\u64ad \u51e0\u7387 \u51cf\u5c11 \u540e\u671f \u9632\u63a7 \u6210\u672c ", "\u7ebd\u7ea6\u65f6\u62a5 \u8457\u540d \u4e13\u680f\u4f5c\u5bb6 Carl   Zimmer \u7ebd\u7ea6\u65f6\u62a5 \u79d1\u5b66 \u56fe\u5f62 \u7f16\u8f91 Jonathan   Corum \u53d1\u8868 \u9898\u4e3a Bad   News   Wrapped   in   Protein :   Inside   the   Coronavirus   Genome   \u6587\u7ae0 \u6587\u7ae0 SARS - CoV - 2 \u7f16\u7801 29 \u86cb\u767d \u6a21\u5f0f\u56fe \u7b80\u660e \u6613\u61c2 \u6587\u5b57 \u5448\u73b0 ", "\u671f\u520a IJAA \u53d1\u5e03\u516c\u544a \u79f0 \u7f9f \u6c2f\u55b9 \u963f\u5947 \u9709\u7d20 \u8054\u5408 \u6cbb\u7597 COVID - 19 \u4e34\u5e8a\u8bd5\u9a8c \u7814\u7a76 \u8bba\u6587 \u7b26\u5408 ISAC \u9884\u671f \u6807\u51c6 \u7279\u522b \u7f3a\u4e4f \u53d7\u8bd5\u8005 \u5165\u9009 \u6807\u51c6 \u60a3\u8005 \u75c5\u60c5 \u5206\u7c7b \u9610\u8ff0 \u4fdd\u8bc1 \u53d7\u8bd5 \u60a3\u8005 \u8bd5\u9a8c ", "\u5fb7\u56fd \u54e5\u5ef7\u6839\u5927\u5b66 \u7814\u7a76 \u56e2\u961f \u53d1\u5e03 \u62a5\u544a \u62a5\u544a \u663e\u793a \u5404\u56fd \u5e73\u5747 \u53d1\u73b0 \u7ea6 6 \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u5168\u4e16\u754c \u611f\u67d3 \u4eba\u6570 \u51e0\u5343\u4e07 \u4e16\u754c \u5404\u56fd \u6b63\u5f0f \u53d1\u5e03 \u5a92\u4f53 \u62a5\u9053 \u65b0\u51a0 \u80ba\u708e \u786e\u8bca \u75c5\u4f8b \u6570 \u4f4e\u4e8e \u771f\u5b9e \u611f\u67d3 \u6570 ", "\u5317\u5361\u7f57\u6765\u7eb3 \u5927\u5b66 \u6559\u5802 \u5c71 \u5206\u6821 \u8457\u540d \u75c5\u6bd2\u5b66 \u4e13\u5bb6 Ralph   Baric \u6559\u6388 \u56e2\u961f \u53d1\u73b0 \u4e00\u79cd \u540d\u4e3a EIDD - 2801 \u53e3\u670d \u5e7f\u8c31\u6297 \u75c5\u6bd2 \u836f\u80fd \u6291\u5236 \u5c0f\u9f20 \u4f53\u5185 \u51a0\u72b6\u75c5\u6bd2 \u964d\u4f4e \u80ba \u635f\u4f24 EIDD - 2801 \u6291\u5236 \u745e\u5fb7 \u897f\u97e6 Remdesivir \u8010\u836f \u75c5\u6bd2 \u4e92\u8865 \u6548\u5e94 \u8be5\u836f \u5f88\u5feb \u4e34\u5e8a\u8bd5\u9a8c ", "\u82f1\u56fd \u5723\u739b\u4e3d \u533b\u9662 \u7814\u7a76 \u4eba\u5458 COVID - 19 \u6cbb\u7597 \u9884\u9632\u6027 \u4ecb\u5165 \u4e34\u5e8a\u8bd5\u9a8c \u8bc4\u4f30 \u5168\u7403 \u6cbb\u7406 \u7b56\u7565 \u6297\u75c5\u6bd2 \u6cbb\u7597 \u6297\u759f \u6cbb\u7597 \u514d\u75ab \u6291\u5236\u5242 / \u514d\u75ab \u8c03\u8282\u5242 \u7ec6\u80de \u8840\u6d46 \u6cbb\u7597 \u6cbb\u7597 \u7b56\u7565 ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u65b0\u51a0 \u80ba\u708e \u534f\u8c03 \u4e13\u5458 \u739b\u4e3d\u4e9a \u8303 \u79d1\u970d\u592b \u79f0 \u540d\u4e3a \u56e2\u7ed3 II Solidarity   II \u8840\u6e05 \u6297\u4f53 \u6d4b\u8bd5 \u7814\u7a76 \u672a\u6765 \u51e0\u5929 \u542f\u52a8 \u8d85\u8fc7 6 \u56fd\u5bb6 \u53c2\u4e0e \u6297\u4f53 \u6d4b\u8bd5 \u6709\u52a9\u4e8e \u66f4\u597d \u75c5\u6bd2 \u4f20\u64ad \u60c5\u51b5 ", "\u7ebd\u7ea6 \u57ce\u5e02 \u5b66\u9662 \u56fd\u9645 \u5173\u7cfb \u5b66\u62c9 \u8a79 \u95e8\u519c \u6559\u6388 \u79f0 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 COVID - 19 \u7f8e\u56fd \u66b4\u53d1 \u6beb\u4e0d\u7559\u60c5 \u63ed\u793a \u7f8e\u56fd\u653f\u5e9c \u56fd\u5bb6 \u5a01\u80c1 \u7814\u5224 \u77ed\u89c6 ", "\u7f8e\u56fd \u7ea6\u7ff0\u65af \u970d\u666e\u91d1\u65af\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u5e0c\u671b \u5f00\u53d1 3D \u6253\u5370 \u547c\u5438\u673a \u5206\u914d\u5668 \u89e3\u51b3 \u547c\u5438\u673a \u77ed\u7f3a \u4ee5\u6b64 \u5e94\u5bf9 COVID - 19 \u75ab\u60c5 ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u603b\u5e72\u4e8b \u8c2d \u5fb7\u585e \u6307\u51fa \u4e16\u536b \u7ec4\u7ec7 \u63a8\u51fa \u52a0\u901f \u65b0\u51a0 \u75ab\u82d7 \u7814\u53d1 \u65b0 \u65b9\u6848 \u5efa\u7acb \u673a\u5236 \u786e\u4fdd \u75ab\u82d7 \u95ee\u4e16 \u540e\u80fd \u5168\u7403 \u516c\u5e73 \u5206\u914d ", "\u6b27\u6d32 \u7814\u7a76 \u56e2\u961f \u63d0\u51fa \u4e00\u79cd \u9884\u9632 SARS - CoV - 2 \u611f\u67d3 \u65b0\u601d\u8def \u5229\u7528 \u4f53\u5916 \u7eaf\u5316 \u91cd\u7ec4 \u4eba\u7c7b ACE2 \u86cb\u767d \u4e2d \u65b0\u51a0 \u75c5\u6bd2 \u4f53\u7ec6\u80de \u9884\u9632 \u611f\u67d3 \u76ee\u7684 ", "\u5339\u5179\u5821 \u5927\u5b66 \u533b\u5b66\u9662 spike \u86cb\u767d \u5f00\u53d1 \u4e00\u79cd \u540d\u4e3a PittCoVacc \u65b0\u578b \u8d34\u7247 \u75ab\u82d7 , \u75ab\u82d7 \u75c7\u72b6 \u60c5\u51b5 \u6fc0\u53d1 \u75c5\u6bd2 \u514d\u75ab ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u4edd \u5c0f\u6797 \u9662\u58eb \u62ab\u9732 \u4e09\u9879 \u79d1\u7814\u6210\u679c \u7814\u7a76 \u7ed3\u679c\u663e\u793a \u4e2d\u533b\u836f \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u8f7b\u75c7 \u60a3\u8005 \u75c5\u60c5 \u65e0\u4e00 \u52a0\u91cd \u91cd\u578b / \u5371\u91cd \u578b \u60a3\u8005 \u6b7b\u4ea1\u7387 \u964d\u4f4e \u5eb7\u590d \u60a3\u8005 \u75c7\u72b6 \u6539\u5584 \u590d\u9633\u7387 \u4f4e ", "\u4e2d\u56fd\u519c\u4e1a\u79d1\u5b66\u9662 \u54c8\u5c14\u6ee8 \u517d\u533b \u7814\u7a76\u6240 \u9648\u5316\u5170 \u9662\u58eb \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 SARS - CoV - 2 \u96ea \u8c82 \u732b \u4e2d \u590d\u5236 \u6548\u7387 \u9ad8 \u72d7 \u732a \u9e21 \u9e2d \u4e2d \u590d\u5236 \u80fd\u529b \u5fae\u5f31 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 SARS - CoV - 2 \u547c\u5438\u9053 \u98de\u6cab \u732b \u4e4b\u95f4 \u4f20\u64ad ", "\u4e2d\u79d1\u9662 \u6b66\u6c49 \u75c5\u6bd2 \u6240\u77f3 \u6b63\u4e3d \u6559\u6388 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 SARS - CoV - 2 \u75ab\u60c5 \u7206\u53d1 \u671f\u95f4 \u611f\u67d3 \u6b66\u6c49 \u732b \u7fa4 \u8c03\u67e5 \u6837\u672c \u4e2d 14.7% \u732b \u95f4\u63a5 \u9176 \u8054 \u514d\u75ab\u5438\u9644 \u5b9e\u9a8c ELISA \u68c0\u6d4b \u65b0\u51a0 \u75c5\u6bd2 ", "\u897f\u73ed\u7259 \u7814\u7a76 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u4e34\u5e8a \u7ea7 \u4eba\u6e90 \u91cd\u7ec4 \u53ef\u6eb6\u6027 ACE2 hrsACE2 \u964d\u4f4e SARS - CoV - 2 \u751f\u957f \u63ed\u793a \u51fa\u4eba \u8840\u7ba1 \u7c7b \u5668\u5b98 \u80be\u810f \u7c7b \u5668\u5b98 \u6613\u53d7 SARS - CoV - 2 \u611f\u67d3 hrsACE2 \u611f\u67d3 \u65e9\u671f \u6291\u5236 \u611f\u67d3 \u53d1\u751f ", "\u5c71\u4e1c \u6f4d\u574a \u536b\u6069 \u533b\u9662\u9662\u957f \u9b4f \u6625\u534e \u65b0\u51a0 \u75c5\u6bd2 \u590d\u9633 \u60a3\u8005 \u5047 \u590d\u9633 \u771f \u5047\u9634 \u60a3\u8005 \u5b9e\u5219 \u6838\u9178 \u68c0\u6d4b \u8bef\u5dee \u5047 \u9634\u6027 \u5b9e\u9645\u4e0a \u60a3\u8005 \u4f53\u5185 \u75c5\u6bd2 \u5e76\u672a \u6e05\u9664 \u51fa\u9662 \u524d \u6838\u9178 \u68c0\u6d4b \u672a \u68c0\u51fa ", "\u5fb7\u56fd \u7814\u7a76 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u75c7\u72b6 \u521d\u671f \u75c5\u6bd2 \u4e0a\u547c\u5438\u9053 \u590d\u5236 \u6d3b\u8dc3 \u75c5\u6bd2 \u8f7d\u91cf \u9ad8 \u904f\u5236 \u65b0\u51a0 \u75c5\u6bd2 \u8513\u5ef6 \u63a7\u5236 \u98de\u6cab \u4f20\u64ad \u975e \u6392\u6cc4\u7269 \u6c61\u67d3\u7269 \u4f20\u64ad ", "\u9999\u6e2f\u5927\u5b66 Benjamin   J .   Cowling \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u5916\u79d1 \u53e3\u7f69 \u75c7\u72b6 \u4f20\u64ad \u4eba\u7c7b \u51a0\u72b6\u75c5\u6bd2 \u6d41\u611f\u75c5\u6bd2 ", "\u5357\u4eac\u533b\u79d1\u5927\u5b66 \u5218\u4e91 \u56e2\u961f \u7814\u7a76 \u91c7\u7528 \u5b9e\u65f6 \u805a\u5408\u9176 \u94fe\u53cd\u5e94 \u6d4b\u8bd5 RT - PCR \u68c0\u6d4b \u7cbe\u6db2 \u777e\u4e38 \u6d3b\u68c0 \u6837\u672c \u4e2d SARS - CoV - 2 \u7814\u7a76 \u53d1\u73b0 \u7cbe\u6db2 \u777e\u4e38 \u6d3b\u68c0 \u6807\u672c \u4e2d\u672a \u53d1\u73b0 SARS - CoV - 2 \u8fd9\u9879 \u7814\u7a76 \u7ed3\u679c\u8868\u660e \u8bc1\u636e \u7537\u6027 \u53d1\u751f SARS - CoV - 2 \u6027\u4f20\u64ad ", "\u897f\u73ed\u7259 \u7814\u7a76 \u56e2\u961f \u63d0\u51fa \u4e00\u79cd \u9884\u9632 SARS - CoV - 2 \u611f\u67d3 \u65b0\u601d\u8def \u4e34\u5e8a \u7ea7 \u91cd\u7ec4 \u53ef\u6eb6\u6027 ACE2 hrsACE2 \u2160 \u671f \u2161 \u671f \u4e34\u5e8a\u8bd5\u9a8c \u4e2d \u6d4b\u8bd5 \u4e2d \u65b0\u51a0 \u75c5\u6bd2 \u963b\u6b62 \u4f53\u7ec6\u80de \u9884\u9632 \u611f\u67d3 \u76ee\u7684 ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u603b\u5e72\u4e8b \u8c2d \u5fb7\u585e \u547c\u5401 \u5404\u56fd \u52a0\u5927 \u516c\u5171\u536b\u751f \u6295\u8d44 \u5404\u56fd \u91cd\u70b9 \u5173\u6ce8 \u4e09\u4e2a \u9886\u57df \u56fd\u5bb6 \u5e94 \u786e\u4fdd \u6838\u5fc3 \u516c\u5171\u536b\u751f \u63aa\u65bd \u63d0\u4f9b \u5145\u8db3 \u8d44\u91d1 \u5404\u56fd \u4e16\u536b \u7ec4\u7ec7 \u5408\u4f5c\u4f19\u4f34 \u5e94 \u533b\u7597\u536b\u751f \u7cfb\u7edf \u57fa\u7840 \u56fd\u5bb6 \u5e94 \u6d88\u9664 \u533b\u7597\u4fdd\u5065 \u8d22\u653f \u969c\u788d ", "\u5fb7\u514b\u8428\u65af \u5927\u5b66 \u7814\u7a76 \u56e2\u961f \u745e\u58eb \u4f2f\u5c14\u5c3c \u5927\u5b66 \u7814\u7a76 \u56e2\u961f \u4f53\u5916 \u4eba\u5de5\u5408\u6210 \u51fa\u65b0 \u51a0 \u75c5\u6bd2 \u7a81\u7834 \u75c5\u6bd2 \u6765\u6e90 \u77ed\u65f6\u95f4 \u4e00\u5468 \u751f\u4ea7 \u6539\u9020 \u6d3b\u6027 \u75c5\u6bd2 \u7528\u4e8e \u75be\u75c5\u8bca\u65ad \u52a8\u7269\u6a21\u578b \u5efa\u7acb \u5bbf\u4e3b \u786e\u8ba4 \u75ab\u82d7 \u7814\u53d1 \u7814\u7a76 ", "\u7f8e\u56fd \u7ebd\u7ea6\u5e02 \u5e03\u6717 \u514b\u65af \u52a8\u7269\u56ed 5 \u65e5 \u53d1\u8868\u58f0\u660e \u8bf4 \u8be5\u56ed \u4e00\u53ea 4 \u5c81 \u96cc\u6027 \u9a6c\u6765\u4e9a \u864e\u65b0\u51a0 \u75c5\u6bd2\u68c0\u6d4b \u9633\u6027 \u53d1\u73b0 \u4eba\u7c7b \u52a8\u7269 \u8eab\u4e0a \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u8bc1\u636e ", "\u4e2d\u56fd\u79d1\u5b66\u9662 \u5916\u7c4d \u9662\u58eb \u8c22\u6653\u4eae 70 \u5eb7\u590d \u671f \u75c5\u4eba \u8840\u6d46 \u91cc \u7b5b\u51fa \u4e00\u5927\u6279 \u9ad8 \u5f3a\u5ea6 \u6297\u4f53 \u591a\u4e2a \u51fa\u8272 \u4e2d \u6d3b\u6027 \u6297\u4f53 \u7b79\u5212 \u540e\u7eed \u52a8\u7269 \u5b9e\u9a8c \u4e34\u5e8a\u5b9e\u9a8c ", "\u8377\u5170 \u56fd\u5bb6 \u79d1\u5b66\u7814\u7a76 \u4eba\u5458 \u5c55\u5f00 \u5e9f\u6c34 \u6d41\u884c\u75c5\u5b66 \u7814\u7a76 \u65b0\u51a0 \u75c5\u6bd2 \u5927\u89c4\u6a21 \u4eba\u7fa4 \u4e2d \u611f\u67d3 \u6c34\u5e73 \u63d0\u4f9b\u6570\u636e \u7814\u7a76 \u4eba\u5458 \u6c61\u6c34 \u68c0\u6d4b COVID - 19 \u65e9\u671f \u9884\u8b66 \u4fe1\u53f7 ", "\u6fb3\u5927\u5229\u4e9a \u7eb3\u4ec0 \u5927\u5b66 \u751f\u7269 \u836f\u7269 \u5f00\u53d1 \u7814\u7a76\u6240 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u5242\u91cf \u4f0a\u7ef4 \u83cc\u7d20 48 \u5c0f\u65f6 \u65b0\u51a0 \u75c5\u6bd2 \u9057\u4f20\u7269\u8d28 RNA \u6e05\u9664 \u963b\u6b62 \u65b0\u51a0 \u75c5\u6bd2 \u7ec6\u80de \u751f\u957f ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u738b\u8fb0 \u56e2\u961f \u67f3\u53f6\u5200 \u53d1\u6587 \u5168\u4e16\u754c \u5206\u4eab \u4e2d\u56fd \u65b9\u8231 \u533b\u9662 \u5efa\u8bbe \u7ba1\u7406 \u7ecf\u9a8c ", "\u79d1\u6280\u90e8 \u5b89\u6392 3.2 \u4ebf\u5143 \u79d1\u7814\u7ecf\u8d39 68 \u5e94\u6025 \u9879 \u5e94\u5bf9 \u75ab\u60c5 \u7279\u4e8b \u7279\u529e \u5feb\u901f \u54cd\u5e94 \u591a\u8def \u5e76\u884c \u591a\u7ec4 \u63a8\u8fdb \u5168\u7a0b \u8ddf\u8e2a \u5168\u7a0b \u670d\u52a1 \u534f\u540c \u5f3a\u5316 \u8054\u52a8 \u56db\u4e2a \u7ec4\u7ec7 \u5f62\u5f0f ", "\u5fb7\u56fd \u590f \u91cc\u7279 \u533b\u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u60a3\u8005 \u4e0a\u547c\u5438\u9053 \u590d\u5236 \u6d3b\u8dc3 \u75c5\u6bd2 \u75c7\u72b6 \u7b2c\u4e00\u5468 \u6392\u6bd2 \u6c34\u5e73 \u9ad8 \u7814\u7a76 \u652f\u6301 \u75c5\u6bd2 \u7caa\u4fbf \u4f20\u64ad ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u4e54\u6770 \u6307\u51fa \u5b55\u4ea7\u5987 \u8bca\u6cbb \u603b\u4f53 \u786e\u8bca \u5b55\u5987 \u8f7b\u75c7 \u5c45\u591a \u5a74\u513f \u8f7b\u75c7 \u6bcd\u5a74 \u5782\u76f4 \u4f20\u64ad \u8fdb\u4e00\u6b65 \u7814\u7a76 ", "3 \u6708 16 \u65e5 \u519b\u4e8b\u79d1\u5b66\u9662 \u519b\u4e8b\u533b\u5b66 \u7814\u7a76\u9662 \u9648\u8587 \u9662\u58eb \u9886\u8854 \u79d1\u7814 \u56e2\u961f \u7814\u5236 \u91cd\u7ec4 \u65b0\u51a0 \u75ab\u82d7 \u83b7\u6279 \u6b66\u6c49 \u542f\u52a8 \u4e34\u5e8a\u8bd5\u9a8c \u7597\u517b \u89c2\u5bdf 14 \u5929\u540e 3 \u6708 31 \u65e5 \u9996\u6279 \u63a5\u79cd \u65b0\u51a0 \u75ab\u82d7 \u4e34\u5e8a\u8bd5\u9a8c \u5fd7\u613f\u8005 \u987a\u5229 \u79bb\u5f00 \u7597\u517b \u673a\u6784 \u8fd4\u56de \u5bb6\u4e2d ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u674e\u5170\u5a1f \u9662\u58eb \u56e2\u961f \u5efa\u8bae \u53d1\u751f \u7ec6\u80de\u56e0\u5b50 \u98ce\u66b4 \u4f34 \u80ba\u90e8 \u5f71\u50cf \u5feb\u901f \u8fdb\u5c55 COVID - 19 \u60a3\u8005 \u4eba\u5de5 \u809d \u8840\u6db2 \u51c0\u5316 \u6cbb\u7597 \u4eba\u5de5 \u809d \u8840\u6db2 \u51c0\u5316\u7cfb\u7edf \u8840\u6d46 \u7f6e\u6362 \u8840\u6d46 \u5438\u9644 \u8840\u6db2 / \u8840\u6d46 \u6ee4\u8fc7 \u8840\u6db2 \u51c0\u5316 \u6a21\u5757 \u6e05\u9664 \u7ec6\u80de\u56e0\u5b50 / \u8d8b\u5316\u56e0\u5b50 ", "\u8881\u6b63\u5b8f / \u5e94 \u5929\u96f7 \u56e2\u961f \u52a8\u7269 \u5b9e\u9a8c \u4e2d \u4e00\u9879 \u4e59\u809d \u6cbb\u7597 \u7814\u7a76\u6210\u679c   \u5229\u7528 \u4e09\u660e\u6cbb \u7597\u6cd5 \u4e59\u809d \u529f\u80fd\u6027 \u6cbb\u6108 \u65b0\u7b56\u7565 ", "\u6e2f\u5927 \u533b\u5b66\u9662 \u9662\u957f \u6881\u5353\u4f1f \u67f3\u53f6\u5200 \u53d1\u6587 \u6b66\u6c49 \u7d27\u5bc6 \u57ce\u5e02 \u9700 \u505a\u597d \u9632\u63a7 ", "\u706b\u795e \u5c71 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u80ba\u708e \u4e13\u79d1\u533b\u9662 \u79fb\u4ea4 \u89e3\u653e\u519b \u533b\u7597\u961f \u7ba1\u7406 ", "\u5409\u5229 \u5fb7 \u745e\u5fb7 \u897f\u97e6 \u8be5\u836f \u53f0\u6e7e\u5927\u5b66 \u6821\u53cb \u6768\u53f0\u83b9 \u4e3b\u5bfc \u7814\u53d1 ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u534e\u4e2d\u519c\u4e1a\u5927\u5b66 \u6559\u6388 \u9648\u7115\u6625 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 SARS \u51a0\u72b6\u75c5\u6bd2 \u7ec6\u80de \u53d7\u4f53 \u8759\u8760 \u4e2d \u53d1\u73b0 SARS \u76f8\u5173 \u75c5\u6bd2 \u62e5\u6709 87.1% \u76f8\u4f3c\u6027 SARS \u75c5\u6bd2 79.5% \u5ea6 \u4e91\u5357 \u8759\u8760 \u6837\u672c \u4e2d \u53d1\u73b0 \u51a0\u72b6\u75c5\u6bd2 \u5ea6\u9ad8\u8fbe 96% ", "\u590d\u65e6\u5927\u5b66 \u4e0a\u6d77\u533b\u5b66\u9662 \u95fb\u7389\u6885 \u5b9e\u9a8c\u5ba4 \u5206\u79bb \u4e0a\u6d77 \u9996\u682a \u65b0\u51a0 \u75c5\u6bd2 \u682a ", "\u4e54\u6770 \u5c1a\u65e0 \u6bcd\u5a74 \u5782\u76f4 \u4f20\u64ad \u53ef\u9760 \u8bc1\u636e ", "\u51a0\u72b6\u75c5\u6bd2 \u4e13\u5bb6 \u52a0\u62ff\u5927 P4 \u5b9e\u9a8c\u5ba4 \u521b\u59cb\u4eba \u53bb\u4e16 \u6297\u51fb SARS \u827e\u6ecb \u57c3 \u535a\u62c9 \u82f1\u96c4 ", "\u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u80ba\u708e \u80cc\u666f \u666e\u901a\u5916\u79d1 \u8bca\u7597 \u9632\u63a7 \u5de5\u4f5c \u5efa\u8bae \u53d1\u5e03 ", "2020 \u5e74 2 \u6708 17 \u65e5 \u533b\u5b66 \u9884 \u5370\u672c \u671f\u520a MedRxiv \u53d1\u8868 \u6b66\u6c49\u5927\u5b66 \u4e2d\u5357 \u533b\u9662\u9662\u957f \u738b\u884c \u73af\u4e3a \u901a\u8baf \u4f5c\u8005 \u6587\u7ae0 Association   between   2019 - nCoV   transmission   and   N95   respirator   use N95 \u53e3\u7f69 \u4fdd\u62a4 \u533b\u52a1\u4eba\u5458 \u514d\u53d7 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 ", "\u67f3\u53f6\u5200 \u91cd\u78c5 \u9ad8\u798f / \u77f3\u6b63\u4e3d \u5efa\u8bae \u65b0\u51a0 \u75c5\u6bd2 \u6539\u540d \u90d1\u5fd7\u660e \u53cd\u5bf9 \u6539\u540d ", "\u91cd\u78c5 \u53d1\u5e03 \u9ad8\u798f 16000 \u86cb\u767d \u975e\u6d32 \u732a\u761f \u75c5\u6bd2 \u9897\u7c92 \u7ed3\u6784 \u4fe1\u606f ", "\u66f9\u5f6c \u67f3\u53f6\u5200 \u8bba\u6587 \u63ed\u793a \u65b0\u51a0 \u81f4\u6b7b \u5371\u9669 \u56e0\u7d20   \u6392\u6bd2 \u671f 20 \u5929 \u98a0\u8986 \u60f3\u8c61 ", "\u66f9\u5f6c \u56e2\u961f \u5206\u6790 \u9996\u6279 \u65b0\u51a0 \u6b7b\u4ea1 \u56e0\u7d20 : \u9ad8\u9f84 \u810f\u5668 \u8870\u7aed ", "\u8463\u5bb6 \u9e3f \u8bf4 \u56e0\u5e94 \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u7206\u53d1 \u6e05\u534e\u5927\u5b66 \u7b2c\u4e00 \u65f6\u95f4 \u7d27\u6025 \u7ec4\u5efa \u533b\u5de5 \u79d1\u6280\u653b\u5173 \u7a81\u51fb\u961f \u5317\u4eac \u6e05\u534e \u957f\u5e9a\u533b\u9662 \u4e34\u5e8a\u533b\u5b66 \u4e13\u5bb6 \u6e05\u534e\u5927\u5b66 \u9662\u7cfb \u4eba\u5de5\u667a\u80fd \u65b0\u4e00\u4ee3 \u4fe1\u606f\u6280\u672f \u4e13\u5bb6 8 \u653b\u5173\u7ec4 \u75ab\u60c5 \u9632\u63a7 \u591a\u4e2a \u91cd\u8981\u73af\u8282 \u9f20\u5e74 \u5927\u5e74\u521d\u4e00 \u52a0\u6025 \u7814\u53d1 \u653b\u5173 \u521b\u65b0 \u7814\u53d1 \u90e8\u7f72 \u4e00\u6279 \u4eba\u5de5\u667a\u80fd \u6280\u672f \u4ea7\u54c1 ", "3   \u6708   17   \u65e5 \u5b98\u65b9 \u91cd\u78c5 \u519b\u4e8b\u79d1\u5b66\u9662 \u519b\u4e8b\u533b\u5b66 \u7814\u7a76\u9662 \u9648\u8587 \u9662\u58eb \u9886\u8854 \u79d1\u7814 \u56e2\u961f \u6210\u529f \u7814\u5236 \u91cd\u7ec4 \u65b0\u51a0 \u75ab\u82d7 \u5e76\u4e8e 3   \u6708   16   \u65e5 \u83b7\u6279 \u5c55\u5f00 \u4e34\u5e8a\u8bd5\u9a8c \u5df2\u77e5 \u8fd9\u662f \u56fd\u5185 \u7b2c\u4e00\u4e2a \u4e34\u5e8a\u8bd5\u9a8c \u65b0\u51a0 \u75ab\u82d7 \u53d7\u8bd5\u8005 \u62db\u52df \u540c\u6b65 \u5c55\u5f00 ", "\u6b66\u6c49 8 \u5bb6 \u673a\u6784 \u7814\u7a76 \u53d1\u73b0 O\u578b \u8840 \u4e0d\u6613 \u67d3\u65b0\u51a0 \u75c5\u6bd2 ", "\u9976\u5b50 \u7cbe\u82f1 \u56e2\u961f \u53d6\u5f97\u6210\u529f \u5206\u6790 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 \u62f7\u8d1d \u8bbe\u5907 \u4e09\u7ef4 \u6784\u9020 ", "\u66f9\u5f6c \u4eba\u53d1 \u8bba\u6587 \u514b\u529b \u829d \u65b0\u51a0 \u91cd\u75c7 \u7597\u6548 ", "\u9976\u5b50 \u9662\u58eb \u65b0 \u7814\u7a76 \u89e3\u6790 \u65b0\u51a0 \u75c5\u6bd2 \u4e2d \u745e\u5fb7 \u897f\u97e6 \u9776\u6807 \u4e09\u7ef4 \u7ed3\u6784 ", "\u8fdb\u4e00\u6b65 \u63d0\u5347 \u5e72\u7ec6\u80de \u6551\u6cbb \u65b0\u51a0 \u80ba\u708e \u4e34\u5e8a \u7814\u7a76 \u9879\u76ee \u79d1\u5b66\u6027 \u89c4\u8303\u6027 \u534f\u8c03 \u4f18\u52bf \u8d44\u6e90 \u6551\u6cbb \u5371 \u91cd\u75c7 \u60a3\u8005 \u4e2d\u56fd \u7ec6\u80de \u751f\u7269\u5b66 \u5b66\u4f1a \u5e72\u7ec6\u80de \u751f\u7269\u5b66 \u5206\u4f1a \u4e2d\u534e\u533b\u5b66\u4f1a \u611f\u67d3 \u75c5 \u5b66\u5206 \u4f1a\u4e8e 3 \u6708 10 \u65e5 \u8054\u5408 \u53d1\u5e03 \u5e72\u7ec6\u80de \u6cbb\u7597 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u80ba\u708e COVID - 19 \u4e34\u5e8a \u7814\u7a76 \u4e13\u5bb6 \u6307\u5bfc \u610f\u89c1 ", "\u7f8e\u56fd\u660e\u5c3c\u82cf\u8fbe\u5927\u5b66 \u4f20\u67d3\u75c5 \u7814\u7a76 \u653f\u7b56 \u4e2d\u5fc3 \u4e3b\u4efb Michael   Osterholm \u6307\u51fa \u65e0\u75c7\u72b6 \u8f7b\u75c7 \u75c5\u4f8b \u6bd4\u4f8b \u7406\u89e3 \u8fd9\u4e00 \u6d41\u884c\u75c5 \u9a71\u52a8 \u56e0\u7d20 \u65e0\u75c7\u72b6 \u611f\u67d3\u8005 \u5173\u6ce8 \u91cd\u70b9 \u8d8a\u6765\u8d8a \u611f\u67d3\u8005 \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u63a5\u89e6 \u53f2 \u53bb\u8fc7 \u75be\u75c5 \u9ad8\u53d1 \u5730\u533a \u8f7b\u5ea6 \u611f\u67d3 \u8fc7\u7a0b \u4e2d \u610f\u8bc6 \u5bfb\u6c42 \u533b\u7597 \u63a5\u53d7 \u4f53\u6e29 \u7b5b\u67e5 \u65f6 \u6f0f\u6389 \u7a0b\u5ea6 \u75c5\u6bd2\u4f20\u64ad \u4e2d \u4f5c\u7528 \u96be\u4ee5\u6349\u6478 ", "\u5f20\u5fd7\u521a \u79f0 \u7a7f\u5c71\u7532 \u51a0\u72b6\u75c5\u6bd2 \u65b0\u51a0 \u75c5\u6bd2 \u57fa\u56e0\u7ec4 \u76f8\u4f3c\u6027 \u5bbf\u4e3b 99% \u76f8\u4f3c\u6027 \u8bc1\u660e \u7a7f\u5c71\u7532 \u51a0\u72b6\u75c5\u6bd2 \u65b0\u51a0 \u75c5\u6bd2 \u540c\u4e00\u4e2a \u75c5\u6bd2 \u7c7b\u65b0\u51a0 \u75c5\u6bd2 \u8bc1\u660e \u7a7f\u5c71\u7532 \u65b0\u51a0 \u75c5\u6bd2 \u5bbf\u4e3b \u65b0\u51a0 \u75c5\u6bd2 \u6f5c\u5728 \u81ea\u7136 \u5bbf\u4e3b ", "\u7b2c\u56db\u519b\u533b\u5927\u5b66 \u9648\u5fd7\u5357 \u6731\u5e73\u53ca \u8fb9\u60e0\u6d01 \u901a\u8baf \u9884 \u5370\u7248 \u5e73\u53f0 bioRxiv \u5728\u7ebf \u53d1\u8868 \u672a\u7ecf \u540c\u884c \u8bc4\u5ba1 \u9898\u4e3a SARS - CoV - 2   invades   host   cells   via   a   novel   route :   CD147 - spike   protein \u7814\u7a76 \u8bba\u6587 \u7814\u7a76 \u53d1\u73b0 SARS - CoV - 2 CD147 \u65b0\u9014\u5f84 \u4fb5\u5165 \u5bbf\u4e3b \u7ec6\u80de S \u86cb\u767d \u5bbf\u4e3b \u7ec6\u80de \u53d7\u4f53 CD147 \u4ecb\u5bfc \u75c5\u6bd2 \u5165\u4fb5 \u4fb5\u88ad SARS - CoV - 2 \u5bbf\u4e3b \u7ec6\u80de \u65b0\u9014\u5f84 CD147 - S \u86cb\u767d \u53d1\u73b0 \u7279\u5b9a \u6297\u75c5\u6bd2 \u836f\u7269 \u5f00\u53d1 \u63d0\u4f9b \u5173\u952e \u76ee\u6807 ", "\u4e54\u6770 \u56e2\u961f \u62a5\u9053 \u4eba\u7c7b \u5375\u6ce1 \u53d1\u80b2 \u8fc7\u7a0b \u57fa\u56e0 \u8868\u8fbe \u8c03\u63a7 \u89c4\u5f8b ", "\u9648\u8587 \u9662\u58eb \u56e2\u961f \u7814\u5236 \u65b0\u51a0 \u75ab\u82d7 \u83b7\u6279 \u4e34\u5e8a\u8bd5\u9a8c ", "\u7f8e\u56fd \u79d1\u5b66 \u6742\u5fd7 \u65f6\u95f4 3 \u6708 27 \u65e5 \u520a\u767b \u4e2d\u56fd \u75be\u63a7\u4e2d\u5fc3 \u4e3b\u4efb \u9ad8\u798f \u9662\u58eb \u91c7\u8bbf \u79d1\u5b66 \u6742\u5fd7 Science \u7f8e\u56fd \u79d1\u5b66 \u4fc3\u8fdb\u4f1a \u51fa\u7248 \u4e00\u4efd \u5b66\u672f\u671f\u520a \u5168\u4e16\u754c \u6743\u5a01 \u5b66\u672f\u671f\u520a \u8fd9\u7bc7 \u91c7\u8bbf \u5386\u65f6 \u6570\u5929 \u6587\u5b57 \u8bed\u97f3 \u90ae\u4ef6 \u7535\u8bdd \u91c7\u8bbf \u65b9\u5f0f \u91c7\u8bbf \u4e2d \u9ad8\u798f \u9662\u58eb \u5206\u4eab \u4e2d\u56fd \u9632\u75ab \u7ecf\u9a8c \u6307\u51fa \u7f8e\u56fd \u6b27\u6d32 \u72af \u9519\u8bef \u4e0d\u6234 \u53e3\u7f69 \u9ad8\u798f \u9662\u58eb \u75c5\u6bd2 \u8d77\u6e90\u4e8e \u6b66\u6c49 \u534e\u5357 \u6d77\u9c9c \u5e02\u573a \u4e2d\u56fd \u5206\u4eab \u75c5\u6bd2 \u6570\u636e \u75ab\u82d7 \u836f\u7269 \u7814\u5236 \u8fdb\u7a0b \u5173\u952e\u95ee\u9898 \u4f5c\u51fa \u89e3\u7b54 ", "\u7ba1\u8f76 \u56e2\u961f \u9a6c\u6765\u4e9a \u7a7f\u5c71\u7532 \u4e2d \u53d1\u73b0 \u76f8\u5173 \u65b0\u51a0 \u75c5\u6bd2 ", "\u4e2d\u56fd \u4e2d\u533b \u79d1\u5b66\u9662 \u9662\u957f \u9ec4\u7490\u7426 \u9662\u58eb \u9886\u961f \u7b2c\u4e00\u6279 \u56fd\u5bb6 \u63f4\u9102 \u6297\u75ab \u4e2d\u533b \u533b\u7597\u961f \u7814\u5236 \u51fa\u5316 \u6e7f \u8d25\u6bd2 \u9897\u7c92 \u4e34\u5e8a\u8bd5\u9a8c \u7533\u8bf7 \u8fd1\u65e5 \u56fd\u5bb6\u836f\u76d1\u5c40 \u6279\u51c6 \u8fd9\u662f \u9996\u4e2a \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u4e2d\u836f \u4e34\u5e8a \u6279\u4ef6 ", "\u7ebd\u7ea6 \u795e\u7ecf\u5916\u79d1 \u5927\u725b \u8a79\u59c6\u65af \u2022 \u53e4\u5fb7\u91cc\u5947 James   T . Goodrich \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u53bb\u4e16 \u533b\u7597\u754c \u75db\u5931 \u4e00\u4f4d \u7cbe\u82f1 ", "\u5e72\u7ec6\u80de \u6cbb\u7597 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u80ba\u708e COVID - 19 \u4e34\u5e8a \u7814\u7a76 \u4e13\u5bb6 \u6307\u5bfc \u610f\u89c1 \u53d1\u5e03 ", "\u65e5\u524d \u4e2d\u56fd\u79d1\u5b66\u9662 \u9662\u58eb \u4e2d\u56fd \u4e2d\u533b \u79d1\u5b66\u9662 \u9996\u5e2d \u7814\u7a76\u5458 \u4edd \u5c0f\u6797 \u56e2\u961f \u62ab\u9732 \u4e09\u9879 \u79d1\u7814\u6210\u679c \u7814\u7a76 \u7ed3\u679c\u663e\u793a \u4e2d\u533b\u836f \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u8f7b\u75c7 \u60a3\u8005 \u75c5\u60c5 \u65e0\u4e00 \u52a0\u91cd \u91cd\u578b / \u5371\u91cd \u578b \u60a3\u8005 \u6b7b\u4ea1\u7387 \u964d\u4f4e \u5eb7\u590d \u60a3\u8005 \u75c7\u72b6 \u6539\u5584 \u590d\u9633\u7387 \u4f4e ", "\u6000\u7591 \u65b0\u51a0 \u75c5\u6bd2 \u6f5c\u4f0f \u6570\u6708 \u610f\u5927\u5229 \u79d1\u5b66\u5bb6 \u8c03\u67e5 \u53bb\u5e74 \u5e74\u5e95 \u53ef\u7591 \u80ba\u708e \u75c5\u4f8b ", "\u6e05\u534e \u56e2\u961f \u7814\u53d1 \u83b7 \u8fdb\u5c55   \u65b0\u51a0 \u80ba\u708e \u75ab\u82d7 5 \u6708\u5e95 \u52a8\u7269 \u8bd5\u9a8c ", "\u5fb7\u56fd ", "\u4e2d\u56fd ", "\u4e2d\u56fd \u75be\u63a7\u4e2d\u5fc3 \u4e13\u5bb6 \u5434\u5c0a\u53cb \u65b0\u51a0 \u80ba\u708e \u75c5\u4f8b 30 79 \u5c81 \u5360 90 ", "\u4e2d\u5c71\u5927\u5b66 \u533b\u5b66\u9662 \u9662\u957f \u90ed\u5fb7\u94f6 \u7ed3\u819c \u56ca \u9f3b \u6cea\u7ba1 \u9f3b\u8154 \u76f8\u8fde \u65b0 \u51a0\u72b6\u75c5\u6bd2 \u773c\u775b \u7ed3\u819c \u611f\u67d3 \u547c\u5438\u9053 \u53ef\u80fd\u6027 \u4e34\u5e8a \u8bc1\u636e \u773c\u7ed3\u819c \u611f\u67d3 \u6548\u7387 \u673a\u5236 ", "\u535e \u4fee\u6b66 \u4f9d\u6cd5 \u89c4\u8303 \u65b0\u51a0 \u80ba\u708e \u5c38\u68c0 \u75c5\u7406 \u8bca\u65ad ", "\u4e2d\u75be\u63a7 \u4e3b\u4efb \u9ad8\u798f \u85c9 \u79d1\u5b66 \u53d1\u58f0 \u89e3\u91ca \u65e9\u671f \u96be\u5b9a \u4f20\u4eba ", "\u4e2d\u5c71\u5927\u5b66 \u533b\u5b66\u9662 \u9662\u957f \u90ed\u5fb7\u94f6 \u9634\u8c0b\u8bba \u4ece\u6765\u4e0d \u63d0\u4f9b \u8bc1\u636e \u79d1\u5b66 \u57fa\u56e0\u7ec4 \u5e8f\u5217 \u75c5\u6bd2 \u8fdb\u5316 \u5206\u6790 \u8bc1\u660e \u75c5\u6bd2 \u6765\u6e90\u4e8e \u81ea\u7136\u754c \u63d0\u4f9b \u5f3a\u6709\u529b \u8bc1\u636e \u8db3\u4ee5 \u51fb\u7834 \u4eba\u5de5\u5408\u6210 \u6d41\u8a00 \u57fa\u56e0\u7ec4 \u5e8f\u5217 \u663e\u793a \u6d41\u884c \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u5171\u6709   29000   \u591a\u4e2a \u6838\u82f7\u9178 \u78b1\u57fa \u7814\u7a76 \u4eba\u5458 \u5df2\u77e5 \u51a0\u72b6\u75c5\u6bd2 \u5bb6\u65cf \u6210\u5458 \u53d1\u73b0 \u8759\u8760 \u6765\u6e90 \u51a0\u72b6\u75c5\u6bd2 \u5173\u7cfb \u6b66\u6c49 \u75c5\u6bd2 \u7814\u7a76\u5458 \u77f3\u6b63\u4e3d \u56e2\u961f \u62a5\u544a \u8759\u8760 \u51a0\u72b6\u75c5\u6bd2 \u6709\u8fd1   1100   \u6838\u82f7\u9178 \u5dee\u5f02 ", "\u9648\u7115\u6625 \u8fd1\u671f \u53d1\u73b0 5 \u836f\u7269 \u75c5\u6bd2 \u6291\u5236\u4f5c\u7528 ", "\u4e2d\u56fd\u79d1\u5b66\u9662 \u9662\u58eb \u9646\u519b \u519b\u533b\u5927\u5b66 \u7b2c\u4e00 \u9644\u5c5e \u533b\u9662 \u75c5\u7406\u79d1 \u4e3b\u4efb \u56fd\u5bb6 \u4e34\u5e8a \u91cd\u70b9 \u4e13\u79d1 \u5168\u519b \u4e34\u5e8a \u75c5\u7406\u5b66 \u7814\u7a76\u6240 \u6240\u957f \u535e \u4fee\u6b66 \u9ad8 \u98ce\u9669 \u5168\u56fd \u9886\u5148 2 \u4f8b\u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u9057\u4f53 \u89e3\u5256 \u63ed\u793a \u53d1\u75c5 \u673a\u5236 \u5206\u6790 \u6b7b\u4ea1 \u539f\u56e0 \u8bca\u7597 \u7ecf\u9a8c \u63d0\u9ad8 \u4e34\u5e8a \u6551\u6cbb \u9632\u63a7 \u6548\u679c \u63d0\u4f9b \u7b2c\u4e00\u624b \u4fe1\u606f ", "\u4e2d\u5c71\u5927\u5b66 \u516c\u5171\u536b\u751f \u5b66\u9662 \u738b\u8302 \u56e2\u961f \u533b\u5b66 \u9884 \u5370\u672c \u7f51\u7ad9 MedRxiv \u53d1\u8868 \u4e00\u7bc7 \u9898\u4e3a Temperature   Significantly   Change   COVID - 19   Transmission   in   429   cities \u8bba\u6587 \u56e2\u961f \u5efa\u7acb \u6570\u636e\u6a21\u578b \u62df \u6a21\u578b \u63a2\u5bfb \u65e5 \u786e\u8bca \u4eba\u6570 \u6e29\u5ea6 \u4e4b\u95f4 \u5173\u7cfb ", "\u4e2d\u56fd \u836f\u5b66\u4f1a \u526f\u7406\u4e8b\u957f \u9648\u5fd7\u5357 \u9662\u58eb \u56e2\u961f \u53d1\u73b0 \u7f8e\u666e\u73e0 \u5355\u6297 \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e ", "\u738b\u8302 \u56e2\u961f \u6536\u96c6 1 \u6708 20 \u65e5\u81f3 2 \u6708 4 \u65e5 429 \u57ce\u5e02 \u5730\u533a \u6bcf\u65e5 \u786e\u8bca \u4eba\u6570 \u6e29\u5ea6 \u6570\u636e \u53d1\u73b0 \u6c14\u6e29 \u65b0\u51a0 \u75c5\u6bd2\u4f20\u64ad \u76f8\u5173\u6027 \u5e73\u5747\u6c14\u6e29 8.72 \u6444\u6c0f\u5ea6 \u65f6 \u65e5 \u7d2f\u8ba1 \u786e\u8bca \u4eba\u6570 \u5cf0\u503c \u79d1\u7814\u4eba\u5458 \u63a8\u6d4b \u9002\u5408 \u65b0\u51a0 \u75c5\u6bd2\u4f20\u64ad \u6e29\u5ea6 \u533a\u95f4 \u65e5 \u5e73\u5747\u6e29\u5ea6 \u8d85\u51fa \u8fd9\u4e00 \u6e29\u5ea6 \u533a\u95f4 \u75ab\u60c5 \u63a7\u5236 \u8fd9\u4e00 \u7ed3\u8bba \u4ee5\u9884 \u5370\u7248 \u8bba\u6587 \u5f62\u5f0f \u53d1\u8868 ", "\u738b\u8302 \u56e2\u961f \u6536\u96c6 1 \u6708 20 \u65e5\u5230 2 \u6708 4 \u65e5 \u671f\u95f4 \u6211\u56fd \u6d77\u5916 26 \u56fd\u5bb6 429 \u57ce\u5e02 \u5730\u533a \u6bcf\u65e5 \u786e\u8bca \u4eba\u6570 \u6e29\u5ea6 \u6570\u636e \u6570\u636e \u57fa\u7840 \u5efa\u6a21 \u53d1\u73b0 \u6c14\u6e29 \u65b0\u51a0 \u75c5\u6bd2\u4f20\u64ad \u76f8\u5173\u6027 ", "\u4e2d\u79d1\u9662 \u9662\u58eb \u535e \u4fee\u6b66 \u80ba\u90e8 \u75c5\u53d8 \u65b0\u51a0 \u80ba\u708e \u7565\u8f7b SARS ", "\u4e2d\u56fd \u75be\u63a7\u4e2d\u5fc3 \u51af\u5f55 \u53ec 20 \u65b0\u51a0 \u80ba\u708e \u68c0\u6d4b \u8bd5\u5242 \u83b7 \u56fd\u5bb6\u836f\u76d1\u5c40 \u6279\u51c6 ", "\u65b0\u51a0 \u75c5\u6bd2 SARS \u75c5\u6bd2 \u6709\u4f55 \u533a\u522b \u8881\u56fd\u52c7 \u6559\u6388 \u8be6\u7ec6\u5206\u6790 ", "\u4e2d\u5c71\u5927\u5b66 \u516c\u5171\u536b\u751f \u5b66\u9662 \u738b\u8302 \u56e2\u961f Medrxiv \u7f51\u7ad9 \u53d1\u5e03 \u4e00\u9879 \u7814\u7a76 \u53d1\u73b0 \u6e29\u5ea6 \u75c5\u6bd2\u4f20\u64ad \u4f4e\u6e29 \u4f4e\u6e7f \u52a0\u6301 \u75c5\u6bd2 \u4f20\u64ad \u53d1\u5c55 ", "\u75c5\u6bd2\u5b66 \u4e13\u5bb6 \u91d1\u51ac\u96c1 \u65b0\u51a0 \u75c5\u6bd2 \u53d8\u5f02 \u7387 SARS HIV \u4f4e ", "\u535e \u4fee\u6b66 \u9662\u58eb \u7cfb\u7edf \u89e3\u5256 \u5df2\u6709 14 \u4f8b \u65b0\u51a0 \u80ba\u708e \u75c5\u7406 \u7814\u7a76 \u6b63 ", "\u5434\u5c0a\u53cb \u7814\u7a76 \u53d1\u73b0 \u65e0\u75c7\u72b6 \u611f\u67d3\u8005 \u4f20\u67d3 \u529b \u76f8\u5f53\u4e8e \u786e\u8bca \u75c5\u4f8b 1 / 3 ", "\u4e2d\u533b\u836f \u4f7f\u7528\u7387 \u8fbe 83.3% \u5f20\u4f2f\u793c 3 \u4f4d \u9662\u58eb \u9886\u5bfc \u56e2\u961f \u6b66\u6c49 \u4e34\u5e8a \u7814\u7a76 \u521d\u6b65 \u7ed3\u679c\u8868\u660e \u4e2d\u533b\u836f \u7597\u6548 \u663e\u73b0 \u4e2d\u533b\u836f \u793e\u533a \u9632\u63a7 \u4e2d \u53d1\u6325 \u4f5c\u7528 ", "\u738b\u798f\u751f \u9662\u58eb \u53d1\u6587 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 \u836f\u7269 \u809d \u635f\u4f24 ", "\u6b66\u6c49 \u75c5\u6bd2 \u6240\u77f3 \u6b63\u4e3d 6 \u5468 \u75c5\u539f \u9274\u5b9a \u75ab\u82d7 \u6253\u4e0b \u57fa\u7840 ", "Science : \u5fb7\u56fd \u79d1\u5b66\u5bb6 \u89e3\u7801 \u65b0\u51a0 \u75c5\u6bd2 \u86cb\u767d\u9176 \u7ed3\u6784 ", "\u5fb7\u56fd \u79d1\u7814\u4eba\u5458 \u6210\u529f \u7834\u89e3 \u51a0\u72b6\u75c5\u6bd2 \u4ee3\u7801 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u7e41\u6b96 \u9700 \u4e3b \u86cb\u767d\u9176 \u7834\u89e3 \u627e\u5230 \u6291\u5236\u5242 ", "\u949f\u5357\u5c71 \u9662\u58eb \u56e2\u961f \u53d7\u9080 \u6b27\u6d32 \u547c\u5438 \u6742\u5fd7 \u4ecb\u7ecd \u65b0\u51a0 \u75ab\u60c5 \u9632\u63a7 \u7ecf\u9a8c ", "\u949f\u5357\u5c71 \u9662\u58eb \u5e7f\u5dde \u547c\u5438 \u5065\u5eb7 \u7814\u7a76\u9662 \u5173\u4f1f\u6770 \u526f\u7814\u7a76\u5458 \u6df1\u5733\u5e02 \u533b\u9662 \u9648 \u8363\u660c \u6559\u6388 \u53d1\u8868 \u8ff0\u8bc4 \u6587\u7ae0 \u4e2d \u63d0\u51fa \u65e0\u75c7\u72b6 \u60a3\u8005 \u4f20\u4eba \u4f20\u67d3\u6e90 \u7caa\u53e3 \u4f20\u64ad \u9014\u5f84 \u91cd\u89c6 \u65e9\u671f \u8bca\u65ad \u9694\u79bb \u786e\u8bca \u75c5\u4f8b \u4e2d\u836f \u5305\u62ec \u8fde\u82b1\u6e05 \u761f \u80f6\u56ca \u516d\u795e\u4e38 \u75c5\u6bd2 \u4f53\u5916 \u6291\u5236\u4f5c\u7528 \u9a8c\u8bc1 \u53d1\u73b0 \u6c2f\u55b9 \u6c22\u6c27 \u6df7\u5408\u6c14\u4f53 \u5438\u5165 \u6539\u5584 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 \u60a3\u8005 \u4e34\u5e8a \u75c7\u72b6 \u4ef7\u503c ", "\u5f3a\u751f \u516c\u53f8 2020 \u5e74 3 \u6708 30 \u65e5 \u5927\u89c4\u6a21 \u6295\u8d44 \u65e8\u5728 \u751f\u4ea7 \u8d85\u8fc7 10 \u4ebf\u5242 \u75ab\u82d7 \u8fd9\u7b14 \u8d44\u91d1 \u652f\u6301 \u5f3a\u751f \u5236\u836f \u5b50\u516c\u53f8   Janssen \u5f00\u53d1 Ad26   SARS - CoV - 2 \u75ab\u82d7 1 \u671f \u4e34\u5e8a\u8bd5\u9a8c \u5f3a\u751f \u516c\u53f8 \u652f\u6301 Moderna \u5f00\u53d1 COVID - 19 \u75ab\u82d7 SARS - CoV - 2   mRNA - 1273 2 \u671f 3 \u671f \u4e34\u5e8a\u8bd5\u9a8c ", "2020 \u5e74 4 \u6708 1 \u65e5 Babraham \u7814\u7a76\u6240 \u7814\u7a76\u6240 \u6240\u957f Michael   Wakelam \u6559\u6388 2020 \u5e74 3 \u6708 31 \u65e5\u56e0 \u7591\u4f3c COVID - 19 \u547c\u5438\u9053 \u5e76\u53d1\u75c7 \u53bb\u4e16 ", "64 \u5c81 \u5357\u975e \u827e\u6ecb\u75c5 \u9996\u5e2d \u79d1\u5b66\u5bb6 Gita   Ramjee \u611f\u67d3 \u65b0\u51a0 \u80ba\u708e \u75c5\u901d ", "\u6559\u80b2\u90e8 \u9a7b\u5916 \u4f7f\u9886\u9986 \u5efa\u7acb \u6d77\u5916 \u7559\u5b66\u4eba\u5458 \u75ab\u60c5 \u68c0\u6d4b \u65e5\u62a5 \u5236\u5ea6 \u53d1\u73b0 \u611f\u67d3 \u7591\u4f3c\u75c5\u4f8b \u7b2c\u4e00 \u65f6\u95f4 \u542f\u52a8 \u5e94\u6025 \u673a\u5236 \u6570\u636e \u6d77\u5916 \u7559\u5b66\u4eba\u5458 \u7fa4\u4f53 \u611f\u67d3 \u6570\u91cf \u6bd4\u4f8b \u603b\u4f53 \u5904\u4e8e \u4f4e \u6c34\u5e73 ", "\u7f8e\u56fd\u767d\u5bab \u51a0\u72b6\u75c5\u6bd2 \u5e94\u5bf9 \u5de5\u4f5c\u7ec4 3 \u6708 31 \u65e5 \u9884\u6d4b \u73b0\u6709 \u5e72\u9884 \u63aa\u65bd \u7f8e\u56fd \u65b0\u51a0 \u80ba\u708e \u6b7b\u4ea1 \u4eba\u6570 \u6700\u7ec8 10 \u4e07\u5230 24 \u4e07 \u4e4b\u95f4 ", "\u56fd \u75be\u63a7\u4e2d\u5fc3 \u4e3b\u4efb \u7f57\u4f2f\u7279 \u96f7\u5fb7 \u83f2\u5c14\u5fb7 \u6307\u51fa \u9ad8\u8fbe 25% \u7f8e\u56fd \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u75c7\u72b6 \u7f8e\u56fd \u75ab\u60c5 \u8513\u5ef6 \u4e4b\u5feb \u539f\u56e0 \u8fd9\u4e3a \u9884\u6d4b \u75ab\u60c5 \u53d1\u5c55 \u9632\u63a7 \u75ab\u60c5 \u5e26\u6765 \u6311\u6218 ", "\u5fb7\u56fd \u67cf\u6797 \u6c99\u91cc \u6cf0 \u5927\u5b66 \u533b\u9662 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u8f7b\u5ea6 \u60a3\u8005 \u8f7b\u75c7 \u7b2c\u4e00\u5468 \u65b0\u51a0 \u75c5\u6bd2 \u4e0a\u547c\u5438\u9053 \u7ec4\u7ec7 \u590d\u5236 \u8131\u843d \u75c7\u72b6 8 \u5929\u540e \u60a3\u8005 \u5589\u90e8 \u80ba\u90e8 \u5206\u79bb \u5177\u5907 \u611f\u67d3 \u80fd\u529b \u75c5\u6bd2 \u6837\u672c ", "\u7f8e\u56fd \u4f20\u67d3\u75c5 \u4e13\u5bb6 \u798f\u5947 \u6307\u51fa \u7f8e\u56fd \u75ab\u60c5 \u5904\u4e8e \u68c0\u6d4b \u7b2c\u4e00\u9636\u6bb5 \u89e3\u51b3 \u75ab\u60c5 \u4ecd\u8981 \u75ab\u82d7 \u75ab\u82d7 \u5f00\u53d1 \u4e00\u5e74 \u4e00\u5e74 \u65f6\u95f4 ", "\u5fb7\u56fd \u7ea2\u5341\u5b57\u4f1a \u732e\u8840 \u90e8 \u6cd5\u5170\u514b\u798f \u5927\u5b66 \u533b\u9662 \u533b\u5b66 \u75c5\u6bd2\u5b66 \u7814\u7a76\u6240 \u8054\u5408 \u7814\u7a76 \u5c0f\u7ec4 \u5f00\u53d1 \u4e00\u79cd \u65b9\u6cd5 \u591a\u4e2a \u91c7\u6837 \u7f6e\u5165 \u4e00\u79cd \u6eb6\u6db2 \u4fd7\u79f0 \u805a\u5408\u9176 \u94fe\u5f0f\u53cd\u5e94 \u6280\u672f ( PCR ) \u68c0\u6d4b \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u65b9\u6cd5 \u5927\u5e45\u63d0\u9ad8 \u68c0\u6d4b \u65b0\u51a0 \u75c5\u6bd2 \u6548\u7387 \u5f71\u54cd \u8bca\u65ad \u8d28\u91cf ", "\u5357\u52a0\u5dde \u5927\u5b66 \u533b\u5b66\u4e2d\u5fc3 Brad   Spellberg \u7814\u7a76 \u53d1\u73b0 \u5371\u9669 \u56e0\u7d20 \u8f7b\u5ea6 \u6d41\u611f \u6837 \u75be\u75c5 \u60a3\u8005 \u4e2d SARS - CoV - 2 \u53d1\u751f\u7387 5 \u60a3\u8005 \u75c5\u60c5 \u8f7b \u75be\u75c5 \u671f\u95f4 \u6d3b\u8dc3 \u793e\u533a \u4e2d \u589e\u52a0 \u4f20\u64ad \u53ef\u80fd\u6027 ", "\u5357\u4eac\u533b\u79d1\u5927\u5b66 \u6c88\u6d2a\u5175 \u9662\u58eb \u56e2\u961f \u62a5\u9053 \u6c5f\u82cf\u7701 \u6dee\u5b89\u5e02 \u8d85\u7ea7 \u4f20\u64ad\u8005 \u6d17\u6d74 \u4e2d\u5fc3 \u611f\u67d3 8 \u7c07\u72b6 \u4f20\u64ad \u6848\u4f8b \u65b0\u51a0 \u75c5\u6bd2 \u9ad8\u6e29 \u9ad8\u6e7f \u6761\u4ef6 \u5b58\u6d3b \u4f20\u64ad \u6027 \u5e76\u672a \u51cf\u5f31 \u8ff9\u8c61 ", "\u9646\u519b \u519b\u533b\u5927\u5b66 \u738b\u519b\u5e73 \u7814\u7a76 \u89c2\u5bdf ACE2 \u80a0\u9053 \u6f58\u6c0f \u7ec6\u80de \u7279\u5f02\u6027 \u5206\u6ccc \u4eba\u7c7b \u9632\u5fa1 \u7d20 HD \u4e4b\u95f4 \u76f8\u4e92\u4f5c\u7528 \u7814\u7a76 \u8bc1\u660e HD5 SARS - CoV - 2   S1 \u80a0 \u4e0a\u76ae\u7ec6\u80de \u5242\u91cf \u4f9d\u8d56\u6027 \u9884\u9632 \u4f5c\u7528 \u63ed\u793a \u51dd\u96c6\u7d20 \u6837\u80a0 \u9632\u5fa1 \u7d20\u5bf9 SARS - CoV - 2 \u5148\u5929 \u9632\u5fa1 \u529f\u80fd ", "\u5fb7\u56fd \u79d1\u7814 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 SARS - CoV - 2 \u60a3\u8005 \u75c7\u72b6 \u8f83\u8f7b \u65e9\u671f SARS - CoV - 2   \u4e0a\u547c\u5438\u9053 \u75c5\u6bd2 \u6392\u51fa \u80fd\u529b \u6700\u5f3a \u540e\u7eed \u7814\u7a76 \u8fdb\u4e00\u6b65 \u786e\u8ba4 ", "\u67f3\u53f6\u5200 \u4e3b\u7f16 \u7406\u67e5\u5fb7 \u970d\u987f \u6307\u51fa \u4e2d\u56fd \u4f20\u9012 COVID - 19 \u75c5\u6bd2 \u4fe1\u606f \u6e05\u6670 \u82f1\u56fd \u672a \u63aa\u65bd \u5e94\u5bf9 \u75ab\u60c5 \u53d1\u5c55 \u917f\u6210 \u5927\u9519 ", "\u6b66\u6c49\u5927\u5b66 \u533b\u9662 \u7814\u7a76 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u7f9f \u6c2f\u55b9 \u6cbb\u7597 COVID - 19 \u671f\u95f4 \u7f29\u77ed \u53d1\u70ed \u54b3\u55fd \u7f13\u89e3 \u65f6\u95f4 \u80ba\u708e \u6539\u5584 ", "\u6e05\u534e\u5927\u5b66 \u5f20\u6797\u7426 \u6559\u6388 \u7814\u7a76 \u56e2\u961f \u5eb7\u590d\u8005 \u8840\u6db2 B \u7ec6\u80de \u4e2d \u6210\u529f \u9274\u5b9a 206 SARS - CoV - 2 S \u86cb\u767d \u53d7\u4f53 \u57df RBD \u7279\u5f02\u6027 \u5355\u514b\u9686 \u6297\u4f53 \u5f3a\u6548 \u4e2d \u6297\u4f53 \u9884\u9632 \u6cbb\u7597 COVID - 19 \u5e0c\u671b \u5019\u9009 \u836f\u7269 ", "\u6e05\u534e\u5927\u5b66 \u4e07\u79d1 \u516c\u5171\u536b\u751f \u5065\u5eb7 \u5b66\u9662 \u6b63\u5f0f \u6210\u7acb \u8fd9\u662f \u6e05\u534e\u5927\u5b66 \u9762\u5411 \u5168\u7403 \u53d1\u5c55\u8d8b\u52bf \u56fd\u5bb6 \u9700\u6c42 \u5efa\u8bbe \u56fd\u9645 \u4e00\u6d41 \u6c34\u5e73 \u65b0\u578b \u516c\u5171\u536b\u751f \u5065\u5eb7 \u5b66\u79d1 \u57f9\u517b \u672a\u6765 \u5f15\u9886 \u56fd\u9645 \u516c\u5171 \u5065\u5eb7 \u4e8b\u4e1a \u53d1\u5c55 \u9ad8\u5c42\u6b21 \u4eba\u624d \u8fc8\u51fa \u4e00\u6b65 ", "\u949f\u5357\u5c71 \u9662\u58eb \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u6162\u963b \u80ba \u7cd6\u5c3f\u75c5 \u9ad8\u8840\u538b \u6076\u6027\u80bf\u7624 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 \u4e34\u5e8a \u9884\u540e \u5bc6\u5207\u76f8\u5173 \u5408\u5e76\u75c7 \u65b0\u51a0 \u60a3\u8005 \u5408\u5e76\u75c7 \u5165\u4f4f ICU \u6b7b\u4ea1 \u98ce\u9669 \u589e\u9ad8 \u5e94\u5bf9 \u6b64\u7c7b \u60a3\u8005 \u4e88\u4ee5 \u8db3\u591f \u9632\u62a4 \u533b\u5b66\u89c2\u5bdf \u5e72\u9884 ", "\u590d\u65e6\u5927\u5b66 \u9646\u8def \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u53d1\u73b0 SARS - CoV - 2 SARS - CoV \u76f8\u6bd4 \u66f4\u597d \u8d28\u819c \u878d\u5408 \u80fd\u529b \u7814\u7a76 \u89e3\u51b3 SARS - CoV - 2   S \u86cb\u767d S2 \u4e9a\u57fa \u4e2d HR1 HR2 \u57df \u87ba\u65cb \u675f 6 - HB \u6838\u5fc3 X\u5c04\u7ebf \u6676\u4f53\u7ed3\u6784 \u63ed\u793a HR1 \u57df \u4e2d \u51e0\u4e2a \u7a81\u53d8 \u6c28\u57fa\u9178 \u6b8b\u57fa HR2 \u57df \u589e\u5f3a \u76f8\u4e92\u4f5c\u7528 \u76f8\u5173 ", "\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662 \u533b\u5b66 \u5b9e\u9a8c \u52a8\u7269 \u7814\u7a76\u6240 \u79e6\u5ddd \u56e2\u961f \u9610\u8ff0 \u5e74\u9f84 \u6052\u6cb3 \u7334\u7ecf \u6c14\u9053 \u611f\u67d3 SARS - CoV - 2 \u4e34\u5e8a \u75c7\u72b6 \u75c5\u6bd2 \u590d\u5236 \u80f8\u90e8 X\u5149 \u7ec4\u7ec7 \u75c5\u7406\u5b66 \u53d8\u5316 \u514d\u75ab \u53d8\u5316 \u53d1\u73b0 \u8001\u5e74 \u6052\u6cb3 \u7334\u6bd4 \u9752\u5e74 \u7334 \u8868\u73b0 \u75c7\u72b6 \u75c5\u7406\u53d8\u5316 \u8fdb\u4e00\u6b65 \u7814\u7a76 SARS - CoV - 2 \u81f4\u75c5\u6027 \u75ab\u82d7 \u6cbb\u7597 \u836f\u7269 \u8bc4\u4ef7 \u610f\u4e49 ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u9648\u5fd7\u5357 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u7f8e\u666e\u73e0 \u5355\u6297 \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u836f\u7269 \u56e2\u961f \u5f00\u53d1 \u6837\u672c\u91cf \u5c1a\u672a \u4e2d\u7f8e \u83b7\u6279 \u4e0a\u5e02 \u6297\u65b0\u51a0 \u6548\u679c \u9700 \u4e25\u8c28 \u4e34\u5e8a\u8bd5\u9a8c \u9a8c\u8bc1 ", "\u6df1\u5733 \u7b2c\u4e09 \u533b\u9662 \u7814\u7a76 \u4eba\u5458 \u5206\u6790 \u670d\u7528 \u8840\u7ba1 \u7d27\u5f20 \u7d20 II \u53d7\u4f53 \u62ee\u6297\u5242 ARB \u7c7b \u964d\u538b\u836f COVID - 19 \u75c5\u4eba \u5f71\u54cd \u6307\u51fa ARB \u7f13\u89e3 \u8001\u5e74 \u60a3\u8005 COVID - 19 \u75c5\u60c5 ", "\u6b66\u6c49\u5927\u5b66 \u5f20 \u65c3 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 COVID - 19 \u60a3\u8005 \u4e2d \u7f9f \u6c2f\u55b9 \u7f29\u77ed \u4e34\u5e8a \u5eb7\u590d \u65f6\u95f4 \u80ba\u708e \u5438\u6536 \u5927\u89c4\u6a21 \u4e34\u5e8a \u57fa\u7840 \u7814\u7a76 \u9610\u660e \u673a\u5236 \u4f18\u5316 \u6cbb\u7597 \u65b9\u6848 ", "\u6df1\u5733\u5e02 \u7b2c\u4e09 \u533b\u9662 \u5f20\u653f \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u5e74\u8f7b \u8f7b\u5ea6 COVID - 19 \u60a3\u8005 \u590d\u9633 \u5165\u9662 \u4e34\u5e8a \u75c7\u72b6 \u75be\u75c5 \u8fdb\u5c55 \u968f\u8bbf \u671f\u95f4 \u7075\u654f RNA \u68c0\u6d4b \u65b9\u6cd5 \u76d1\u6d4b \u60a3\u8005 \u7814\u7a76 COVID - 19 \u60a3\u8005 \u6062\u590d\u671f \u7ba1\u7406 \u63d0\u4f9b \u7ecf\u9a8c \u4fe1\u606f \u8bc1\u636e ", "\u519b\u4e8b\u533b\u5b66\u79d1\u5b66\u9662 \u66f9\u8bda \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 SARS - CoV MERS - CoV SARS - CoV - 2 N \u86cb\u767d MASP - 2 \u8865\u4f53 \u6fc0\u6d3b \u51dd\u96c6\u7d20 \u9014\u5f84 \u4e2d \u5173\u952e \u4e1d\u6c28\u9178 \u86cb\u767d\u9176 \u5bfc\u81f4 \u5f02\u5e38 \u8865\u4f53 \u6fc0\u6d3b \u708e\u75c7 \u52a0\u5267 \u80ba \u635f\u4f24 \u53d1\u73b0 \u8865\u4f53 \u6291\u5236 \u4ee3\u8868 \u9ad8 \u81f4\u75c5\u6027 \u51a0\u72b6\u75c5\u6bd2 \u80ba\u708e \u5e38\u89c1 \u6cbb\u7597 \u65b9\u6cd5 ", "\u6e05\u534e\u5927\u5b66 \u7ed3\u6784 \u751f\u7269\u5b66 \u9ad8\u7cbe\u5c16 \u521b\u65b0 \u4e2d\u5fc3 \u8c2d\u65ed \u7814\u7a76 \u56e2\u961f \u8759\u8760 \u57fa\u56e0\u7ec4 \u529f\u80fd \u7b5b\u9009 \u53d1\u73b0 \u9274\u5b9a \u4e00\u7cfb\u5217 \u75c5\u6bd2 \u4f9d\u8d56 \u5bbf\u4e3b \u57fa\u56e0 \u6700\u7ec8 \u53d1\u73b0 \u5bbf\u4e3b \u86cb\u767d MTHFD1 \u6291\u5236\u5242 carolacton \u6291\u5236 \u65b0\u51a0 \u75c5\u6bd2 \u590d\u5236 ", "\u52a0\u5dde\u5927\u5b66 \u6234\u7ef4\u65af \u5206\u6821 \u533b\u5b66\u9662 Bradley   Sanville \u7814\u7a76 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u745e\u5fb7 \u6614\u97e6 \u6cbb\u6108 \u91cd\u75c7 \u60a3\u8005 \u75c5\u4f8b \u6570\u8fc7 \u5c11 \u4e34\u5e8a\u8bd5\u9a8c \u9a8c\u8bc1 remdesivir \u4e34\u5e8a \u6548\u679c ", "\u6e05\u534e\u5927\u5b66 \u5f20\u6797\u7426 \u56e2\u961f \u7814\u53d1 \u62e5\u6709 \u81ea\u4e3b \u77e5\u8bc6\u4ea7\u6743 \u75c5\u6bd2 \u8f7d\u4f53 \u817a\u75c5\u6bd2 \u75ab\u82d7 mRNA \u5355\u514b\u9686 \u6297\u4f53 \u836f\u7269 \u8fdb\u5c55 \u56e2\u961f \u542f\u52a8 \u76db\u535a\u836f \u836f\u660e \u5eb7\u5fb7 \u8054\u5408\u653b\u5173 \u6253\u901a \u7814\u53d1 \u8bd5\u9a8c \u751f\u4ea7 \u5168 \u94fe\u6761 5 \u6708\u5e95 \u75ab\u82d7 \u6297\u4f53 \u836f\u7269 \u52a8\u7269 \u5b89\u5168\u6027 \u6709\u6548\u6027 \u8bd5\u9a8c \u9636\u6bb5 ", "Google \u6b63\u5f0f \u542f\u52a8 \u4e00\u9879 \u540d\u4e3a \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u516c\u5171\u6570\u636e \u96c6 COVID - 19   Public   Datasets \u9879\u76ee \u9879\u76ee \u6258\u7ba1 \u75ab\u60c5 \u76f8\u5173 \u516c\u5171\u6570\u636e \u8d44\u6599\u5e93 \u5f00\u653e \u7528\u4e8e \u6784\u5efa \u673a\u5668 \u5b66\u4e60 \u6a21\u578b \u5bf9\u6297 \u75ab\u60c5 ", "\u7f8e\u56fd \u75be\u75c5 \u63a7\u5236 \u9884\u9632 \u4e2d\u5fc3 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u7f8e\u56fd \u91cd\u75c7 \u76d1\u62a4 \u75c5\u623f \u4e2d \u8d85\u8fc7 \u56db\u5206\u4e4b\u4e09 COVID - 19 \u60a3\u8005 \u81f3\u5c11 \u4e00\u79cd \u6f5c\u5728 \u75be\u75c5 \u8fd9\u662f \u4e00\u79cd \u6162\u6027 \u5065\u5eb7 \u7cd6\u5c3f\u75c5 \u5fc3\u810f\u75c5 \u8bc1\u660e \u5bfc\u81f4 \u4f4f\u9662 \u4e25\u91cd\u540e\u679c ", "\u89e3\u653e\u519b \u4e2d\u90e8 \u6218\u533a \u603b\u533b\u9662 \u673a\u6784 \u7814\u7a76 \u4eba\u5458 \u5206\u6790 \u63a2\u8ba8 1 \u4f8b \u75c5\u6bd2 \u6392\u6bd2 \u671f\u957f \u8fbe 49 \u5929 \u75c7\u72b6 \u8f7b\u5fae COVID - 19 \u65b0\u51a0 \u80ba\u708e \u75c5\u4f8b \u60c5\u51b5 \u7814\u7a76 \u53d1\u73b0 \u60a3\u8005 \u611f\u67d3 \u75c5\u6bd2 \u6bd2\u6027 \u4f4e \u4f20\u64ad \u80fd\u529b \u8f83\u5f31 \u643a\u5e26 \u75c5\u6bd2 \u65f6\u95f4 \u8d85\u957f \u65b0\u51a0 \u75c5\u6bd2 \u65b0 \u4e9a\u578b ", "\u590d\u65e6\u5927\u5b66 \u516c\u5171\u536b\u751f \u4e34\u5e8a \u4e2d\u5fc3 \u5f20\u6c38\u632f \u6559\u6388 \u7814\u7a76 \u56e2\u961f \u63a8\u6d4b \u65b0\u51a0 \u75ab\u60c5 \u5927\u89c4\u6a21 \u66b4\u53d1 \u524d \u75c5\u6bd2 \u5173\u952e\u70b9 \u4f4d \u7a81\u53d8 \u66f4\u597d \u4eba\u7c7b \u5bbf\u4e3b ", "\u65af\u5766\u798f\u5927\u5b66 \u5f00\u653e \u6570\u636e \u79d1\u5b66 \u673a\u5668 \u5b66\u4e60 \u5de5\u5177 COVID - 19 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u7814\u7a76 \u5efa\u6a21 CS472   Data   science   and   AI   for   COVID - 19 \u91cd\u70b9 \u7814\u7a76 \u6570\u636e \u79d1\u5b66 \u673a\u5668 \u5b66\u4e60 \u5de5\u5177 COVID - 19 \u8c03\u67e5 \u5efa\u6a21 ", "\u8c37\u6b4c \u7814\u7a76 \u526f\u603b\u88c1 \u4e92\u8054\u7f51 \u521b\u9020\u8005 \u6e29\u7279 \u745f\u592b Vint   Cerf Twitter \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u68c0\u6d4b \u5448 \u9633\u6027 \u5efa\u8bae \u89c2\u770b \u559c\u5267\u6f14\u5458 \u7ea6\u7ff0 \u5965\u5229\u5f17 John   Oliver HBO \u7535\u89c6\u53f0 \u8282\u76ee \u7f8e\u56fd \u9884\u9632\u63aa\u65bd ", "\u6e05\u534e\u5927\u5b66 \u7ed3\u6784 \u751f\u7269\u5b66 \u9ad8\u7cbe\u5c16 \u521b\u65b0 \u4e2d\u5fc3 \u673a\u6784 \u7814\u7a76 \u4eba\u5458 \u8759\u8760 \u7ec6\u80de \u4e24\u4e07\u591a\u4e2a \u57fa\u56e0 \u7cfb\u7edf \u7b5b\u67e5 \u6570\u5341\u4e2a \u75c5\u6bd2 \u590d\u5236 \u4f9d\u8d56 \u5173\u952e \u8759\u8760 \u57fa\u56e0 \u53d1\u73b0 \u65b0 \u5bbf\u4e3b \u57fa\u56e0 MTHFD1 \u7814\u7a76 \u53d1\u73b0 \u5bbf\u4e3b \u86cb\u767d MTHFD1 \u6291\u5236\u5242 carolacton \u6291\u5236 \u65b0\u51a0 \u75c5\u6bd2 \u590d\u5236 ", "\u5fb7\u56fd \u75ca\u6108 \u75ab\u82d7 \u516c\u53f8 \u5f00\u53d1 \u4e00\u79cd \u4fe1\u4f7f \u6838\u7cd6\u6838\u9178 mRNA \u75ab\u82d7 \u8ba1\u5212 \u521d\u590f \u4e34\u5e8a\u8bd5\u9a8c \u6700\u5feb \u5e74\u5e95 \u6295\u5165\u4f7f\u7528 ", "\u65e6 \u5927\u5b66 \u9646\u8def \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u53d1\u73b0 SARS - CoV - 2 SARS - CoV \u76f8\u6bd4 \u66f4\u597d \u8d28\u819c \u878d\u5408 \u80fd\u529b \u7814\u7a76 \u89e3\u51b3 SARS - CoV - 2   S \u86cb\u767d S2 \u4e9a\u57fa \u4e2d HR1 HR2 \u57df \u87ba\u65cb \u675f 6 - HB \u6838\u5fc3 X\u5c04\u7ebf \u6676\u4f53\u7ed3\u6784 \u63ed\u793a HR1 \u57df \u4e2d \u51e0\u4e2a \u7a81\u53d8 \u6c28\u57fa\u9178 \u6b8b\u57fa HR2 \u57df \u589e\u5f3a \u76f8\u4e92\u4f5c\u7528 \u76f8\u5173 ", "\u5b98\u65b9 \u901a\u62a5 \u9996\u4f8b \u4e0d\u660e \u539f\u56e0 \u80ba\u708e \u60a3\u8005 \u53d1\u75c5 ", "\u4e0a\u6d77\u5e02 \u516c\u5171\u536b\u751f \u4e34\u5e8a \u4e2d\u5fc3 \u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u6b66\u6c49 \u4e2d\u5fc3\u533b\u9662 \u6b66\u6c49\u5e02 \u75be\u63a7\u4e2d\u5fc3 \u4e2d\u56fd \u75be\u63a7\u4e2d\u5fc3 \u4f20\u67d3\u75c5 \u9884\u9632 \u63a7\u5236 \u8054\u5408 \u6fb3\u5927\u5229\u4e9a \u6089\u5c3c\u5927\u5b66 \u6210\u529f \u7834\u8bd1 \u6b66\u6c49 \u53d1\u73b0 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u57fa\u56e0\u7ec4 \u75c5\u6bd2 \u57fa\u56e0\u7ec4 \u5e8f\u5217 \u4fe1\u606f \u5171\u4eab Virologic . org \u7f51\u7ad9 GenBank \u79d1\u5b66 \u6742\u5fd7 \u6b21\u65e5 \u53d1\u6587 \u5168\u7403 \u516c\u5171\u536b\u751f \u8fc7\u7a0b \u4e2d \u4ed8\u51fa \u52aa\u529b \u4eba\u5458 \u627f\u8ba4 \u611f\u8c22 \u8363\u8a89 ", "\u79d1\u6280\u90e8 \u526f \u90e8\u957f \u5f90 \u5357\u5e73 \u7ec4\u7ec7 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u8054\u9632 \u8054\u63a7 \u5de5\u4f5c \u673a\u5236 \u79d1\u7814 \u653b\u5173\u7ec4 \u7b2c\u4e00\u6b21 \u4f1a\u8bae \u4f1a\u8bae \u6210\u7acb \u949f\u5357\u5c71 \u9662\u58eb \u7ec4\u957f \u5305\u62ec \u674e\u5170\u5a1f \u5728\u5185 14 \u4f4d \u4e13\u5bb6 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u80ba\u708e \u75ab\u60c5 \u8054\u9632 \u8054\u63a7 \u5de5\u4f5c \u673a\u5236 \u79d1\u7814 \u653b\u5173 \u4e13\u5bb6\u7ec4 ", "\u77f3\u6b63\u4e3d \u7814\u7a76\u5458 \u516c\u5f00 \u75c5\u6bd2 \u9274\u5b9a \u65f6\u95f4\u8868 1 \u6708 3 \u65e5 \u8840\u6e05\u5b66 \u68c0\u6d4b \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u5efa\u7acb \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u7279\u5f02\u6027 \u6838\u9178 \u68c0\u6d4b \u65b9\u6cd5 1 \u6708 5 \u65e5 \u5206\u79bb \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 1 \u6708 11 \u65e5 \u786e\u8ba4 7 \u4f8b \u60a3\u8005 \u4e2d 5 \u4f8b \u60a3\u8005 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u4e2d \u6297\u4f53 1 \u6708 14 \u65e5 \u8bc1\u660e \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u5229\u7528 SARS \u75c5\u6bd2 \u540c\u6e90 \u53d7\u4f53 ACE2 \u611f\u67d3 ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u6b63\u5f0f \u5f15\u53d1 \u6b64\u8f6e \u80ba\u708e \u75c5\u6bd2 \u547d\u540d 2019 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 2019 - nCoV ", "\u56fd\u52a1\u9662 \u56fd\u5bb6 \u536b\u5065\u59d4 \u59d4\u6258 \u674e\u5170\u5a1f \u949f\u5357\u5c71 \u9662\u58eb \u4e00\u884c 6 \u6b66\u6c49 \u542c\u53d6 \u6b66\u6c49 \u60c5\u51b5\u6c47\u62a5 \u67e5\u770b \u73b0\u573a ", "\u56fd\u5bb6 \u536b\u5065\u59d4 \u9ad8\u7ea7\u522b \u4e13\u5bb6\u7ec4 \u7ec4\u957f \u8d76\u8d74 \u6b66\u6c49 \u652f\u63f4 \u7ec4\u957f \u949f\u5357\u5c71 \u9662\u58eb \u7ec4\u5458 \u5305\u62ec \u56fd\u5bb6 \u536b\u5065\u59d4 \u9ad8\u7ea7\u522b \u4e13\u5bb6 \u7ec4\u6210\u5458 \u9ad8\u798f \u674e\u5170\u5a1f \u8881\u56fd\u52c7 \u66fe\u5149 ", "\u5317\u4eac\u5927\u5b66 \u5e7f\u897f \u4e2d\u533b\u836f\u5927\u5b66 \u5b81\u6ce2\u5927\u5b66 \u6b66\u6c49 \u751f\u7269 \u5de5\u7a0b\u5b66\u9662 \u5b66\u8005 \u8054\u5408\u653b\u5173 Journal   of   Medical   Virology   \u5728\u7ebf \u53d1\u8868 \u4e00\u7bc7 \u7814\u7a76 \u8bba\u6587 \u79f0 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 2019 - nCoV \u8759\u8760 \u51a0\u72b6\u75c5\u6bd2 \u8d77\u6e90 \u672a\u77e5 \u51a0\u72b6\u75c5\u6bd2 \u4e4b\u95f4 \u91cd\u7ec4 \u75c5\u6bd2 \u86c7 \u643a\u5e26 2019 - nCoV \u75c5\u6bd2 \u91ce\u751f\u52a8\u7269 ", "\u56fd\u5bb6 \u57fa\u56e0\u7ec4 \u79d1\u5b66 \u6570\u636e\u4e2d\u5fc3 \u6b63\u5f0f \u53d1\u5e03 2019 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u8d44\u6e90\u5e93 \u6570\u636e\u5206\u6790 2019 - nCoV 2003 \u5e74 \u7206\u53d1 SARS \u75c5\u6bd2 \u57fa\u56e0\u7ec4 \u5e8f\u5217 \u5ea6\u4e3a 80% 2017 \u5e74 2 \u6708 \u56fd\u5185 \u8759\u8760 \u4e2d \u91c7\u96c6 Bat   SARS - like   coronavirus   isolate   bat - SL - CoVZC45 \u57fa\u56e0\u7ec4 \u5e8f\u5217 \u76f8\u4f3c\u6027 \u5ea6\u4e3a 88% ", "\u738b\u8fb0 \u9662\u58eb \u9ad8\u798f \u9662\u58eb \u8054\u540d \u67f3\u53f6\u5200 \u6742\u5fd7 The   Lancet \u5728\u7ebf \u53d1\u8868 \u9898\u4e3a \u300c A   novel   coronavirus   outbreak   of   global   health   concern \u8bc4\u8bba \u6587\u7ae0 \u7cfb\u7edf \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u75ab\u60c5 \u8fdb\u5c55 \u60c5\u51b5 \u6307\u51fa \u5c06\u6765 \u4e34\u5e8a \u57fa\u7840\u79d1\u5b66 \u7814\u7a76 \u65b9\u5411 ", "\u6743\u5a01 \u533b\u5b66\u6742\u5fd7 \u65b0\u82f1\u683c\u5170 \u533b\u5b66\u6742\u5fd7 \u53d1\u8868 \u4e2d\u56fd \u75be\u63a7\u4e2d\u5fc3 \u4e3b\u4efb \u9ad8\u798f \u9886\u8854 \u76f8\u5173 \u7814\u7a76 \u8bba\u6587 \u62ab\u9732 \u4e2d\u56fd \u79d1\u5b66\u5bb6 \u53d1\u73b0 \u5206\u79bb \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 2019 - nCov \u5168\u8fc7\u7a0b ", "\u8fbd\u5b81\u7701 \u9996\u6279 8 \u5e94\u6025 \u79d1\u6280 \u653b\u5173\u9879\u76ee \u542f\u52a8 ", "\u827e\u6ecb\u75c5 \u836f\u7269 \u963b\u6b62 \u51a0\u72b6\u75c5\u6bd2 ", "\u4e2d\u56fd \u75be\u75c5 \u9884\u9632 \u63a7\u5236\u4e2d\u5fc3 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u80ba\u708e \u75ab\u60c5 \u4e00\u7ea7 \u54cd\u5e94 \u6001\u52bf \u5206\u6790 \u98ce\u9669 \u8bc4\u4f30 \u7ec4 \u53d1\u5e03 2019 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u6001\u52bf \u8fdb\u5c55 \u98ce\u9669 \u8bc4\u4f30 ", "\u6218 \u75ab\u60c5   \u6210\u90fd \u9996\u6279 8 \u5e94\u6025 \u79d1\u6280 \u653b\u5173\u9879\u76ee \u6b63\u5f0f \u542f\u52a8 ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 WHO \u65b0\u51a0 \u75c5\u6bd2 \u75ab\u60c5 \u5168\u7403\u6027 \u7206\u53d1 \u56fd\u9645 \u5173\u6ce8 \u7a81\u53d1 \u516c\u5171\u536b\u751f \u4e8b\u4ef6 PHEIC ", "\u75c5\u6bd2 \u730e\u4eba \u4e4b\u79f0 \u4f0a\u6069 \u5229\u666e\u91d1 \u6559\u6388 \u7f8e\u56fd \u51fa\u53d1 \u5e7f\u5dde \u76ee\u7684   \u4e2d\u56fd \u76f8\u5173 \u90e8\u95e8 \u4eba\u58eb \u6c9f\u901a   \u786e\u4fdd \u4e2d\u56fd \u5168\u7403 \u516c\u5171 \u536b\u751f\u754c   \u75ab\u60c5 \u63a7\u5236 \u949f\u5357\u5c71 \u6c9f\u901a \u4e2d\u5c71\u5927\u5b66 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u80ba\u708e \u75ab\u60c5 \u79d1\u7814 \u5408\u4f5c \u63a2\u8ba8 ", "\u5e7f\u897f \u542f\u52a8 \u9996\u6279 \u6218 \u75ab \u56fd\u9645 \u79d1\u6280 \u5408\u4f5c \u5e94\u6025 \u4e13\u9879 ", "\u674e\u5170\u5a1f \u56e2\u961f \u63a8\u8350 \u836f\u7269 \u4f53\u5916 \u7ec6\u80de \u5b9e\u9a8c \u56e2\u961f \u53d1\u73b0 \u963f\u6bd4 \u6735\u5c14 \u8fbe\u82a6 \u97e6\u80fd \u6291\u5236 \u51a0\u72b6\u75c5\u6bd2 ", "\u4e2d\u79d1\u9662 \u674e\u5170\u5a1f \u56e2\u961f \u6b66\u6c49 \u53d1\u73b0 \u963f\u6bd4 \u591a\u5c14 \u8fbe\u82a6 \u97e6\u5728 \u4f53\u5916 \u5b9e\u9a8c \u4e2d \u65b0\u51a0 \u75c5\u6bd2 \u6291\u5236\u4f5c\u7528 \u56fd\u5bb6 \u536b\u5065\u59d4 \u63a8\u8350 ", "\u56fd\u5bb6 \u536b\u5065\u59d4 \u53d1\u5e03 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u80ba\u708e \u8bca\u7597 \u65b9\u6848 \u8bd5\u884c \u7b2c\u4e94\u7248 \u7591\u4f3c\u75c5\u4f8b \u786e\u8bca \u75c5\u4f8b \u8bca\u65ad \u6807\u51c6 \u65b0\u7248 \u6307\u5357 \u65e0\u75c7\u72b6 \u611f\u67d3\u8005 \u4f20\u67d3\u6e90 ", "\u5f20\u4f2f\u793c \u9662\u58eb \u56e2\u961f \u53d1\u73b0 \u8fde\u82b1\u6e05 \u761f\u53ef \u9632\u6cbb \u65b0\u51a0 \u80ba\u708e \u63a8\u8350 ", "\u5c71\u897f\u7701 \u7d27\u6025 \u7acb\u9879 14 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u80ba\u708e \u9632\u6cbb \u79d1\u7814 \u653b\u5173\u9879\u76ee ", "\u9655\u897f\u7701 \u9996\u6279 8 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u5e94\u6025 \u79d1\u6280 \u653b\u5173\u9879\u76ee \u542f\u52a8 ", "\u4e2d\u533b\u836f \u65b9\u5242 \u7b5b\u9009 \u7814\u7a76 \u9636\u6bb5\u6027 \u8fdb\u5c55 4 \u7701 \u8bd5\u70b9 \u4e34\u5e8a \u89c2\u5bdf \u663e\u793a \u6e05\u80ba \u6392\u6bd2 \u6c64 \u6cbb\u7597 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u80ba\u708e \u60a3\u8005 \u603b \u6709\u6548\u7387 \u53ef\u8fbe 90% ", "\u534e\u5357\u519c\u4e1a\u5927\u5b66 \u7a7f\u5c71\u7532 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u6f5c\u5728 \u5bbf\u4e3b ", "\u6297\u75c5\u6bd2 \u836f\u7269 \u745e\u5fb7 \u897f\u97e6 \u4e34\u5e8a\u8bd5\u9a8c \u6b66\u6c49 \u91d1\u94f6 \u6f6d \u533b\u9662 \u542f\u52a8 ", "\u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u6f5c\u5728 \u5bbf\u4e3b \u7a7f\u5c71\u7532 \u534e\u5357 \u519c\u5927 \u5cad\u5357 \u73b0\u4ee3\u519c\u4e1a \u79d1\u5b66 \u6280\u672f \u5e7f\u4e1c\u7701 \u5b9e\u9a8c\u5ba4 \u6c88\u6c38\u4e49 \u6559\u6388 \u8096\u7acb\u534e \u6559\u6388 \u79d1\u7814\u4eba\u5458 \u8054\u5408 \u519b\u4e8b\u79d1\u5b66\u9662 \u519b\u4e8b\u533b\u5b66 \u7814\u7a76\u9662 \u6768\u745e\u99a5 \u7814\u7a76\u5458 \u5e7f\u5dde \u52a8\u7269\u56ed \u79d1\u7814\u90e8 \u9648\u6b66 \u9ad8\u7ea7 \u517d\u533b \u5e08 \u6700\u65b0 \u7814\u7a76 \u5206\u79bb \u7a7f\u5c71\u7532 \u03b2 \u51a0\u72b6\u75c5\u6bd2 \u682a \u611f\u67d3 \u6bd2\u682a \u57fa\u56e0 \u5e8f\u5217 \u5ea6\u9ad8\u8fbe 99% ", "\u56fd\u52a1\u9662 \u8054\u9632 \u8054\u63a7 \u673a\u5236 \u65b0\u95fb \u53d1\u5e03\u4f1a \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u80ba\u708e \u6682 \u547d\u540d \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u80ba\u708e \u7b80\u79f0 \u65b0\u51a0 \u80ba\u708e \u82f1\u6587 \u7b80\u79f0 NCP ", "\u4e2d\u56fd \u79d1\u7814 \u56e2\u961f \u6700\u65b0 \u7814\u53d1 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u75ab\u82d7 \u52a8\u7269 \u8bd5\u9a8c \u6b3e \u75ab\u82d7 \u4e2d\u56fd \u75be\u63a7\u4e2d\u5fc3 \u4e0a\u6d77 \u540c\u6d4e\u5927\u5b66 \u533b\u5b66\u9662 \u4e0a\u6d77 \u751f\u7269 \u6280\u672f \u516c\u53f8 \u65af \u5fae\u751f\u7269 \u8bbe\u8ba1 \u5f00\u53d1 \u65af \u5fae\u751f\u7269 \u63d0\u4f9b \u751f\u4ea7 \u75ab\u82d7 \u6837\u672c \u65b0 \u75ab\u82d7 \u6837\u672c 100 \u591a\u53ea \u5065\u5eb7 \u5c0f\u9f20 \u8eab\u4e0a \u6ce8\u5c04 ", "OpenKG   \u53d1\u5e03 \u591a\u4e2a \u65b0\u51a0 \u75c5\u6bd2 \u76f8\u5173 \u5f00\u653e \u77e5\u8bc6 \u56fe\u8c31 \u6b64\u524d OpenKG \u8054\u5408 \u540c\u6d4e\u5927\u5b66 \u6d59\u6c5f\u5927\u5b66 \u4e1c\u5357\u5927\u5b66 \u6d77\u4e42 \u77e5 \u4fe1\u606f \u79d1\u6280 \u6587\u56e0 \u4e92\u8054 \u5c0f\u7c73 \u4eba\u5de5\u667a\u80fd \u5b9e\u9a8c\u5ba4 \u6b66\u6c49 \u79d1\u6280 \u5927\u5b66 \u590d\u65e6\u5927\u5b66 \u6d77\u77e5 \u667a\u80fd \u77e5\u8bc6 \u56fe\u8c31 \u6280\u672f \u4e13\u5bb6 \u8054\u5408 \u6784\u5efa \u65b0\u51a0 \u75c5\u6bd2 \u76f8\u5173 \u77e5\u8bc6 \u56fe\u8c31 ", "\u4e16\u536b \u7ec4\u7ec7 \u6b63\u5f0f \u547d\u540d \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u80ba\u708e COVID - 19 ", "\u6e56\u5317 \u4e34\u5e8a \u8bca\u65ad \u7eb3\u5165 \u786e\u8bca \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u80ba\u708e \u786e\u8bca \u75c5\u4f8b \u6fc0\u589e ", "\u7f8e\u56fd   CDC   \u53d1\u5e03   2020   \u5e74   1   \u6708 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u611f\u67d3 \u98ce\u9669 \u4eba\u7fa4 \u8c03\u67e5\u62a5\u544a     20% \u8fd1\u671f \u4e2d\u56fd \u65c5\u884c \u53f2 \u5c5e \u5bc6\u5207\u63a5\u89e6 ", "\u52a0\u62ff\u5927 \u9996\u4f8b \u786e\u8bca 2019 \u5e74 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u75c5\u4f8b \u8868\u73b0 \u8f7b\u5ea6 \u80ba\u708e \u7efc\u5408 \u75c5\u4f8b \u75c7\u72b6 \u6807\u660e \u5bb6\u4e2d \u975e \u533b\u9662 \u9694\u79bb \u7ba1\u7406 \u75ab\u60c5 \u904f\u5236 \u66b4\u53d1 \u7b56\u7565 ", "CRISPR \u57fa\u56e0 \u7f16\u8f91 \u5927\u795e \u5f20\u950b \u6559\u6388 \u56e2\u961f \u53d1\u5e03 CRISPR / Cas13 SHERLOCK \u6280\u672f \u68c0\u6d4b \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u8be6\u7ec6 \u64cd\u4f5c \u6d41\u7a0b \u6587\u6863 \u7ecf\u9a8c \u8bc1 \u65b9\u6cd5 \u68c0\u6d4b \u65b0\u51a0 \u75c5\u6bd2 \u5f02\u5e38 \u7075\u654f \u5fae\u5347 \u91cc 10 - 100 \u75c5\u6bd2 \u62f7\u8d1d \u68c0\u6d4b ", "\u5e7f\u4e1c \u63a8\u51fa \u6218\u75ab \u4eba\u624d \u8d37 \u52a9\u529b \u7814\u53d1 \u653b\u5173 \u989d\u5ea6 3000 \u4e07\u5143 \u652f\u6301 \u75ab\u60c5 \u9632\u63a7 \u6280\u672f \u4ea7\u54c1 \u836f\u7269 \u7814\u53d1 \u751f\u4ea7 ", "\u975e\u6d32 \u9996\u6b21 \u53d1\u73b0 \u611f\u67d3 \u57c3\u53ca , \u57c3\u53ca \u536b\u751f \u4eba\u53e3 \u90e8 \u8ffd\u8e2a \u53d7 \u5f71\u54cd \u56fd\u5bb6 \u6e38\u5ba2 \u8ba1\u5212 \u53d1\u73b0 \u75c5\u4f8b , \u75c5\u6bd2 \u6d4b\u8bd5 \u5448 \u9633\u6027 \u75c7\u72b6 , \u9694\u79bb \u4e2d \u5904\u4e8e \u7a33\u5b9a \u72b6\u6001 ", "\u65b0\u51a0 \u75c5\u6bd2 \u9996\u4e2a \u86cb\u767d\u8d28 \u7ed3\u6784 \u6210\u529f \u89e3\u6790 : \u5fb7\u514b\u8428\u65af \u5927\u5b66 \u5965\u65af\u6c40 \u5206\u6821 \u7814\u7a76 \u4eba\u5458 \u5229\u7528 \u51b7\u51bb\u7535 \u955c \u6280\u672f \u89e3\u6790   2019 - nCoV   \u4e09\u805a\u4f53   S   \u86cb   \u878d\u5408 \u524d \u6784\u8c61   EM   \u7ed3\u6784 \u7814\u7a76 \u7528\u4e8e \u5feb\u901f \u5f00\u53d1 \u8bc4\u4f30   MCMs \u89e3\u51b3 \u6301\u7eed \u516c\u5171\u536b\u751f \u5371\u673a ", "AI   \u8f85\u52a9 \u8bca\u65ad \u65b0\u51a0 \u80ba\u708e 20   \u79d2 96%   \u51c6\u786e\u7387 \u963f\u91cc\u5df4\u5df4 \u8fbe\u6469\u9662 \u963f\u91cc \u4e91 \u8054\u5408 \u51fa\u54c1   \u65b0\u51a0 \u75c5\u6bd2 \u80ba\u708e   AI   \u8f85\u8bca \u52a9\u624b \u7528\u6237 \u533b\u751f \u5feb\u901f \u7591\u4f3c\u75c5\u4f8b \u8bca\u65ad ", "\u738b\u798f\u751f \u9662\u58eb \u56e2\u961f \u53d1\u5e03 \u9996\u4efd \u65b0\u51a0 \u80ba\u708e \u75c5\u7406 \u62a5\u544a \u9057\u4f53 \u5fae\u521b \u53d6\u6837 ", "\u5fb7\u56fd \u5415\u8d1d\u514b \u5927\u5b66 Rolf   Hilgenfeld \u6559\u6388 2003 \u5e74 \u53c2\u4e0e \u4e2d\u56fd \u6297\u51fb SARS \u6597\u4e89 \u8bf4 RNA \u75c5\u6bd2 \u81ea\u9650\u6027 \u610f\u5473\u7740 \u751f\u75c5 \u611f\u67d3\u8005 \u65f6\u95f4 \u75c5\u6bd2 \u6297\u4f53 ", "\u4e2d\u56fd 80 \u9879 COVID - 19 \u6f5c\u5728 \u7597\u6cd5 \u8fd0\u884c \u5c1a\u5f85 \u4e34\u5e8a\u8bd5\u9a8c \u5305\u62ec \u827e\u6ecb\u75c5\u6bd2 \u836f\u7269 \u5e72\u7ec6\u80de \u4e2d\u836f \u8bd5\u56fe \u4e34\u5e8a \u8bc1\u660e \u4ef7\u503c ", "\u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u540c\u6d4e \u533b\u5b66\u9662 \u6cd5\u533b \u75c5\u7406\u5b66 \u4e13\u5bb6 \u5218\u826f \u6559\u6388 \u5b66\u8005 \u4e13\u5bb6 \u63a8\u52a8 \u5168\u56fd \u9996\u6279 \u4e24\u4f8b \u65b0\u51a0 \u80ba\u708e \u901d\u8005 \u9057\u4f53 \u89e3\u5256 \u6b66\u6c49 \u91d1\u94f6 \u6f6d \u533b\u9662 \u987a\u5229\u5b8c\u6210 \u4e24\u5177 \u89e3\u5256 \u75c5\u7406 \u9001\u68c0 ", "\u56fd\u9645 \u75c5\u6bd2 \u5206\u7c7b \u59d4\u5458\u4f1a ICTV \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u547d\u540d SARS CoV 2 \u5f15\u53d1 \u4e2d\u56fd \u5b66\u8005 \u8d28\u7591 18 \u65e5 \u9ad8\u798f \u77f3\u6b63\u4e3d \u591a\u4f4d \u4e2d\u56fd \u4e13\u5bb6 \u8054\u540d \u67f3\u53f6\u5200 \u7ebf\u4e0a \u5e73\u53f0 \u520a\u53d1 \u6587\u7ae0 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u547d\u540d \u63d0\u51fa \u5efa\u8bae \u547c\u5401 \u75c5\u6bd2 \u547d\u540d HCoV 19 2019 \u5e74 \u51a0\u72b6\u75c5\u6bd2 ", "\u4e0a\u6d77 \u4e13\u5bb6 \u56e2\u961f \u63a2\u7d22 \u65b0\u51a0 \u80ba\u708e \u6cbb\u7597 \u65b9\u6848 \u6cbb\u6108\u7387 53% \u8c03\u6574 \u4f18\u5316 \u4e0a\u6d77 \u8bca\u7597 \u89c4\u8303 \u8fd1\u671f \u516c\u5e03 ", "\u4e2d\u534e \u6d41\u884c\u75c5\u5b66 \u6742\u5fd7 \u53d1\u5e03 \u4e00\u7bc7 \u8bba\u6587 \u9009\u53d6 2020 \u5e74 2 \u6708 11 \u65e5 \u4e2d\u56fd \u5185\u5730 \u4f20\u67d3\u75c5 \u62a5\u544a \u4fe1\u606f\u7cfb\u7edf \u4e2d \u4e0a\u62a5 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u80ba\u708e \u75c5\u4f8b \u56de\u987e\u6027 \u7814\u7a76 1 \u6708 20 \u65e5 \u53d1\u75c5 \u4eba\u6570 6174 \u786e\u8bca \u75c5\u4f8b \u4e4b\u95f4 291 \u5dee\u5f02 \u6298\u5c04\u51fa \u75ab\u60c5 \u9632\u63a7 \u521d\u671f \u8584\u5f31 \u5904 ", "\u6770\u6bc5 \u751f\u7269 \u8054\u624b \u6d59\u6c5f\u7701 \u75be\u63a7\u4e2d\u5fc3 \u963f\u91cc \u8fbe\u6469\u9662 \u533b\u7597 AI \u56e2\u961f \u63a8\u51fa \u65b0\u51a0 \u75c5\u6bd2 \u81ea\u52a8\u5316 \u5168 \u57fa\u56e0\u7ec4 \u68c0\u6d4b \u5206\u6790 \u5e73\u53f0 \u963f\u91cc \u7b97\u6cd5 \u751f\u4fe1 \u5206\u6790 \u65f6\u95f4 \u4ece\u6570 \u5c0f\u65f6 \u7f29\u77ed \u534a\u5c0f\u65f6 \u5927\u5e45\u63d0\u9ad8 \u7591\u4f3c\u75c5\u4f8b \u786e\u8bca \u901f\u5ea6 \u51c6\u786e\u7387 ", "\u4e49\u7fd8 \u795e\u5dde \u62ff\u5230 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u5e8f\u5217 11 \u5929 \u6210\u529f \u8868\u8fbe S \u86cb\u767d \u53d7\u4f53 \u57df \u86cb\u767d \u5229\u7528 \u771f\u6838\u7ec6\u80de \u86cb\u767d \u8868\u8fbe \u4f53\u7cfb \u89c4\u6a21\u5316 \u751f\u4ea7 \u751f\u7269\u5b66 \u68c0\u6d4b \u7eaf\u5ea6 \u9ad8\u8fbe 95% \u4eba\u7c7b \u7ec6\u80de \u53d7\u4f53 \u80fd\u529b \u5404\u5927 \u79d1\u7814 \u56e2\u961f \u514d\u8d39 \u7533\u9886 ", "\u8d5b\u8bfa\u83f2 \u5168\u7403 \u75ab\u82d7 \u4e8b\u4e1a\u90e8 \u5229\u7528 \u5148\u524d \u5f00\u53d1 SARS \u75ab\u82d7 \u7ecf\u9a8c \u7f8e\u56fd \u751f\u7269\u533b\u5b66 \u9ad8\u7ea7 \u7814\u7a76 \u5f00\u53d1\u5c40 BARDA \u5408\u4f5c , \u5229\u7528 \u5148\u8fdb \u57fa\u56e0 \u91cd\u7ec4 \u6280\u672f \u5e73\u53f0 \u52a0\u901f \u5f00\u53d1\u65b0 \u51a0 \u75c5\u6bd2 COVID - 19 \u75ab\u82d7 ", "\u897f\u6e56 \u5927\u5b66 \u7814\u7a76 \u56e2\u961f \u79d1\u5b66 \u9884 \u5370\u7248 \u5e73\u53f0 bioRxiv \u4e0a\u7ebf \u6700\u65b0 \u7814\u7a76\u6210\u679c \u5468\u5f3a \u5b9e\u9a8c\u5ba4 \u5229\u7528 \u51b7\u51bb\u7535 \u955c \u6280\u672f \u5168\u7403 \u9996\u6b21 \u6210\u529f \u89e3\u6790 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u53d7\u4f53 ACE2 \u5168\u957f \u7ed3\u6784 \u8fd9\u662f \u4e16\u754c \u9996\u6b21 \u89e3\u6790 ACE2 \u5168\u957f \u7ed3\u6784 ", "\u6c55\u5934\u5927\u5b66 \u7ca4\u6e2f \u65b0 \u53d1 \u4f20\u67d3\u75c5 \u8054\u5408 \u5b9e\u9a8c\u5ba4 \u9999\u6e2f\u5927\u5b66 \u65b0 \u53d1 \u4f20\u67d3\u6027 \u75be\u75c5 \u56fd\u5bb6 \u91cd\u70b9 \u5b9e\u9a8c\u5ba4 \u5e7f\u897f \u533b\u79d1\u5927\u5b66 \u80e1\u8273\u73b2 \u8bfe\u9898\u7ec4 \u9884 \u5370\u672c \u7f51\u7ad9 bioRxiv \u8054\u5408 \u53d1\u5e03 \u6700\u65b0 \u7814\u7a76 \u534e\u5357\u5730\u533a \u8d70\u79c1 \u7a7f\u5c71\u7532 \u591a\u4e2a \u6837\u54c1 \u4e2d \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u51a0\u72b6\u75c5\u6bd2 \u51a0\u72b6\u75c5\u6bd2 \u53d7\u4f53 \u57df RBD \u7a7f\u5c71\u7532 \u6837\u672c \u4e2d \u51a0\u72b6\u75c5\u6bd2 \u65b0\u51a0 \u75c5\u6bd2 \u5ea6\u8fbe 97% ", "\u54c8\u4f5b\u5927\u5b66 \u5e7f\u5dde \u547c\u5438 \u5065\u5eb7 \u7814\u7a76\u9662 \u6052\u5927 \u96c6\u56e2 \u4e09\u65b9 \u8054\u5408 \u6210\u7acb \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u80ba\u708e \u79d1\u7814 \u653b\u575a \u5c0f\u7ec4 \u79d1\u7814 \u653b\u575a \u5c0f\u7ec4 \u5305\u62ec \u56fd\u5bb6 \u536b\u5065\u59d4 \u9ad8\u7ea7\u522b \u4e13\u5bb6\u7ec4 \u7ec4\u957f \u949f\u5357\u5c71 \u9662\u58eb \u54c8\u4f5b\u5927\u5b66\u533b\u5b66\u9662 \u9662\u957f GeorgeDaley \u9662\u58eb \u54c8\u4f5b\u5927\u5b66\u533b\u5b66\u9662 \u526f \u9662\u957f DavidGolan \u514d\u75ab \u7cfb\u4e3b\u4efb ArleneSharpe \u9662\u58eb \u54c8\u4f5b\u5927\u5b66 \u96f7\u6839 \u7814\u7a76\u6240 \u4e3b\u4efb BruceWalker \u9662\u58eb \u54c8\u4f5b\u5927\u5b66 \u4f20\u67d3 \u75be\u75c5 \u52a8\u6001 \u4e2d\u5fc3 \u4e3b\u4efb MarcLipstich \u4e39\u5a1c \u6cd5\u4f2f \u764c\u75c7 \u7814\u7a76\u9662 \u4f20\u67d3\u75c5 \u7cfb\u4e3b\u4efb LindseyBaden \u5e7f\u5dde \u547c\u5438 \u5065\u5eb7 \u7814\u7a76\u9662 \u9662\u957f \u5efa\u884c \u6559\u6388 \u547c\u5438 \u75be\u75c5 \u56fd\u5bb6 \u91cd\u70b9 \u5b9e\u9a8c\u5ba4 \u526f \u4e3b\u4efb \u8d75 \u91d1\u5b58 \u6559\u6388 \u56fd\u5185\u5916 \u6743\u5a01\u4e13\u5bb6 \u8fd9\u662f \u4e16\u754c \u9876\u7ea7 \u56e2\u961f ", "\u65b0\u51a0 \u75ab\u82d7 \u91cd\u5927\u7a81\u7834 \u7f8e \u79d1\u5b66\u5bb6 \u7ed8\u5236 S \u86cb\u767d \u8d85\u6e05 \u7ed3\u6784 Science   \u6742\u5fd7 \u520a\u53d1 \u7f8e\u56fd \u5fb7\u514b\u8428\u65af \u5927\u5b66 \u5965\u65af\u6c40 \u5206\u6821   Jason   S   McLellan   \u56e2\u961f \u4e00\u7bc7 \u91cd\u78c5 \u6210\u679c \u7814\u7a76 \u4eba\u5458 \u51b7\u51bb\u7535 \u955c   Cryo - EM   \u6280\u672f \u89e3\u6790 \u51fa\u65b0 \u51a0 \u75c5\u6bd2   S   \u86cb\u767d \u4e09\u805a\u4f53   3.5   \u57c3 \u539f\u5b50 \u5206\u8fa8\u7387 \u7ed3\u6784 ", "\u5e7f\u4e1c \u75be\u63a7\u4e2d\u5fc3 \u73e0\u6d77 \u75be\u63a7\u4e2d\u5fc3 \u4e2d\u5c71\u5927\u5b66 \u9644\u5c5e \u7b2c\u4e94 \u533b\u9662 \u9999\u6e2f\u5927\u5b66 \u8054\u5408 \u7814\u7a76 \u56e2\u961f \u65b0\u82f1\u683c\u5170 \u533b\u5b66\u6742\u5fd7 NEJM \u53d1\u6587 \u4e24\u4e2a \u7ed3\u8bba \u65e0\u75c7\u72b6 \u611f\u67d3\u8005 \u75c7\u72b6 \u611f\u67d3\u8005 \u75c5\u6bd2 \u8f7d\u91cf \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u6838\u9178 \u6392\u51fa \u6a21\u5f0f \u6d41\u611f \u4e24\u4e2a \u7ed3\u8bba \u63d0\u793a \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u4eba\u9645 \u4e2d \u6f5c\u5728 \u4f20\u64ad \u529b \u4f4e\u4f30 ", "\u7f8e\u56fd \u4e54\u6cbb\u4e9a \u5357\u65b9 \u5927\u5b66 \u6ce2\u58eb\u987f\u5927\u5b66 \u8054\u5408 \u7814\u7a76 \u56e2\u961f \u53d1\u6587 \u79f0 \u4e2d\u56fd \u7701\u4efd 2020 \u5e74 1 \u6708 20 \u65e5\u81f3 2 \u6708 9 \u65e5 \u5206\u6790 COVID - 19 \u6d41\u884c\u75c5 \u500d\u589e \u65f6\u95f4 \u603b\u4f53 \u5e73\u5747 \u500d\u589e \u65f6\u95f4 1.3 3.4 \u5929 \u4e4b\u95f4 \u6e56\u5317 \u4f30\u8ba1 2.5 \u5929 \u6d41\u884c\u75c5 \u53d1\u5c55 \u6d41\u884c\u75c5 \u500d\u589e \u65f6\u95f4 \u589e\u52a0 \u793e\u4f1a \u9694\u79bb \u63aa\u65bd \u51cf\u7f13 \u6d41\u884c\u75c5 \u901f\u5ea6 ", "\u536b\u5065\u59d4 \u56de\u5e94 \u75ab\u82d7 \u7814\u53d1 \u8fdb\u5c55 5 \u6761 \u6280\u672f \u8def\u7ebf \u6b63 \u540c\u6b65 \u7814\u7a76 \u5305\u62ec \u706d \u6d3b\u75ab\u82d7 \u91cd\u7ec4 \u57fa\u56e0\u5de5\u7a0b \u75ab\u82d7 \u817a\u75c5\u6bd2 \u8f7d\u4f53 \u75ab\u82d7 \u6838\u9178 \u75ab\u82d7 \u51cf\u6bd2 \u6d41\u611f\u75c5\u6bd2 \u75ab\u82d7 \u8f7d\u4f53 \u75ab\u82d7 ", "\u7ee7 \u9999\u6e2f\u5927\u5b66 \u7ba1\u8f76 \u516c\u5e03 \u7a7f\u5c71\u7532 \u75c5\u6bd2 \u5e8f\u5217 \u63ed\u793a \u5173\u952e \u7a7f\u5c71\u7532 \u51a0\u72b6\u75c5\u6bd2 \u5173\u952e \u57fa\u56e0 \u4eba\u7c7b \u611f\u67d3 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u540c\u6e90\u6027 \u9ad8\u8fbe 97% \u534e\u5357\u519c\u4e1a\u5927\u5b66 \u7814\u7a76 \u56e2\u961f 2 \u6708 21 \u65e5 \u51cc\u6668 \u79d1\u5b66 \u9884 \u5370\u7248 \u7f51\u7ad9 bioRxiv \u629b\u51fa \u8bba\u6587 \u9996\u6b21 \u516c\u5e03 \u7814\u7a76 \u7a7f\u5c71\u7532 \u51a0\u72b6\u75c5\u6bd2 \u57fa\u56e0 \u5e8f\u5217 \u7ed3\u679c\u663e\u793a \u7a7f\u5c71\u7532 \u51a0\u72b6\u75c5\u6bd2 \u4e00\u90e8\u5206 \u57fa\u56e0 \u4eba\u7c7b \u611f\u67d3 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u540c\u6e90\u6027 \u8fbe 99% \u5168\u7ec4 \u57fa\u56e0 \u540c\u6e90\u6027 90% \u8fdc \u4f4e\u4e8e \u8759\u8760 \u51a0\u72b6\u75c5\u6bd2 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u5168 \u57fa\u56e0\u7ec4 96% \u540c\u6e90\u6027 \u7a7f\u5c71\u7532 \u5bbf\u4e3b \u6570\u636e ", "\u75c5\u6bd2 \u6eaf\u6e90 \u7814\u7a76 \u949f\u5357\u5c71 \u9662\u58eb \u56e2\u961f \u4e13\u5bb6 \u547c\u5438 \u75be\u75c5 \u56fd\u5bb6 \u91cd\u70b9 \u5b9e\u9a8c\u5ba4 \u526f \u4e3b\u4efb \u8d75 \u91d1\u5b58 \u6559\u6388 \u56e2\u961f \u8054\u5408 \u5e7f\u5dde \u6d77\u5173 \u9996\u6b21 \u5e7f\u5dde \u611f\u67d3 \u75c5\u4f8b \u6837\u672c \u7caa\u4fbf \u6807\u672c \u4e2d\u4e2d \u6210\u529f \u5206\u79bb \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 COVID - 19 \u6bd2\u682a \u8fdb\u4e00\u6b65 \u75ab\u82d7 \u836f\u7269 \u7814\u7a76 \u6253\u4e0b\u57fa\u7840 ", "\u4e2d\u79d1\u9662 \u5168 \u57fa\u56e0\u7ec4 \u6570\u636e \u89e3\u6790 \u8bc1\u5b9e \u534e\u5357 \u6d77\u9c9c \u5e02\u573a \u75c5\u6bd2 \u6e90\u5934 \u4e2d\u56fd\u79d1\u5b66\u9662 \u897f\u53cc\u7248\u7eb3 \u70ed\u5e26 \u690d\u7269\u56ed \u8054\u5408 \u534e\u5357\u519c\u4e1a\u5927\u5b66 \u5317\u4eac \u8111\u79d1 \u4e2d\u5fc3 \u79d1\u7814\u4eba\u5458 \u6536\u96c6 \u5168\u4e16\u754c \u9886\u57df \u5171\u4eab GISAID   EpiFluTM \u6570\u636e\u5e93 \u4e2d \u8986\u76d6 \u56db\u5927\u6d32 12 \u56fd\u5bb6 93 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u6837\u672c \u57fa\u56e0\u7ec4 \u6570\u636e \u622a\u6b62 2 \u6708 12 \u65e5 \u5168 \u57fa\u56e0\u7ec4 \u6570\u636e \u89e3\u6790 \u8ffd\u6eaf \u4f20\u67d3\u6e90 \u6269\u6563 \u8def\u5f84 \u53d1\u73b0 \u534e\u5357 \u6d77\u9c9c \u5e02\u573a \u65e0\u5173 \u6837\u672c ", "\u65b0\u51a0 \u75c5\u6bd2 \u5173\u952e \u86cb\u767d \u5206\u5b50\u7ed3\u6784 \u56fe \u95ee\u4e16 \u7f8e\u5a92\u79f0 \u4e00\u7ec4 \u7814\u7a76 \u4eba\u5458 \u5f04\u6e05 \u75c5\u6bd2 \u7528\u4ee5 \u5165\u4fb5 \u4eba\u7c7b \u7ec6\u80de \u4e00\u79cd \u5173\u952e \u86cb\u767d\u8d28 \u523a\u7a81 \u86cb\u767d \u5206\u5b50\u7ed3\u6784 \u75ab\u82d7 \u7814\u53d1 \u5f00\u542f \u5927\u95e8 ", "\u745e\u58eb \u5b66\u8005 \u4eba\u5de5\u5408\u6210 \u51fa\u65b0 \u51a0 \u75c5\u6bd2 \u745e\u58eb \u4f2f\u5c14\u5c3c \u5927\u5b66 Jorerg   Jores Volker   Thiel \u56e2\u961f \u63d0\u51fa \u53cd\u5411 \u9057\u4f20\u5b66 \u75c5\u6bd2 \u6784\u9020 \u7b56\u7565 \u65e0\u9700 \u75c5\u4eba \u6837\u672c \u4e2d \u63d0\u53d6 \u5b8c\u6574 \u75c5\u6bd2 \u75c5\u6bd2 \u6838\u9178 \u5e8f\u5217 \u53d1\u8868 \u4e00\u5468 \u9175\u6bcd \u751f\u4ea7 \u6d3b\u6027 \u65b0\u51a0 \u75c5\u6bd2 \u9700\u6c42 \u6539\u9020 \u5b9e\u9a8c\u6240 \u9700 \u75c5\u6bd2 \u5de5\u5177 \u63d0\u793a \u65b0\u51a0 \u75c5\u6bd2 \u5408\u6210 \u6539\u9020 \u5feb\u901f \u9014\u5f84 \u5927\u5927\u51cf\u5c11 \u75c5\u6bd2 \u53d8\u5f02 \u7814\u7a76 \u5e26\u6765 \u56f0\u96be ", "\u5929\u6d25\u533b\u79d1\u5927\u5b66 \u9644\u5c5e \u80bf\u7624\u533b\u9662 \u5f90\u6ce2 \u6559\u6388 \u56e2\u961f \u56fd\u5bb6 \u8d85\u7ea7\u8ba1\u7b97\u673a \u5929\u6d25 \u4e2d\u5fc3 \u7814\u7a76 \u56e2\u961f \u53d1\u6587 \u4ecb\u7ecd \u5408\u4f5c \u7814\u53d1 \u5229\u7528 CT \u56fe\u50cf \u8f85\u52a9 \u8bca\u65ad \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u80ba\u708e \u4eba\u5de5\u667a\u80fd \u6a21\u578b \u6a21\u578b \u9274\u522b \u65b0\u51a0 \u80ba\u708e \u75c5\u6bd2\u6027 \u80ba\u708e \u603b \u51c6\u786e\u5ea6 \u53ef\u8fbe 83% \u5feb\u901f \u9ad8\u6548 ", "\u738b\u8fb0 \u9662\u58eb Lancet \u53d1\u6587 \u79f0 \u590d\u5de5 \u540e\u5e94 \u9694\u79bb \u7b56\u7565 ", "\u6d59\u6c5f \u5b98\u5ba3\u65b0\u51a0 \u80ba\u708e \u75ab\u82d7 \u7814\u7a76 \u8fdb\u5c55 \u91cd\u7ec4 \u86cb\u767d \u75ab\u82d7 \u7b2c\u4e00\u6279 \u9884 \u5b9e\u9a8c \u5c0f\u9f20 \u6d4b\u8bd5 \u6297\u4f53 mRNA \u75ab\u82d7 \u7814\u53d1 \u52a8\u7269 \u5b9e\u9a8c \u9636\u6bb5 \u91cd\u7ec4 \u817a\u75c5\u6bd2 \u8f7d\u4f53 \u75ab\u82d7 \u7814\u53d1 \u91cd\u7ec4 \u75c5\u6bd2 \u6269\u589e \u57f9\u517b \u8fd1\u671f \u52a8\u7269 \u5b9e\u9a8c \u706d \u6d3b\u75ab\u82d7 \u7814\u53d1 \u7b5b\u9009 \u7b2c\u56db\u4ee3 \u75ab\u82d7 \u6bd2\u682a ", "\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40 \u5df2\u65b0\u6279 \u4e24\u4e2a \u65b0\u51a0 \u80ba\u708e \u75c5\u6bd2\u68c0\u6d4b \u8bd5\u5242\u76d2 \u6e05\u534e\u5927\u5b66 \u53c2\u4e0e \u8bbe\u8ba1 \u5f00\u53d1 \u516d\u9879 \u547c\u5438\u9053 \u75c5\u6bd2 \u6838\u9178 \u68c0\u6d4b \u8bd5\u5242\u76d2 \u6052\u6e29 \u6269\u589e \u82af\u7247 \u6cd5 \u8bd5\u5242\u76d2 1.5 \u5c0f\u65f6 \u4e00\u6b21\u6027 \u68c0\u6d4b \u5305\u62ec \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 2019 - nCoV \u5728\u5185 6 \u547c\u5438\u9053 \u5e38\u89c1 \u75c5\u6bd2 \u5168\u7403 \u9996\u4e2a 1.5 \u5c0f\u65f6 \u68c0\u6d4b \u5305\u62ec \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u5728\u5185 6 \u9879 \u547c\u5438\u9053 \u75c5\u6bd2 \u6838\u9178 \u68c0\u6d4b \u82af\u7247 \u8bd5\u5242\u76d2 \u4ea7\u54c1 \u5df2\u83b7 15 \u9879 \u6388\u6743 \u4e13\u5229 ", "\u56fd \u5236\u836f \u516c\u53f8 Moderna \u6210\u529f \u7814\u5236 \u65b0\u51a0 \u75c5\u6bd2 SARS - CoV - 2 \u4eba\u4f53 \u75ab\u82d7 \u7b2c\u4e00\u6279 \u75ab\u82d7 \u9001 \u7f8e\u56fd \u56fd\u5bb6\u536b\u751f\u7814\u7a76\u9662 \u5f00\u542f \u5b89\u5168\u6027 \u4e34\u5e8a\u8bd5\u9a8c \u8ba1\u5212 \u6708\u5e95 20 - 25 \u540d \u5065\u5eb7 \u5fd7\u613f\u8005 \u836f\u7269 \u6d4b\u8bd5 7 \u6708 8 \u6708 \u516c\u5e03 ", "\u4e16\u536b \u4e13\u5bb6 \u79f0 \u4e2d\u56fd \u65b9\u6cd5 \u552f\u4e00 \u8bc1\u5b9e \u65b9\u6cd5 \u56fd \u75ab\u60c5 \u5347\u7ea7 \u4e16\u536b \u7ec4\u7ec7 \u603b\u5e72\u4e8b \u9ad8\u7ea7\u987e\u95ee \u5e03\u9c81\u65af \u827e\u5c14\u6c83\u5fb7 \u7279\u6548\u836f \u75ab\u82d7 \u60c5\u51b5 \u4e2d\u56fd \u505a\u6cd5 \u62ef\u6551 \u751f\u547d \u62ef\u6551 \u751f\u547d \u786e\u8bca \u60a3\u8005 \u6570\u636e \u4e0b\u964d \u4e2d\u56fd \u65b9\u6cd5 \u552f\u4e00 \u4e8b\u5b9e\u8bc1\u660e \u6210\u529f \u65b9\u6cd5 ", "\u6c88\u9633 \u5316\u5de5\u5927\u5b66 \u751f\u7269\u5b66 \u7814\u7a76\u6240 \u6240\u957f \u5c39 \u79c0\u5c71 \u535a\u58eb \u56e2\u961f \u7f8e\u56fd \u5bc6\u6b47\u6839 \u7687\u5bb6 \u6a61\u6811 \u535a\u8499\u7279 Michael   B   Chancellor \u56e2\u961f \u53d1\u6587 \u63ed\u793a \u9006\u8f6c\u5f55 \u73af \u4ecb\u5bfc \u7b49\u6e29 \u6269\u589e RT - LAMP \u6280\u672f \u63a2\u7d22 \u5feb\u901f \u68c0\u6d4b \u75c5\u6bd2 \u65b0 \u65b9\u6cd5 \u4e24\u79cd \u65b9\u6cd5 \u64cd\u4f5c \u7b80\u5355 \u73b0\u573a 45 \u5206\u949f \u5185\u51fa \u68c0\u6d4b ", "Rolf   Hilgenfeld \u540c\u4e8b \u8bbe\u60f3 \u4e00\u79cd \u89e3\u51b3\u65b9\u6848 \u5e7f\u8c31\u6297 \u75c5\u6bd2 \u836f\u7269 \u5f62\u5f0f \u51a0\u72b6\u75c5\u6bd2 \u80a0\u9053\u75c5\u6bd2 \u5bfc\u81f4 \u611f\u5192 \u75c5\u75c7 ; \u624b\u8db3 \u53e3\u75c5 ; \u590f\u5b63 \u6d41\u611f \u75c5\u6bd2 \u86cb\u767d\u8d28 \u5207\u5272 \u8fc7\u7a0b ", "\u7f8e\u56fd\u54e5\u4f26\u6bd4\u4e9a\u5927\u5b66 \u516c\u5171\u536b\u751f \u5b66\u9662 \u611f\u67d3 \u514d\u75ab \u4e2d\u5fc3 \u4e3b\u4efb \u4f20\u67d3\u75c5 \u5b66 \u4e13\u5bb6 \u5229\u666e\u91d1 \u6559\u6388 ( Walter   Ian   Lipkin ) \u5e26\u9886 \u56e2\u961f \u6210\u529f \u7814\u5236 \u51c6\u786e\u7387 \u5927\u4e3a \u63d0\u5347 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u68c0\u6d4b \u8bd5\u5242 \u51e0\u4f4d \u77e5\u540d \u79d1\u5b66\u5bb6 \u8bc1\u660e   \u65b0\u51a0 \u75c5\u6bd2 \u5927\u81ea\u7136 \u975e \u5b9e\u9a8c\u5ba4 \u4eba\u5de5 \u5236\u9020 \u4ea7\u7269 ", "\u7f8e\u56fd \u542f\u52a8 \u9996\u4e2a \u745e\u5fb7 \u897f\u97e6 \u4e34\u5e8a\u8bd5\u9a8c \u7f8e\u56fd \u56fd\u7acb \u536b\u751f \u7814\u7a76\u9662 NIH \u745e\u5fb7 \u897f\u97e6 \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u4e34\u5e8a\u8bd5\u9a8c \u542f\u52a8 \u8bd5\u9a8c \u5185\u5e03\u62c9\u65af\u52a0 \u5927\u5b66 \u533b\u5b66\u4e2d\u5fc3 University   of   Nebraska   Medical   Center \u4f4f\u9662 \u60a3\u8005 \u8eab\u4e0a \u91c7\u7528 \u968f\u673a \u63a7\u5236 \u65b9\u6cd5 \u8bc4\u4f30 \u6cbb\u7597 \u65b9\u6848 \u5b89\u5168\u6027 \u6709\u6548\u6027 \u56f4\u7ed5 \u745e\u5fb7 \u897f\u97e6 \u5409\u5229 \u5fb7 \u79d1\u5b66 \u516c\u53f8 \u4e2d\u56fd \u7533\u8bf7   8   \u4ef6 \u4e13\u5229   3   \u4ef6 \u4e13\u5229 \u6388\u6743   5   \u4ef6 \u5ba1\u67e5 \u8fc7\u7a0b \u4e2d ", "\u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u5206\u5b50 \u6307\u7eb9 \u56fd\u5185 \u4e09\u4e2a \u7814\u7a76 \u56e2\u961f \u6210\u679c 1 . \u4e0a\u6d77 \u6b66\u6c49 \u5317\u4eac \u6089\u5c3c \u7814\u7a76 \u4eba\u5458 \u56e2\u961f \u5b8f \u57fa\u56e0\u7ec4 metagenomic RNA   \u6d4b\u5e8f \u4e00\u540d \u6b66\u6c49 \u6d77\u9c9c \u5e02\u573a \u5de5\u4f5c \u60a3\u8005 \u4e2d \u53d1\u73b0 \u4e00\u79cd \u672a\u77e5 \u51a0\u72b6\u75c5\u6bd2 2 . \u4e2d\u56fd \u75be\u75c5 \u63a7\u5236 \u9884\u9632 \u4e2d\u5fc3 \u6d3e\u9063 \u56e2\u961f 3 \u540d \u60a3\u8005 \u652f\u6c14\u7ba1 \u80ba\u6ce1 \u704c \u6d17\u6db2 \u4e2d \u5206\u79bb \u57f9\u517b \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 3 . \u6b66\u6c49 \u5317\u4eac \u7814\u7a76 \u56e2\u961f 5 \u540d \u80ba\u708e \u60a3\u8005 \u4e2d \u53d1\u73b0 \u75c5\u6bd2 5 \u57fa\u56e0\u7ec4 \u5e8f\u5217 \u5b58\u653e GISAID \u6570\u636e\u5e93 \u4e2d \u53d1\u73b0 \u8fd9\u4e00 \u75c5\u6bd2 ACE2 \u53d7\u4f53 \u5bbf\u4e3b \u7ec6\u80de \u8fd9\u4e00 \u4fb5\u5165 \u65b9\u5f0f SARS - CoV ", "\u4e2d\u5c71\u5927\u5b66 \u516c\u5171\u536b\u751f \u5b66\u9662 \u738b\u8302 \u56e2\u961f \u533b\u5b66 \u9884 \u5370\u672c \u7f51\u7ad9 medRxiv \u53d1\u8868 \u7edf\u8ba1 \u786e\u8bca \u4eba\u6570 \u8282\u70b9 \u6c14\u6e29 \u9996\u6b21 \u63d0\u51fa \u65b0\u51a0 \u80ba\u708e \u7206\u53d1 \u6c14\u5019 \u4e4b\u95f4 \u5bc6\u5207\u5173\u7cfb \u63d0\u793a \u75c5\u6bd2 \u4f20\u64ad \u6700\u9002 \u6e29\u5ea6 \u7206\u53d1 \u6e90 \u6b66\u6c49 \u539f\u56e0 ", "\u590d\u65e6\u5927\u5b66 \u8054\u5408 \u827e\u8dc3 \u751f\u7269 \u9996\u4f8b \u65b0\u51a0 \u75c5\u6bd2 \u5168\u4eba\u6e90 \u6297\u4f53 \u56e2\u961f \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u80ba\u708e \u5eb7\u590d \u60a3\u8005 \u6765\u6e90 \u6837\u672c \u4e2d \u5206\u79bb B \u7ec6\u80de PCR \u514b\u9686 \u6297\u4f53 \u53ef\u53d8 \u533a \u5feb\u901f \u83b7\u53d6 \u7b5b\u9009 \u767e\u682a \u5168\u4eba\u6e90 \u6297\u4f53 \u53d1\u73b0 \u591a\u682a \u8bc6\u522b \u65b0\u51a0 \u75c5\u6bd2 WHO \u6700\u65b0 \u547d\u540d SARS - CoV - 2 RBD \u6297\u539f \u8fd9\u9879 \u7814\u7a76 \u5f00\u53d1 \u5168\u4eba\u6e90 \u4e2d\u548c\u6027 \u6297\u4f53 \u836f Human   NeutralizationAntibody \u63d0\u4f9b \u5feb\u901f \u7814\u53d1 \u65b9\u6848 \u5019\u9009 \u6297\u4f53 \u6210\u679c \u6297\u4f53 \u5eb7\u590d \u75c5\u4eba \u4f53\u5185 \u5929\u7136 \u5168\u4eba\u6e90 \u65b0\u51a0 \u75c5\u6bd2 \u6297\u4f53 ", "\u5229\u666e\u91d1 \u6559\u6388 \u56e2\u961f \u8367\u5149 \u67d3\u8272 \u6269\u589e PCR \u8bd5\u5242 \u7075\u654f\u5ea6 \u63d0\u9ad8 \u6570\u500d \u72ec\u7279 \u8840\u6e05 \u82af\u7247 \u6700\u5177 \u7279\u5f02\u6027 \u80bd \u6bb5 \u505a ELISA \u51c6\u786e \u4fbf\u5b9c \u64cd\u4f5c \u4e24\u4e2a \u6280\u672f \u6709\u52a9\u4e8e \u8bca\u65ad \u63d0\u9ad8 \u7075\u654f\u5ea6 \u51c6\u786e \u6297\u4f53 \u82af\u7247 \u6280\u672f \u591a\u91cd \u8367\u5149 \u5b9a\u91cf PCR \u68c0\u6d4b \u6837\u672c \u641c\u96c6 \u75be\u75c5 \u53d1\u751f \u9636\u6bb5 \u591a\u79cd \u75c5\u4f8b \u641c\u96c6 \u6b64\u524d \u5229\u666e\u91d1 \u6559\u6388 \u65b9\u6cd5 \u9a8c\u8bc1 \u6210\u529f \u65e0\u507f \u63d0\u4f9b \u4e2d\u56fd ", "\u79d1\u5b66\u5bb6 \u52aa\u529b \u627e\u51fa \u4e16\u754c \u4e25\u91cd\u7834\u574f \u51a0\u72b6\u75c5\u6bd2 \u6765\u6e90 \u5e7f\u5dde \u534e\u5357\u519c\u4e1a\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u5efa\u8bae \u7a7f\u5c71\u7532 \u52a8\u7269 \u6765\u6e90 \u591a\u7bc7 \u8bba\u6587 \u7814\u7a76 \u53d1\u73b0 \u975e\u6cd5 \u8d29\u5356 \u7a7f\u5c71\u7532 \u51b7\u51bb \u7ec6\u80de\u6837\u672c \u4e2d \u51a0\u72b6\u75c5\u6bd2 \u4eba\u7c7b \u8eab\u4e0a \u53d1\u73b0 \u75c5\u6bd2 \u5ea6\u8fbe 90% \u7a7f\u5c71\u7532 \u56fd\u5bb6 \u62a5\u9053 \u5730\u65b9 \u6709\u4eba \u611f\u67d3 \u8fd9\u662f \u503c\u5f97 \u601d\u8003 ", "\u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u75ab\u82d7 \u5f00\u53d1 \u501f\u9274 SARS \u75ab\u82d7 \u7814\u7a76 \u5f00\u53d1\u65b0 \u51a0 \u75ab\u82d7 \u5728\u6280\u672f\u4e0a \u6709\u592a\u5927 \u96be\u5ea6 \u75c5\u4f8b \u6570\u91cf \u6613\u611f \u4eba\u7fa4 \u66f4\u662f \u6570\u91cf \u4e0d\u96be \u62db\u52df \u8db3\u591f \u5fd7\u613f\u8005 \u53c2\u4e0e \u4e34\u5e8a\u8bd5\u9a8c \u5f00\u53d1 \u51fa\u65b0 \u51a0 \u75c5\u6bd2 \u5019\u9009 \u75ab\u82d7 \u52a8\u7269\u6a21\u578b \u8bc1\u660e \u56fd\u5bb6 \u4f18\u5148 \u63a8\u8fdb \u75ab\u82d7 \u4e34\u5e8a\u8bd5\u9a8c \u6280\u672f \u592a \u96be\u5ea6 \u653f\u7b56 \u4e00\u8def \u7eff\u706f \u79d1\u5b66 \u4e25\u8c28 \u4e34\u5e8a\u8bd5\u9a8c \u5728\u77ed\u671f\u5185 ", "\u7f8e\u56fd \u5409\u5229 \u5fb7 \u79d1\u5b66 \u542f\u52a8 \u4e24\u9879 \u4e09\u671f \u4e34\u5e8a \u7814\u7a76 \u8bc4\u4f30 \u745e\u5fb7 \u897f\u97e6 \u6cbb\u7597 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u80ba\u708e \u6210\u4eba \u60a3\u8005 \u4e2d \u5b89\u5168\u6027 \u6709\u6548\u6027 3 \u6708 \u8fd9\u4e24\u9879 \u4e34\u5e8a\u8bd5\u9a8c \u5c06\u5165 \u7ec4\u7ea6 1000 \u540d \u60a3\u8005 5 \u6708\u4efd \u516c\u5e03 ", "\u65b0\u51a0 \u80ba\u708e \u836f\u7269 \u4e34\u5e8a\u8bd5\u9a8c \u8d44\u683c 5 \u6b3e \u836f\u54c1 73 \u76f8\u5173 \u836f\u54c1 \u5404\u5927 \u533b\u9662 \u4e34\u5e8a 259 \u8bd5\u9a8c 5 \u836f\u54c1 \u4e2d \u836f\u54c1 \u65b0\u51a0 \u75c5\u6bd2 \u76f8\u5173 \u65b0\u836f \u5409\u5229 \u5fb7 \u745e\u5fb7 \u897f\u97e6 \u56db\u4e2a \u836f \u6cd5 \u7ef4\u62c9 \u97e6 \u53c8\u79f0 \u6cd5\u5339\u62c9\u97e6 \u7247 \u6ce8\u5c04\u7528 \u897f\u7ef4\u6765\u53f8 \u94a0 CAStem \u7ec6\u80de \u6ce8\u5c04\u6db2 BDB - 001 \u6ce8\u5c04\u6db2 ", "\u4e0a\u4e2a\u6708 \u676d\u5dde Ascletis   Pharma \u4e2d\u56fd \u5f53\u5c40 \u7533\u8bf7 \u4e34\u5e8a\u8bd5\u9a8c \u4e2d \u6d4b\u8bd5 \u4e24\u79cd HIV \u86cb\u767d\u9176 \u6291\u5236\u5242 \u5229\u6258 \u97e6 ASC09 \u6cbb\u7597 \u65b0 \u51a0\u72b6\u75c5\u6bd2 \u82cf\u5dde BrightGene \u751f\u7269\u533b\u5b66 \u6280\u672f \u516c\u53f8 2 \u6708\u521d \u751f\u4ea7 Gilead   Science \u516c\u53f8 \u5e7f\u8c31 \u7814\u7a76 \u6297\u75c5\u6bd2 \u836f\u7269 remdesivir GS - 5734 \u6700\u6709 \u524d\u9014 \u5e7f\u8c31 \u6d3b\u6027 \u6297\u75c5\u6bd2 \u836f \u51a0\u72b6\u75c5\u6bd2 RNA \u75c5\u6bd2 \u5982\u9ad8 \u81f4\u75c5\u6027 \u57c3 \u535a\u62c9 \u75c5\u6bd2 \u79bd\u6d41\u611f \u75c5\u6bd2 ", "\u7b2c\u4e00\u4f8b \u65b0\u51a0 \u80ba\u708e \u901d\u8005 \u9057\u4f53 \u89e3\u5256 12 \u5929\u540e \u5c38\u89e3 \u62a5\u544a \u516c\u5e03 \u79f0 \u65b0\u51a0 \u80ba\u708e \u75c5\u53d8 \u805a\u7126 \u80ba\u90e8 \u810f\u5668 \u635f\u4f24 \u8bc1\u636e\u4e0d\u8db3 \u80ba\u90e8 \u7ea4\u7ef4\u5316 \u5b9e\u53d8 SARS \u5bfc\u81f4 \u75c5\u53d8 \u6e17\u51fa\u6027   SARS   . \u65b0\u51a0 \u80ba\u708e \u6b7b\u8005 \u5c38\u4f53 \u75c5\u7406\u89e3\u5256 \u4e34\u5e8a \u6cbb\u7597 \u8bca\u65ad \u63d0\u4f9b \u652f\u6301 ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u79f0 \u75ab\u60c5 1 \u6708 23 \u65e5\u81f3 2 \u6708 2 \u65e5 \u671f\u95f4 \u9ad8\u5cf0 \u7a33\u5b9a\u4e0b\u6765 \u7a33\u6b65 \u4e0b\u964d \u4e2d\u56fd \u63aa\u65bd \u75c5\u4f8b \u4e8b\u5b9e\u8bc1\u660e 2019 \u51a0\u72b6\u75c5\u6bd2 \u63a7\u5236 \u75c5\u6bd2 \u672a \u53d1\u751f \u53d8\u5f02 \u4e13\u5bb6\u7ec4 \u62a5\u544a \u5217\u660e \u63d0\u51fa 22 \u9879 \u5efa\u8bae \u4e16\u536b \u7ec4\u7ec7 \u672c\u6b21 \u75ab\u60c5 \u56fd\u9645 \u5173\u6ce8 \u7a81\u53d1 \u516c\u5171\u536b\u751f \u4e8b\u4ef6 \u8fd9\u662f \u8b66\u6212 \u7ea7\u522b ", "\u4ee5\u8272\u5217 \u79d1\u6280\u90e8 27 \u65e5 \u8be5\u56fd \u7814\u7a76 \u4eba\u5458 \u52a0\u5feb \u5f00\u53d1 \u4e00\u79cd \u53e3\u670d \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u75ab\u82d7 \u7814\u7a76 \u4eba\u5458 \u5e0c\u671b 8 10 \u5468\u5185 \u5236\u9020 \u75ab\u82d7 \u6709\u671b 90 \u5929\u5185 \u4e34\u5e8a\u8bd5\u9a8c ", "\u65b0\u51a0 \u75c5\u6bd2 \u795e\u7ecf\u7cfb\u7edf \u4f24\u5bb3 \u91cd\u75c7 \u60a3\u8005 \u6613 \u53d1\u751f \u6025\u6027 \u8111\u8840\u7ba1 \u75be\u75c5 \u610f\u8bc6 \u969c\u788d \u795e\u7ecf\u7cfb\u7edf \u75c5\u53d8 \u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u9644\u5c5e \u534f\u548c\u533b\u9662 \u795e\u7ecf\u5185\u79d1 \u4e3b\u4efb \u80e1\u6ce2 \u56e2\u961f 2 \u6708 25 \u65e5 \u53d1\u8868 \u4e00\u7bc7 \u8bba\u6587 \u9996\u4efd \u63ed\u793a \u65b0\u51a0 \u80ba\u708e \u5f71\u54cd \u795e\u7ecf\u7cfb\u7edf \u7814\u7a76 214 \u540d\u65b0\u51a0 \u80ba\u708e \u4f4f\u9662 \u60a3\u8005 \u56de\u987e\u6027 \u75c5\u4f8b \u7814\u7a76 \u53d1\u73b0 \u8d85 \u4e09\u6210 \u60a3\u8005 \u795e\u7ecf\u7cfb\u7edf \u8868\u73b0 \u8fd9\u4e00 \u6bd4\u4f8b \u91cd\u75c7 \u60a3\u8005 \u4e2d \u9ad8 ", "\u7f8e\u56fd \u897f\u5357 \u533b\u5b66\u4e2d\u5fc3 \u7814\u7a76 \u79f0\u901a \u533b\u7528 \u53e3\u7f69 N95 \u53e3\u7f69 \u9884\u9632 \u6d41\u611f \u75c5\u6bd2\u6027 \u547c\u5438\u9053 \u75be\u75c5 \u6548\u679c \u663e \u5dee\u5f02 ", "\u75c5\u6bd2\u611f\u67d3 \u8bf1\u5bfc \u7ec6\u80de\u56e0\u5b50 \u98ce\u66b4 \u4e0a\u8c03 2019 - nCoV \u5bbf\u4e3b \u7ec6\u80de \u53d7\u4f53 ACE2 \u8868\u8fbe \u8fdb\u4e00\u6b65 \u52a0\u901f \u75c5\u6bd2 \u611f\u67d3 \u4f20\u64ad \u4e8b\u5148 \u50a8\u5907 \u964d\u4f4e ACE2 \u8868\u8fbe \u836f\u7269 siRNA \u6838\u9178 \u836f\u7269 \u672a\u6765 \u514b\u670d \u75c5\u6bd2\u611f\u67d3 \u5f00\u8f9f \u65b0 \u65b9\u6cd5 ", "Rolf   Hilgenfeld Hong   Hong \u540c\u4e8b \u52aa\u529b \u5f00\u53d1 \u4e00\u79cd \u5e7f\u8c31 \u6297\u75c5\u6bd2 \u836f\u7269 \u75c5\u6bd2 \u9776\u5411 \u51a0\u72b6\u75c5\u6bd2 \u80a0\u75c5\u6bd2 \u75c5\u6bd2 \u51a0\u72b6\u75c5\u6bd2 \u4e2d\u5747 \u86cb\u767d\u8d28 \u5207\u5272 \u86cb\u767d\u9176 \u80a0\u75c5\u6bd2 \u4e2d 3C \u86cb\u767d\u9176 \u75c5\u6bd2 \u590d\u5236 \u81f3\u5173\u91cd\u8981 ", "\u5168\u7403 \u591a\u5730 \u75c5\u6bd2 \u5b9e\u9a8c\u5ba4 \u91cc \u75c5\u6bd2 \u730e\u624b \u501f\u52a9 \u51b7\u51bb\u7535 \u955c \u6280\u672f \u65b0\u51a0 \u75c5\u6bd2 \u62cd \u5927\u5206\u5b50 \u9ad8\u6e05 \u7167\u7247 \u770b\u6e05\u695a \u5206\u5b50 \u7ea7\u522b \u7ed3\u6784 \u5229\u7528 \u7535\u5b50\u663e\u5fae\u955c \u75c5\u6bd2 \u5206\u5b50 \u89d2\u5ea6 \u4e8c\u7ef4 \u56fe\u50cf \u8ba1\u7b97\u673a \u4e09\u7ef4\u91cd\u5efa \u6700\u7ec8 \u5b8c\u6574 \u4e09\u7ef4 \u7535\u955c \u7ed3\u6784\u56fe \u53d1\u73b0 \u5229\u7528 SARS \u75c5\u6bd2 \u6297\u4f53 \u5bf9\u6297 \u65b0\u51a0 \u75c5\u6bd2 ", "\u4e16\u536b \u7ec4\u7ec7 \u6307\u51fa \u65b0\u51a0 \u80ba\u708e \u91cd\u75c7 \u60a3\u8005 \u6c27\u6c14 \u6cbb\u7597 \u6cbb\u7597 \u624b\u6bb5 \u56fd\u5bb6 \u5b8c\u5584 \u8109\u640f \u8840\u6c27\u4eea \u533b\u7528 \u6c27\u6c14 \u7cfb\u7edf \u53ef\u7528\u6027 \u4e16\u536b \u7ec4\u7ec7 \u6307\u51fa \u91cd\u75c7 \u60a3\u8005 \u6b7b\u4ea1\u7387 \u8d85\u8fc7 50% \u5e94 \u4f18\u5316 \u73b0\u884c \u91cd\u75c7 \u60a3\u8005 \u6cbb\u7597 \u63aa\u65bd \u5982\u80ba \u4fdd\u62a4\u6027 \u901a\u6c14 ", "\u949f\u5357\u5c71 \u56e2\u961f \u6700\u65b0 \u6210\u679c \u65b0\u51a0 \u75c5\u6bd2 \u6f5c\u4f0f\u671f \u4e2d\u4f4d\u6570 4 \u5929 43.8% \u60a3\u8005 \u5165\u9662 \u65f6\u6709 \u53d1\u70ed \u75c7\u72b6 \u76d1\u89c6 \u75c5\u4f8b \u5b9a\u4e49 \u53d1\u70e7 \u68c0\u6d4b \u9519\u8fc7 \u53d1\u70ed \u60a3\u8005 \u6b7b\u4ea1 \u4eba\u6570 \u65b0\u51a0 \u75c5\u6bd2 \u75c5\u6b7b\u7387 \u4f4e\u4e8e SARS MERS ", "\u6211\u56fd \u80ba \u79fb\u690d \u7b2c\u4e00 \u8457\u540d \u80ba \u79fb\u690d \u4e13\u5bb6 \u9648\u9759\u745c \u6559\u6388 \u56e2\u961f \u5386\u7ecf 5 \u5c0f\u65f6 \u6c5f\u82cf \u65e0\u9521 \u6210\u529f \u5168\u7403 \u9996\u4f8b \u65b0\u51a0 \u80ba\u708e \u75c5\u4f8b \u53cc\u80ba \u79fb\u690d\u624b\u672f ", "\u4e2d\u56fd\u79d1\u5b66\u9662 \u9662\u58eb \u89e3\u653e\u519b\u603b\u533b\u9662 \u7b2c\u4e94 \u533b\u5b66\u4e2d\u5fc3 \u6559\u6388 \u738b\u798f\u751f \u56e2\u961f \u56fd\u9645 \u533b\u5b66\u671f\u520a \u67f3\u53f6\u5200 - \u80c3\u80a0\u75c5 \u5b66 \u809d\u810f \u75c5\u5b66 \u5728\u7ebf \u53d1\u8868 \u8bc4\u8bba \u6587\u7ae0 COVID - 19 \u76f8\u5173 \u809d \u635f\u4f24 \u8bca\u6cbb \u6311\u6218 \u53d1\u73b0 \u65b0\u51a0 \u80ba\u708e \u8f7b\u75c7 \u91cd\u75c7 \u60a3\u8005 \u4e2d \u6bd4\u4f8b \u809d\u810f \u529f\u80fd \u5f02\u5e38\u60c5\u51b5 ", "\u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 COVID - 19 \u611f\u67d3 \u5e8f\u5217 \u95f4\u9694 \u662f\u4ece \u603b\u5171 28 \u611f\u67d3\u8005 - \u611f\u67d3\u8005 \u4e2d \u4f30\u8ba1 \u4e2d\u4f4d \u5e8f\u5217 \u95f4\u9694 \u6bd4\u4e2d\u4f4d \u6f5c\u4f0f\u671f \u77ed \u75c7\u72b6 \u53d1\u751f \u524d \u4f20\u64ad \u6bd4\u4f8b \u5f88\u5927 \u6848\u4ef6 \u53d1\u751f \u65f6\u95f4 \u5feb\u901f \u6d41\u901d \u8fde\u7eed \u65f6\u95f4 \u95f4\u9694 \u77ed \u96be\u8ffd\u8e2a \u8054\u7cfb\u4eba ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u52a9\u7406 \u603b\u5e72\u4e8b \u5e03\u9c81\u65af \u827e\u5c14\u6c83\u5fb7 Bruce   Aylward \u5317\u4eac \u60c5\u51b5\u901a\u62a5 \u4f1a\u4e0a \u96f7\u59c6 \u6614\u97e6 \u62e5\u6709 \u4e00\u79cd \u836f\u7269 ", "\u56fd\u5bb6 \u536b\u5065\u59d4 \u529e\u516c\u5385 \u6b63\u5f0f \u536b\u5065\u59d4 \u4e0b\u53d1 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u80ba\u708e \u8bca\u7597 \u65b9\u6848 \u8bd5\u884c \u7b2c\u4e03\u7248 \u66f4\u65b0 \u5e45\u5ea6 \u8f83\u5927 \u9996\u6b21 \u589e\u52a0 \u75c5\u7406 \u63cf\u8ff0 \u6297\u4f53 \u68c0\u6d4b \u7eb3\u5165 \u8bca\u65ad \u6807\u51c6 ", "\u9999\u6e2f \u6e14\u519c \u81ea\u7136 \u62a4\u7406 \u7f72 \u6e14\u62a4\u7f72 \u53d1\u8a00 \u79f0 \u4e00\u53ea \u5ba0\u7269\u72d7 \u65b0\u51a0 \u75c5\u6bd2 \u53cd\u590d \u6d4b\u8bd5 \u4e2d\u5747 \u5448 \u5f31\u9633\u6027 \u7ed3\u679c\u663e\u793a \u5ba0\u7269\u72d7 \u5df2\u4f4e \u7a0b\u5ea6 \u611f\u67d3 \u75c5\u6bd2 \u503c\u5f97\u6ce8\u610f \u72d7 \u53d1\u75c5 \u63d0\u793a \u75c5\u6bd2 \u72d7 \u8eab\u4f53 \u4e2d \u590d\u5236 \u5f15\u53d1 \u75be\u75c5 \u6b66\u6c49 \u60c5\u51b5 \u65b0\u51a0 \u75c5\u6bd2\u4f20\u64ad \u53d1\u73b0 \u5ba0\u7269\u72d7 \u4e34\u5e8a \u6b7b\u4ea1 \u73b0\u8c61 \u72d7 \u4f20\u72d7 \u72d7 \u4f20\u4eba \u53ef\u80fd\u6027 \u8bc1\u636e \u652f\u6301 ", "\u65b0\u51a0 \u75c5\u6bd2 \u795e\u7ecf\u7cfb\u7edf \u635f\u5bb3 \u4e34\u5e8a \u8fdb\u4e00\u6b65 \u9a8c\u8bc1 \u5317\u4eac \u5730\u575b \u533b\u9662 \u6536\u6cbb \u4e00\u4f8b 56 \u5c81 \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u57fa\u56e0 \u6d4b\u5e8f \u8bc1\u5b9e \u8111\u810a\u6db2 \u4e2d SARS - CoV - 2 \u65b0\u51a0 \u75c5\u6bd2 \u4e34\u5e8a \u8bca\u65ad \u75c5\u6bd2\u6027 \u8111\u708e \u60a3\u8005 \u4e2d\u67a2\u795e\u7ecf \u7cfb\u7edf \u53d7\u6bd2 \u4fb5\u88ad ", "\u56fd\u5bb6 \u536b\u751f \u5065\u5eb7 \u59d4 \u4eba\u529b\u8d44\u6e90 \u793e\u4f1a\u4fdd\u969c\u90e8 \u56fd\u5bb6\u4e2d\u533b\u836f\u7ba1\u7406\u5c40 \u6388\u4e88 \u5317\u4eac\u5927\u5b66\u7b2c\u4e00\u533b\u9662 \u91cd\u75c7 \u6551\u6cbb \u533b\u7597\u961f   113   \u96c6\u4f53 \u300c \u5168\u56fd \u536b\u751f \u5065\u5eb7 \u7cfb\u7edf \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u9632\u63a7 \u5de5\u4f5c \u5148\u8fdb\u96c6\u4f53 \u79f0\u53f7 \u6388\u4e88 \u4e01 \u65b0\u6c11   472   \u4f4d \u540c\u5fd7 \u300c \u5168\u56fd \u536b\u751f \u5065\u5eb7 \u7cfb\u7edf \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u9632\u63a7 \u5de5\u4f5c \u5148\u8fdb\u4e2a\u4eba \u79f0\u53f7 \u8ffd\u6388 \u5f90\u8f89   34   \u4f4d \u540c\u5fd7 \u300c \u5168\u56fd \u536b\u751f \u5065\u5eb7 \u7cfb\u7edf \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u9632\u63a7 \u5de5\u4f5c \u5148\u8fdb\u4e2a\u4eba \u79f0\u53f7 \u83b7\u5956 \u4eab\u53d7 \u7701\u90e8\u7ea7 \u8868\u5f70 \u5956\u52b1 \u83b7\u5f97\u8005 \u5f85\u9047 ", "\u65b0\u51a0 \u80ba\u708e \u81ea\u9650\u6027 \u75be\u75c5 \u6297\u75c5\u6bd2 \u836f\u7269 \u6297\u75c5\u6bd2 \u836f\u7269 \u4e34\u5e8a \u526f\u4f5c\u7528 \u5e94\u4ee5 \u635f\u5bb3 \u75c5\u4eba \u4e3a\u5148 \u75c5\u4eba \u526f\u4f5c\u7528 \u8010\u53d7 \u5766\u8a00 \u590d\u9633 \u4f20\u64ad \u529b\u6709 \u591a\u5927\u5c1a \u9633\u6027 \u771f \u75c5\u6bd2 \u75c5\u6bd2 \u5c38\u4f53 \u788e\u7247 \u7814\u7a76 \u6709\u6ca1\u6709 \u4f20\u67d3\u6027 ", "\u6b66\u6c49\u534f\u548c\u533b\u9662 \u897f\u9662 \u533a \u5317\u4eac \u5730\u575b \u533b\u9662 \u4eac\u6c49 \u65b0\u51a0 \u80ba\u708e \u533b\u7597 \u6551\u6cbb 5G \u8fdc\u7a0b \u89c6\u9891 \u7814\u8ba8\u4f1a \u8fd9\u662f \u5317\u4eac \u533b\u7597\u961f \u652f\u63f4 \u6b66\u6c49 39 \u5929 \u89c4\u6a21 \u89c6\u9891\u4f1a\u8bae \u4e0e\u4f1a \u4e13\u5bb6 \u5371\u91cd \u60a3\u8005 \u6551\u6cbb \u8fdb\u4e00\u6b65\u63d0\u9ad8 \u6cbb\u6108\u7387 \u964d\u4f4e \u75c5\u4ea1 \u7387 \u5c55\u5f00 \u8ba8\u8bba ", "\u5434\u4e91\u6d9b \u90d1\u5fd7\u660e \u9ec4\u8000\u4f1f \u8881\u56fd\u52c7   12   \u4f4d\u4e2d \u7f8e\u534e\u4eba \u5b66\u8005 \u9876\u7ea7 \u533b\u5b66\u671f\u520a \u67f3\u53f6\u5200 \u53d1\u8868 \u516c\u5f00\u4fe1 \u652f\u6301 \u65b0\u51a0 \u75c5\u6bd2 \u547d\u540d   SARS - CoV - 2 \u5b66\u8005   SARS   \u65b0\u75c5\u6bd2 \u547d\u540d \u6709\u52a9\u4e8e \u516c\u4f17 \u4fdd\u6301\u8b66\u60d5 \u540e\u7eed \u65b0\u75c5\u6bd2 \u505a\u597d ", "\u5317\u4eac\u5e02 \u75be\u63a7\u4e2d\u5fc3 \u56e2\u961f 82 \u540d \u611f\u67d3\u8005 \u6536\u96c6 \u7c7b\u578b \u6807\u672c N \u57fa\u56e0 \u7279\u5f02\u6027 \u5b9a\u91cf RT - PCR \u68c0\u6d4b \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u60a3\u8005 \u53d1\u75c5 \u65e9\u671f \u4f53\u5185 \u65b0\u51a0 \u75c5\u6bd2 \u8f7d\u91cf \u66f4\u9ad8 ", "\u6211\u56fd \u5b66\u8005 \u53d1\u73b0 SARS - CoV - 2 \u7ed3\u6784 \u5168\u8c8c \u6df1\u5733 \u56fd\u5bb6 \u611f\u67d3\u6027 \u75be\u75c5 \u4e34\u5e8a\u533b\u5b66 \u7814\u7a76 \u4e2d\u5fc3 / \u5357\u65b9 \u79d1\u6280 \u5927\u5b66 \u9644\u5c5e \u533b\u9662 ( \u6df1\u5733\u5e02 \u7b2c\u4e09 \u533b\u9662 ) \u5357\u65b9 \u79d1\u6280 \u5927\u5b66 \u8054\u5408 \u56e2\u961f \u9996\u6b21 \u89c2\u5bdf \u771f\u5b9e SARS - CoV - 2 \u5f62\u8c8c \u6355\u6349\u5230 \u75c5\u6bd2 \u4fb5\u67d3 \u5bbf\u4e3b \u7ec6\u80de \u4e2d \u4e2d\u95f4\u72b6\u6001 ", "\u6b66\u6c49 \u534e\u5357 \u5e02\u573a \u75ab\u60c5 \u6e90\u5934 \u4e4b\u5916 \u5206\u578b \u75c5\u6bd2 \u53d1\u73b0 \u6d59\u6c5f\u5927\u5b66 \u4e2d\u5c71\u5927\u5b66 \u5723\u8def\u6613\u65af \u5927\u5b66 \u5408\u4f5c \u53d1\u73b0 \u7a81\u53d8 \u4f4d\u70b9 \u75c5\u6bd2 \u5206\u4e3a I \u578b II \u578b II \u578b SARS - CoV - 2 \u6b66\u6c49 \u534e\u5357 \u5e02\u573a \u75ab\u60c5 \u6e90\u5934 I \u578b \u75ab\u60c5 \u53d1\u751f \u5730\u65b9 \u60a3\u8005 \u5e02\u573a ", "\u9996\u90fd\u533b\u79d1\u5927\u5b66 \u9644\u5c5e \u5317\u4eac\u540c\u4ec1\u533b\u9662 \u53d1\u8868\u6587\u7ae0 \u6307\u51fa \u9ad8\u9f84 \u7537\u6027 COVID - 19 \u9884\u540e \u8f83\u5dee \u5371\u9669 \u56e0\u7d20 \u7537\u6027 \u503e\u5411 \u9ad8 \u75be\u75c5 \u7a0b\u5ea6 \u6b7b\u4ea1\u7387 ", "\u4e0a\u6d77\u4ea4\u901a\u5927\u5b66 \u7cfb\u7edf \u751f\u7269\u533b\u5b66 \u7814\u7a76\u9662 \u9676\u751f\u7b56 \u56e2\u961f \u6210\u529f \u6784\u5efa \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u86cb\u767d\u8d28 \u7ec4 \u82af\u7247 ", "Fauci Lane Redfield \u6307\u51fa \u7814\u7a76 \u5de5\u4f5c \u89e3\u51b3 COVID - 19 \u7814\u7a76 \u5de5\u4f5c \u5305\u62ec \u65e9\u671f \u4e34\u5e8a\u8bd5\u9a8c \u5019\u9009 \u75ab\u82d7 \u6d4b\u8bd5 \u5019\u9009 \u836f\u7269 \u4e34\u5e8a\u8bd5\u9a8c \u5305\u62ec NIAID \u8d44\u52a9 \u5b9e\u9a8c\u6027 \u6297\u75c5\u6bd2 \u836f\u7269 \u745e\u5fb7 \u897f\u97e6 remdesivir ,   \u79f0\u4e3a GS - 5734 \u4e34\u5e8a \u8bd5   \u9a8c \u8fd9\u9879 \u745e\u5fb7 \u897f\u97e6 \u4e34\u5e8a\u8bd5\u9a8c 2020 \u5e74 2 \u6708 21 \u65e5 \u62db\u52df \u53c2\u4e0e\u8005 ", "\u6570\u5b57\u6a21\u578b \u663e\u793a \u56fd\u5916 \u75ab\u60c5 \u5e72\u9884 \u6548\u679c \u6709\u9650 \u590d\u65e6\u5927\u5b66 \u5efa\u7acb \u56de\u5f52 \u6570\u5b57\u6a21\u578b \u53d1\u73b0 \u4e2d\u56fd \u5916 COVID - 19 \u7a33\u5b9a \u8fd1\u4f3c \u6307\u6570 \u578b \u589e\u957f \u6a21\u578b 19 \u5929 \u60a3\u8005 \u6570\u91cf \u589e\u957f 10 \u500d \u663e\u793a \u5f3a\u6709\u529b \u5e72\u9884 \u63aa\u65bd ", "\u6258\u73e0 \u5355\u6297 Tocilizumab \u91cd\u75c7 COVID - 19 \u60a3\u8005 \u4e34\u5e8a \u9a8c\u8bc1 \u6548\u679c \u673a\u5236 \u963b\u65ad IL - 6 \u6291\u5236 \u708e\u75c7 \u56e0\u5b50 \u98ce\u66b4 \u75c5\u4eba \u6570\u91cf \u6709\u9650 \u540e\u7eed \u9700 \u7814\u7a76 ", "\u65c5\u884c \u63a7\u5236 COVID - 19 \u75ab\u60c5 \u7f8e\u56fd Northeastern \u5927\u5b66 Florida \u5927\u5b66 \u8bfe\u9898\u7ec4 \u6210\u5458 \u6570\u5b57\u6a21\u62df \u7ed3\u679c\u8868\u660e \u516c\u5171\u536b\u751f \u5e72\u9884 \u63aa\u65bd \u4f20\u64ad \u6548\u7387 \u964d\u4f4e \u81f3\u5c11 50 \u9ad8 90 \u5f80\u8fd4 \u4e2d\u56fd \u5927\u9646 \u65c5\u884c \u63a7\u5236 COVID - 19 \u6d41\u884c ", "\u6211\u56fd \u591a\u5bb6 \u79d1\u7814\u673a\u6784 \u8054\u5408 \u4e91\u5357 \u65b0 \u53d1\u73b0 \u4e00\u79cd \u8759\u8760 \u51a0\u72b6\u75c5\u6bd2 \u529b\u8bc1 \u65b0\u51a0 \u75c5\u6bd2 \u8d77\u6e90\u4e8e \u81ea\u7136 ", "WHO \u6b63\u5f0f \u53d1\u5e03 COVID - 19 \u5168\u7403 \u7814\u7a76 \u8def\u7ebf\u56fe \u5305\u62ec \u75c5\u6bd2 \u81ea\u7136\u53f2 \u6d41\u884c\u75c5\u5b66 \u75ab\u82d7 \u8bca\u65ad \u8bd5\u5242 \u6cbb\u7597 \u5de5\u5177 \u4e34\u5e8a \u7ba1\u7406 \u4f26\u7406 \u8003\u91cf \u793e\u4f1a\u79d1\u5b66 \u5728\u5185 9 \u5173\u952e \u9886\u57df \u6838\u5fc3 \u4f18\u5148 \u4e8b\u9879 ", "\u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u9632\u63a7 \u6210\u679c \u79d1\u6280\u90e8 13 \u90e8\u95e8 \u7ec4\u5efa \u56fd\u52a1\u9662 \u8054\u9632 \u8054\u63a7 \u673a\u5236 \u79d1\u6280 \u653b\u5173\u7ec4 \u8bbe\u7acb \u75ab\u82d7 \u7814\u53d1 \u4e13\u73ed \u7b2c\u4e00\u6279 \u7b5b\u9009 8 \u5bb6 \u673a\u6784 \u786e\u7acb 9 \u9879 \u706d \u6d3b\u75ab\u82d7 \u57fa\u56e0\u5de5\u7a0b \u91cd\u7ec4 \u4e9a \u5355\u4f4d \u75ab\u82d7 \u817a\u75c5\u6bd2 \u8f7d\u4f53 \u75ab\u82d7 \u51cf\u6bd2 \u6d41\u611f\u75c5\u6bd2 \u8f7d\u4f53 \u75ab\u82d7 \u6838\u9178 \u75ab\u82d7 \u4e94\u6761 \u6280\u672f \u8def\u7ebf \u63a8\u8fdb \u75ab\u82d7 \u653b\u5173 \u5de5\u4f5c \u4eba\u5de5\u667a\u80fd \u6570\u636e \u6280\u672f \u75ab\u60c5 \u9632\u63a7 \u5730\u88ab ", "\u65b0\u51a0 \u80ba\u708e \u4e34\u5e8a \u6551\u6cbb \u6210\u679c \u79d1\u6280\u653b\u5173 \u4e00\u6279 \u836f\u7269 \u6551\u6cbb \u6280\u672f \u75be\u75c5 \u6551\u6cbb \u78f7\u9178 \u6c2f\u55b9 \u6258\u73e0 \u5355\u6297 \u4e2d\u533b\u836f \u65b9\u5242 \u6ce8\u5c04\u6db2 \u4e00\u6279 \u63a8\u8350 \u836f\u7269 \u5eb7\u590d\u8005 \u8840\u6d46 \u8840\u6db2 \u51c0\u5316 \u6cbb\u7597 \u6cbb\u7597 \u65b9\u6cd5 \u7eb3\u5165 \u8bca\u7597 \u65b9\u6848 \u63a8\u52a8 \u5e72\u7ec6\u80de \u5355\u514b\u9686 \u6297\u4f53 \u5148\u8fdb \u6280\u672f \u7528\u4e8e \u5371\u91cd\u75c7 \u60a3\u8005 \u6cbb\u7597 \u7814\u7a76 \u4e34\u5e8a\u5b9e\u8df5 \u5236\u5b9a \u5206\u578b \u5206\u5c42 \u6cbb\u7597 \u7b56\u7565 \u4f18\u5316 \u6cbb\u7597 \u65b9\u6848 \u5305\u62ec \u963b\u65ad \u8f7b\u578b \u666e\u901a\u578b \u91cd\u75c7 \u8f6c\u5316 \u6cbb\u7597 \u65b9\u6848 \u5305\u62ec \u91cd\u578b \u5371\u91cd \u578b \u60a3\u8005 \u6551\u6cbb \u65b9\u6848 ", "\u65b0\u51a0 \u80ba\u708e \u68c0\u6d4b \u8bca\u65ad \u6210\u679c 14 \u68c0\u6d4b \u4ea7\u54c1 \u83b7\u6279 \u4e34\u5e8a \u6574\u4f53 \u68c0\u6d4b \u6c34\u5e73 \u63d0\u9ad8 \u56fd\u5185 \u8bca\u65ad\u68c0\u6d4b \u9700\u6c42 \u6297\u4f53 \u6838\u9178 \u4e24\u7c7b \u68c0\u6d4b \u8bd5\u5242 \u8865\u5145 \u8fdb\u4e00\u6b65\u63d0\u9ad8 \u68c0\u51fa\u7387 ", "\u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u79d1\u7814 \u4e94\u5927 \u4e3b\u653b \u65b9\u5411 1 . \u75c5\u6bd2 \u75c5\u539f \u6d41\u884c\u75c5\u5b66 \u7814\u7a76 2 . \u52a8\u7269\u6a21\u578b \u6784\u5efa 3 . \u75c5\u6bd2\u68c0\u6d4b \u8bca\u65ad 4 . \u836f\u7269 \u7814\u53d1 \u4e34\u5e8a \u6551\u6cbb 5 . \u75ab\u82d7 \u7814\u53d1 ", "\u534e\u4e2d\u79d1\u6280 \u79d1\u7814 \u653b\u5173 \u6210\u679c 1 . \u6297\u4f53 \u5feb\u901f \u68c0\u6d4b \u8bd5\u5242\u76d2 \u4e00\u6ef4 \u8840 15 \u5206\u949f 2 . \u4eba\u4f53 \u6d4b\u6e29 \u7ea2\u5916 \u70ed\u50cf\u4eea 0.3 \u79d2 \u6d4b\u6e29 3 . AI \u8f85\u52a9 \u533b\u5b66\u5f71\u50cf \u8bca\u65ad\u7cfb\u7edf \u63d0\u4f9b \u7cbe\u51c6 \u65b0\u51a0 \u80ba\u708e \u8bca\u65ad 4 . \u75c5\u75c7 \u7a0b\u5ea6 \u673a\u5668 \u5b66\u4e60 \u8f85\u52a9 \u5206\u7c7b \u9884\u8b66 \u8f6f\u4ef6 \u75c5\u4f8b \u5206\u7c7b \u9884\u6d4b \u6beb\u79d2 \u7ea7 \u8f93\u51fa 5 . \u86cb\u767d \u4e9a \u5355\u4f4d \u75ab\u82d7 \u65b0\u51a0 \u80ba\u708e \u75ab\u82d7 \u7c7b\u578b ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u534e\u4e2d\u79d1\u5927 \u6821\u957f \u674e\u5143\u5143 \u79f0 \u534e\u4e2d\u79d1\u5927 \u6295\u5165 28 \u79d1\u7814\u5355\u4f4d \u6297\u75ab \u7814\u7a76 \u91cd\u70b9 \u56e2\u961f 24 \u7814\u7a76 \u65b9\u5411 \u65b0\u51a0 \u75c5\u6bd2 \u6d41\u884c\u75c5\u5b66 \u5feb\u901f \u8bca\u65ad\u68c0\u6d4b \u8bd5\u5242 \u836f\u7269 \u75ab\u82d7 \u7814\u53d1 \u4e34\u5e8a \u8bca\u6cbb \u75be\u75c5 \u9632\u63a7 \u673a\u5236 \u9632\u62a4 \u4ea7\u54c1 \u88c5\u5907 \u5fc3\u7406 \u5e72\u9884 \u516c\u5171\u536b\u751f \u6cbb\u7406 \u73b0\u4ee3\u5316 \u7efc\u5408 \u7814\u7a76 \u79d1\u5b66 ", "\u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u6297\u4f53 \u65f6\u95f4\u6bb5 100% \u6297\u4f53 \u9633\u6027 \u5c1a \u6297\u4f53 \u591a\u957f\u65f6\u95f4 ", "\u7f8e\u56fd \u897f\u8fbe \u8d5b\u5948 \u533b\u7597 \u4e2d\u5fc3 \u5317\u4eac\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u622a\u6b62 2020 \u5e74 3 \u6708 1 \u65e5 \u7f8e\u56fd \u6570\u5343 \u611f\u67d3 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u8fdc\u8fdc \u8d85\u8fc7 \u516c\u5f00 \u62a5\u9053 \u4eba\u6570 ", "\u7f8e\u56fd \u79d1\u5b66 \u6742\u5fd7 \u7f51\u7ad9 \u76f8\u5173 \u62a5\u9053 \u4e2d \u7f8e\u56fd \u65af\u514b\u91cc\u666e\u65af \u7814\u7a76\u6240 \u751f\u7269\u5b66\u5bb6 \u514b\u91cc\u65af\u8482\u5b89 \u5b89\u5fb7\u68ee \u63a8\u6d4b \u8bf4 \u65b0\u51a0 \u75c5\u6bd2 \u534e\u5357 \u6d77\u9c9c \u5e02\u573a \u4e09\u79cd \u573a\u666f \u4e00\u540d \u611f\u67d3\u8005 \u4e00\u53ea \u52a8\u7269 \u4e00\u7fa4 \u52a8\u7269 \u5e26\u5230 \u5e02\u573a \u65b0\u51a0 \u75c5\u6bd2 \u8d77\u6e90 \u5bbf\u4e3b \u96be\u4ee5 \u5b9a\u8bba \u75c5\u6bd2 \u6eaf\u6e90 \u957f\u65f6\u95f4 ", "\u949f\u5357\u5c71 \u56e2\u961f \u65b0 \u7b5b\u67e5 \u65b9\u5f0f \u6ef4\u8840 15 \u5206\u949f \u7814\u53d1 IgM - IgG \u8054\u5408 \u6297\u4f53 \u68c0\u6d4b \u654f\u611f\u6027 \u8fdc\u9ad8\u4e8e IgM IgG \u6297\u4f53 \u68c0\u6d4b \u5e8a \u65c1\u7528 \u6307\u5c16 \u91c7\u8840 \u65b9\u5f0f \u68c0\u6d4b ", "\u9999\u6e2f\u5927\u5b66 \u6d41\u884c\u75c5\u5b66 \u5bb6\u672c \u8003\u6797 science \u53d1\u6587 \u8d28\u7591 \u5165\u5883 \u7b5b\u67e5 \u6ca1\u7528   75% \u65b0\u51a0 \u60a3\u8005 \u672a \u68c0\u6d4b \u51fa\u5165\u5883 \u6e29\u5ea6 \u67aa\u6765 \u68c0\u6d4b \u51c6\u786e \u53d1\u73b0 \u611f\u67d3 \u4e58\u5ba2 \u56f0\u96be \u611f\u67d3\u8005 \u591a\u79cd \u65b9\u5f0f \u94bb\u7a7a\u5b50 \u673a\u573a \u68c0\u6d4b ", "\u4e2d\u65e5\u53cb\u597d\u533b\u9662 \u66f9\u5f6c \u6b66\u6c49 \u91d1\u94f6 \u6f6d \u533b\u9662 \u9648\u534e \u8054\u5408 \u7814\u7a76 \u56e2\u961f \u67f3\u53f6\u5200 \u53d1\u6587 \u79f0 \u5e74\u9f84 SOFA \u9ad8 \u5165\u9662 \u65f6 D - \u4e8c\u805a\u4f53 \u6c34\u5e73 \u5927\u4e8e 1 g / L \u65b0\u51a0 \u80ba\u708e \u81f4\u6b7b \u76f8\u5173 \u5371\u9669 \u56e0\u7d20 ", "\u4e16\u536b \u7ec4\u7ec7 \u5b98\u7f51 \u5e38\u89c1\u95ee\u9898 \u6307\u5357 \u4e2d \u5220\u9664 \u7248\u672c \u63d0\u51fa \u65b0\u51a0 \u9632\u6cbb \u4f20\u7edf \u8349\u672c \u836f\u7269 \u89e3\u91ca \u79f0 \u8bed\u8a00 \u5bbd\u6cdb \u4f20\u7edf \u8349\u672c \u836f\u7269 \u7f13\u89e3 2019 \u51a0\u72b6\u75c5\u6bd2 \u75c5 \u5f15\u53d1 \u8f7b\u75c7 ", "\u4e16\u536b \u7ec4\u7ec7 \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u5168\u7403 \u6d41\u884c \u7279\u5f81 ", "\u949f\u5357\u5c71 \u9662\u58eb \u9996\u5c4a \u65b0\u51a0 \u80ba\u708e \u5b66\u79d1 \u7ebf\u4e0a \u8bba\u575b \u72ec\u5bb6 \u53d1\u5e03 \u6700\u65b0 \u7814\u7a76\u6210\u679c \u5f00\u53d1 \u5feb\u901f \u68c0\u6d4b \u8bd5\u7eb8 \u6052\u6e29 \u6269\u589e \u82af\u7247 \u4e24\u4e2a \u65b0 \u8bca\u65ad \u9274\u522b\u6cd5 ", "\u949f\u5357\u5c71 \u8a00 \u75ab\u60c5 \u7206\u53d1 \u4e2d\u56fd \u53d1\u6e90 \u4e2d\u56fd \u8bc1\u5b9e \u610f\u5927\u5229 \u75c5\u6bd2\u5b66 \u7814\u7a76 \u4e13\u5bb6 \u516c\u5e03 \u8bc1\u636e \u8868\u73b0 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u53bb\u5e74 \u79cb\u5b63 \u4f20\u4eba \u8ff9\u8c61 \u4e2d\u56fd \u611f\u67d3\u8005 \u7f8e\u56fd \u6b63 \u5904\u4e8e \u6d41\u611f\u75c5\u6bd2 \u75ab\u60c5 \u9ad8\u53d1\u671f ", "\u5317\u4eac\u5927\u5b66 \u56e2\u961f \u7f8e\u56fd \u56fd\u7acb \u536b\u751f \u7814\u7a76\u9662 NIH \u5408\u4f5c \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u75be\u75c5 COVID - 19 \u6f5c\u4f0f\u671f \u65b0 \u7814\u7a76 \u6307\u51fa \u6982\u7387 \u5b66\u4e2d \u77e5\u540d \u66f4\u65b0 \u7406\u8bba renewal   theory \u4f30\u8ba1 \u53d1\u73b0 \u65b0\u51a0 \u75be\u75c5 \u6f5c\u4f0f\u671f \u5df2\u77e5 \u66f4\u957f 10 \u60a3\u8005 \u6f5c\u4f0f\u671f \u957f\u4e8e 14 \u5929 ", "\u4e2d\u56fd \u75be\u75c5 \u9884\u9632 \u63a7\u5236\u4e2d\u5fc3 \u75c5\u6bd2 \u75c5 \u9884\u9632 \u63a7\u5236 \u8c2d\u6587\u6770 \u56e2\u961f \u60a3\u8005 \u547c\u5438\u9053 \u7caa\u4fbf \u8840\u6837 \u591a\u4e2a \u90e8\u4f4d \u6807\u672c \u4e2d \u68c0\u6d4b SARS - CoV - 2 \u611f\u67d3 \u5168\u8eab\u6027 ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u949f\u5357\u5c71 \u56e2\u961f \u53c2\u4e0e \u7814\u53d1 \u65b0\u578b \u667a\u80fd\u5316 \u54bd \u62ed\u5b50 \u91c7\u6837 \u673a\u5668\u4eba \u7cfb\u7edf \u9996\u671f \u4e34\u5e8a\u8bd5\u9a8c \u4e2d \u53d7\u8bd5\u8005 \u91c7\u6837 \u91c7\u6837 \u529b\u5ea6 \u5747\u5300 \u9636\u6bb5\u6027 \u8fdb\u5c55 ", "\u9762\u5bf9 \u5168\u7403 \" \u6d41\u884c \" \u4e2d\u56fd \u533b\u7597 \u4e13\u5bb6 \u643a\u5e26 \u533b\u7597 \u7269\u8d44 \u9a70\u63f4 \u610f\u5927\u5229 \u4f0a\u62c9\u514b \u56fd\u5bb6 \u4e2d\u592e \u6307\u5bfc\u7ec4 \u4e13\u5bb6 \u7ec4\u6210\u5458 \u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u5929\u6d25 \u4e2d\u533b\u836f\u5927\u5b66 \u6821\u957f \u5f20\u4f2f\u793c \u6b66\u6c49 \u63a5\u53d7 \u8bb0\u8005 \u91c7\u8bbf \u65f6 \u4ecb\u7ecd \u4e2d\u56fd \u5e26\u53bb \u7269\u8d44 \u4e2d\u6709 \u56fd\u5b9d \u4e2d\u533b\u836f \u4e24\u79cd \u4e2d\u836f \u4f20\u7edf \u4e2d\u6210\u836f \u8fde\u82b1\u6e05 \u761f \u9897\u7c92 \u91d1\u82b1 \u6e05\u611f ", "\u7f8e\u56fd \u56fd\u5bb6 \u8fc7\u654f \u4f20\u67d3\u75c5 \u7814\u7a76\u6240 ( NIAID ) \u4e3b\u4efb Anthony   Fauci \u544a\u8bc9 \u8bb0\u8005 \" \u6700\u574f \u60c5\u51b5 \u75ab\u60c5 \u8fdb\u4e00\u6b65 \" \u8bf4 \u963b\u6b62 \u75ab\u60c5 \u7206\u53d1 \u62ef\u6551 \u751f\u547d \u4e16\u754c \u4e00\u79cd \u75ab\u82d7 ", "\u4e16\u754c \u9876\u7ea7 \u671f\u520a \u79d1\u5b66 \u6742\u5fd7 \u4e3b\u7f16   H .   Holden   Thorp   \u5728\u7ebf \u53d1\u8868 \u9898\u4e3a   Do   us   a   favor   \u793e\u8bba \u6587\u7ae0 \u6587\u7ae0 \u4e2d \u7279\u6717\u666e \u603b\u7edf \u52a0\u5feb \u65b0\u51a0 \u80ba\u708e \u75ab\u82d7 \u7814\u53d1 \u901f\u5ea6 Holden   \u7f8e\u56fd\u653f\u5e9c \u51e0\u5e74 \u6f20\u89c6 \u79d1\u5b66 \u5927\u5e45 \u524a\u51cf \u79d1\u7814 \u9884\u7b97 \u603b\u7edf \u4e4b\u95f4 \u5feb\u70b9 \u7814\u5236 \u75ab\u82d7 Holden   \u7f8e\u56fd \u56fd\u5bb6 \u8fc7\u654f \u4f20\u67d3\u75c5 \u7814\u7a76\u6240 \u957f\u671f \u8d1f\u8d23\u4eba \u5b89\u4e1c\u5c3c \u30fb \u798f\u5947 Anthony   Fauci \u53cd\u590d \u544a\u8bc9 \u7279\u6717\u666e \u603b\u7edf \u7814\u5236 \u75ab\u82d7 \u81f3\u5c11 \u4e00\u5e74 \u65f6\u95f4 \u5236\u836f \u516c\u53f8 \u9ad8 \u7ba1\u4eec \u4f20\u8fbe \u4fe1\u606f   3   \u6708   11   \u65e5\u665a \u7f8e\u56fd \u786e\u8bca \u65b0\u51a0 \u80ba\u708e \u75c5\u4f8b   1327   \u4f8b \u6d89\u53ca   43   \u4e2a\u5dde \u534e\u76db\u987f \u7279\u533a \u6b7b\u4ea1 \u75c5\u4f8b   38   \u4f8b 24   \u4e2a\u5dde \u534e\u76db\u987f \u7279\u533a \u7d27\u6025\u72b6\u6001 CNN   \u6307\u51fa \u7f8e\u56fd \u62c9\u54cd \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u5168\u56fd \u6d41\u884c \u8b66\u62a5 ", "Covid - 19 \u7206\u53d1 \u65e9\u671f \u53d1\u751f \u513f\u7ae5 \u4e2d \u6b66\u6c49\u5927\u5b66 \u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u590d\u65e6\u5927\u5b66 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u65e9\u671f \u4e00\u540d \u4e2d\u5ea6 \u91cd\u5ea6 \u547c\u5438\u7cfb\u7edf \u75be\u75c5 \u60a3\u8005 \u513f\u7ae5 \u5bb6\u5c5e \u63a5\u89e6 \u534e\u5357 \u6d77\u9c9c \u6279\u53d1\u5e02\u573a \u63a5\u89e6 ", "\u79d1\u5b66 \u6742\u5fd7 \u65e5\u524d \u53d1\u6587 \u79f0 \u65e0\u75c7\u72b6 \u60a3\u8005 \u6f5c\u4f0f\u671f \u60a3\u8005 \u4f53\u6e29 \u68c0\u6d4b \u8bbe\u5907 \u5047 \u9634\u6027 \u5047 \u9633\u6027 \u9690\u7792 \u75c5\u60c5 \u539f\u56e0 \u673a\u573a \u5165\u5883 \u7b5b\u67e5 \u5f88\u96be \u963b\u6b62 \u51a0\u72b6\u75c5\u6bd2 \u4f20\u64ad \u975e\u5178 \u57c3 \u535a\u62c9 \u4f20\u67d3\u75c5 \u7ecf\u9a8c \u5165\u5883 \u68c0\u67e5 \u4e2d \u53d1\u73b0 \u611f\u67d3 \u4e58\u5ba2 \u7f55\u89c1 \u7b5b\u67e5 \u4eba\u5458 \u786e\u5b9e \u5076\u7136 \u53d1\u73b0 \u75c5\u4f8b \u75ab\u60c5 \u66b4\u53d1 \u8fc7\u7a0b \u5f71\u54cd ", "\u65b0\u52a0\u5761 \u56fd\u5bb6 \u4f20\u67d3\u75c5 \u4e2d\u5fc3 Oon - Tek   Ng \u7814\u7a76 \u8ffd\u8e2a 2020 \u5e74 1 \u6708 30 \u65e5 \u767b\u4e0a \u6b66\u6c49 \u65b0\u52a0\u5761 \u822a\u73ed 94 \u5f97\u51fa\u7ed3\u8bba \u7b5b\u9009 \u65e0\u75c7\u72b6 \u8f7b\u5fae \u75c7\u72b6 \u60a3\u8005 \u63a7\u5236 \u75ab\u60c5 \u81f3\u5173\u91cd\u8981 ", "\u534e\u4e1c\u7406\u5de5\u5927\u5b66 \u836f\u5b66\u9662 / \u4e0a\u6d77\u5e02 \u65b0\u836f \u8bbe\u8ba1 \u91cd\u70b9 \u5b9e\u9a8c \u674e\u6d2a\u6797 \u56e2\u961f \u6b66\u6c49\u5927\u5b66 \u75c5\u6bd2\u5b66 \u56fd\u5bb6 \u91cd\u70b9 \u5b9e\u9a8c\u5ba4 \u5f90\u53ef \u56e2\u961f \u53d1\u73b0 \u53d1\u73b0 \u4e34\u5e8a \u5df2\u6709 \u836f\u7269 \u6c1f \u7c73\u7279 Leflunomide \u7279\u7acb \u6c1f\u80fa Teriflunomide \u51a0 \u75c5\u6bd2 \u80ba\u708e \u4e34\u5e8a \u6025\u9700 \u65b0 \u8bbe\u8ba1 \u5019\u9009 \u836f\u7269 S312 S416 \u6709\u671b \u5f00\u53d1 \u6297 RNA \u75c5\u6bd2 \u7279\u6548 \u65b0\u836f ", "\u5e7f\u5dde\u5e02 \u5987\u5973\u513f\u7ae5 \u533b\u7597 \u4e2d\u5fc3 \u4e34\u5e8a \u7814\u7a76 \u56e2\u961f \u53d1\u73b0 \u5206\u6790 10 \u4f8b \u786e\u8bca \u60a3\u513f \u6d41\u884c\u75c5\u5b66 \u4e34\u5e8a \u7279\u5f81 \u7814\u7a76 \u53d1\u73b0 \u513f\u7ae5 \u75c5\u4f8b \u4e2d \u65b0\u51a0 \u75c5\u6bd2 \u7caa\u53e3 \u4f20\u64ad \u53ef\u80fd\u6027 \u809b\u62ed \u5b50 \u6838\u9178 \u68c0\u6d4b \u9633\u6027 \u8f83\u957f\u65f6\u95f4 \u80a0\u9053 \u6392\u6bd2 \u65f6\u95f4 \u8f83\u957f \u7814\u7a76 \u513f\u7ae5 \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u4e34\u5e8a \u8bca\u6cbb \u63d0\u4f9b \u53c2\u8003 \u513f\u7ae5 \u75c5\u4f8b \u786e\u8bca \u6cbb\u7597 \u5eb7\u590d \u89c2\u5bdf \u63d0\u4f9b \u65b0 \u601d\u8def \u65b9\u5411 ", "\u91cd\u5e86\u5927\u5b66 \u533b\u5b66\u9662 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u6c14\u6e29 \u9ad8 \u56fd\u5bb6 \u5730\u533a \u65b0\u51a0 \u75c5\u6bd2 \u75be\u75c5 \u60a3\u8005 \u6cbb\u6108\u7387 \u9ad8\u4e8e \u6c14\u6e29 \u4f4e \u56fd\u5bb6 \u5730\u533a 20 \u6444\u6c0f\u5ea6 \u6cbb\u6108\u7387 \u589e\u52a0 \u5206\u754c\u7ebf ", "\u7f8e\u56fd \u9a6c\u91cc\u5170\u5927\u5b66 \u673a\u6784 \u7814\u7a76 \u4eba\u5458 \u5206\u6790 \u6e29\u5ea6 \u7eac\u5ea6 \u65b0\u51a0 \u80ba\u708e \u76f8\u5173\u6027 \u7b80\u5316 \u5929\u6c14 \u6a21\u578b \u9884\u6d4b \u65b0\u51a0 \u80ba\u708e \u6f5c\u5728 \u6269\u6563 \u7814\u7a76 \u53d1\u73b0 \u75c5\u6bd2\u4f20\u64ad \u7eac\u5ea6 \u6e29\u5ea6 \u4e4b\u95f4 \u76f8\u5173\u6027 \u5f88\u5f3a \u5c1a\u672a \u8bc1\u660e \u56e0\u679c\u5173\u7cfb ", "\u6e05\u534e\u5927\u5b66 \u575a\u9633 \u6731\u51e4\u624d \u5408\u4f5c \u56e2\u961f \u673a\u5668 \u5b66\u4e60 \u65b9\u6cd5 \u6210\u529f \u9884\u6d4b \u7279\u5b9a \u51a0\u72b6\u75c5\u6bd2 \u5019\u9009 \u836f\u7269 \u7814\u7a76 \u53d1\u73b0 PARP1 \u6291\u5236\u5242 CVL218 \u6cbb\u7597 COVID - 19 \u6f5c\u5728 \u6cbb\u7597\u5242 ", "\u7b2c\u56db\u519b\u533b\u5927\u5b66 \u9648\u5fd7\u5357 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 SARS - CoV - 2 CD147 \u65b0\u9014\u5f84 \u4fb5\u5165 \u5bbf\u4e3b \u7ec6\u80de S \u86cb\u767d \u5bbf\u4e3b \u7ec6\u80de \u53d7\u4f53 CD147 \u4ecb\u5bfc \u75c5\u6bd2 \u5165\u4fb5 \u7814\u7a76 \u4fb5\u88ad SARS - CoV - 2 \u5bbf\u4e3b \u7ec6\u80de \u65b0\u9014\u5f84 CD147 - S \u86cb\u767d \u53d1\u73b0 \u7279\u5b9a \u6297\u75c5\u6bd2 \u836f\u7269 \u5f00\u53d1 \u63d0\u4f9b \u5173\u952e \u76ee\u6807 ", "\u590d\u661f \u533b\u836f \u8054\u624b mRNA \u7597\u6cd5 \u4f01\u4e1a BioNTech \u4e2d\u56fd \u72ec\u5bb6 \u5f00\u53d1 \u5546\u4e1a\u5316 BioNTech \u4e13\u6709 mRNA \u6280\u672f \u5e73\u53f0 \u7814\u53d1 COVID - 19 \u75ab\u82d7 \u4ea7\u54c1 ", "\u9996\u90fd\u673a\u573a \u8bbe\u7f6e \u5904\u7f6e \u4e13\u533a \u56fd\u9645 \u6e2f\u6fb3\u53f0\u5730\u533a \u8fdb\u6e2f \u822a\u73ed \u505c\u9760 \u9996\u90fd\u673a\u573a \u5904\u7f6e \u4e13\u533a 3 \u6708 16 \u65e5\u8d77 \u5883\u5916 \u8fdb\u4eac \u4eba\u5458 \u9700 \u8f6c\u9001 \u89c2\u5bdf\u70b9 \u9694\u79bb \u89c2\u5bdf 14 \u5929 ", "SARS \u7814\u53d1 \u8f6c\u57fa\u56e0 \u5c0f\u9f20 \u4f9b\u4e0d\u5e94\u6c42 \u5b9e\u9a8c\u5ba4 \u7ade\u76f8 \u65b0\u51a0 \u75c5\u6bd2 \u52a8\u7269 \u7814\u7a76 \u52a8\u7269\u6a21\u578b \u63ed\u793a \u611f\u67d3 \u53d1\u751f \u5f00\u53d1 \u836f\u7269 \u75ab\u82d7 ", "\u56fd\u5bb6\u81ea\u7136\u79d1\u5b66\u57fa\u91d1\u59d4\u5458\u4f1a \u53d1\u5e03 \u75ab\u60c5 \u73af\u5883 \u6b21\u751f \u98ce\u9669 \u9632\u63a7 \u91cd\u5927\u9879\u76ee \u6307\u5357 \u9879\u76ee \u9884\u7b97 \u8d39\u7528 \u8fbe   2000   \u4e07\u5143 / \u9879 \u8d44\u52a9 \u671f\u9650   5   \u5e74 ", "\u7f8e\u56fd \u9a6c\u91cc\u5170\u5927\u5b66 \u5206\u6790 \u6e29\u5ea6 \u7eac\u5ea6 COVID - 19 \u76f8\u5173\u6027 \u9884\u6d4b 2020 \u5e74 3 \u6708 4 \u6708 \u5317\u90e8 \u533a\u57df \u6e29\u5ea6 \u4f4e \u4f20\u64ad ", "\u5317\u4eac \u89e3\u653e\u519b\u603b\u533b\u9662 \u7b2c\u4e94 \u533b\u7597 \u4e2d\u5fc3 \u7814\u7a76 \u4eba\u5458 \u53d1\u6587 \u6210 \u80a5\u80d6 \u60a3\u8005 \u4e94\u79cd \u764c\u75c7 \u60a3\u8005 \u66f4\u6613 \u60a3 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u5efa\u8bae COVID - 19 \u7206\u53d1 \u671f\u95f4 \u5e94 \u7279\u522b \u4fdd\u62a4 \u514d\u53d7 SARS - Cov - 2 \u611f\u67d3 ", "\u6e05\u534e\u5927\u5b66 \u6c5f\u82cf\u7701 \u75be\u63a7\u4e2d\u5fc3 \u5408\u4f5c \u56e2\u961f \u5f00\u53d1 \u6570\u636e \u9a71\u52a8 \u836f\u7269 \u5b9a\u4f4d \u6846\u67b6 \u53d1\u73b0 PARP1 \u6291\u5236\u5242 CVL218 \u6cbb\u7597 COVID - 19 \u6f5c\u5728 \u6cbb\u7597\u5242 ", "\u4e0a\u6d77\u5e02\u79d1\u59d4 \u4e3b\u4efb \u5f20 \u5168\u79f0 \u75ab\u82d7 \u7814\u53d1 \u8def\u7ebf \u90e8\u7f72 \u63a8\u8fdb \u75ab\u82d7 \u7814\u53d1 \u8fdb\u5c55 mRNA \u75ab\u82d7 \u542f\u52a8 \u7075\u957f\u7c7b \u52a8\u7269 \u6bd2\u7406 \u836f\u6548 \u9884 \u5b9e\u9a8c \u9884\u8ba1 4 \u6708 \u4e2d\u65ec \u4e34\u5e8a\u8bd5\u9a8c \u75c5\u6bd2 \u6837 \u9897\u7c92 VLP \u75ab\u82d7 \u5c0f\u9f20 \u514d\u75ab \u5b9e\u9a8c \u7279\u5f02\u6027 \u6297\u4f53 ", "\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662 \u533b\u5b66 \u52a8\u7269 \u5b9e\u9a8c \u7814\u7a76\u6240 \u79e6\u5ddd \u56e2\u961f \u5efa\u7acb \u6052\u6cb3 \u7334 SARS - CoV - 2 \u611f\u67d3 \u6a21\u578b \u9610\u8ff0 \u6052\u6cb3 \u7334 COVID - 19 \u7279\u5f81 SARS - CoV - 2 \u6c14\u9053 \u611f\u67d3 \u7ed3\u819c \u611f\u67d3 \u9014\u5f84 \u5eb7\u590d \u53d1\u751f \u611f\u67d3 \u73b0\u8c61 \u65b0\u51a0 \u80ba\u708e \u75be\u75c5 \u9884\u540e \u75ab\u82d7 \u8bbe\u8ba1 \u610f\u4e49 ", "\u4e0a\u6d77\u5e02 \u536b\u751f \u5065\u5eb7 \u59d4\u526f \u4e3b\u4efb \u8863\u627f\u4e1c \u4e0a\u6d77 \u65b9\u6848 \u6807\u672c\u517c\u6cbb \u4e2d\u897f\u533b \u72ec\u7279 \u6a21\u5f0f \u521d\u6b65 \u7ed3\u679c\u663e\u793a \u7f9f \u6c2f\u55b9 \u6cbb\u7597 \u8f7b\u75c7 ", "\u56fd\u5bb6 \u536b\u5065\u59d4 \u65b0\u95fb \u53d1\u8a00\u4eba \u7c73\u950b \u4ecb\u7ecd \u56fd\u5185 \u75ab\u60c5 \u9632\u63a7 \u5f62\u52bf \u6301\u7eed \u5883\u5916 \u75ab\u60c5 \u52a0\u901f \u6269\u6563 \u5916\u9632 \u8f93\u5165 \u6211\u56fd \u75ab\u60c5 \u9632\u63a7 \u91cd\u4e2d\u4e4b\u91cd ", "\u65b0\u52a0\u5761 \u591a\u4e2a \u7814\u7a76 \u673a\u6784 \u4e13\u5bb6 \u79f0 \u51e0\u540d \u65b0\u52a0\u5761 \u65b0\u51a0 \u60a3\u8005 \u4f53\u5185 \u75c5\u6bd2 \u7f3a\u5931 \u4e00\u6bb5 \u6838\u82f7\u9178 \u8fd9\u662f \u65b0\u51a0 \u75c5\u6bd2 \u4eba\u7fa4 \u4e2d \u4f20\u64ad \u7b2c\u4e00\u4e2a \u8fdb\u5316 \u4e8b\u4ef6 \u7f3a\u5931 \u65b0\u51a0 \u75c5\u6bd2 \u4f20\u64ad \u81f3\u5c11 4 \u5468 \u7f3a\u5931 \u751f\u7269\u5b66 \u540e\u679c \u672a\u77e5 \u75c5\u6bd2 \u8868\u578b phenotype \u5f71\u54cd ", "\u7a7a\u519b \u519b\u533b\u5927\u5b66 \u9648\u5fd7\u5357 \u9662\u58eb \u53d1\u73b0 SARS - CoV - 2 \u53d7\u4f53 CD147 \u65b0\u9014\u5f84 \u4fb5\u5165 \u5bbf\u4e3b \u7ec6\u80de \u75c5\u6bd2 S \u86cb\u767d \u5bbf\u4e3b \u7ec6\u80de \u53d7\u4f53 CD147 \u4ecb\u5bfc \u75c5\u6bd2 \u5165\u4fb5 \u7814\u7a76 \u4e2d \u4fb5\u88ad SARS - CoV - 2 \u5bbf\u4e3b \u7ec6\u80de \u65b0\u9014\u5f84 CD147 S \u86cb\u767d \u53d1\u73b0 \u7279\u5b9a \u6297\u75c5\u6bd2 \u836f\u7269 \u5f00\u53d1 \u63d0\u4f9b \u7ebf\u7d22 \u610f\u4e49 ", "\u56fd \u533b\u5b66 \u79d1\u5b66\u9662 \u533b\u5b66 \u52a8\u7269 \u5b9e\u9a8c \u7814\u7a76\u6240 \u79e6\u5ddd \u56e2\u961f \u7814\u7a76 \u6052\u6cb3 \u7334 \u773c\u7ed3\u819c \u9014\u5f84 \u611f\u67d3 SARS - CoV - 2 \u8fd9\u4e3a \u76d1\u7763 \u9884\u9632 \u63d0\u4f9b \u6570\u636e ", "\u7f8e\u56fd \u5fc3\u810f\u75c5 \u5b66\u4f1a ACC \u53d1\u5e03 \u4e00\u4efd \u4e34\u5e8a \u516c\u544a \u63d0\u9192 \u5fc3\u8840\u7ba1 \u75be\u75c5 \u60a3\u8005 \u75ab\u60c5 \u4e4b\u4e0b \u9762\u4e34 \u6f5c\u5728 \u98ce\u9669 \u5efa\u8bae \u4e00\u7cfb\u5217 \u9884\u9632\u63aa\u65bd ", "\u65f6\u95f4 3 \u6708 16 \u65e5 \u7f8e\u56fd COVID - 19 \u8bd5\u9a8c \u75ab\u82d7 \u9996\u6279 \u5fd7\u613f\u8005 \u897f\u96c5\u56fe \u63a5\u53d7 \u6ce8\u5c04 \u75ab\u82d7 \u2160 \u671f \u4e34\u5e8a\u8bd5\u9a8c \u4e00\u90e8\u5206 . \u75ab\u82d7 \u79f0\u4e3a mRNA - 1273 \u2160 \u671f \u4e34\u5e8a\u8bd5\u9a8c \u51ef\u6492 \u533b\u7597 Kaiser   Permanente \u897f\u96c5\u56fe \u534e\u76db\u987f \u5065\u5eb7 \u7814\u7a76\u6240 KPWHRI \u7f8e\u56fd \u56fd\u7acb \u536b\u751f \u7814\u7a76\u9662 NIH \u4e0b\u5c5e \u7f8e\u56fd \u56fd\u5bb6 \u8fc7\u654f \u4f20\u67d3\u75c5 \u7814\u7a76\u6240 NIAID \u8d44\u52a9 \u8ba1\u5212 \u7ea6 6 \u5468\u5185 \u62db\u52df 45 \u540d 18 55 \u5c81 \u5065\u5eb7 \u6210\u4eba \u5fd7\u613f\u8005 . ", "\u79d1\u6280\u90e8 \u751f\u7269 \u4e2d\u5fc3 \u4e3b\u4efb \u5f20 \u65b0\u6c11 \u6cd5\u5339\u62c9\u97e6 \u5b89\u5168\u6027 \u7597\u6548 \u836f\u54c1 \u53ef\u53ca \u79d1\u7814 \u653b\u5173\u7ec4 \u7ec4\u7ec7 \u4e13\u5bb6 \u8bba\u8bc1 \u6b63\u5f0f \u533b\u7597 \u6551\u6cbb \u7ec4 \u63a8\u8350 \u5efa\u8bae \u7eb3\u5165 \u65b0\u578b \u51a0\u72b6 \u80ba\u708e \u8bca\u7597 \u65b9\u6848 ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 WHO \u603b\u5e72\u4e8b \u8c2d \u5fb7\u585e \u9884\u9632 \u611f\u67d3 \u633d\u6551 \u751f\u547d \u65b9\u6cd5 \u6253\u7834 \u4f20\u64ad \u94fe \u68c0\u6d4b \u9694\u79bb \u56fd\u5bb6 \u4fe1\u606f \u68c0\u6d4b \u68c0\u6d4b \u68c0\u6d4b   \u68c0\u6d4b \u7591\u4f3c\u75c5\u4f8b ", "\u591a\u7bc7 \u7814\u7a76 \u663e\u793a \u513f\u7ae5 \u65b0\u51a0 \u75c5\u6bd2 \u6613 \u611f\u8005 \u5bb6\u5ead \u805a\u96c6 \u6027 \u611f\u67d3 \u539f\u56e0 \u513f\u7ae5 \u611f\u67d3 \u75c7\u72b6 \u8f7b \u5178\u578b \u5ffd\u7565 \u6f0f\u8bca \u5ffd\u7565 \u513f\u7ae5 \u611f\u67d3 \u5bb6\u5ead \u611f\u67d3 \u6e90\u5934 \u513f\u7ae5 \u80a0\u9053 \u6392\u6bd2 \u5468\u671f\u957f \u76f8 \u6210\u4eba \u60a3\u8005 \u6f5c\u4f0f \u65f6\u95f4 \u66f4\u957f ", "\u7f8e\u56fd \u79d1\u5b66\u5bb6 \u5fd7\u613f\u8005 \u8eab\u4e0a \u6ce8\u5c04 \u7b2c\u4e00\u79cd \u5b9e\u9a8c\u6027 \u51a0\u72b6\u75c5\u6bd2 \u75ab\u82d7 \u8fd9\u662f \u4fdd\u62a4 \u4e16\u754c \u514d\u4e8e \u6b63 \u8086\u610f \u8513\u5ef6 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 \u91cc\u7a0b\u7891 ", "\u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u5218\u4e9a\u5170 \u56e2\u961f \u56db\u4e2a \u5b55\u5987 \u8ddf\u8e2a \u89c2\u5bdf \u663e\u793a \u75c5\u6bd2\u611f\u67d3 \u51fa\u751f \u65f6 \u5b55\u5987 \u4f20\u67d3\u7ed9 \u65b0\u751f\u513f \u5305\u62ec \u5256\u8179\u4ea7 \u5206\u5a29 ", "\u673a\u6784 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u4e0e\u975e A \u8840\u578b \u76f8\u6bd4 A\u578b \u8840\u578b COVID - 19 \u98ce\u9669 \u9ad8 O\u578b \u8840 \u4f4e \u611f\u67d3 \u98ce\u9669 ", "\u5c60 \u5466 \u5466 \u56e2\u961f \u6307\u51fa \u9632\u8303 \u5e94\u5bf9 \u516c\u5171\u536b\u751f \u5371\u673a \u5173\u952e \u759f\u75be \u6d41\u884c \u56fd\u5bb6 \u505a\u597d \u5e94\u5bf9 COVID - 19 \u5e26\u6765 \u6311\u6218 \u7a0b\u5ea6 \u51cf\u5c11 \u759f\u75be \u63a7\u5236 \u7834\u574f ", "\u590d\u65e6\u5927\u5b66 \u59dc\u4e16\u52c3 \u6307\u51fa \u7d27\u6025 \u5236\u5b9a \u5e94\u5bf9 \u65b0 \u51a0\u72b6\u75c5\u6bd2 \u63aa\u65bd \u6c38\u8fdc \u7b2c\u4e00\u4f4d ", "\u4e2d\u56fd\u79d1\u6280\u5927\u5b66 \u9b4f\u6d77\u660e \u56e2\u961f \u81f4\u75c5\u6027 GM - CSF   +   Th1 \u7ec6\u80de \u708e\u6027 CD14   +   CD16   + \u5355\u6838\u7ec6\u80de \u8fc7\u5ea6 \u6fc0\u6d3b \u514d\u75ab \u80ba\u90e8 \u514d\u75ab \u75c5\u7406\u5b66 \u5bfc\u81f4 \u6709\u5bb3 \u4e34\u5e8a\u8868\u73b0 \u5bfc\u81f4 \u6025\u6027 \u6b7b\u4ea1 \u8fdb\u4e00\u6b65 \u65b0\u51a0 \u80ba\u708e \u9ad8 \u6b7b\u4ea1\u7387 \u5f88\u5927 \u539f\u56e0 \u7ec6\u80de\u56e0\u5b50 \u98ce\u66b4 ", "\u4e2d\u592e \u6307\u5bfc\u7ec4 \u4e13\u5bb6 \u7ec4\u6210\u5458 \u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u5929\u6d25 \u4e2d\u533b\u836f\u5927\u5b66 \u6821\u957f \u5f20\u4f2f\u793c \u7814\u7a76 \u53d1\u73b0 \u4e2d\u836f \u91d1\u82b1 \u6e05\u611f \u6cbb\u7597 \u8f7b\u5ea6 \u666e\u901a\u578b \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u7597\u6548 \u786e\u5207 \u60a3\u8005 \u9000\u70ed \u65f6\u95f4 \u8f7b\u75c7 \u8f6c\u91cd \u6bd4\u4f8b \u4e0b\u964d \u75c7\u72b6 \u6539\u5584 \u708e\u75c7 \u5438\u6536 \u4f5c\u7528 ", "\u5357\u65b9 \u79d1\u6280 \u5927\u5b66 8 \u5bb6 \u5355\u4f4d \u7814\u7a76 \u4eba\u5458 \u6700\u65b0 \u7814\u7a76 \u663e\u793a A B O AB \u8840\u578b \u65b0\u51a0 \u80ba\u708e \u6613\u611f\u6027 \u5173\u8054 O\u578b \u8840\u5bf9 \u65b0\u51a0 \u80ba\u708e \u4e0d\u6613 \u611f \u98ce\u9669 \u4f4e A\u578b \u8840\u5bf9 \u65b0\u51a0 \u80ba\u708e \u6613\u611f \u98ce\u9669 \u9ad8 ", "\u519b\u4e8b\u79d1\u5b66\u9662 \u519b\u4e8b\u533b\u5b66 \u7814\u7a76\u9662 \u9648\u8587 \u9662\u58eb \u9886\u8854 \u79d1\u7814 \u56e2\u961f \u6210\u529f \u7814\u5236 \u91cd\u7ec4 \u65b0\u51a0 \u75ab\u82d7 \u91cd\u7ec4 \u65b0\u51a0 \u75ab\u82d7 \u83b7\u6279 \u542f\u52a8 \u5c55\u5f00 \u4e34\u5e8a\u8bd5\u9a8c ", "\u4e2d\u56fd\u533b\u5b66\u79d1\u5b66\u9662 \u533b\u5b66 \u5b9e\u9a8c \u52a8\u7269 \u7814\u7a76\u6240 \u79e6\u5ddd \u56e2\u961f \u9996\u6b21 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u7ed3\u819c \u9014\u5f84 \u4f20\u64ad \u5b9e\u9a8c \u8bc1\u636e \u6052\u6cb3 \u7334 \u773c\u7ed3\u819c \u9014\u5f84 \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 \u75c5\u6bd2 \u611f\u67d3 1 \u5929\u540e \u7ed3\u819c \u8f6c\u79fb \u547c\u5438\u9053 \u7ec4\u7ec7 \u8fd9\u4e3a \u75c5\u6bd2 \u9884\u9632 \u63d0\u4f9b \u7406\u8bba \u652f\u6301 ", "\u7f8e\u56fd \u56fd\u5bb6 \u8fc7\u654f \u4f20\u67d3\u75c5 \u7814\u7a76\u6240 \u673a\u6784 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u6c14\u6eb6\u80f6 \u4e2d 3 \u5c0f\u65f6 \u68c0\u6d4b \u5230\u6d3b \u65b0\u51a0 \u75c5\u6bd2 \u94dc \u8868\u9762 \u65b0\u51a0 \u75c5\u6bd2 \u5b58\u6d3b \u591a\u8fbe 4 \u5c0f\u65f6 \u786c\u7eb8\u677f \u8868\u9762 \u81f3\u591a \u5b58\u6d3b 24 \u5c0f\u65f6 \u5851\u6599 \u4e0d\u9508\u94a2 \u8868\u9762 \u5b58\u6d3b 2 3 \u5929 ", "\u6b66\u6c49\u5927\u5b66 \u5b98\u7f51 3 \u6708 15 \u65e5 \u665a\u95f4 \u53d1\u5e03 \u8ba3\u544a \u4e2d\u56fd\u5171\u4ea7\u515a \u4f18\u79c0\u515a\u5458 \u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u8457\u540d \u5927\u5730 \u6d4b\u91cf\u5b66\u5bb6 \u6559\u80b2\u5bb6 \u6b66\u6c49\u5927\u5b66 \u6559\u6388 \u535a\u58eb\u751f \u5bfc\u5e08 \u5b81\u6d25 \u751f \u9662\u58eb \u75c5 \u533b\u6cbb\u65e0\u6548 2020 \u5e74 3 \u6708 15 \u65e5 16 \u65f6 06 \u5206\u5728 \u6b66\u6c49 \u901d\u4e16 \u4eab\u5e74 88 \u5c81 ", "\u7f8e\u56fd \u53d1\u5e03 100 \u9875 \u6297\u75ab \u62a5\u544a \u62a5\u544a \u9884\u793a \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u4e25\u5cfb\u5f62\u52bf \u6982\u8ff0 \u653f\u5e9c \u5e94\u5bf9 \u63aa\u65bd \u62a5\u544a \u4e2d\u6709 \u63d0\u5230 \u75ab\u60c5 \u6d41\u884c \u7269\u8d44 \u77ed\u7f3a \u6301\u7eed 18 \u6708 ", "\u591a\u4efd \u62a5\u544a \u79f0 \u52a8\u7269\u56ed \u4eba\u755c \u60a3\u75c5 \u884c\u4e1a\u534f\u4f1a \u4e25\u9632 \u52a8\u7269 \u75ab\u60c5 \u4e2d\u56fd \u52a8\u7269\u56ed \u534f\u4f1a \u660e\u786e\u8981\u6c42 \u4f1a\u5458\u5355\u4f4d \u9972\u517b \u7e41\u80b2 \u91ce\u751f\u52a8\u7269 \u573a\u9986 \u5b9e\u65bd \u516c\u4f17 \u9694\u79bb \u9972\u517b \u7ba1\u7406\u4eba\u5458 \u9694\u79bb \u64cd\u4f5c \u63a5\u89e6 \u91ce\u751f\u52a8\u7269 \u6682\u505c \u91ce\u751f\u52a8\u7269 \u5bf9\u5916 \u8f6c\u8fd0 ", "\u590d\u65e6\u5927\u5b66 \u673a\u6784 \u7814\u7a76 \u4eba\u5458 \u5efa\u7acb \u4eba\u6e90\u7c7b \u5668\u5b98 SARS - COV - 2 \u611f\u67d3 \u6a21\u578b SARS - COV - 2 \u611f\u67d3 \u80c6\u7ba1 \u7ec6\u80de \u65b0\u51a0 \u75c5\u6bd2 \u7ec6\u80de \u55dc\u6027 \u81f4\u75c5 \u673a\u5236 \u7814\u7a76 \u540e\u7eed \u836f\u7269 \u7814\u53d1 \u63d0\u4f9b \u5de5\u5177 \u63d0\u793a \u80c6\u7ba1 \u529f\u80fd \u7d0a\u4e71 \u65b0\u578b \u51a0\u72b6 \u75c5\u6bd2\u611f\u67d3\u8005 \u809d\u810f \u635f\u4f24 \u8bf1\u56e0 ", "\u9976\u5b50 \u9662\u58eb \u56e2\u961f \u53d1\u73b0 \u62a5\u544a SARS - Cov - 2 \u8f85\u52a9\u56e0\u5b50 nsp7 nsp8 \u5168\u957f nsp12 cryo - EM \u7ed3\u6784 \u89c2\u5bdf \u75c5\u6bd2 \u590d\u5236 \u8f6c\u5f55 \u5173\u952e \u6b8b\u57fa \u7814\u7a76 \u63d0\u4f9b \u5206\u6790 \u663e\u793a \u745e\u5fb7 \u6614\u97e6 \u805a\u5408\u9176 \u7ed3\u6784 \u63d0\u4f9b \u51a0\u72b6\u75c5\u6bd2 \u590d\u5236 / \u8f6c\u5f55 \u673a\u5236 \u6838\u5fc3 \u7ec4\u6210\u90e8\u5206 \u89c1\u89e3 \u8bbe\u8ba1 \u75c5\u6bd2 RdRp \u65b0\u578b \u6297\u75c5\u6bd2 \u6cbb\u7597 \u836f\u7269 \u63d0\u4f9b \u601d\u8def ", "\u6fb3\u5927\u5229\u4e9a \u58a8\u5c14\u672c\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 COVID - 19 \u60a3\u8005 \u4f53\u5185 \u6297\u4f53 \u5206\u6ccc \u7ec6\u80de ASCs \u5375\u6ce1 \u8f85\u52a9\u6027 T \u7ec6\u80de TFH \u7ec6\u80de \u6d3b\u5316 CD4   +   T \u7ec6\u80de CD8   +   T \u7ec6\u80de \u6570\u91cf \u660e\u663e\u589e\u52a0 \u68c0\u6d4b COVID - 19 \u51a0\u72b6\u75c5\u6bd2 SARS - CoV - 2 \u514d\u75ab \u7403\u86cb\u767d M IgM IgG \u6297\u4f53 \u7814\u7a76 \u65b0 \u75c5\u6bd2 SARS - CoV - 2 \u5f15\u53d1 \u5f3a\u5927 \u56e0\u7d20 \u514d\u75ab ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u63a8\u8350 \u51e0\u79cd \u6d88\u6bd2\u6db2 \u914d\u65b9 \u5c1a\u65e0 \u65b0\u51a0 \u75c5\u6bd2 \u9a8c\u8bc1 85 \u4e59\u9187 WHO \u63a8\u8350 1 \u53f7 \u914d\u65b9 \u75c5\u6bd2 \u4f20\u67d3\u6027 \u964d\u4f4e 5.9% \u75c5\u6bd2 \u6d53\u5ea6 \u51cf\u5c11 40 \u2013   80 75 \u5f02\u4e19\u9187 WHO \u63a8\u8350 2 \u53f7 \u914d\u65b9 \u4f4e\u6d53\u5ea6 \u8868\u73b0 \u66f4\u597d \u6740\u75c5\u6bd2 \u6548\u679c \u6d53\u5ea6 30 \u65f6 \u5373\u706d\u6d3b \u75c5\u6bd2 ", "\u5170\u5dde\u5927\u5b66 \u516c\u5171\u536b\u751f \u5b66\u9662 \u7f57\u658c \u56e2\u961f \u6536\u96c6 \u56fd \u6b66\u6c49\u5e02 COVID - 19 \u6bcf\u65e5 \u6b7b\u4ea1 \u4eba\u6570 \u6c14\u8c61 \u7a7a\u6c14 \u6c61\u67d3\u7269 \u6570\u636e \u91c7\u7528 \u6570\u5b66\u6a21\u578b \u7814\u7a76 \u6e29\u5ea6 \u6e7f\u5ea6 \u663c\u591c \u6e29\u5dee COVID - 19 \u65e5 \u6b7b\u4ea1\u7387 \u5f71\u54cd \u53d1\u73b0 COVID - 19 \u6b7b\u4ea1\u7387 \u663c\u591c \u6e29\u5dee \u5448 \u6b63 \u76f8\u5173 \u76f8\u5bf9\u6e7f\u5ea6 \u5448 \u8d1f\u76f8\u5173 \u7814\u7a76 \u6e29\u5ea6 \u53d8\u5316 \u6e7f\u5ea6 \u5f71\u54cd COVID - 19 \u6b7b\u4ea1\u7387 \u56e0\u7d20 ", "\u6b66\u6c49 \u513f\u7ae5\u533b\u9662 \u673a\u6784 \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u513f\u7ae5 \u611f\u67d3 SARS - CoV - 2 \u60a3\u513f \u8868\u73b0 \u65e0\u75c7\u72b6 \u65e0\u75c7\u72b6 \u513f\u7ae5 \u60a3\u8005 \u4f20\u64ad \u6f5c\u529b \u6307\u5bfc \u63a7\u5236 \u6d41\u884c\u75c5 \u63aa\u65bd \u5236\u5b9a ", "\u65af\u514b \u5229\u666e\u65af \u7814\u7a76\u6240 \u7814\u7a76 \u4eba\u5458 \u5df2\u77e5 \u51a0\u72b6\u75c5\u6bd2 \u682a \u57fa\u56e0\u7ec4 \u5e8f\u5217 \u6570\u636e SARS - CoV - 2 \u81ea\u7136 \u8fc7\u7a0b ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u738b\u8fb0 \u56e2\u961f \u4e34\u5e8a \u4e2d \u53d1\u73b0 \u91cd\u75c7 \u65b0\u51a0 \u80ba\u708e \u6210\u4eba \u4f4f\u9662 \u60a3\u8005 \u53d1\u75c5 12 \u5929\u5185 \u6d1b\u5339 \u97e6 / \u5229\u6258 \u97e6 \u5546\u54c1 \u540d \u514b\u529b \u829d \u83b7\u76ca \u8d8b\u52bf \u4e34\u5e8a\u8bd5\u9a8c \u63d0\u4f9b \u53c2\u8003\u4ef7\u503c ", "\u4e2d\u65e5 \u533b\u9662 \u547c\u5438 \u5371\u91cd\u75c7 \u533b\u5b66\u79d1 \u4e3b\u4efb \u66f9\u5f6c \u4e13\u5bb6 199 \u540d\u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 \u60a3\u8005 \u4e34\u5e8a \u6cbb\u7597 \u4e2d \u53d1\u73b0 HIV \u86cb\u767d\u9176 \u6291\u5236\u5242 \u514b\u529b \u829d \u6d1b\u5339 \u97e6 - \u5229\u6258 \u97e6 \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u6548\u679c ", "\u4e0a\u6d77 \u79d1\u6280 \u5927\u5b66 - \u6e05\u534e\u5927\u5b66 \u6297\u65b0\u51a0 \u75c5\u6bd2 \u8054\u5408\u653b\u5173 \u56e2\u961f \u6b21 \u7cbe\u7ec6 \u63cf\u7ed8\u51fa \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 RdRp - nsp7 - nsp8 \u590d\u5236 \u673a\u5668 \u5185\u90e8 \u6784\u9020 \u745e\u5fb7 \u897f\u97e6 \u6548\u5e94 \u5206\u5b50 \u7cbe\u786e \u9776\u5411 \u6291\u5236 \u590d\u5236 \u673a\u5668 \u6838\u5fc3 \u5143\u4ef6 \u75c5\u6bd2 RNA \u805a\u5408\u9176 \u53d1\u6325 \u836f\u6548 \u6d3b\u6027 \u63d0\u51fa \u673a\u5236 \u89e3\u91ca \u8fd9\u4e3a \u6df1\u5165\u7814\u7a76 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u590d\u5236 \u5206\u5b50 \u673a\u7406 \u5960\u5b9a \u7406\u8bba \u57fa\u7840 \u5f00\u53d1 \u6297\u65b0\u51a0 \u80ba\u708e \u7279\u6548\u836f \u5f00\u8f9f \u65b0\u9014\u5f84 ", "\u9999\u6e2f\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u8bc4\u4f30 SARS - CoV - 2 \u73af\u5883 \u6761\u4ef6 \u5b58\u6d3b \u60c5\u51b5 \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 4 \u7a33\u5b9a 14 \u5929 \u5927\u90e8\u5206 \u75c5\u6bd2 \u4f9d\u65e7 \u5b58\u6d3b 22 \u6761\u4ef6 7 \u5929 \u68c0\u6d4b \u5b58\u6d3b \u75c5\u6bd2 14 \u5929 \u68c0\u6d4b \u4e0d\u5230 56 30   min 70 5   min \u68c0\u6d4b \u4e0d\u5230 \u611f\u67d3\u6027 \u75c5\u6bd2 ", "\u4e2d\u5c71\u5927\u5b66 \u7814\u7a76 \u56e2\u961f \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u53d7\u4f53 ACE2 \u514d\u75ab \u7ec6\u80de \u4e2d \u8868\u8fbe \u76f8\u5173\u6027 \u5371\u91cd\u75c7 \u76f8\u5173 \u5916\u5468\u8840 \u5e72\u6270\u7d20 - alpha \u603b\u91cf \u5371\u91cd\u75c7 \u75c5\u7a0b \u5bc6\u5207\u76f8\u5173 \u7814\u7a76 \u9996\u6b21 \u63cf\u8ff0 \u65b0\u51a0 \u75c5\u6bd2\u611f\u67d3 \u5371\u91cd\u75c5 \u514d\u75ab \u7279\u5f81 ", "\u4e2d\u56fd \u75be\u63a7\u4e2d\u5fc3 \u7814\u7a76\u5458 \u51af\u5f55 \u53ec \u6279\u51c6 \u4e0a\u5e02 \u65b0\u51a0 \u80ba\u708e \u68c0\u6d4b \u8bd5\u5242 \u5305\u62ec \u4e24\u7c7b \u4e00\u7c7b \u6838\u9178 \u68c0\u6d4b \u8bd5\u5242 \u4e00\u7c7b \u6297\u4f53 \u68c0\u6d4b \u8bd5\u5242 \u6297\u4f53 \u68c0\u6d4b \u7528\u4e8e \u6838\u9178 \u68c0\u6d4b \u9634\u6027 \u75c5\u4f8b \u8f85\u52a9 \u8bca\u65ad \u75c5\u4f8b \u6392\u67e5 \u7b5b\u67e5 \u6838\u9178 \u68c0\u6d4b \u65b9\u6cd5 ", "\u5317\u4eac\u5927\u5b66\u7b2c\u4e00\u533b\u9662 \u611f\u67d3 \u75be\u75c5 \u79d1\u4e3b\u4efb \u738b\u8d35\u5f3a \u65b0\u51a0 \u80ba\u708e \u75c5\u6bd2\u611f\u67d3 \u4e00\u79cd \u6025\u6027 \u75c5\u6bd2\u6027 \u4f20\u67d3\u75c5 \u7279\u6548 \u6cbb\u7597 \u836f\u7269 \u7c7b \u75be\u75c5 \u529e\u6cd5 \u5bf9\u75c7 \u652f\u6301 \u6cbb\u7597 ", "\u7279\u6717\u666e \u767d\u5bab \u53d1\u5e03\u4f1a \u4e00\u79cd \u5e38\u89c1 \u6297 \u759f\u75be \u836f\u7269 \u5f88\u5feb \u5904\u65b9 \u524d\u63d0 \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 ", "\u5357\u65b9 \u533b\u79d1\u5927\u5b66 \u516c\u5171\u536b\u751f \u5b66\u9662 \u5f20\u5176\u5a01 \u6559\u6388 \u56e2\u961f \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u7a81\u53d8 \u589e\u5f3a \u65b0\u51a0 \u75c5\u6bd2 \u8868\u9762 \u523a\u7a81 \u86cb\u767d \u7ed3\u6784 \u7a33\u5b9a\u6027 \u7a81\u53d8 \u75c5\u6bd2 \u682a \u53d7\u4f53 \u4eb2\u548c\u529b \u589e\u5f3a \u75c5\u6bd2 \u4f20\u67d3\u6027 \u53d7 \u56e0\u7d20 \u5f71\u54cd \u4f20\u67d3\u6027 \u63d0\u9ad8 \u6982\u7387 \u4e8b\u4ef6 ", "\u4e2d\u65e5\u53cb\u597d\u533b\u9662 \u526f \u9662\u957f \u66f9\u5f6c \u56e2\u961f \u6d1b\u5339 \u97e6 / \u5229\u6258 \u97e6 \u4e34\u5e8a\u8bd5\u9a8c \u62ab\u9732 \u7814\u7a76 \u91cd\u75c7 \u65b0\u51a0 \u80ba\u708e \u6210\u4eba \u4f4f\u9662 \u60a3\u8005 \u4e2d \u6d1b\u5339 \u97e6 / \u5229\u6258 \u97e6 \u6539\u5584 \u60a3\u8005 \u4e34\u5e8a \u72b6\u51b5 \u964d\u4f4e \u6b7b\u4ea1\u7387 \u672a \u51cf\u5c11 \u60a3\u8005 \u54bd\u90e8 \u75c5\u6bd2 \u8f7d\u91cf \u53d1\u751f \u80c3\u80a0\u9053 \u4e0d\u826f\u53cd\u5e94 ", "\u75ab\u60c5 \u53d1\u9175 \u5f71\u54cd \u82f1 \u4f1f\u8fbe \u65b0\u578b \u51a0\u72b6 \u80ba\u708e \u75c5\u6bd2 \u7814\u7a76 \u4eba\u5458 \u514d\u8d39 \u63d0\u4f9b 90 \u5929 \u57fa\u56e0\u7ec4 \u6d4b\u5e8f \u8f6f\u4ef6 \u4f7f\u7528\u6743 \u8f6f\u4ef6 \u540d\u4e3a Parabricks \u57fa\u56e0\u7ec4 \u6d4b\u5e8f \u8f6f\u4ef6 \u7531\u82f1 \u4f1f\u8fbe GPU \u9a71\u52a8 \u6570\u636e\u5206\u6790 \u901f\u5ea6 \u63d0\u5347 50 \u500d \u8fdb\u4e00\u6b65 \u52a0\u901f \u57fa\u56e0\u7ec4 \u5206\u6790 \u63d0\u9ad8 \u7814\u7a76 \u6548\u7387 ", "\u79d1\u4e9a \u533b\u7597 \u91c7\u7528 \u6df1\u5ea6 \u5b66\u4e60 \u6280\u672f \u5f00\u53d1\u65b0 \u51a0 \u80ba\u708e 3D \u68c0\u6d4b \u795e\u7ecf\u7f51\u7edc COVNet \u80ba\u90e8 CT \u4e2d \u63d0\u53d6 \u5404\u7c7b \u5f71\u50cf \u7279\u5f81 \u9274\u522b \u65b0\u51a0 \u80ba\u708e ", "\u65e5\u672c \u5ddd\u5d0e \u751f\u7269 \u6570\u636e \u516c\u53f8 \u7814\u7a76 \u4eba\u5458 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u57fa\u56e0 \u5efa\u7acb \u75c5\u6bd2 \u7e41\u6b96 \u53d8\u5f02 \u6811\u72b6 \u7ed3\u6784 \u7ed3\u679c\u663e\u793a \u53f0\u6e7e \u7f8e\u56fd \u65e5\u672c \u75c5\u6bd2 \u72ec\u7acb \u4e16\u754c \u5730\u65b9 \u4f20\u64ad \u75c5\u6bd2 \u6b66\u6c49 \u75c5\u6bd2 ", "\u5168\u7403 \u75ab\u60c5 \u6d41\u884c \u8d8b\u52bf \u5df2\u6210 \u77ed\u671f\u5185 2 \u6708 \u63a7\u5236 \u75ab\u60c5 \u53ef\u80fd\u6027 \u8d8a\u6765\u8d8a \u6d77\u5916 \u75ab\u60c5 \u672a\u6765 2 - 3 \u6708 \u4e2d \u65f6\u95f4 \u53cd\u5411 \u5f71\u54cd \u4e2d\u56fd \u75ab\u60c5 \u8f93\u5165 \u6027 \u75c5\u4f8b \u65e5\u5e38\u5316 \u9632 \u8f93\u5165 \u6027 \u75c5\u4f8b \u590d\u4ea7 \u590d\u5de5 \u4e4b\u95f4 \u627e\u5230 \u5408\u9002 \u5e73\u8861 \u6446\u5728 \u4e2d\u56fd \u9762\u524d ", "\u4e2d\u5c71\u5927\u5b66 \u56e2\u961f \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u60a3\u8005 \u9996\u6b21 \u75c7\u72b6 \u7caa\u4fbf \u5373\u53ef \u5448\u73b0 \u6838\u9178 \u9633\u6027 \u4e0d\u4ec5\u5982\u6b64 \u60a3\u8005 \u547c\u5438\u9053 \u6837\u672c \u65b0 \u51a0\u72b6\u75c5\u6bd2 \u68c0\u6d4b \u8f6c \u9634\u6027 \u7caa\u4fbf \u6837\u672c \u5448 \u75c5\u6bd2 \u9633\u6027 \u65f6\u95f4 \u53ef\u957f \u8fbe\u8fd1 5 \u5468 ", "\u6e05\u534e\u5927\u5b66 \u9976\u5b50 \u7814\u7a76 \u56e2\u961f \u7814\u7a76 \u62a5\u544a SARS - Cov - 2 \u8f85\u52a9\u56e0\u5b50 nsp7 nsp8 \u5168\u957f nsp12 cryo - EM \u7ed3\u6784 \u5206\u8fa8\u7387 2.9 \u57c3 \u7ed3\u6784 \u63d0\u4f9b \u51a0\u72b6\u75c5\u6bd2 \u590d\u5236 / \u8f6c\u5f55 \u673a\u5236 \u6838\u5fc3 \u7ec4\u6210\u90e8\u5206 \u89c1\u89e3 \u8bbe\u8ba1 \u75c5\u6bd2 RdRp \u65b0\u578b \u6297\u75c5\u6bd2 \u6cbb\u7597 \u836f\u7269 \u63d0\u4f9b \u601d\u8def ", "Didier   Raoulta \u56e2\u961f \u7814\u7a76 \u663e\u793a \u786b\u9178 \u7f9f \u6c2f\u55b9 \u6cbb\u7597 COVID - 2019 \u75c5\u4eba \u7597\u6548 \u7814\u7a76 \u6cbb\u7597 \u65b0\u578b \u51a0\u72b6 \u80ba\u708e \u60a3\u8005 \u63d0\u4f9b \u53c2\u8003 \u4f5c\u7528 ", "\u534e\u76db\u987f\u5927\u5b66 \u7814\u7a76 \u56e2\u961f \u9996\u6b21 \u6279\u9732 \u91cd\u75c7 \u60a3\u8005 \u4e34\u5e8a\u8868\u73b0 \u7279\u5f81 \u7ed3\u5c40 \u6700\u521d \u75c7\u72b6 \u5305\u62ec \u547c\u5438 \u6025\u4fc3 76 \u53d1\u70e7 52 \u54b3\u55fd 48 2020 \u5e74 3 \u6708 17 \u65e5 \u6b7b\u4ea1\u7387 67 \u91cd\u75c7 \u60a3\u8005 24 ICU \u51fa\u9662 \u7387\u4e3a 9.5 ", "\u5fb7\u56fd \u5415\u8d1d\u514b \u5927\u5b66 \u751f\u7269\u5316\u5b66 \u7814\u7a76\u6240 Rolf   Hilgenfeld \u56e2\u961f \u8bbe\u8ba1 \u5408\u6210 \u62df \u80bd \u03b1 - \u916e \u9170\u80fa \u03b2 \u51a0\u72b6\u75c5\u6bd2 \u03b1 \u51a0\u72b6\u75c5\u6bd2 \u86cb\u767d\u9176 \u80a0\u75c5\u6bd2 3C \u86cb\u767d\u9176 \u5e7f\u8c31 \u6291\u5236\u5242 \u7814\u7a76 \u62a5\u544a \u672a SARS - CoV - 2   Mpro \u03b1 - \u916e \u9170\u80fa \u6291\u5236\u5242 \u590d\u5408\u7269 X\u5c04\u7ebf \u7ed3\u6784 ", "\u4e91\u5357\u5927\u5b66 \u5f20\u5fd7\u521a \u56e2\u961f \u63ed\u793a \u9a6c\u6765 \u7a7f\u5c71\u7532 SARS - CoV - 2 \u7c7b\u4f3c \u75c5\u6bd2 \u6f5c\u5728 \u81ea\u7136 \u5bbf\u4e3b \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u8fd9\u6279 \u9a6c\u6765 \u7a7f\u5c71\u7532 \u643a\u5e26 SARS - CoV - 2 \u76f8\u8fd1 \u51a0\u72b6\u75c5\u6bd2 \u547d\u540d Pangolin - CoV SARS - CoV - 2 \u4e2d \u89c2\u5bdf Pangolin - CoV RaTG13 S1   /   S2 \u5207\u5272 \u4f4d\u70b9 \u4e22\u5931 \u5047\u5b9a Furin \u86cb\u767d\u9176 \u8bc6\u522b \u5e8f\u5217 \u57fa\u5e8f \u8fd9\u9879 \u7814\u7a76 \u7a7f\u5c71\u7532 \u7269\u79cd SARS - CoV - 2 \u5929\u7136 \u5e93 ", "\u4e2d\u56fd \u91cd\u7ec4 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 2019 - COV \u75ab\u82d7 \u817a\u75c5\u6bd2 \u8f7d\u4f53 \u2160 \u671f \u4e34\u5e8a\u8bd5\u9a8c \u9996\u6279 \u5fd7\u613f\u8005 \u6ce8\u5c04 \u8bd5\u9a8c \u4e3b\u529e\u5355\u4f4d \u519b\u4e8b\u79d1\u5b66\u9662 \u533b\u5b66 \u7814\u7a76\u9662 \u751f\u7269\u5de5\u7a0b \u7814\u7a76\u6240 \u5eb7\u5e0c\u8bfa \u751f\u7269 \u80a1\u4efd\u516c\u53f8 \u8bd5\u9a8c \u76ee\u7684 \u6d4b\u8bd5 \u8bc4\u4ef7 \u91cd\u7ec4 \u65b0\u51a0 \u75c5\u6bd2 \u75ab\u82d7 \u817a\u75c5\u6bd2 \u8f7d\u4f53 \u5b89\u5168\u6027 \u6709\u6548\u6027 ", "\u7f8e\u56fd \u5317\u5361\u7f57\u6765\u7eb3 \u5927\u5b66 \u7814\u7a76 \u56e2\u961f \u53d1\u73b0 HCMV \u63a5\u79cd BLT - L \u4eba\u80ba \u690d\u5165\u7269 \u8bf1\u5bfc HCMV \u7279\u5f02\u6027 IgM IgG T \u7ec6\u80de \u63a7\u5236 \u4f53\u5185 \u611f\u67d3 LoM BLT - L \u5c0f\u9f20 \u4eba\u6e90\u5316 \u5c0f\u9f20 \u6613\u611f\u6027 \u6269\u5c55 \u4eba\u7c7b \u75c5\u539f\u4f53 \u6a21\u578b \u7528\u4e8e \u7814\u7a76 \u75c5\u539f\u4f53 \u590d\u5236 \u53d1\u75c5 \u673a\u7406 \u514d\u75ab \u6027 \u4eba\u7c7b \u7597\u6cd5 ", "Angus   Cameron \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 COVID - 19 \u6b7b\u4ea1\u7387 \u663c\u591c \u6e29\u5dee \u5448 \u6b63 \u76f8\u5173 \u76f8\u5bf9\u6e7f\u5ea6 \u5448 \u8d1f\u76f8\u5173 \u663c\u591c \u6e29\u5dee \u589e\u52a0 1 \u5355\u4f4d COVID - 19 \u6b7b\u4ea1\u7387 \u589e\u52a0 2.92 \u8fd9\u9879 \u7814\u7a76 \u6e29\u5ea6 \u53d8\u5316 \u6e7f\u5ea6 \u5f71\u54cd COVID - 19 \u6b7b\u4ea1\u7387 \u56e0\u7d20 ", "\u5fb7\u56fd \u7814\u7a76 \u4eba\u5458 \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u4e00\u79cd \u5355\u94fe RNA \u6b63\u94fe \u5305\u819c \u4e59\u578b \u51a0\u72b6\u75c5\u6bd2 \u57fa\u56e0\u7ec4 \u7f16\u7801 \u975e \u7ed3\u6784 \u86cb\u767d \u7ed3\u6784 \u86cb\u767d \u8f85\u52a9\u86cb\u767d ", "\u5e7f\u5dde \u533b\u79d1\u5927\u5b66 \u547c\u5438 \u75be\u75c5 \u56fd\u5bb6 \u91cd\u70b9 \u5b9e\u9a8c\u5ba4 \u4e3b\u4efb \u949f\u5357\u5c71 \u7814\u7a76 \u56e2\u961f \u53d1\u73b0 \u8fde\u82b1\u6e05 \u761f\u80fd \u6291\u5236 \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 SARS - CoV - 2 \u7ec6\u80de \u4e2d \u590d\u5236 \u53d1\u6325 \u6297\u65b0\u51a0 \u75c5\u6bd2 \u6d3b\u6027 \u4f5c\u7528 ", "\u5fb7\u56fd \u5415\u8d1d\u514b \u5927\u5b66 \u673a\u6784 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u4e00\u79cd \u540d\u4e3a Mpro \u86cb\u767d\u9176 \u65b0\u51a0 \u75c5\u6bd2 \u4e2d \u86cb\u767d\u9176 \u75c5\u6bd2 \u590d\u5236 \u8fc7\u7a0b \u4e2d\u8d77 \u5173\u952e\u4f5c\u7528 \u9ad8\u5f3a\u5ea6 X\u5c04\u7ebf \u89e3\u7801 \u86cb\u767d\u9176 \u4e09\u7ef4 \u7ed3\u6784 ", "\u7f8e\u56fd \u98df\u54c1 \u836f\u54c1 \u7ba1\u7406\u5c40 \u5b98\u7f51 \u6570\u636e\u5e93 \u663e\u793a \u5409\u5229 \u5fb7 \u79d1\u5b66 \u516c\u53f8 \u5f00\u53d1 \u7814 \u6297\u75c5\u6bd2 \u7597\u6cd5 \u745e\u5fb7 \u897f\u97e6 \u83b7\u6279 \u5b64\u513f \u836f \u8d44\u683c \u9002\u5e94\u75c7 \u51a0\u72b6\u75c5\u6bd2 \u75be\u75c5 2019 COVID - 19 ", "\u8377\u5170 \u6fb3\u5927\u5229\u4e9a \u5fb7\u56fd \u82f1\u56fd \u7814\u7a76 \u4eba\u5458 \u5f88\u5feb \u65b0 \u51a0\u72b6\u75c5\u6bd2 \u975e\u4f20\u7edf \u65b9\u6cd5 \u4e34\u5e8a\u8bd5\u9a8c \u6d4b\u8bd5 \u4e00\u79cd \u767e\u5e74 \u5386\u53f2 \u6297 \u7ed3\u6838\u75c5 TB \u75ab\u82d7 \u5361\u4ecb\u82d7 \u6539\u5584 \u4eba\u4f53 \u514d\u75ab\u7cfb\u7edf \u66f4\u597d \u62b5\u6297 SARS - COV - 2 \u75c5\u6bd2 \u611f\u67d3   ", "\u90d1\u5dde\u5927\u5b66 \u738b\u5b87\u660e \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u671f\u95f4 \u4f26\u7406\u9053\u5fb7 \u5ba1\u67e5 \u52a0\u5feb \u6279\u51c6 \u7387 \u964d\u4f4e ", "Moderna \u79cb\u5b63 \u533b\u62a4\u4eba\u5458 \u63d0\u4f9b \u5b9e\u9a8c\u6027 COVID - 19 \u75ab\u82d7 Moderna \u89e3\u51b3\u65b9\u6848 \u4eba\u4f53 \u7c7b\u4f3c \u75c5\u6bd2 \u65e0\u5bb3 \u86cb\u767d\u8d28 \u6fc0\u53d1 \u62b5\u6297 \u86cb\u767d\u8d28 \u62b5\u6297 \u75c5\u6bd2 \u6297\u4f53 ", "\u8d5b\u9ed8\u98de \u8bca\u65ad\u68c0\u6d4b \u65b9\u6848 \u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40   ( FDA )   \u53d1\u5e03 \u4e00\u9879 \u7d27\u6025 \u6388\u6743   ( EUA ) \u7f8e\u56fd CLIA \u8ba4\u8bc1 \u5b9e\u9a8c\u5ba4 \u7528\u4e8e \u5bfc\u81f4 COVID - 19   SARS - CoV - 2 \u75c5\u6bd2 \u6838\u9178 \u68c0\u6d4b \u68c0\u6d4b \u65b9\u6848 \u8d5b\u9ed8\u98de Applied   Biosystems   TaqPath   Assay \u6280\u672f \u5305\u62ec \u6837\u672c \u5236\u5907 \u4eea\u5668 \u5206\u6790 \u5b9e\u9a8c\u5ba4 \u6536\u5230 \u60a3\u8005 \u6837\u672c 4 \u5c0f\u65f6 \u4e4b\u5185 \u5373\u53ef \u63d0\u4f9b \u68c0\u6d4b ", "\u7f8e\u56fd\u54e5\u4f26\u6bd4\u4e9a\u5927\u5b66 \u516c\u5171\u536b\u751f \u5b66\u9662 \u611f\u67d3 \u514d\u75ab \u4e2d\u5fc3 \u4e3b\u4efb \u4f20\u67d3\u75c5 \u5b66 \u4e13\u5bb6 \u5229\u666e\u91d1 \u6559\u6388 ( Walter   Ian   Lipkin ) \u786e\u8bca \u611f\u67d3 \u65b0\u51a0 \u75c5\u6bd2 ", "\u5e7f\u5dde \u533b\u79d1\u5927\u5b66 \u9644\u5c5e \u5e7f\u5dde\u5e02 \u7b2c\u516b \u533b\u9662 \u7814\u7a76 \u4eba\u5458 \u6307\u51fa \u6d1b\u5339 \u97e6 / \u5229\u6258 \u97e6 \u514b\u529b \u829d \u963f\u6bd4 \u6735\u5c14 \u5355\u836f \u6cbb\u7597 \u8f7b\u5ea6 \u4e2d\u5ea6 COVID - 19 \u4e34\u5e8a \u6cbb\u7597 \u4e2d \u6536\u6548\u751a\u5fae \u6d1b\u5339 \u97e6 / \u5229\u6258 \u97e6 \u6cbb\u7597 \u5bfc\u81f4 \u75c5\u4eba \u4e0d\u826f\u53cd\u5e94 ", "\u7a7a\u519b \u519b\u533b\u5927\u5b66 \u9648\u5fd7\u5357 \u7814\u7a76 \u56e2\u961f \u53d1\u73b0 \u4eba\u6e90\u5316 \u6297 CD147 \u6297\u4f53 meplazumab \u7f8e\u666e\u73e0 \u5355\u6297 \u6cbb\u7597 COVID - 19 \u80ba\u708e \u60a3\u8005 \u7814\u7a76 \u652f\u6301 meplazumab \u7f8e\u666e\u73e0 \u5355\u6297 \u6cbb\u7597 COVID - 19 \u80ba\u708e \u836f\u7269 \u5927\u89c4\u6a21 \u4e34\u5e8a \u7814\u7a76 ", "\u4e2d\u56fd\u79d1\u5b66\u9662 \u5fae\u751f\u7269 \u7814\u7a76\u6240 \u4e25\u666f\u534e \u7814\u7a76 \u56e2\u961f \u53d1\u73b0 SARS - CoV - 2 - CTD hACE2 \u539f\u5b50 \u76f8\u4e92\u4f5c\u7528 \u9610\u660e \u75c5\u6bd2 \u81f4\u75c5 \u673a\u7406 \u6709\u671b \u6fc0\u53d1 \u65b0\u5174 \u75c5\u539f\u4f53 \u65b0\u578b \u9776\u5411 \u6cbb\u7597 ", "\u534e\u4e2d\u79d1\u6280\u5927\u5b66 \u9644\u5c5e \u540c\u6d4e \u533b\u9662 \u5987\u4ea7\u79d1 Wu   Jianli \u56e2\u961f \u6d4b\u8bd5 \u4e09\u540d \u65b0\u751f\u513f SARS - CoV - 2 \u4e00\u540d \u65b0\u751f\u513f \u51fa\u751f 36 \u5c0f\u65f6 \u611f\u67d3 SARS - CoV - 2 \u957f\u671f \u6f5c\u5728 \u6bcd\u5a74 \u5782\u76f4 \u4f20\u64ad \u8fdb\u4e00\u6b65 \u7814\u7a76 ", "\u9999\u6e2f\u5927\u5b66 \u7814\u7a76 \u56e2\u961f \u53d1\u73b0 \u65b0\u578b \u578b \u51a0\u72b6\u75c5\u6bd2 \u80ba\u708e \u60a3\u8005 \u553e\u6db2 \u75c5\u6bd2 \u8f7d\u91cf \u75c7\u72b6 \u7b2c\u4e00\u5468 \u65f6\u95f4 \u4e0b\u964d \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u521d\u671f \u75c5\u6bd2 \u8f7d\u91cf \u89e3\u91ca \u65b0\u51a0 \u80ba\u708e \u5feb\u901f \u4f20\u64ad \u7279\u6027 ", "\u5317\u4eac\u5927\u5b66\u7b2c\u4e00\u533b\u9662 \u611f\u67d3 \u79d1 \u4e3b\u4efb\u533b\u5e08 \u738b\u8d35\u5f3a \u6307\u51fa 29 \u4f8b\u65b0\u51a0 \u80ba\u708e \u75c5\u4ea1 \u60a3\u8005 \u9057\u4f53 \u89e3\u5256 \u603b\u4f53 \u80ba\u90e8 \u75c5\u53d8 \u91cd \u514d\u75ab\u7cfb\u7edf \u6253\u51fb \u53d7\u7d2f \u91cd \u8fdb\u4e00\u6b65 \u68c0\u6d4b \u53d1\u73b0 \u75c5\u6bd2 \u75c5\u4ea1 \u60a3\u8005 \u80ba\u91cc ", "\u4e2d\u56fd\u5de5\u7a0b\u9662 \u9662\u58eb \u9ec4\u7490\u7426 \u56e2\u961f \u63a5\u5230 \u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40 \u901a\u77e5 \u56e2\u961f \u7814\u5236 \u5316\u6e7f \u8d25\u6bd2 \u9897\u7c92 \u4e34\u5e8a\u8bd5\u9a8c \u6279\u4ef6 \u9996\u4e2a \u83b7\u6279 \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u4e2d\u836f \u65b0\u836f \u4e34\u5e8a\u8bd5\u9a8c \u6279\u4ef6 ", "\u83f2\u5f8b\u5bbe \u78a7\u7476 \u7efc\u5408 \u533b\u9662 \u8fd1\u65e5 \u6b63\u5f0f \u4e0a\u7ebf \u534e\u4e3a \u4e91 AI \u5f71\u50cf \u7b5b\u67e5 \u7cfb\u7edf \u65b0\u51a0 \u80ba\u708e \u5feb\u901f \u7b5b\u67e5 \u65b9\u6848 \u7d2f\u79ef \u56fd\u5185 \u4f17\u591a \u65b0\u51a0 \u75ab\u60c5 \u6848\u4f8b \u4e9a\u6d32 \u6b27\u6d32 \u62c9\u7f8e \u51e0\u5341\u4e2a \u56fd\u5bb6 \u6297\u75ab \u63d0\u4f9b \u6280\u672f \u7ecf\u9a8c ", "\u4ee5\u8272\u5217\u56fd\u9632\u90e8 \u65b0\u51a0 \u80ba\u708e \u75c5\u4eba \u58f0\u97f3 \u5206\u6790 \u58f0\u97f3 \u6307\u7eb9 \u4e5f\u8bb8 \u6709\u52a9\u4e8e \u53d1\u73b0 \u5176\u4ed6\u4eba \u65b0\u51a0 \u80ba\u708e \u75c7\u72b6 \u68c0\u6d4b \u6cbb\u7597 \u91cd\u70b9 ", "\u4e1c\u4eac\u5927\u5b66 \u786e\u8ba4 \u7532\u78fa\u9178 \u8418\u83ab\u53f8 \u6cbb\u7597 \u65b0\u51a0 \u80ba\u708e \u7279\u6548 \u8d5b\u5347 \u836f\u4e1a \u516c\u53f8 \u751f\u4ea7 \u7532\u78fa\u9178 \u8418\u83ab\u53f8 \u9879\u76ee \u4e34\u5e8a III \u671f \u9636\u6bb5 \u542f\u52a8 \u56db\u5bb6 \u4e34\u5e8a \u4e2d\u5fc3 \u8bd5\u9a8c \u5165\u7ec4 \u8fdb\u5c55 \u987a\u5229 ", "\u610f\u5927\u5229 14 \u5bb6 \u7814\u7a76 \u4e2d\u5fc3 \u610f\u5927\u5229 COVID - 19 \u75ab\u60c5 \u6df1\u5165\u7814\u7a76 \u7ed3\u679c\u663e\u793a \u65b0\u578b \u51a0\u72b6\u75c5\u6bd2 \u65e9 2020 \u5e74 1 \u6708 1 \u65e5 \u4f26\u5df4\u7b2c \u5927\u533a \u6d41\u884c 2 \u6708 20 \u65e5 \u610f\u5927\u5229 1 \u53f7 \u75c5\u4eba \u53d1\u73b0 \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u53d1\u73b0 \u524d \u610f\u5927\u5229 \u53d1\u5c55 \u6570\u4e2a \u661f\u671f ", "\u4e16\u536b \u7ec4\u7ec7 \u603b\u5e72\u4e8b \u8c2d \u5fb7\u585e \u5401\u5401 \u5c01\u9501 \u63aa\u65bd \u56fd\u5bb6 \u5229\u7528 \u7a97\u53e3\u671f \u8fdb\u653b \u75c5\u6bd2 \u5e0c\u671b \u5f85\u5728\u5bb6\u91cc \u963b\u6b62 \u4eba\u53e3 \u6d41\u52a8 \u51cf\u8f7b \u536b\u751f\u7cfb\u7edf \u538b\u529b \u5404\u56fd \u9700 \u7cbe\u51c6 \u9488\u5bf9\u6027 \u63aa\u65bd \u5236\u6b62 \u4f20\u64ad \u633d\u6551 \u751f\u547d ", "\u7f8e\u56fd \u5236\u836f \u4f01\u4e1a \u5409\u5229 \u5fb7 \u53d1\u5e03 \u58f0\u660e \u79f0 \u7f8e\u56fd \u98df\u54c1 \u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40 FDA \u63d0\u51fa\u7533\u8bf7 \u6536\u56de \u6388\u4e88 \u745e\u5fb7 \u897f\u97e6 \u5b64\u513f \u836f \u8d44\u683c \u653e\u5f03 \u5b64\u513f \u836f \u8d44\u683c \u76f8\u5173 \u4f18\u60e0 \u6743\u76ca ", "\u79d1\u6280\u90e8 \u526f \u90e8\u957f \u5f90 \u5357\u5e73 \u4ecb\u7ecd \u75ab\u60c5 \u53d1\u751f \u4e2d\u56fd \u79d1\u6280\u754c \u6210\u7acb \u79d1\u7814 \u653b\u5173\u7ec4 \u56f4\u7ed5 \u4e34\u5e8a \u6551\u6cbb \u836f\u7269 \u75ab\u82d7 \u7814\u53d1 \u75c5\u6bd2 \u6eaf\u6e90 \u4f20\u64ad \u68c0\u6d4b \u8bd5\u5242 \u8bbe\u5907 \u52a8\u7269\u6a21\u578b \u6784\u5efa \u4e94\u5927 \u65b9\u5411 \u4e00\u6279 \u5207\u5b9e \u7ba1\u7528 \u79d1\u6280\u6210\u679c ", "\u610f\u5927\u5229 \u56fd\u5bb6 \u536b\u751f \u7814\u7a76\u6240 2 \u6708 21 \u65e5\u81f3 3 \u6708 12 \u65e5 \u4e4b\u95f4 \u62a5\u544a 13882 \u4f8b \u786e\u8bca \u75c5\u4f8b \u5206\u6790 \u4e2d \u7537\u6027 \u5360 58% 803 \u4f8b \u6b7b\u4ea1 \u75c5\u4f8b \u4e2d \u7537\u6027 \u5360 72% \u65b0\u51a0 \u80ba\u708e \u4f4f\u9662 \u60a3\u8005 \u4e2d \u7537\u6027 \u75c5\u4ea1 \u7387 \u5973\u6027 \u9ad8 75% ", "\u5317\u4eac\u5e08\u8303\u5927\u5b66 \u7814\u7a76 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u4e2d\u56fd \u5b9e\u65bd \u4e25\u683c\u63a7\u5236 \u63aa\u65bd \u51cf\u8f7b COVID - 19 \u4f20\u64ad ", "\u4e2d\u56fd \u75be\u75c5 \u9884\u9632 \u63a7\u5236\u4e2d\u5fc3 \u51af\u5b50\u5065 \u56e2\u961f \u7814\u7a76 \u53d1\u73b0 \u75ab\u60c5 \u65e9\u671f \u9636\u6bb5 COVID - 19 7.4 \u5929 \u589e\u52a0\u4e00\u500d \u751f\u6b96 \u6570 R0 \u4f30\u8ba1 2.2 2019 \u5e74 12 \u6708 \u4e2d \u4eb2\u5bc6 \u63a5\u89e6 \u4e4b\u95f4 \u53d1\u751f \u4e4b\u95f4 \u4f20\u64ad \u5e94 \u5371\u9669 \u4eba\u7fa4 \u8001\u5e74\u4eba \u4e2d \u9884\u9632 \u51cf\u5c11 \u4f20\u64ad \u63aa\u65bd ", "\u4e2d\u56fd\u79d1\u5b66\u9662 \u526f \u79d8\u4e66\u957f \u4e2d\u56fd\u79d1\u5b66\u9662 \u9662\u58eb \u5468\u742a 1 \u6708 \u4e2d\u56fd \u516c\u5e03 \u75c5\u6bd2 \u5168 \u5e8f\u5217 \u5f00\u53d1 \u591a\u79cd\u4e0d\u540c \u68c0\u6d4b \u624b\u6bb5 \u68c0\u6d4b \u7075\u654f\u5ea6 \u68c0\u6d4b \u65f6\u95f4 \u8d8a\u6765\u8d8a \u65b9\u5411 \u53d1\u5c55 \u56fd\u5bb6\u836f\u76d1\u5c40 \u516c\u5e03 \u591a\u6279 \u68c0\u6d4b \u8bd5\u5242\u76d2 \u76f8\u5173 \u88c5\u5907 \u88c5\u5907 \u6d77\u5916 \u63a8\u5e7f \u51fa\u53e3 \u68c0\u6d4b \u624b\u6bb5 \u9769\u547d\u6027 \u66f4\u65b0 ", "\u82f1\u56fd \u56fd\u5bb6 \u91cd\u75c7 \u76d1\u62a4 \u5ba1\u8ba1 \u7814\u7a76 \u4e2d\u5fc3 ICNARC \u53d1\u51fa \u4e00\u4efd \u6700\u65b0 \u7814\u7a76 \u62a5\u544a \u5206\u6790 \u5168\u82f1 \u5165\u4f4f ICU 196 \u540d \u91cd\u75c7 \u75c5\u60a3 \u9884\u8b66 64% \u8fc7\u91cd \u80a5\u80d6 \u4eba\u58eb \u82f1\u56fd\u653f\u5e9c \u7f8e\u56fd \u75be\u75c5 \u63a7\u5236 \u9884\u9632 \u4e2d\u5fc3 CDC \u80a5\u80d6 \u4eba\u7fa4 \u5212\u4e3a \u65b0\u51a0 \u80ba\u708e \u9ad8\u5371 \u4eba\u7fa4 \u82f1\u56fd\u653f\u5e9c \u5efa\u8bae \u81ea\u6211 \u9694\u79bb ", "\u6e56\u5317\u7701 \u536b\u751f \u5065\u5eb7 \u59d4\u5458\u4f1a \u526f \u4e3b\u4efb \u67f3\u4e1c \u6e56\u5317\u7701 \u6b66\u6c49\u5e02 \u9632\u6269\u6563 \u5916\u653e \u8f93\u51fa \u9636\u6bb5\u6027 \u6210\u679c \u75ab\u60c5 \u9632\u63a7 \u5f62\u52bf \u6b66\u6c49 \u4e3b\u6218\u573a \u75ab\u60c5 \u4f20\u64ad \u963b\u65ad ", "\u6b27\u6d32 \u75be\u75c5 \u9884\u9632 \u63a7\u5236\u4e2d\u5fc3 \u65e5\u524d \u53d1\u5e03 \u9884\u5907\u6027 \u98ce\u9669 \u5206\u6790 \u79f0 \u65b0\u51a0 \u75c5\u6bd2 \u75ab\u60c5 \u6c14\u6e29 \u590f\u5b63 \u7ed3\u675f \u53ef\u80fd\u6027 \u4f4e ", "\u7f8e\u56fd \u56fd\u5bb6 \u8fc7\u654f \u4f20\u67d3\u75c5 \u7814\u7a76\u6240 \u4e3b\u4efb Anthony   S .   Fauci \u79f0\u65b0\u51a0 \u80ba\u708e \u5b63\u8282\u6027 \u5468\u671f\u6027 \u75be\u75c5 \u505a\u597d \u5e94\u5bf9 \u5168\u7403 \u75ab\u60c5 \u8fce\u6765 \u4e8c\u6b21 \u7206\u53d1 ", "\u4e2d\u592e \u5e94\u5bf9 \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u5de5\u4f5c \u9886\u5bfc \u5c0f\u7ec4\u4f1a\u8bae \u6307\u51fa \u53d1\u73b0 \u65e0\u75c7\u72b6 \u611f\u67d3\u8005 \u56db\u79cd \u9014\u5f84   \u65b0\u51a0 \u80ba\u708e \u75c5\u4f8b \u5bc6\u5207\u63a5\u89e6 \u533b\u5b66\u89c2\u5bdf \u671f\u95f4 \u4e3b\u52a8 \u68c0\u6d4b   \u805a\u96c6 \u6027 \u75ab\u60c5 \u8c03\u67e5 \u4e2d \u4e3b\u52a8 \u68c0\u6d4b   \u65b0\u51a0 \u80ba\u708e \u75c5\u4f8b \u4f20\u67d3\u6e90 \u8ffd\u8e2a \u8fc7\u7a0b \u4e2d \u66b4\u9732 \u4eba\u7fa4 \u4e3b\u52a8 \u68c0\u6d4b \u3000   \u65b0\u51a0 \u80ba\u708e \u75c5\u4f8b \u6301\u7eed \u4f20\u64ad \u5730\u533a \u65c5\u884c \u53f2 \u5c45\u4f4f \u53f2 \u4eba\u5458 \u4e3b\u52a8 \u68c0\u6d4b ", "\u6b66\u6c49\u5927\u5b66 \u6768\u83c1 \u56e2\u961f \u53d1\u73b0 IgM \u6297\u4f53 \u6c34\u5e73 \u5347\u9ad8 \u65b0\u751f\u513f \u5b50\u5bab \u611f\u67d3 \u75c5\u6bd2   IgM \u6297\u4f53 \u80ce\u76d8 \u8f6c\u79fb \u80ce\u513f \u6bcd\u4eb2 \u8bca\u65ad COVID - 19 \u5206\u5a29 \u5a74\u513f \u66b4\u9732 23 \u5929 \u65b0\u751f\u513f \u708e\u75c7 \u809d \u635f\u4f24 \u5b9e\u9a8c\u5ba4 \u95f4\u63a5 \u652f\u6301 \u5782\u76f4 \u4f20\u64ad \u53ef\u80fd\u6027 ", "\u6b66\u6c49\u5927\u5b66 \u5f20\u851a \u56e2\u961f \u65b0\u751f\u513f \u8840\u6db2 \u6837\u54c1 \u4e2d \u68c0\u6d4b \u75c5\u6bd2 \u7279\u5f02\u6027 \u6297\u4f53 2 \u4f8b \u5a74\u513f \u4e2d \u68c0\u6d4b IgM \u6bcd\u5a74 \u5782\u76f4 \u4f20\u64ad ", "\u7ba1\u8f76 \u6559\u6388 \u53d1\u73b0 \u8d70\u79c1 \u4e2d\u56fd \u7a7f\u5c71\u7532 \u4e2d \u68c0\u6d4b \u51a0\u72b6\u75c5\u6bd2   SARS - CoV - 2   \u51a0\u72b6\u75c5\u6bd2 \u8f83\u8fd1 \u4eb2\u7f18 \u5173\u7cfb \u7a7f\u5c71\u7532 \u51a0\u72b6\u75c5\u6bd2 \u7b2c\u4e8c\u4e2a \u54fa\u4e73\u52a8\u7269 \u5bbf\u4e3b \u5e94 \u4e25\u4ee4\u7981\u6b62 \u91ce\u751f\u52a8\u7269 \u5e02\u573a \u4ea4\u6613 \u7a7f\u5c71\u7532 \u672a\u6765 \u75c5\u6bd2\u611f\u67d3 \u4eba\u7c7b \u98ce\u9669 \u964d \u6700\u4f4e ", "\u82f1\u56fd\u4f26\u6566\u5927\u5b66 \u536b\u751f \u70ed\u5e26 \u533b\u5b66\u9662 \u4f20\u67d3\u75c5 \u6570\u5b66\u6a21\u578b \u4e2d\u5fc3 Kiesha   Prem \u535a\u58eb \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u80ba\u708e \u75ab\u60c5 \u66b4\u53d1 \u671f\u95f4 \u6b66\u6c49 \u591a\u9879 \u5e72\u9884 \u63aa\u65bd \u904f\u5236 \u75c5\u6bd2 \u8513\u5ef6 \u5f97\u4ee5 \u75ab\u60c5 \u5feb\u901f \u5e73\u606f \u533b\u7597 \u6551\u6cbb \u5173\u952e \u5598\u606f \u7a7a\u95f4 \u6700\u7ec8 \u5927\u5e45 \u51cf\u5c11 \u611f\u67d3 \u603b \u75c5\u4f8b \u6570 ", "\u590d\u65e6\u5927\u5b66 \u516c\u5171\u536b\u751f \u4e34\u5e8a \u4e2d\u5fc3 \u5f20\u6c38\u632f \u6559\u6388 \u7814\u7a76 \u56e2\u961f \u53d1\u73b0 \u65b0\u51a0 \u75ab\u60c5 \u5927\u89c4\u6a21 \u66b4\u53d1 \u524d \u4eba\u7fa4 \u4e2d \u7ecf\u5386 \u4e00\u6bb5\u65f6\u95f4 \u9690\u6027 \u4f20\u64ad \u65e9\u671f \u611f\u67d3\u8005 \u65e0\u75c7\u72b6 \u75c7\u72b6 \u8f7b\u5fae \u96f6\u661f \u80ba\u708e \u75c5\u4f8b \u672a \u75c5\u6bd2 \u5173\u952e\u70b9 \u4f4d \u7a81\u53d8 \u66f4\u597d \u4eba\u7c7b \u5bbf\u4e3b ", "\u5b81\u6ce2\u5e02 \u75be\u75c5 \u9884\u9632 \u63a7\u5236\u4e2d\u5fc3 \u4f20\u67d3\u75c5 \u9632\u5236 \u9648\u5955 \u56e2\u961f \u53d1\u73b0 \u786e\u8bca \u75c5\u4f8b \u5bc6\u5207\u63a5\u89e6 \u611f\u67d3\u7387 6.3% \u65e0\u75c7\u72b6 \u611f\u67d3\u8005 \u5bc6\u5207\u63a5\u89e6 \u611f\u67d3\u7387 4.11% \u65b0\u51a0 \u65e0\u75c7\u72b6 \u611f\u67d3\u8005 \u5bc6\u63a5 \u611f\u67d3\u7387 \u786e\u8bca \u5dee\u5f02 ", "\u54c8\u4f5b\u5927\u5b66\u533b\u5b66\u9662 \u4e13\u5bb6 \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u653b\u51fb \u9f3b\u5b50 \u91cc \u5173\u952e \u7ec6\u80de \u89e3\u91ca \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u55c5\u89c9 \u5473\u89c9 \u4e27\u5931 \u55c5\u89c9 \u611f\u67d3 \u65b0\u51a0 \u80ba\u708e \u6700\u521d \u4fe1\u53f7 ", "\u4e16\u754c\u536b\u751f\u7ec4\u7ec7 \u603b\u5e72\u4e8b \u8c2d \u5fb7\u585e \u6307\u51fa \u65b0\u51a0 \u80ba\u708e \u75ab\u82d7 \u7814\u5236 \u81f3\u5c11 12 18 \u6708 \u56fd\u5bb6 \u672a\u7ecf \u8bc1\u660e \u6cbb\u7597 \u65b9\u6cd5 ", "\u949f\u5357\u5c71 \u9662\u58eb \u6307\u51fa \u56fd\u5185 \u75ab\u60c5 \u6ce2 \u9ad8\u5cf0 \u4e2d\u56fd \u7fa4\u9632 \u7fa4\u63a7 \u57fa\u7840 \u65b0\u589e \u75c5\u4f8b \u5c40\u9650 \u5f88\u5c0f \u4eba\u7fa4 \u4e2d ", "\u5e7f\u5dde \u533b\u79d1\u5927\u5b66 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 nCoVN \u8868\u8fbe \u4e24\u5468 iPSC \u5f62\u6001 \u589e\u6b96\u7387 \u53d1\u751f \u53d8\u5316 nCoVN \u7834\u574f iPSC \u80fd\u6027 \u4e3a\u6210 \u7ea4\u7ef4\u7ec6\u80de \u8fd9\u4e3a SARS - CoV - 2 \u81f4\u75c5 \u673a\u7406 \u63d0\u4f9b \u65b0 \u89c1\u8bc6 ", "\u6df1\u5733\u5e02 \u7b2c\u4e09 \u533b\u9662 \u5218\u6620\u971e \u7814\u7a76 \u53d1\u73b0 \u8f93\u6ce8 \u6062\u590d\u671f \u60a3\u8005 \u8840\u6d46 \u6539\u5584 COVID - 19 \u91cd\u75c7 \u60a3\u8005 \u4e34\u5e8a \u75c7\u72b6 \u9700 \u8fdb\u4e00\u6b65 \u8bd5\u9a8c ", "\u519b\u4e8b\u79d1\u5b66\u9662 \u519b\u4e8b\u533b\u5b66 \u7814\u7a76\u9662 \u9648\u8587 \u9662\u58eb \u7814\u7a76 \u5355\u7ec6\u80de \u6280\u672f \u8868\u5f81 COVID - 19 \u4e2d \u6062\u590d 10 \u4f8b \u60a3\u8005 \u5916\u5468\u8840 \u5355\u6838\u7ec6\u80de \u8f6c\u5f55 \u53d8\u5316 \u7814\u7a76 \u63d0\u4f9b \u6062\u590d \u521d\u671f \u708e\u75c7 \u514d\u75ab \u7279\u5f81 \u7b2c\u4e00\u4e2a \u8bc1\u636e COVID - 19 \u60a3\u8005 \u51fa\u9662 \u8106\u5f31 \u7814\u7a76 \u65b0\u578b BCR \u4fe1\u53f7\u8f6c\u5bfc \u9274\u5b9a \u5bfc\u81f4 \u5f00\u53d1 \u7528\u4e8e \u6cbb\u7597 COVID - 19 \u75ab\u82d7 \u6297\u4f53 ", "\u6b66\u5927 \u4e2d\u5357 \u533b\u9662 \u7814\u7a76 \u4eba\u5458 \u53d1\u73b0 \u65b0\u51a0 \u75c5\u6bd2 \u635f\u5bb3 \u7537\u6027 \u6027\u817a \u63d0\u793a \u6f5c\u5728 \u6027\u817a \u529f\u80fd \u51cf\u9000 \u63d0\u9192 \u65b0\u51a0 \u80ba\u708e \u5eb7\u590d \u60a3\u8005 \u80b2\u9f84 \u7537\u6027 \u5e94 \u5173\u6ce8 \u6027\u817a \u529f\u80fd \u8bc4\u4f30 \u65f6\u95f4 \u95f4\u9694 \u91cd\u590d \u68c0\u6d4b ", "\u4fc4\u7f57\u65af\u8054\u90a6 \u751f\u7269\u533b\u836f \u7f72 \u836f\u7269 \u4fdd\u62a4 \u79d1\u7814 \u751f\u4ea7 \u4e2d\u5fc3 \u4e2d\u56fd \u6cd5\u56fd \u7ecf\u9a8c \u7814\u53d1 \u4e00\u79cd \u6297\u759f\u836f \u7532\u6c1f\u55b9 \u65b0\u51a0 \u80ba\u708e \u6cbb\u7597 \u65b9\u6848 \u751f\u7269\u533b\u836f \u7f72 \u65b0\u95fb\u5904 \u7814\u53d1 \u6210\u679c \u63d0\u8bae \u7eb3\u5165 \u4fc4\u7f57\u65af \u536b\u751f\u90e8 \u6cbb\u7597 \u65b0\u51a0 \u75c5\u6bd2 \u7cfb\u7edf \u6307\u5357 \u4e4b\u4e2d ", "\u6c88\u9633 \u540c\u8054 \u96c6\u56e2\u516c\u53f8 \u7814\u53d1 \u53ef\u5229 \u9709\u7d20 \u4ea7\u54c1 \u914d\u5408 \u79d1\u6280\u90e8 \u56fd\u5185 \u65b0\u51a0 \u80ba\u708e \u60a3\u8005 \u4e34\u5e8a\u8bd5\u9a8c \u8bd5\u9a8c \u60c5\u51b5 \u53ef\u5229 \u9709\u7d20 \u65b0\u51a0 \u80ba\u708e \u6cbb\u7597 \u7597\u6548 ", "\u6089\u5c3c\u5927\u5b66 \u751f\u547d \u73af\u5883 \u79d1\u5b66 \u5b66\u9662 \u533b\u5b66 \u79d1\u5b66 \u5b66\u9662 \u7231\u5fb7\u534e \u970d\u5c14\u59c6 \u65af \u6559\u6388 \u7814\u7a76 \u53d1\u73b0 \u65b0\u51a0 \u80ba\u708e \u65e9\u671f \u6848\u4f8b \u534e\u5357 \u6d77\u9c9c \u5e02\u573a \u75c5\u6bd2 \u6e90\u5934 \u6700\u521d \u731c\u6d4b ", "deCODE \u57fa\u56e0 \u516c\u53f8 \u51b0\u5c9b \u786e\u8bca \u75c5\u4f8b \u57fa\u56e0 \u6d4b\u5e8f \u5206\u6790 \u53d1\u73b0 40 \u65b0\u51a0 \u75c5\u6bd2 \u53d8\u4f53 \u75c5\u6bd2\u5b66\u5bb6 \u65b0\u51a0 \u75c5\u6bd2 \u6700\u7ec8 \u8fdb\u5316 \u66f4\u5177 \u4f20\u67d3\u6027 \u4f4e \u81f4\u75c5\u6027 \u75c5\u6bd2 ", "\u675c\u5170 \u5927\u5b66 \u533b\u5b66\u9662 \u7f57\u4f2f\u7279 \u30fb \u52a0\u91cc \u6559\u6388 \u7814\u7a76 \u53d1\u73b0 \u65b0\u578b \u75c5\u6bd2 \u5b9e\u9a8c\u5ba4 \u4e2d \u6784\u5efa \u76ee\u7684\u6027 \u4eba\u4e3a \u64cd\u63a7 \u75c5\u6bd2 \u81ea\u7136 "]}